

JC854 U.S. PTO
06/16/00

06-19-00

A

**NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)**

☐ Duplicate
(check, if applicable)

JC857 U.S. PTO
09/596194
06/16/00

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Attorney Docket No. 10147-11U1 (MBIO99-054)
First Named Inventor: Susan J. Kirst
Express Mail Label No. EL471633143US
Total Pages of Transmittal Form: 2

Transmitted herewith for filing is the non-provisional utility patent application entitled:

**NOVEL GENES ENCODING PROTEINS HAVING DIAGNOSTIC,
PREVENTIVE, THERAPEUTIC, AND OTHER USES**

which is:

an ☐ Original; or

a ☐ Continuation, ☐ Divisional, or ☒ Continuation-in-part (CIP)
of prior Application No. 09/342,364, filed June 29, 1999.

☐ This non-provisional patent application is based on Provisional Patent Application
No. &@, filed &@.

Enclosed are:

- ☒ Specification (including Abstract) and claims: 191 pages.
- ☒ Non-executed Declaration.
- ☐ Copy of Declaration from prior application.
- ☐ Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
- ☒ 109 sheets of drawings (formal).
- ☐ Microfiche computer program (Appendix).
- ☒ Nucleotide and/or Amino Acid Sequence Submission, including:
 - ☒ Computer readable copy ☒ Paper Copy (86 pages) ☒ Verified Statement.
- ☐ Under PTO-1595 cover sheet, an assignment of the invention.
- ☐ Certified copy of &@ Application No. &@, filed &@, is filed:
 - ☐ herewith or ☐ in prior application &@.
- ☐ Verified Statement Claiming Small Entity Status under 37 CFR 1.9 and 1.27.
 - ☐ was filed in the prior non-provisional application, and such status is still proper and desired (37 CFR 1.28(a));
 - ☐ is enclosed herewith; ☐ is no longer desired.
- ☐ Preliminary Amendment.
- ☐ Information Disclosure Statement, PTO-1449, and cited references.

The filing fee has been calculated as shown below:


			SMALL ENTITY		LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE: \$345		BASIC FEE: \$690	
Total	23-20 =	3	X9	\$	OR	X18 \$ 54
Independent	2- 3=	0	X39	\$	OR	X78 \$ 0
Multiple Dependent Claims Present: 0			\$130	\$	OR	\$260 \$ 0
			TOTAL	\$	OR	TOTAL \$ 0*

*** Note: The filing fee is not being paid at this time.**

The Commissioner is hereby authorized to charge payment of the following fees or credit any overpayment to Deposit Account No. 50-1017. One additional copy of this sheet is enclosed.

- ☐ The above calculated filing fee \$ 0.
- ☐ Any additional fees required under 37 C.F.R. § 1.16.
- ☒ Any additional fees required under 37 C.F.R. §1.17.
- ☒ If the filing of any paper during the prosecution of this application requires an extension of time in order for the paper to be timely filed, applicant(s) hereby petition(s) for the appropriate extension of time pursuant to 37 C.F.R. §1.136(a).

CORRESPONDENCE ADDRESS:

June 16, 2000 By: 
 (Date) **Gary B. Colby**
 Registration No. 40,961
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
 One Commerce Square
 2005 Market Street - Suite 2200
 Philadelphia, PA 19103
 Telephone: 215-965-1200
 Facsimile: 215-965-1210
 E-Mail: GColby@akingump.com
 Direct Dial: 215-965-1285

☒ Customer Number or Bar Code Label: 000570

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of Susan J. Kirst et al. :
Serial No.: Not Yet Assigned :
Filed: Herewith :
For: NOVEL GENES ENCODING PROTEINS : Attorney Docket
HAVING DIAGNOSTIC, PREVENTIVE : No. 10147-11U1 (210147.0025)
THERAPEUTIC, AND OTHER USES : (MBIO99-054)

JC857 U.S. PTO
09/596194
06/16/00

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

- (X) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.

Respectfully submitted,

SUSAN J. KIRST et al.

By: 

GARY D. COLBY, Ph.D., J.D.

Registration No. 40,961

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street - Suite 2200

Philadelphia, PA 19103-7086

Telephone: 215-965-1200

Direct Dial: 215-965-1285

Facsimile: 215-965-1210

E-Mail: GColby@akingump.com

5 NOVEL GENES ENCODING PROTEINS HAVING
DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES

Cross Reference to Related Applications

 This application is a continuation-in-part of co-pending United States
10 Patent Application number 09/342,364, filed June 29, 1999.

Background of the Invention

 The molecular bases underlying many human and animal physiological
states (e.g., diseased and homeostatic states of various tissues) remain unknown.

15 Nonetheless, it is well understood that these states result from interactions among the
proteins and nucleic acids present in the cells of the relevant tissues. In the past, the
complexity of biological systems overwhelmed the ability of practitioners to
understand the molecular interactions giving rise to normal and abnormal physiological
states. More recently, though, the techniques of molecular biology, transgenic and null
20 mutant animal production, computational biology, pharmacogenomics, and the like
have enabled practitioners to discern the role and importance of individual genes and
proteins in particular physiological states.

 Knowledge of the sequences and other properties of genes (particularly
including the portions of genes encoding proteins) and the proteins encoded thereby
25 enables the practitioner to design and screen agents which will affect, prospectively or
retrospectively, the physiological state of an animal tissue in a favorable way. Such
knowledge also enables the practitioner, by detecting the levels of gene expression and
protein production, to diagnose the current physiological state of a tissue or animal and
to predict such physiological states in the future. This knowledge furthermore enables
30 the practitioner to identify and design molecules which bind with the polynucleotides
and proteins, *in vitro*, *in vivo*, or both.

The present invention provides sequence information for polynucleotides derived from human genes and for proteins encoded thereby, and thus enables the practitioner to assess, predict, and affect the physiological state of various human tissues.

5

Summary of the Invention

The present invention is based, at least in part, on the discovery of a variety of human cDNA molecules which encode proteins which are herein designated INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. These seven proteins, fragments thereof, derivatives thereof, and variants thereof are collectively referred to herein as the polypeptides of the invention or the proteins of the invention. Nucleic acid molecules encoding polypeptides of the invention are collectively referred to as nucleic acids of the invention.

The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, the present invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, the present invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

The invention also features nucleic acid molecules which are at least 40% (or 50%, 60%, 70%, 80%, 90%, 95%, or 98%) identical to the nucleotide

sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151 ("a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151"), or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) consecutive nucleotide residues of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 50% (or 60%, 70%, 80%, 90%, 95%, or 98%) identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof.

In preferred embodiments, the nucleic acid molecules have the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, the fragment including at least 8 (10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, or 200) consecutive amino acids of any of SEQ ID NOs: 3-8, 11-32, 35-

37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151.

The invention includes nucleic acid molecules which encode a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of
5 SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® PTA-147, PTA-150, 207230, and PTA-151, wherein the nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleic acid sequence encoding any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59,
10 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 50%, preferably 60%, 75%, 90%, 95%, or 98% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37,
15 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98.

Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 40%, preferably 50%, 75%, 85%, or 95% identical the nucleic acid sequence encoding any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98,
20 and isolated polypeptides or proteins which are encoded by a nucleic acid molecule consisting of the nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92.

Also within the invention are polypeptides which are naturally occurring
25 allelic variants of a polypeptide that includes the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the

nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof. In some embodiments, the isolated nucleic acid molecules encode a cytoplasmic, transmembrane, extracellular, or other domain of a polypeptide of the invention. In other embodiments, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention.

Another aspect of the invention provides vectors, e.g., recombinant expression vectors, comprising a nucleic acid molecule of the invention. In another embodiment, the invention provides isolated host cells, e.g., mammalian and non-mammalian cells, containing such a vector or a nucleic acid of the invention. The invention also provides methods for producing a polypeptide of the invention by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector encoding a polypeptide of the invention such that the polypeptide of the invention is produced.

Another aspect of this invention features isolated or recombinant proteins and polypeptides of the invention. Preferred proteins and polypeptides possess at least one biological activity possessed by the corresponding naturally-occurring human polypeptide. An activity, a biological activity, and a functional activity of a

polypeptide of the invention refers to an activity exerted by a protein or polypeptide of the invention on a responsive cell as determined *in vivo*, or *in vitro*, according to standard techniques. Such activities can be a direct activity, such as an association with or an enzymatic activity on a second protein or an indirect activity, such as a cellular processes mediated by interaction of the protein with a second protein.

By way of example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof exhibit the ability to affect growth, proliferation, survival, differentiation, and activity of human pancreas, skeletal muscle, heart, brain, placenta, lung, liver, and kidney cells. INTERCEPT 217 modulates cellular binding to one or more mediators, modulates activity and release of one or more pancreatic secreted digestive enzymes, and protects tissue from endogenous digestive enzymes. Thus, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, or treat disorders relating to aberrant endogenous digestive enzyme activity, inappropriate interaction (or non-interaction) of cells with mediators, inappropriate cellular development and proliferation, inappropriate inflammation, and inappropriate immune responses. Exemplary disorders for which INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof are useful include immune disorders (e.g., insufficient immune responses and auto-immune disorders), infectious diseases, auto-immune disorders, pancreatic disorders (e.g., pancreatitis and pancreatic carcinoma), disorders related to mal-expression of growth factors, cancers, inflammatory disorders, acute and chronic traumas, and the like.

Further by way of example, INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof exhibit the ability to affect growth, proliferation, survival, differentiation, and activity of human fetal cells and spleen cells and of (e.g., bacterial or fungal) cells and viruses which infect humans. Furthermore, INTERCEPT 297 modulates organization, structure, and function of biological membranes. Thus, INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to affect development and persistence of atherogenesis and arteriosclerosis, for example, or to modulate transmembrane transport processes such as ion transport across neuronal

and muscle cell membranes (e.g., ion transport relating to nerve impulse conduction and muscle contraction). INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, or treat transmembrane transport disorders such as cystic fibrosis, pain, seizure, epilepsy, mental disorders, and the like.

- 5 Other exemplary disorders for which INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof are useful include disorders involving generation and persistence of an immune response to bacterial, fungal, and viral infections.

Still further by way of example, TANGO 276 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human heart, placenta, brain, lung, liver, skin, kidney, pancreas, spleen, and fetal tissues. TANGO 276 guides neuronal growth and development and modulates growth, homeostasis, and regeneration of other epithelial tissues. TANGO 276 is a secreted protein which mediates cellular interaction with cells, molecules, and structures (e.g., extracellular matrix) in the extracellular environment. TANGO 276 is therefore involved in growth, organization, migration, and adhesion of tissues and the cells which constitute those tissues. Furthermore, TANGO 276 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells and immune system cells. Thus, TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used, for example, to prevent, diagnose, or treat disorders characterized by aberrant organization or development of a tissue or organ, for modulating migration and adhesion of cells (e.g., in disorders such as cancer metastasis, autoimmune disorders, and graft-versus-host disease or in normal or aberrant processes involving angiogenesis, such as tumor growth and persistence), for guiding neural axon development and regeneration, for modulating differentiation of cells of the immune system (e.g., to treat bacterial, fungal, or viral infection or to prevent, diagnose, or treat autoimmune disorders), for modulating cytokine production by cells of the immune system (e.g., to prevent, detect, or treat inflammation and pain), for modulating reactivity of cells of the immune system toward cytokines, for modulating initiation

and persistence of an inflammatory response, and for modulating proliferation of epithelial cells.

Yet further by way of example, TANGO 292 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human keratinocytes, including embryonic keratinocytes. TANGO 292, a transmembrane protein, is also involved in binding and uptake of calcium and other metal ions, and in responses of cells which express it to the presence and uptake of such ions. TANGO 292 polypeptides, nucleic acids, and modulators thereof can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 292 protein. These activities include, for example, bone uptake, maintenance, and deposition, formation, maintenance, and repair of cartilage and skin, formation and maintenance of extracellular matrices, movement of cells through extracellular matrices, coagulation and dissolution of blood components, and deposition of materials in and on arterial walls. TANGO 292 is also related to a variety of disorders which involve these activities. Such disorders include, for example, various bone-related disorders such as osteoporosis, skeletal development disorders, bone fragility, traumatic bone injuries, rickets, osteomalacia, Paget's disease, and other bone disorders, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other disorders of the joints and cartilage, skin disorders such as psoriasis, eczema, scleroderma, and skin tumors (e.g., keratoses, squamous cell carcinomas, malignant melanomas, and Kaposi's sarcomas), iron deficiency anemia, hemophilia, inappropriate blood coagulation, stroke, arteriosclerosis, atherosclerosis, aneurysm, and other disorders related to blood and blood vessels, metastasis and other disorders related to inappropriate movement of cells through extracellular matrices, and the like. TANGO 292 polypeptides, nucleic acids, and modulators thereof can thus be used to prevent, diagnose, and treat one or more of these disorders. TANGO 292 is also involved in skin disorders such as psoriasis, eczema, scleroderma, skin tumors (e.g., keratoses, squamous cell carcinomas, malignant melanomas, and Kaposi's sarcomas), in placental disorders such as placenta previa and *abruptio placentae*, in liver disorders such as

cirrhosis of the liver, liver fibrosis, hepatitis, and hepatic cancers, in kidney disorders such as urolithiasis, glomerulonephritis, nephrosis, renal cell carcinomas, and renal failure (both acute and chronic), in lung disorders such as cystic fibrosis, chronic obstructive pulmonary diseases (e.g., emphysema, bronchitis, and bronchiectasis), lung
5 cancers, and asthma, in pancreatic disorders such as diabetes, pancreatitis, pancreatic cancers, and pancreatic insufficiency, in cardiac disorders such as coronary artery disease (and other ischemic heart diseases), arrhythmia, congestive heart failure, endocarditis, and pericarditis, and the like. Thus, TANGO 292 polypeptides, nucleic acids, and modulators thereof can thus be used to prevent, diagnose, and treat one or
10 more of these disorders.

As an additional example, TANGO 325 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human tissues such as vascular endothelium, including aortic endothelium, other heart tissues, placenta, liver, kidney, and pancreas tissues. Thus, TANGO 325
15 polypeptides, nucleic acids, and modulators thereof can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 325 protein in tissues in which it is expressed. Such activities include, for example, modulation of cardiac contractility and vasomotor tone, modulation of leukocyte extravasation, sensing physiological signals by the endocrine system,
20 modulating growth, development, maintenance, and regeneration of neurons, and the like. Disorders related to these activities include, by way of example and not limitation, cardiovascular disorders such as arteriosclerosis, atherosclerosis, coronary artery disease (and other ischemic heart diseases), angina, myocardial infarction, restenotic disorders, hypertension, Buerger's disease, aneurysm, stroke, arrhythmia,
25 congestive heart failure, endocarditis, and pericarditis, placental disorders such as placenta previa and *abruptio placentae*, liver disorders such as cirrhosis of the liver, liver fibrosis, hepatitis, and hepatic cancers, kidney disorders such as urolithiasis, glomerulonephritis, nephrosis, renal cell carcinomas, and renal failure (both acute and chronic), pancreatic disorders such as diabetes, pancreatitis, pancreatic cancers, and

pancreatic insufficiency, neurological system disorders, immune and auto-immune disorders, hyperthyroidism, hypothyroidism, diabetes, goiter, growth and developmental disorders, and the like.

Further by way of example, TANGO 331 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human fetal, lung, spleen, and thymus cells and tissues. As described herein, TANGO 331 is involved in physiological activities such as maintenance of epithelia, carcinogenesis, modulation and storage of protein factors and metals, lactation, and infant nutrition. TANGO 331 also modulates cellular binding and uptake of cytokines, growth factors, and metal ions. Thus, TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, and treat disorders such as breast cancer, insufficient lactation, infant nutritional and growth disorders, malnutrition and mineral deficiency disorders, hemochromatosis, inappropriate calcification of body tissues, bone disorders such as osteoporosis, autoimmune disorders, insufficient or inappropriate host responses to infection, acquired immune deficiency syndrome, and the like.

As another example, TANGO 332 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human brain and other tissues. As described herein, TANGO 332 is involved in modulating establishment and maintenance of neural connections, cell-to-cell adhesion, tissue and extracellular matrix invasivity, and the like. Thus, TANGO 332 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, and treat disorders such as brain cancers (e.g., gliomas, astrocytomas, medulloblastomas, ependymomas, Schwannomas, pituitary adenomas, teratomas, and the like), disorders of neural connection establishment or maintenance, impaired cognitive function, dementia, senility, Alzheimer's disease, mental retardation, inflammation, immune and autoimmune responses, and the like.

In one embodiment, a polypeptide of the invention has an amino acid sequence sufficiently identical to an identified domain of a polypeptide of the

invention. As used herein, the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or
5 nucleotide sequences have a common structural domain and/or common functional activity. For example, amino acid or nucleotide sequences which contain a common structural domain having about 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.

In one embodiment, the isolated polypeptide of the invention lacks both
10 a transmembrane and a cytoplasmic domain. In another embodiment, the polypeptide lacks both a transmembrane domain and a cytoplasmic domain and is soluble under physiological conditions.

The polypeptides of the present invention, or biologically active portions thereof, can be operably linked to a heterologous amino acid sequence to form
15 fusion proteins. The invention further features antibody substances that specifically bind a polypeptide of the invention such as monoclonal or polyclonal antibodies, antibody fragments, single-chain antibodies, and the like. In addition, the polypeptides of the invention or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable
20 carriers. These antibody substances can be made, for example, by providing the polypeptide of the invention to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.

In another aspect, the present invention provides methods for detecting the presence of the activity or expression of a polypeptide of the invention in a
25 biological sample by contacting the biological sample with an agent capable of detecting an indicator of activity such that the presence of activity is detected in the biological sample.

In another aspect, the invention provides methods for modulating activity of a polypeptide of the invention comprising contacting a cell with an agent

that modulates (inhibits or enhances) the activity or expression of a polypeptide of the invention such that activity or expression in the cell is modulated. In one embodiment, the agent is an antibody that specifically binds to a polypeptide of the invention.

In another embodiment, the agent modulates expression of a polypeptide
5 of the invention by modulating transcription, splicing, or translation of an mRNA encoding a polypeptide of the invention. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense with respect to the coding strand of an mRNA encoding a polypeptide of the invention.

The present invention also provides methods to treat a subject having a
10 disorder characterized by aberrant activity of a polypeptide of the invention or aberrant expression of a nucleic acid of the invention by administering an agent which is a modulator of the activity of a polypeptide of the invention or a modulator of the expression of a nucleic acid of the invention to the subject. In one embodiment, the modulator is a protein of the invention. In another embodiment, the modulator is a
15 nucleic acid of the invention. In other embodiments, the modulator is a peptide, peptidomimetic, or other small molecule.

The present invention also provides diagnostic assays for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a polypeptide of the invention,
20 (ii) mis-regulation of a gene encoding a polypeptide of the invention, and (iii) aberrant post-translational modification of a polypeptide of the invention wherein a wild-type form of the gene encodes a polypeptide having the activity of the polypeptide of the invention.

In another aspect, the invention provides a method for identifying a
25 compound that binds to or modulates the activity of a polypeptide of the invention. In general, such methods entail measuring a biological activity of the polypeptide in the presence and absence of a test compound and identifying those compounds which alter the activity of the polypeptide.

The invention also features methods for identifying a compound which modulates the expression of a polypeptide or nucleic acid of the invention by measuring the expression of the polypeptide or nucleic acid in the presence and absence of the compound.

5 In yet a further aspect, the invention provides substantially purified antibodies or fragments thereof, including non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide having an amino acid sequence comprising a sequence selected from the group consisting of

10 (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

15 (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

20 (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and
25 washing in 0.2× SSC, 0.1% SDS at 65°C.

In various embodiments, the substantially purified antibodies of the invention, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies.

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence comprising a sequence selected from the group consisting of

5 (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of
10 SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

(iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and
15 a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under
20 conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the
25 invention can be polyclonal antibodies or monoclonal antibodies.

In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide having an amino acid sequence comprising a sequence selected from the group consisting of

(i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

5 (iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

(iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG
10 software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a
15 cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

20 In a particularly preferred embodiment, the antibody substance of the invention specifically binds with an extracellular domain of one of INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. Preferably, the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs:
25 6, 14-18, 37, 43, 51, 58, 63, 83, or 93.

Any of the antibodies of the invention can be conjugated with a therapeutic moiety or with a detectable substance. Non-limiting examples of detectable substances that can be conjugated with the antibodies of the invention include an

enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 comprises Figures 1A through 1M. The nucleotide sequence (SEQ ID NO: 1) of a cDNA encoding the human INTERCEPT 217 protein described herein is listed in Figures 1A through 1E. The open reading frame (ORF; residues 215 to 1579; SEQ ID NO: 2) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 3) of human INTERCEPT 217 is listed. Figure 1F is a hydrophilicity plot of human INTERCEPT 217 protein, in which the locations of cysteine residues ("Cys") and potential N-glycosylation sites ("Ngly") are indicated by vertical bars and the predicted extracellular ("out"), intracellular ("ins"), or transmembrane ("TM") locations of the protein backbone is indicated by a horizontal bar. An alignment of the amino acid sequences of human INTERCEPT 217 protein ("H"; SEQ ID NO: 3) and porcine ribonuclease inhibitor protein ("P"; SwissProt Accession number P10775; SEQ ID NO: 64) is shown in Figures 1G and 1H, wherein identical amino acid residues are indicated by ":" and similar amino acid residues are indicated by ".". These alignments were made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4). The nucleotide sequence (SEQ ID NO: 92) of an ORF encoding the murine INTERCEPT 217 protein described herein is listed in Figures 1I

through 1K. The ORF is indicated by nucleotide triplets, beneath which the amino acid sequence (SEQ ID NO: 93) of murine INTERCEPT 217 is listed. Figure 1L is a hydrophilicity plot of murine INTERCEPT 217 protein, in which the locations of cysteine residues ("Cys") and potential N-glycosylation sites ("Ngly") are indicated by vertical bars and the predicted extracellular ("out"), intracellular ("ins"), or transmembrane ("TM") locations of the protein backbone is indicated by a horizontal bar. An alignment of the amino acid sequences of human INTERCEPT 217 protein ("H"; SEQ ID NO: 3) and murine INTERCEPT 217 protein ("M"; SEQ ID NO: 93) is shown in Figure 1M, wherein identical amino acid residues are indicated by "|" and similar amino acid residues are indicated by ".". These alignments were made using the BESTFIT software (BLOSUM62 scoring matrix, gap opening penalty = 12, frameshift gap penalty = 5, gap extension penalty = 4).

Figure 2 comprises Figures 2A through 2D. The nucleotide sequence (SEQ ID NO: 9) of a cDNA encoding the human INTERCEPT 297 protein described herein is listed in Figures 2A, 2B, and 2C. The open reading frame (ORF; residues 40 to 1152; SEQ ID NO: 10) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 11) of human INTERCEPT 297 is listed. Figure 2D is a hydrophilicity plot of human INTERCEPT 297 protein.

Figure 3 comprises Figures 3A through 3R. The nucleotide sequence (SEQ ID NO: 33) of a cDNA encoding the human TANGO 276 protein described herein is listed in Figures 3A to 3D. The ORF (residues 58 to 786; SEQ ID NO: 34) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 35) of human TANGO 276 is listed. Figure 3E is a hydrophilicity plot of TANGO 276 protein. An alignment of the amino acid sequences of human TANGO 276 protein ("H"; SEQ ID NO: 35) and murine protein M-Sema-F ("M"; SEQ ID NO: 65) is shown in Figures 3F to 3H. In Figures 3I through 3R, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 276 protein ("H"; SEQ ID NO: 33) and the nucleotide sequences of the cDNA encoding murine protein M-Sema-F ("M"; SEQ ID NO: 66) is shown. These alignments were made using the

ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4).

Figure 4 comprises Figures 4A through 4M. The nucleotide sequence (SEQ ID NO: 38) of a cDNA encoding the human TANGO 292 protein described
5 herein is listed in Figures 4A to 4C. The ORF (residues 205 to 882; SEQ ID NO: 39) of the cDNA is indicated by nucleotide triplets, beneath which the amino acid sequence (SEQ ID NO: 40) of human TANGO 292 is listed. Figure 4D is a hydrophilicity plot of human TANGO 292 protein. The nucleotide sequence (SEQ ID NO: 81) of a cDNA encoding the gerbil TANGO 292 protein described herein is listed in Figures 4E to 4H.
10 The ORF (residues 89 to 763; SEQ ID NO: 82) of the cDNA is indicated by nucleotide triplets, below which the amino acid sequence (SEQ ID NO: 83) of gerbil TANGO 292 is listed. Figures 4I to 4K are an alignment of the nucleotide sequences of the ORF encoding human TANGO 292 protein ("H"; SEQ ID NO: 38) and the nucleotide sequence of the ORF encoding gerbil TANGO 292 protein ("G"; SEQ ID NO: 81),
15 made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), wherein identical nucleotide residues are indicated by "|". Figure 4L is an alignment of the human (H) and gerbil (G) TANGO 292 amino acid sequences, made using the same software and parameters, wherein identical amino acid residues are indicated by
20 "| " and similar amino acid residues are indicated by ".". Figure 4M is a hydrophilicity plot of gerbil TANGO 292 protein.

Figure 5 comprises Figures 5A through 5Mxviii. The nucleotide sequence (SEQ ID NO: 46) of a cDNA encoding the human TANGO 325 protein described herein is listed in Figures 5A through 5E. The ORF (residues 135 to 2000;
25 SEQ ID NO: 47) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 48) of human TANGO 325 is listed. Figure 5F is a hydrophilicity plot of TANGO 325 protein. An alignment of the amino acid sequences of TANGO 325 ("325"; SEQ ID NO: 48) and Slit-1 protein ("Slit"; SEQ ID NO: 67) protein is shown in Figures 5G to 5L. In Figures 5Mi to 5Mxviii, an alignment of the

nucleotide sequences of the cDNA encoding human TANGO 325 protein ("325"; SEQ ID NO: 33) and the nucleotide sequence of the cDNA encoding Slit-1 protein ("Slit"; SEQ ID NO: 68) is shown. This alignment was made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening
5 pentalty = 12, gap extension penalty = 4).

Figure 6 comprises Figures 6A through 6J. The nucleotide sequence (SEQ ID NO: 54) of a cDNA encoding the human TANGO 331 protein described herein is listed in Figures 6A, 6B, and 6C. The ORF (residues 114 to 1172; SEQ ID NO: 55) of the cDNA is indicated by nucleotide triplets, above which the amino acid
10 sequence (SEQ ID NO: 56) of human TANGO 331 is listed. Figure 6D is a hydrophilicity plot of TANGO 331 protein. An alignment of the amino acid sequences of human TANGO 331 protein ("H"; SEQ ID NO: 56) and Chinese hamster protein HT ("C"; SEQ ID NO: 69; GenBank Accession No. U48852) is shown in Figure 6E. In
15 Figures 6F through 6J, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 331 protein ("H"; SEQ ID NO: 54) and the nucleotide sequence of the cDNA encoding Chinese hamster protein HT ("C"; SEQ ID NO: 70) is shown. These alignments were made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening pentalty = 12, gap extension penalty = 4).

Figure 7 comprises Figures 7A through 7U. The nucleotide sequence (SEQ ID NO: 59) of a cDNA encoding the human TANGO 332 protein described herein is listed in Figures 7A through 7E. The ORF (residues 173 to 2185; SEQ ID NO: 60) of the cDNA is indicated by nucleotide triplets, above which the amino acid
20 sequence (SEQ ID NO: 61) of human TANGO 332 protein is listed. Figure 7F is a hydrophilicity plot of TANGO 332 protein. An alignment of the amino acid sequences of TANGO 332 protein ("332"; SEQ ID NO: 61) and BEF protein ("BEF"; SEQ ID NO: 71) is shown in Figures 7G and 7H. An alignment of the amino acid sequences of human TANGO 332 protein ("H"; SEQ ID NO: 61) and murine brevidin protein ("M"; SEQ ID NO: 72) is shown in Figures 7I to 7K. In Figures 7L through 7U, an alignment
25

of the nucleotide sequences of the cDNA encoding human TANGO 332 protein ("H"; SEQ ID NO: 60) and the nucleotide sequence of the cDNA encoding murine brevidin protein ("M"; SEQ ID NO: 73) is shown. These alignments were made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4).

Detailed Description of the Invention

The present invention is based, at least in part, on the discovery of a variety of human cDNA molecules which encode proteins which are herein designated
10 INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. These proteins exhibit a variety of physiological activities, and are included in a single application for the sake of convenience. It is understood that the allowability or non-allowability of claims directed to one of these proteins has no bearing on the allowability of claims directed to the others. The
15 characteristics of each of these proteins and the cDNAs encoding them are now described separately.

INTERCEPT 217

A cDNA clone (designated jthqc035f08) encoding at least a portion of
20 human INTERCEPT 217 protein was isolated from a human prostate cDNA library. The human INTERCEPT 217 protein is predicted by structural analysis to be a transmembrane protein. In addition, cDNA clones (including those designated jtmca047g07, jtmob373b05, and jambd078d12) encoding at least a portion of murine INTERCEPT 217 protein were isolated from murine cDNA libraries.

25 The full length of the cDNA encoding human INTERCEPT 217 protein (Figure 1; SEQ ID NO: 1) is 2895 nucleotide residues. The ORF of this cDNA, nucleotide residues 215 to 1579 of SEQ ID NO: 1 (i.e., SEQ ID NO: 2), encodes a 455-amino acid transmembrane protein (Figure 1; SEQ ID NO: 3). The murine ORF (Figure 1; SEQ ID NO: 92) comprises at least 962 nucleotide residues. The protein

encoded by the murine ORF comprises at least 320 amino acid residues (i.e., SEQ ID NO: 93), and is also a transmembrane protein.

The invention also includes purified human INTERCEPT 217 protein, both in the form of the immature 455 amino acid residue protein (SEQ ID NO: 3) and
5 in the form of the mature, approximately 435 amino acid residue protein (SEQ ID NO: 5). Mature human INTERCEPT 217 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature INTERCEPT 217 protein and cleaving the signal sequence therefrom.

10 The invention thus includes purified murine INTERCEPT 217 protein, both in the immature form comprising the 320 amino acid residues of SEQ ID NO: 93 and in the mature form comprising the approximately 305 carboxyl terminal amino acid residues of SEQ ID NO: 93 (i.e., comprising SEQ ID NO: 95). Mature murine INTERCEPT 217 protein can be synthesized without the signal sequence polypeptide
15 at the amino terminus thereof, or it can be synthesized by generating immature INTERCEPT 217 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human and murine INTERCEPT 217 proteins, the invention includes fragments, derivatives, and variants of these INTERCEPT 217 proteins, as described herein. These proteins, fragments,
20 derivatives, and variants are collectively referred to herein as INTERCEPT 217 polypeptides of the invention or INTERCEPT 217 proteins of the invention.

The invention also includes nucleic acid molecules which encode an INTERCEPT 217 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 1, in
25 SEQ ID NO: 92 (i.e., the murine ORF), or in some portion of either of these, such as the portion which encodes mature human INTERCEPT 217 protein, immature human INTERCEPT 217 protein, or a domain of human INTERCEPT 217 protein. These nucleic acids are collectively referred to as INTERCEPT 217 nucleic acids of the invention.

INTERCEPT 217 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. Each of these molecules is included in the invention. As used herein, the term "family" is intended to mean two or more proteins or nucleic acid molecules

5 having a common or similar domain structure and having sufficient amino acid or nucleotide sequence identity as defined herein. Family members can be from either the same or different species. For example, a family can comprise two or more proteins of human origin, or can comprise one or more proteins of human origin and one or more of non-human origin (e.g., the human and murine INTERCEPT 217 proteins described

10 herein).

A common domain present in INTERCEPT 217 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such

15 as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a

20 lipid bilayer. Thus, in one embodiment, a INTERCEPT 217 protein contains a signal sequence corresponding to about amino acid residues 1 to 20 of SEQ ID NO: 3 (SEQ ID NO: 4). The signal sequence is cleaved during processing of the mature protein.

INTERCEPT 217 proteins can include an extracellular domain. As used herein, an "extracellular domain" refers to a portion of a protein which is localized to

25 the non-cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell. The human INTERCEPT 217 protein extracellular domain is located from about amino acid residue 21 to about amino acid residue 383 of SEQ ID NO: 3 (SEQ ID NO: 6). The murine INTERCEPT 217 protein extracellular

domain is located from about amino acid residue 17 to about amino acid residue 213 of SEQ ID NO: 93 (SEQ ID NO: 96).

In addition, INTERCEPT 217 includes a transmembrane domain. As used herein, a "transmembrane domain" refers to an amino acid sequence which is at least about 20 to 25 amino acid residues in length and which contains at least about 65-70% hydrophobic amino acid residues such as alanine, leucine, phenylalanine, protein, tyrosine, tryptophan, or valine. In a preferred embodiment, a transmembrane domain contains at least about 15 to 30 amino acid residues, preferably about 20-25 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues. Thus, in one embodiment, an INTERCEPT 217 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 384 to 403 of SEQ ID NO: 3 (SEQ ID NO: 7) or to about amino acid residues 214 to 233 of SEQ ID NO: 93 (SEQ ID NO: 97).

The present invention includes INTERCEPT 217 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain. As used herein, a "cytoplasmic domain" refers to a portion of a protein which is localized to the cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell. The human INTERCEPT 217 cytoplasmic domain is located from about amino acid residue 404 to amino acid residue 455 of SEQ ID NO: 3 (SEQ ID NO: 8). The murine INTERCEPT 217 cytoplasmic domain is located from about amino acid residue 234 to amino acid residue 320 of SEQ ID NO: 93 (SEQ ID NO: 98).

In one embodiment, the amino acid residues of human INTERCEPT 217 corresponding to SEQ ID NO: 8 are part of an extracellular domain, and the amino acid residues corresponding to SEQ ID NO: 6 are part of a cytoplasmic domain. In another embodiment, the amino acid residues of murine INTERCEPT 217 corresponding to SEQ ID NO: 98 are part of an extracellular domain, and the amino acid residues corresponding to SEQ ID NO: 96 are part of a cytoplasmic domain.

INTERCEPT 217 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Tables IA (for human INTERCEPT 217) and IB (for murine INTERCEPT 217), as predicted by computerized sequence analysis of INTERCEPT 217 proteins using amino acid sequence comparison software (comparing the amino acid sequence of INTERCEPT 217 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, or 10 or more of the post-translational modification sites listed in Tables IA and IB.

10

Table IA

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 3	Amino Acid Sequence
N-glycosylation site	107 to 110	NASG
	272 to 275	NCSS
	301 to 304	NTSV
	362 to 365	NQTH
	368 to 371	NVSV
Protein kinase C phosphorylation site	120 to 122	TLR
	192 to 194	SNR
	295 to 297	SLR
Casein kinase II phosphorylation site	199 to 202	SVPE
	440 to 443	TPPD
Tyrosine Kinase Phosphorylation Site	282 to 289	KRPEEHLY

Table IA (Continued)

N-myristoylation site	8 to 13	GTLLCM
	19 to 24	GTPDSE
	103 to 108	GVFVNA
	179 to 184	GLSATH
	323 to 328	GSRDGS
	348 to 353	GLFVCL
	390 to 395	GCAVGL
	449 to 454	GQASTS
Leucine zipper pattern	45 to 66	See Fig. 1
Leucine rich repeat amino terminal domain (LLRNT)	33 to 61	See Fig. 1
Leucine rich repeat (LRR) Domain	62 to 85	See Fig. 1
	86 to 109	See Fig. 1
	110 to 133	See Fig. 1
	134 to 157	See Fig. 1
	158 to 181	See Fig. 1
	184 to 207	See Fig. 1
Leucine rich repeat carboxyl terminal (LLRCT) domain	219 to 274	See Fig. 1

Table IB

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 93	Amino Acid Sequence
N-glycosylation site	102 to 105	NCSV
	131 to 134	NTSV
	192 to 195	NQTL
	198 to 201	NVSV
cAMP- and cGMP-dependent protein kinase site	280 to 283	RKAS
Protein kinase C phosphorylation site	125 to 127	SLR
	143 to 145	SPK
	279 to 281	SRK
Casein kinase II phosphorylation site	29 to 32	SIPE
	273 to 276	TPPD
N-myristoylation site	9 to 14	GLGLTR
	178 to 183	GVFVCL
	220 to 225	GCIVGL
	239 to 244	GCCHCC
Amidation Site	293 to 296	PGKK
Immunoglobulin Domain	14 to 37	See Fig. 1
Leucine rich repeat (LRR) Domain	49 to 104	See Fig. 1
Leucine rich repeat carboxyl terminal (LLRCT) domain	123 to 184	See Fig. 1

Among the domains that occur in INTERCEPT 217 proteins are LRR domains, LRRNT domains, LRRCT domains, and immunoglobulin domains. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains. In other embodiments, the protein has at least one of each of the LRR, LRRNT, and LRRCT domains described herein in Tables IA and IB. In other embodiments, the protein has at least one LRRNT domain, at least one LRRCT domain, and a plurality of (e.g., 2, 3, 4, or more) LRR domains.

One or more LRR domains are present in a variety of proteins involved in protein-protein interactions. Such proteins include, for example, proteins involved in signal transduction, cell-to-cell adhesion, cell-to-extracellular matrix adhesion, cell development, DNA repair, RNA processing, and cellular molecular recognition processes. Specialized LRR domains, designated LRR amino terminal (LRRNT) domains and LRR carboxyl terminal (LRRCT) domains often occur near the amino and carboxyl, respectively, ends of a series of LRR domains. Human INTERCEPT 217 protein has eight clustered LRR domains, including (from the amino terminus toward the carboxyl terminus of INTERCEPT 217) an LRRNT domain, six LRR domains, and an LRRCT domain.

The organization of LRR domains in human INTERCEPT 217 protein closely mirrors the organization of LRR domains in human platelet glycoprotein IB alpha chain precursor (GP-IB α), which also has eight clustered LRR domains from about amino acid residue 19 to about amino acid residue 281 thereof. The eight LRR domains of GP-IB α include an LRRNT domain at the end of the cluster nearest the amino terminus of GP-IB α and an LRRCT domain at the end of the cluster nearest the carboxyl terminus of GP-IB α . GP-IB α is a membrane-bound protein of human platelets that is involved in binding of von Willebrand's factor and in aggregation of platelets during thrombus formation. Thus, INTERCEPT 217 is involved in both normal and aberrant physiological activities involving blood clotting and thrombus

formation. Examples of disorders involving such activities include, for example, stroke, embolism (e.g., cerebral, renal, and pulmonary emboli), hemophilia, restenotic injury, prosthesis-associated thrombogenesis, atherosclerosis, and arteriosclerosis.

INTERCEPT 217 is involved in one or more physiological processes in which these other LRR domain-containing proteins are involved, namely binding of cells with extracellular proteins such as soluble extracellular proteins and cell surface proteins of other cells.

Human INTERCEPT 217 comprises a leucine zipper region at about amino acid residue 45 to about amino acid residue 66 (i.e., 45 LsctglgLqdvpaELpaa tadL 66). Leucine zipper regions are known to be involved in dimerization of proteins. Leucine zipper regions interact with one another, leading to formation of homo- or hetero-dimers between proteins, depending on their identity. The presence in INTERCEPT 217 of a leucine zipper region is a further indication that this protein is involved in protein-protein interactions.

The amino acid sequence of human INTERCEPT 217 protein includes multiple potential proline-rich Src homology 3 (SH3) domain binding sites in the cytoplasmic portion of the protein. SH3 domains mediate specific assembly of protein complexes, presumably by interacting with proline-rich protein domains (Morton and Campbell (1994) *Curr. Biol.* 4:615-617). SH3 domains also mediate interactions between proteins involved in transmembrane signal transduction. Coupling of proteins mediated by SH3 domains has been implicated in a variety of physiological systems, including those involving regulation of cell growth and proliferation, endocytosis, and activation of respiratory burst.

SH3 domains have been described in the art (e.g., Mayer et al. (1988) *Nature* 332:272-275; Musacchio et al. (1992) *FEBS Lett.* 307:55-61; Pawson and Schlessinger (1993) *Curr. Biol.* 3:434-442; Mayer and Baltimore (1993) *Trends Cell Biol.* 3:8-13; Pawson (1993) *Nature* 373:573-580), and occur in a variety of cytoplasmic proteins, including several (e.g., protein tyrosine kinases) involved in transmembrane signal transduction. Among the proteins in which one or more SH3

domains occur are protein tyrosine kinases such as those of the Src, Abl, Bkt, Csk and ZAP70 families, mammalian phosphatidylinositol-specific phospholipases C-gamma-1 and -2, mammalian phosphatidylinositol 3-kinase regulatory p85 subunit, mammalian Ras GTPase-activating protein (GAP), proteins which mediate binding of guanine

5 nucleotide exchange factors and growth factor receptors (e.g., vertebrate GRB2, *Caenorhabditis elegans* sem-5, and *Drosophila* DRK proteins), mammalian Vav oncoprotein, guanidine nucleotide releasing factors of the CDC 25 family (e.g., yeast CDC25, yeast SCD25, and fission yeast ste6 proteins), MAGUK proteins (e.g., mammalian tight junction protein ZO-1, vertebrate erythrocyte membrane protein p55,

10 *C. elegans* protein lin-2, rat protein CASK, and mammalian synaptic proteins SAP90/PSD-95, CHAPSYN-110/PSD-93, SAP97/DLG1, and SAP102), proteins which interact with vertebrate receptor protein tyrosine kinases (e.g., mammalian cytoplasmic protein Nck and oncoprotein Crk), chicken Src substrate p80/85 protein (cortactin), human hemopoietic lineage cell specific protein Hs1, mammalian

15 dihydropyridine-sensitive L-type calcium channel beta subunit, human myasthenic syndrome antigen B (MSYB), mammalian neutrophil cytosolic activators of NADPH oxidase (e.g., p47 {NCF-1}, p67 {NCF-2}, and *C. elegans* protein B0303.7), myosin heavy chains (MYO3) from amoebae, from slime molds, and from yeast, vertebrate and *Drosophila* spectrin and fodrin alpha chain proteins, human amphiphysin, yeast actin-

20 binding proteins ABP1 and SLA3, yeast protein BEM1, fission yeast protein scd2 (ral3), yeast BEM1-binding proteins BOI2 (BEB1) and BOB1 (BOI1), yeast fusion protein FUS1, yeast protein RSV167, yeast protein SSU81, yeast hypothetical proteins YAR014c, YFR024c, YHL002w, YHR016c, YJL020C, and YHR114w, hypothetical fission yeast protein SpAC12C2.05c, and *C. elegans* hypothetical protein F42H10.3.

25 Of these proteins, multiple SH3 domains occur in vertebrate GRB2 protein, *C. elegans* sem-5 protein, *Drosophila* DRK protein, oncoprotein Crk, mammalian neutrophil cytosolic activators of NADPH oxidase p47 and p67, yeast protein BEM1, fission yeast protein scd2, yeast hypothetical protein YHR114w, mammalian cytoplasmic protein Nck, *C. elegans* neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast

actin-binding protein SLA1. Of these proteins, three or more SH3 domains occur in mammalian cytoplasmic protein Nck, *C. elegans* neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast actin-binding protein SLA1. The presence of SH3 domain binding sites in INTERCEPT 217 indicates that INTERCEPT 217 interacts
5 with one or more of these and other SH3 domain-containing proteins and is thus involved in physiological processes in which one or more of these or other SH3 domain-containing proteins are involved.

Human INTERCEPT 217 exhibits amino acid sequence similarity to porcine ribonuclease inhibitor, a protein which binds with high affinity to pancreatic
10 ribonucleases and inhibits their activity. INTERCEPT 217 thus is involved with similar physiological processes in humans. An alignment of the amino acid sequences of human INTERCEPT 217 and porcine ribonuclease inhibitor protein (SwissProt Accession number P10775) is shown in Figure 1G. In this alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring
15 matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 20.5% identical. An alignment of human (SEQ ID NO: 3) and murine INTERCEPT 217 amino acid sequences (SEQ ID NO: 93; made using BESTFIT software, BLOSUM62 scoring matrix, gap opening penalty = 12, frameshift gap penalty = 5, gap extension penalty = 4). In this alignment, the human and murine amino acid sequences are 71.3%
20 identical in the overlapping region. Alignment of human and murine INTERCEPT 217 ORFs indicated 79.9% nucleotide sequence identity in the overlapping region.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human INTERCEPT 217 protein includes an approximately 20 (i.e., 18, 19, 20, 21, or 22) amino acid residue signal peptide
25 (amino acid residues 1 to 20 of SEQ ID NO: 3; SEQ ID NO: 4) preceding the mature INTERCEPT 217 protein (i.e., approximately amino acid residues 21 to 455 of SEQ ID NO: 3; SEQ ID NO: 5). In one embodiment, human INTERCEPT 217 protein includes an extracellular domain (amino acid residues 21 to 383 of SEQ ID NO: 3; SEQ ID NO: 6); a transmembrane domain (amino acid residues 384 to 403 of SEQ ID NO: 3; SEQ

ID NO: 7); and a cytoplasmic domain (amino acid residues 404 to 455 of SEQ ID NO: 3; SEQ ID NO: 8). In an alternative embodiment, human INTERCEPT 217 protein includes a cytoplasmic domain (amino acid residues 21 to 383 of SEQ ID NO: 3; SEQ ID NO: 6); a transmembrane domain (amino acid residues 384 to 403 of SEQ ID NO: 3; SEQ ID NO: 7); and an extracellular domain (amino acid residues 404 to 455 of SEQ ID NO: 3; SEQ ID NO: 8).

The SIGNALP program predicted that murine INTERCEPT 217 protein includes an approximately 15 (i.e., 13, 14, 15, 16, or 17) amino acid residue signal peptide (amino acid residues 1 to 16 of SEQ ID NO: 93; SEQ ID NO: 94) preceding the mature INTERCEPT 217 protein (i.e., approximately amino acid residues 16 to 320 of SEQ ID NO: 93; SEQ ID NO: 95). In one embodiment, murine INTERCEPT 217 protein includes an extracellular domain (amino acid residues 16 to 213 of SEQ ID NO: 93; SEQ ID NO: 96); a transmembrane domain (amino acid residues 214 to 233 of SEQ ID NO: 93; SEQ ID NO: 97); and a cytoplasmic domain (amino acid residues 234 to 320 of SEQ ID NO: 93; SEQ ID NO: 98). In an alternative embodiment, murine INTERCEPT 217 protein includes a cytoplasmic domain (amino acid residues 16 to 213 of SEQ ID NO: 93; SEQ ID NO: 96); a transmembrane domain (amino acid residues 214 to 233 of SEQ ID NO: 93; SEQ ID NO: 97); and an extracellular domain (amino acid residues 234 to 320 of SEQ ID NO: 93; SEQ ID NO: 98).

Figure 1F depicts a hydrophilicity plot of human INTERCEPT 217 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 20 of SEQ ID NO: 3 is the signal sequence of human INTERCEPT 217 (SEQ ID NO: 4). The hydrophobic region which corresponds to amino acid residues 384 to 403 of SEQ ID NO: 3 is the transmembrane domain of human INTERCEPT 217 (SEQ ID NO: 7). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human INTERCEPT 217 protein

from about amino acid residue 355 to about amino acid residue 380 appears to be located at or near the surface of the protein, while the region from about amino acid residue 190 to about amino acid residue 210 appears not to be located at or near the surface. Figure 1L depicts a hydrophilicity plot of murine INTERCEPT 217 protein.

5 The predicted molecular weight of human INTERCEPT 217 protein without modification and prior to cleavage of the signal sequence is about 49.8 kilodaltons. The predicted molecular weight of the mature human INTERCEPT 217 protein without modification and after cleavage of the signal sequence is about 47.4 kilodaltons.

10 The predicted molecular weight of murine INTERCEPT 217 protein, without modification and prior to cleavage of the signal sequence is about 35.5 kilodaltons. The predicted molecular weight of the mature human INTERCEPT 217 protein without modification and after cleavage of the signal sequence is about 33.8 kilodaltons.

15 Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding INTERCEPT 217 is expressed in two forms, one having an apparent approximate size of about 6 kilobases and another having an apparent approximate size of about 3 kilobases (i.e., corresponding to the size of the INTERCEPT 217 cDNA). These experiments indicated that INTERCEPT 217 is
20 expressed in the tissues listed in Table II, wherein "++" indicates strong expression, "+" indicates lower expression, and "+/-" indicates still lower expression.

Table II

Animal	Tissue	Relative Level of Expression
Human	pancreas	++
	skeletal muscle	+
	heart	+/-
	brain	+/-
	placenta	+/-
	lung	+/-
	liver	+/-
	kidney	+/-

An assay to detect possible secretion of INTERCEPT 217 protein was negative. This assay was performed as follows. About 8×10^5 293T cells were

5 incubated at 37°C in wells containing growth medium (Dulbecco's modified Eagle's medium {DMEM} supplemented with 10% fetal bovine serum) under a 5% (v/v) CO₂, 95% air atmosphere to about 60-70% confluence. The cells were then transfected using a standard transfection mixture comprising 2 micrograms of DNA and 10 microliters of LIPOFECTAMINE™ (GIBCO/BRL Catalog no. 18342-012) per well. The

10 transfection mixture was maintained for about 5 hours, and then replaced with fresh growth medium and maintained in an air atmosphere. Each well was gently rinsed twice with DMEM which did not contain methionine or cysteine (DMEM-MC; ICN Catalog no. 16-424-54). About 1 milliliter of DMEM-MC and about 50 microcuries of TRANS-³⁵S™ reagent (ICN Catalog no. 51006) were added to each well. The wells

15 were maintained under the 5% CO₂ atmosphere described above and incubated at 37°C for a selected period. Following incubation, 150 microliters of conditioned medium was removed, centrifuged to remove floating cells and debris, and combined with 150 microliters of 2× SDS sample buffer. The sample was boiled at 100°C for 5 minutes, and about 40 microliters of sample was loaded onto a NOVEX™ 4-20% (w/v) SDS-

containing polyacrylamide gel. Following electrophoresis, the gel was stained for protein and dried according to the NOVEX™ procedure. The dried gel was exposed to radiation-sensitive film in order to detect the position of secreted proteins.

5 Biological function of INTERCEPT 217 proteins, nucleic acids encoding them,
 and modulators of these molecules

INTERCEPT 217 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that INTERCEPT 217 is expressed in pancreas,
10 skeletal muscle, heart, brain, placenta, lung, liver, and kidney tissue, INTERCEPT 217 protein is involved in one or more biological processes which occur in these tissues. In particular, INTERCEPT 217 is involved in modulating binding of cells of one or more of these tissues with proteins of other cells or with secreted proteins which occur in the extracellular environment of one or more of these tissues. INTERCEPT 217 is
15 especially implicated in disorders of skeletal muscle (e.g., protection of skeletal muscle cells during ischemia and in bruised tissue), and more especially those involving the pancreas (e.g., diabetes, pancreatitis, and the like).

Structural similarity of human INTERCEPT 217 protein with human GP-IB α indicates that INTERCEPT 217 is involved in binding extracellular proteins
20 and other ligands. INTERCEPT 217 protein is involved in binding of proteins which induce release of pancreatic digestive enzymes (e.g., amylases, lipases, proteases, and nucleases) from pancreatic cells, and in disorders associated with insufficient or inappropriate release of such enzymes. INTERCEPT 217 protein is also involved in binding of secreted pancreatic digestive enzymes in pancreatic tissue, thereby
25 protecting pancreatic tissue from autodigestion. Thus, INTERCEPT 217 protein is involved in disorders such as diabetes, pancreatitis, and pancreatic carcinoma which involve acute and chronic autodigestive damage to pancreatic tissues. Homology of INTERCEPT 217 protein with porcine ribonuclease inhibitor protein is a further indication of this involvement.

The presence of LRR domains in human INTERCEPT 217 protein and detection of its expression in a variety of tissues indicate that the tissue protective functions of INTERCEPT 217 are not limited to pancreatic tissues, but are involved in protection of other tissues as well (e.g., skeletal muscle, heart, brain, placenta, lung,
5 liver, prostate, and kidney tissues). INTERCEPT 217 is therefore involved in protection of these (and likely other tissues) from the effects of inflammation, autoimmunity, infection, and acute and chronic traumas.

Presence in INTERCEPT 217 protein of multiple SH3 domain binding sites indicates that INTERCEPT 217 protein interacts with one or more SH3 domain-
10 containing proteins. Thus, INTERCEPT 217 protein mediates binding of proteins (i.e., binding of proteins to INTERCEPT 217 and to one another to form protein complexes) in cells in which it is expressed. INTERCEPT 217 is also involved in transduction of signals between the exterior environment of cells (i.e., including from other cells) and the interior of cells in which it is expressed. INTERCEPT 217 mediates regulation of
15 cell growth and proliferation, endocytosis, activation of respiratory burst, and other physiological processes triggered by transmission of a signal via a protein with which INTERCEPT 217 interacts.

INTERCEPT 217-related molecules can be used to modulate one or more of the activities in which INTERCEPT 217 is involved and can also be used to
20 prevent, diagnose, or treat one or more of the disorders in which INTERCEPT 217 is involved.

INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can, for example, be used to treat pancreatic disorders, such as pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital
25 cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). INTERCEPT 217 polypeptides, nucleic acids, and modulators

thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat disorders of skeletal muscle, such as muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and congenital muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), myopathies (e.g., inflammatory myopathies {e.g., dermatomyositis and polymyositis}, myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (e.g., phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, carnitine deficiency, carnitine palmityl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because INTERCEPT 217 exhibits expression in heart tissue, INTERCEPT 217 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders (e.g., ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, e.g., infection, toxins, or

drugs), inflammations (e.g., bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (e.g., hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive encephalopathy), and tumors (e.g., neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain. INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat pulmonary (i.e., lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion, pulmonary edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), and tumors (e.g., bronchogenic carcinoma, bronchioloalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat cardiovascular disorders, such as ischemic

heart disease (e.g., angina pectoris, myocardial infarction, and chronic ischemic heart disease), hypertensive heart disease, pulmonary heart disease, valvular heart disease (e.g., rheumatic fever and rheumatic heart disease, endocarditis, mitral valve prolapse, and aortic valve stenosis), congenital heart disease (e.g., valvular and vascular

5 obstructive lesions, atrial or ventricular septal defect, and patent ductus arteriosus), and myocardial disease (e.g., myocarditis, congestive cardiomyopathy, and hypertrophic cardiomyopathy). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

10 In yet another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Najjar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and
15 thrombosis), hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis), cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more
20 of these disorders.

In still another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis,
25 glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis),

tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy), acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

10 INTERCEPT 297

A cDNA clone (designated jthsa085g01) encoding at least a portion of human INTERCEPT 297 protein was isolated from a human fetal spleen cDNA library. The human INTERCEPT 297 protein is predicted by structural analysis to be a transmembrane protein.

15 The full length of the cDNA encoding human INTERCEPT 297 protein (Figure 2; SEQ ID NO: 9) is 1518 nucleotide residues. The ORF of this cDNA, nucleotide residues 40 to 1152 of SEQ ID NO: 9 (i.e., SEQ ID NO: 10), encodes a 371-amino acid transmembrane protein (Figure 2; SEQ ID NO: 11).

The invention thus includes purified human INTERCEPT 297 protein, both in the form of a 371 amino acid residue protein (SEQ ID NO: 11) in which the 'signal sequence' (i.e., the portion of INTERCEPT 297 protein corresponding to amino acid residues 1 to 18) described in this section is not cleaved and in the form of a 353 amino acid residue protein (SEQ ID NO: 13) in which the 'signal sequence' is cleaved. Human INTERCEPT 297 protein can exist with or without the signal sequence polypeptide at the amino terminus thereof. It is likely that the 'signal sequence' is not cleaved, but is instead a transmembrane domain of the protein.

In addition to full length human INTERCEPT 297 proteins, the invention includes fragments, derivatives, and variants of these INTERCEPT 297 proteins, as described herein. These proteins, fragments, derivatives, and variants are

collectively referred to herein as INTERCEPT 297 polypeptides of the invention or INTERCEPT 297 proteins of the invention.

The invention also includes nucleic acid molecules which encode an INTERCEPT 297 polypeptide of the invention. Such nucleic acids include, for
5 example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 9 or some portion thereof, such as the portion which encodes mature INTERCEPT 297 protein, immature INTERCEPT 297 protein, or a domain of INTERCEPT 297 protein. These nucleic acids are collectively referred to as INTERCEPT 297 nucleic acids of the invention.

10 INTERCEPT 297 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.

A common domain present in INTERCEPT 297 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10
15 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-
20 60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a INTERCEPT 297 protein contains a signal sequence corresponding to about amino acid residues 1 to 18 of SEQ ID NO: 11 (SEQ ID NO: 12). The signal sequence can be cleaved during processing of the mature
25 protein, but it is likely that amino acid residues 1 to 18 of SEQ ID NO: 11 represent a (non-cleaved) transmembrane region of the protein.

INTERCEPT 297 proteins can include one or more extracellular domains. In one embodiment of the human INTERCEPT 297 protein, extracellular domains are located from about amino acid residues 19 to 47, from about amino acid

residues 110 to 118, from about amino acid residues 162 to 175, from about amino acid residues 234 to 260, and from about amino acid residues 313 to 319 of SEQ ID NO: 11 (SEQ ID NOs: 14-18, respectively). In an alternative embodiment, extracellular domains are located from about amino acid residue 69 to 88, from about amino acid residue 138 to 144, from about amino acid residue 193 to 215, from about amino acid residue 284 to 292, and from about amino acid residue 337 to 371 of SEQ ID NO: 11 (SEQ ID NOs: 28-32, respectively).

In addition, INTERCEPT 297 includes one or more transmembrane domains. In one embodiment, a INTERCEPT 297 protein of the invention contains transmembrane domains corresponding to about amino acid residues 48 to 68, about amino acid residues 89 to 109, about amino acid residues 119 to 137, about amino acid residues 145 to 161, about amino acid residues 176 to 192, about amino acid residues 216 to 233, about amino acid residues 261 to 283, about amino acid residues 293 to 312, and about amino acid residues 320 to 336 of SEQ ID NO: 11 (SEQ ID NOs: 19-27, respectively). As indicated above, it is likely that the 'signal sequence' of INTERCEPT 297 is an additional (and non-cleaved) transmembrane region.

The present invention includes INTERCEPT 297 proteins having one or more cytoplasmic domains. In one embodiment of the human INTERCEPT 297 protein, cytoplasmic domains are located from about amino acid residue 69 to 88, from about amino acid residue 138 to 144, from about amino acid residue 193 to 215, from about amino acid residue 284 to 292, and from about amino acid residue 337 to 371 of SEQ ID NO: 11 (SEQ ID NOs: 28-32, respectively). In an alternative embodiment, cytoplasmic domains are located from about amino acid residues 19 to 47, from about amino acid residues 110 to 118, from about amino acid residues 162 to 175, from about amino acid residues 234 to 260, and from about amino acid residues 313 to 319 of SEQ ID NO: 11 (SEQ ID NOs: 14-18, respectively).

INTERCEPT 297 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table III, as predicted by computerized sequence analysis of

INTERCEPT 297 proteins using amino acid sequence comparison software (comparing the amino acid sequence of INTERCEPT 297 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15,
5 or 20 or more of the post-translational modification sites listed in Table III.

Table III

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 11	Amino Acid Sequence
N-glycosylation site	110 to 113	NMTS
	269 to 272	NISS
Protein kinase C phosphorylation site	24 to 26	SAK
	290 to 292	TTR
	297 to 299	SLR
Casein kinase II phosphorylation site	78 to 81	SSVD
	165 to 168	SKHD
	245 to 248	TLED
	354 to 357	SEQE
N-myristoylation site	18 to 23	GSINTL
	35 to 40	GCGGSK
	53 to 58	GMFLGE
	74 to 79	GQSDSS
	147 to 152	GILATI
	236 to 241	GSFSGN
	268 to 273	GNISSI
	280 to 285	GISVTK
Amidation site	136 to 139	LGRR
DUF6 domain	44 to 171	See Fig. 2

Among the domains that occur in INTERCEPT 297 protein is a DUF6 domain. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet
5 more preferably at least about 85%, and most preferably at least about 95% identical to this DUF6 domain.

The DUF6 domain is a transmembrane domain that is highly conserved among eukaryote, prokaryote, and archae kingdoms. This high degree of domain sequence conservation indicates that proteins of the class which includes INTERCEPT
10 297 are involved in fundamental membrane physiology of living cells. INTERCEPT 297 protein is therefore involved in disorders which are associated with aberrant membrane function including, for example, disorders involving abnormal membrane fluidity, disorders involving aberrant transmembrane transport, disorders involving abnormal membrane organization, disorders involving abnormal membrane synthesis,
15 disorders involving aberrant cell division, and the like.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human INTERCEPT 297 protein includes an approximately 18 (i.e., 16, 17, 18, 19, or 20) amino acid residue signal peptide (amino acid residues 1 to 18 of SEQ ID NO: 11; SEQ ID NO: 12) preceding the mature
20 INTERCEPT 297 protein (i.e., approximately amino acid residues 19 to 371 of SEQ ID NO: 11; SEQ ID NO: 13). In one embodiment, human INTERCEPT 297 protein includes about five extracellular domains (amino acid residues 19 to 47, 110 to 118, 162 to 175, 234 to 260, and 313 to 319 of SEQ ID NO: 11); about nine transmembrane domains (amino acid residues 48 to 68, 89 to 109, 119 to 137, 145 to 161, 176 to 192,
25 216 to 233, 261 to 283, 293 to 312, and 320 to 326 of SEQ ID NO: 11); and about five cytoplasmic domains (amino acid residues 69 to 88, 138 to 144, 193 to 215, 284 to 292, and 337 to 371 of SEQ ID NO: 11). In an alternative embodiment, human INTERCEPT 297 protein includes about five cytoplasmic domains (amino acid residues 19 to 47, 110 to 118, 162 to 175, 234 to 260, and 313 to 319 of SEQ ID NO:

11); about nine transmembrane domains (amino acid residues 48 to 68, 89 to 109, 119 to 137, 145 to 161, 176 to 192, 216 to 233, 261 to 283, 293 to 312, and 320 to 326 of SEQ ID NO: 11); and about five extracellular domains (amino acid residues 69 to 88, 138 to 144, 193 to 215, 284 to 292, and 337 to 371 of SEQ ID NO: 11).

5 Figure 2D depicts a hydrophilicity plot of human INTERCEPT 297 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. Hydrophobic region corresponding to the signal sequence and the transmembrane domains are observed in this figure. As described elsewhere herein, relatively hydrophilic regions
10 are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human INTERCEPT 297 protein from about amino acid residue 165 to about amino acid residue 175 appears to be located at or near the surface of the protein.

 The predicted molecular weight of human INTERCEPT 297 protein
15 without modification and prior to cleavage of the signal sequence is about 40.2 kilodaltons. The predicted molecular weight of the mature human INTERCEPT 297 protein without modification and after cleavage of the signal sequence is about 38.2 kilodaltons.

20 Biological function of INTERCEPT 297 proteins, nucleic acids encoding them, and modulators of these molecules

INTERCEPT 297 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that INTERCEPT 297 is expressed in human fetal
25 spleen, INTERCEPT 297 protein is involved in one or more biological processes which occur in fetal and spleen tissues. In particular, INTERCEPT 297 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, spleen and fetal cells of the animal in which it is normally expressed. Thus, INTERCEPT 297 has a role in disorders which affect these cells and

their growth, proliferation, survival, differentiation, and activity (e.g., hematologic and immune disorders). Expression of INTERCEPT 297 in an animal is also involved in modulating growth, proliferation, survival, differentiation, and activity of cells and viruses which are foreign to the host (i.e., bacterial, fungal, and viral infections).

5 INTERCEPT 297 bears amino acid sequence similarity to *Caenorhabditis elegans* protein C2G12.12, and therefore exhibits one or more activities analogous to that protein.

INTERCEPT 297 nucleic acids, proteins, and modulators thereof can be used to modulate the proliferation, differentiation, or function of cells of the spleen
10 (e.g., cells of the splenic connective tissue, splenic smooth muscle cells, and endothelial cells of the splenic blood vessels). INTERCEPT 297 nucleic acids, proteins, and modulators thereof can also be used to modulate the proliferation, differentiation, and function of cells that are processed within the spleen (e.g., regenerated or phagocytized within the spleen, erythrocytes, B and T lymphocytes, and
15 macrophages). Thus, INTERCEPT 297 nucleic acids, proteins, and modulators thereof can be used to treat disorders of the spleen (including disorders of the fetal spleen). Examples of splenic disorders include, splenic lymphoma, splenomegaly, and phagocytotic disorders (e.g., those in which macrophage engulfment of bacteria and viruses in the bloodstream is inhibited). INTERCEPT 297 polypeptides, nucleic acids,
20 and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Structural analysis of INTERCEPT 297 and the presence of a DUF6 domain therein indicate that INTERCEPT 297 is involved in disorders which affect membrane structure and function. INTERCEPT 297 can be used to affect development
25 and persistence of disorders involving inappropriate membrane structure and function, such as atherogenesis, arteriosclerosis, and various transmembrane transport disorders. Other exemplary disorders for which INTERCEPT 297 is useful include disorders involving generation and persistence of an immune response to bacterial, fungal, and viral infections. INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof

can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

The structure of INTERCEPT 297 is analogous to the structures of integral membrane proteins responsible for transmembrane transport of molecules such as sugars, ions, and the like. INTERCEPT 297 is thus involved in one or more transmembrane transport-related disorders such as cystic fibrosis, nerve conduction disorders (e.g., pain and loss or failure of sensation), muscle contraction disorders (e.g., cardiac insufficiency), metal ion uptake disorders (e.g., hemochromatosis), and the like. INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 276

A cDNA clone (designated jthsa006e01) encoding at least a portion of human TANGO 276 protein was isolated from a human fetal spleen cDNA library. The human TANGO 276 protein is predicted by structural analysis to be a secreted protein.

The full length of the cDNA encoding human TANGO 276 protein (Figure 3; SEQ ID NO: 33) is 2811 nucleotide residues. The ORF of this cDNA, nucleotide residues 58 to 786 of SEQ ID NO: 33 (i.e., SEQ ID NO: 34), encodes a 243-amino acid secreted protein (Figure 3; SEQ ID NO: 35).

The invention thus includes purified human TANGO 276 protein, both in the form of the immature 243 amino acid residue protein (SEQ ID NO: 35) and in the form of the mature, approximately 223 amino acid residue protein (SEQ ID NO: 37). Mature human TANGO 276 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 276 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human TANGO 276 proteins, the invention includes fragments, derivatives, and variants of these TANGO 276 proteins, as described herein. These proteins, fragments, derivatives, and variants

are collectively referred to herein as TANGO 276 polypeptides of the invention or TANGO 276 proteins of the invention.

The invention also includes nucleic acid molecules which encode a TANGO 276 polypeptide of the invention. Such nucleic acids include, for example, a
5 DNA molecule having the nucleotide sequence listed in SEQ ID NO: 33 or some portion thereof, such as the portion which encodes mature TANGO 276 protein, immature TANGO 276 protein, or a domain of TANGO 276 protein. These nucleic acids are collectively referred to as TANGO 276 nucleic acids of the invention.

TANGO 276 proteins and nucleic acid molecules encoding them
10 comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human TANGO 276 protein and the murine protein designated M-Sema-F (see Inagaki et al. (1995) *FEBS Lett.* 370:269-272), as shown in Figures 3F to 3H.

A common domain present in TANGO 276 proteins is a signal
15 sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino
20 acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 276 protein contains a signal sequence corresponding to about amino acid residues 1 to 20 of SEQ ID NO: 35 (SEQ
25 ID NO: 36). The signal sequence is cleaved during processing of the mature protein.

TANGO 276 proteins can exist in a secreted form, such as a mature protein having the amino acid sequence of amino acid residues 21 to 243 of SEQ ID NO: 35 (SEQ ID NO: 37).

TANGO 276 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IV, as predicted by computerized sequence analysis of TANGO 276 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 276 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, or all 8 of the post-translational modification sites listed in Table IV.

Table IV

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 35	Amino Acid Sequence
N-glycosylation site	106 to 109	NQTE
	121 to 124	NASH
cAMP- or cGMP-dependent protein kinase phosphorylation site	43 to 46	RRFS
Protein kinase C phosphorylation site	194 to 196	SLK
Casein kinase II phosphorylation site	34 to 37	SSGE
	57 to 60	TLTE
N-myristoylation site	16 to 21	GLGIGA
	68 to 73	GAREAL
Sema domain	53 to 141	See Fig. 3

10

A Sema domain occurs in human TANGO 276 protein. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to this Sema domain.

15

Sema domains occur in semaphorin proteins. Semaphorins are a large family of secreted and transmembrane proteins, some of which function as repellent signals during neural axon guidance. The Sema domain and a variety of semaphorin proteins in which it occurs are described, for example, in Winberg et al. (1998 *Cell* 5 95:903-916). Sema domains also occur in human hepatocyte growth factor receptor (SwissProt Accession no. P08581) and the similar neuronal and epithelial transmembrane receptor protein (SwissProt Accession no. P51805). The presence of a Sema domain in human TANGO 276 protein indicates that TANGO 276 is involved in one or more physiological processes in which the semaphorins are involved, has 10 biological activity in common with one or more of the semaphorins, or both.

Human TANGO 276 protein exhibits considerable sequence similarity to murine M-Sema F protein (GenBank Accession no. S79463), as indicated herein in Figures 3F to 3H. Figures 3F to 3H depict an alignment of the amino acid sequences of human TANGO 276 protein (SEQ ID NO: 35) and murine M-Sema F protein (SEQ ID 15 NO: 65). In this alignment (pam120.mat scoring matrix, gap opening penalty = 12, gap extension penalty = 4), the amino acid sequences of the proteins are 76.1% identical. Figures 3I through 3R depict an alignment of the nucleotide sequences of cDNA encoding human TANGO 276 protein (SEQ ID NOs: 33) and murine cDNA encoding M-Sema F protein (SEQ ID NO: 66). In this alignment (pam120.mat scoring matrix, 20 gap opening penalty = 12, gap extension penalty = 4), the nucleic acid sequences of the cDNAs are 79.7% identical. Thus, TANGO 276 is related to murine M-Sema F and shares functional similarities to that protein.

It is known that semaphorins are bi-functional, capable of functioning either as attractive axonal guidance proteins or as repellent axonal guidance proteins 25 (Wong et al. (1997) *Development* 124:3597-3607). Furthermore, semaphorins bind with neuronal cell surface proteins designated plexins, which are expressed on both neuronal cells and cells of the immune system (Comeau et al. (1998) *Immunity* 8:473-482; Jin and Strittmatter (1997) *J. Neurosci.* 17:6256-6263).

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 276 protein includes an approximately 20 (i.e., 18, 19, 20, 21, or 22) amino acid signal peptide (amino acid residues 1 to 20 of SEQ ID NO: 35; SEQ ID NO: 36) preceding the mature TANGO

5 276 protein (i.e., approximately amino acid residues 21 to 243 of SEQ ID NO: 34; SEQ ID NO: 37). Human TANGO 276 protein is a secreted protein.

Figure 3E depicts a hydrophilicity plot of human TANGO 276 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region
10 which corresponds to about amino acid residues 1 to 20 of SEQ ID NO: 35 is the signal sequence of human TANGO 276. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 276 protein from about amino
15 acid residue 90 to about amino acid residue 105 appears to be located at or near the surface of the protein, while the region from about amino acid residue 170 to about amino acid residue 180 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 276 protein without modification and prior to cleavage of the signal sequence is about 27.1 kilodaltons.

20 The predicted molecular weight of the mature human TANGO 276 protein without modification and after cleavage of the signal sequence is about 24.8 kilodaltons.

Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding TANGO 276 is expressed in the tissues listed in Table V, wherein "++" indicates a greater level of expression and "+" indicates a lower level of
25 expression.

Table V

Animal	Tissue	Relative Level of Expression
Human	heart	++
	placenta	++
	brain	+
	lung	+
	liver	+
	skin	+
	kidney	+
	pancreas	+

Biological function of TANGO 276 proteins, nucleic acids encoding them, and modulators of these molecules

- 5 TANGO 276 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 276 is expressed in human heart and placenta tissues, to a lesser extent in brain, lung, liver, skin, kidney, and pancreas tissues, and in fetal spleen tissue, TANGO 276 protein is involved in one or more
- 10 biological processes which occur in these tissues. In particular, TANGO 276 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, heart, placenta, spleen, brain, lung, liver, skin, kidney, and pancreas cells of the animal in which it is normally expressed. Thus, TANGO 276 has a role in disorders which affect these cells and their growth,
- 15 proliferation, survival, differentiation, and activity.

Because TANGO 276 exhibits expression in the heart, TANGO 276 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 276 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic

cardiomyopathy, and congenital heart disease. TANGO 276 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

5 In another example, TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

10 In another example, TANGO 276 polypeptides, nucleic acids, or modulators thereof, can be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, e.g., infection, toxins, or drugs), inflammations (e.g., bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (e.g., hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive
15 encephalopathy), and tumors (e.g., neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain. TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

20 TANGO 276 polypeptides, nucleic acids, and modulators thereof can be associated with pulmonary (i.e., lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion, pulmonary edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis,
25 hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), and tumors (e.g., bronchogenic carcinoma,

bronchioloalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). TANGO 276 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 276 polypeptides, nucleic acids, and
5 modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Najjar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced
10 hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Exemplary skin disorders with which TANGO 276 can be associated
15 include, by way of example, psoriasis, infections, wounds (and healing of wounds), inflammation, dermatitis, acne, benign and malignant dermatological tumors, and the like. TANGO 276 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to prognosticate, diagnose, treat, and inhibit one or more of these disorders.

20 In another example, TANGO 276 polypeptides, nucleic acids, or modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus
25 erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial

nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Pancreatic disorders in which TANGO 276 can be involved include pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). TANGO 276 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

The presence of the Sema domain in TANGO 276 indicates that this protein is involved in development of neuronal and epithelial tissues and also functions as a repellant protein which guides axonal development. TANGO 276 modulates nerve growth and regeneration and also modulates growth and regeneration of other epithelial tissues. TANGO 276 is thus involved in a variety of neuronal disorder including, but not limited to, one or more of seizure, epilepsy, (regeneration of) neuronal damage, pain (including, for example, migraine, headache, and other chronic pain), infections of the central nervous system, multiple sclerosis, sleep disorders, psychological disorders, nerve root disorders, and the like. Presence of a Sema domain in TANGO 276 further indicates that TANGO 276 has one or more physiological roles in common with other proteins (e.g., secreted and transmembrane semaphorins, collapsins, neuropilins, plexins, and the like) in which the Sema domain occurs. Thus, TANGO 276 is implicated in development, maintenance, and regeneration of neuronal connections and

networks, in modulating differentiation of cells of the immune system, in modulating cytokine production by cells of the immune system, in modulating reactivity of cells of the immune system toward cytokines, in modulating initiation and persistence of an inflammatory response, and in modulating proliferation of epithelial cells. Sema domain-containing proteins have also been implicated in development and progression of small cell lung cancer, in normal brain development, and immune system regulation. This indicates that TANGO 276 is also involved in one or more of these processes and in disorders relating to these processes (e.g., small cell lung cancer, brain development disorders, and immune and auto-immune disorders). TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

The observation that TANGO 276 shares identity with the murine semaphorin protein designated M-Sema F suggests that TANGO 276 has activity identical or analogous to the activity of this protein. These observations indicate that TANGO 276 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells. Thus, TANGO 276 protein is useful, for example, for modulating and guiding neural axon development and for modulating establishment and maintenance of neuronal networks.

TANGO 292

A cDNA clone (designated jthkf040b11) encoding at least a portion of human TANGO 292 protein was isolated from a human normal embryonic keratinocyte cDNA library. A corresponding gerbil cDNA clone (designated jtiba040e12) was also isolated, and encoded at least a portion of gerbil TANGO 292 protein. The human and TANGO 292 proteins are predicted by structural analysis to be transmembrane proteins.

The full length of the cDNA encoding human TANGO 292 protein (Figure 4; SEQ ID NO: 38) is 2498 nucleotide residues. The ORF of this cDNA, nucleotide residues 205 to 882 of SEQ ID NO: 38 (i.e., SEQ ID NO: 39), encodes a

226-amino acid residue transmembrane protein (Figure 4; SEQ ID NO: 40). The full length of the cDNA encoding gerbil TANGO 292 protein (Figure 4; SEQ ID NO: 81) is 2002 nucleotide residues. The ORF of this cDNA, nucleotide residues 89 to 763 of SEQ ID NO: 81 (i.e., SEQ ID NO: 82), encodes a 225-amino acid transmembrane protein (Figure 4; SEQ ID NO: 83).

The invention thus includes purified human TANGO 292 protein, both in the form of the immature 226 amino acid residue protein (SEQ ID NO: 40) and in the form of the mature, approximately 209 amino acid residue protein (SEQ ID NO: 42). The invention also includes purified gerbil TANGO 292 protein, both in the form of the immature 225-amino acid residue (SEQ ID NO: 83) protein and in the form of the mature, approximately 208-amino acid residue protein (SEQ ID NO: 85). Mature human or gerbil TANGO 292 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 292 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human and gerbil TANGO 292 proteins, the invention includes fragments, derivatives, and variants of these TANGO 292 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 292 polypeptides of the invention or TANGO 292 proteins of the invention.

The invention also includes nucleic acid molecules which encode a TANGO 292 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 38 or 81 or some portion thereof, such as the portion which encodes mature human or gerbil TANGO 292 protein, immature human or gerbil TANGO 292 protein, or a domain of human or gerbil TANGO 292 protein. These nucleic acids are collectively referred to as TANGO 292 nucleic acids of the invention.

TANGO 292 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional

features. This family includes, for example, human and gerbil TANGO 292 proteins and nucleic acid molecules described herein.

A common domain present in TANGO 292 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 292 protein contains a signal sequence corresponding to about amino acid residues 1 to 17 of SEQ ID NO: 40 (SEQ ID NO: 41) or to about amino acid residues 1 to 17 of SEQ ID NO: 83 (SEQ ID NO: 84). The signal sequence is cleaved during processing of the mature protein.

TANGO 292 proteins can include an extracellular domain. The human TANGO 292 protein extracellular domain is located from about amino acid residue 18 to about amino acid residue 113 of SEQ ID NO: 40 (SEQ ID NO: 43). The gerbil TANGO 292 protein extracellular domain includes at least about amino acid residues 18 to 112 of SEQ ID NO: 83 (SEQ ID NO: 86).

In addition, TANGO 292 include a transmembrane domain. In one embodiment, a human TANGO 292 protein contains a transmembrane domain corresponding to about amino acid residues 114 to 138 of SEQ ID NO: 40 (SEQ ID NO: 44). Gerbil TANGO 292 protein includes a transmembrane domain corresponding to about amino acid residues 113 to 137 of SEQ ID NO: 83 (SEQ ID NO: 87).

The present invention includes TANGO 292 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain. The human TANGO 292 cytoplasmic domain is located from about amino acid residue 139 to amino acid residue 226 of SEQ ID NO: 40 (SEQ ID

NO: 45). The gerbil TANGO 292 cytoplasmic domain is located from about amino acid residue 138 to amino acid residue 225 of SEQ ID NO: 83 (SEQ ID NO: 88).

TANGO 292 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VIa as predicted by computerized sequence analysis of human TANGO 292 protein, or in Table VIb as predicted by computerized sequence analysis of gerbil TANGO 292 protein, using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 292 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, or all of the post-translational modification sites listed in Table VIa or in Table VIb.

Table VIa

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 40	Amino Acid Sequence
cAMP- or cGMP-dependent protein kinase phosphorylation site	197 to 200	RKHS
Protein kinase C phosphorylation site	37 to 39	TSK
	97 to 99	SAK
	102 to 104	TTK
	196 to 198	TRK
Casein kinase II phosphorylation site	37 to 40	TSKE
	103 to 106	TKSD
	180 to 183	SVED
N-myristoylation site	116 to 121	GLLTGL
Vitamin K-dependent carboxylation domain	56 to 98	See Fig. 4

Table VIb

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 83	Amino Acid Sequence
cAMP- or cGMP-dependent protein kinase phosphorylation site	196 to 199	RKHS
Protein kinase C phosphorylation site	23 to 25	SLK
	37 to 39	SKK
	96 to 98	SVK
	101 to 103	TTR
	155 to 157	TRR
	195 to 197	TRK
Casein kinase II phosphorylation site	74 to 77	SYEE
	102 to 105	TRSD
	155 to 157	THEE
	195 to 197	SSSE
N-myristoylation site	33 to 38	GVFASK
	115 to 120	GLLTGL
Vitamin K-dependent carboxylation domain	55 to 92	See Fig. 4

Among the domains that occur in TANGO 292 protein is a vitamin K-
5 dependent carboxylation domain. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to this vitamin K-dependent carboxylation domain.

The vitamin K-dependent carboxylation domain has the following consensus sequence, wherein standard single-letter amino acid codes are used and 'X' refers to any amino acid residue.

-X₁₂-E-X₃-E-X-C-X₆-(D or E or N)-X-(L or I or V or M or F or Y)-X₉-(F or Y or W)-

- 5 Glutamic acid residues within this consensus region are potential vitamin K-dependent carboxylation sites. Human TANGO 292 has 9 glutamic acid residues in the vitamin K-dependent carboxylation domain located from about amino acid residue 56 to 98 of SEQ ID NO: 40, namely at amino acid residues 58, 66, 68, 71, 72, 77, 78, 81, and 86 of
- 10 SEQ ID NO: 40, and gerbil TANGO 292 has 10 glutamic acid residues in the vitamin K-dependent carboxylation domain located from about amino acid residue 55 to 92 of SEQ ID NO: 83, namely at amino acid residues 57, 65, 67, 70, 71, 76, 77, 80, 86, and 87 of SEQ ID NO: 83. In one embodiment, the protein of the invention is carboxylated at one or more of these glutamic acid residues. In some proteins in which a vitamin K-dependent carboxylation domain occurs, many of the glutamic acid residues which
- 15 occur from the amino terminus of the protein through the conserved aromatic residue at the carboxyl terminal end of the domain are carboxylated. Human TANGO 292 has 13 glutamic acid residues in the region from the amino terminus of (both the immature and mature forms of) the protein and the tryptophan residue at amino acid residue 93 of SEQ ID NO: 40, and also has another glutamic acid residue at position 95 of SEQ ID
- 20 NO: 40 which can also be carboxylated. In addition, human TANGO 292 protein has four sets of paired (i.e., adjacent) glutamic acid residues, at residues 33-34, 40-41, 71-72, and 77-78 and a pair of glutamic acid residues (66 and 68) which are separated by a single residue. Similarly, gerbil TANGO 292 has 12 glutamic acid residues in the region from the amino terminus of (both the immature and mature forms of) the protein
- 25 and the tryptophan residue at amino acid residue 92 of SEQ ID NO: 83, and also has another glutamic acid residue at position 94 of SEQ ID NO: 83 which can also be carboxylated. In addition, gerbil TANGO 292 protein has three sets of glutamic acid residues, at residues 70-71, 76-77, and 86-87, and a pair of glutamic acid residues (65 and 67) which are separated by a single residue. The protein of the invention includes

proteins which are carboxylated at one or more of the individual or paired glutamic acid residues.

TANGO 292, like other vitamin K-dependent carboxylation domain-containing proteins, is involved in binding, uptake, and response to metal cations such as calcium, to proteins, and to small molecules. Other proteins in which a vitamin K-dependent carboxylation domain occurs include, for example, osteocalcin (bone-Gla protein), matrix Gla protein, various plasma proteins such as prothrombin, coagulation factors VII, IX, and X, proline rich Gla domain-containing proteins PRGP1 and PRGP2, and proteins C, S, and Z. Thus, TANGO 292 is involved in physiological processes in which one or more of these other vitamin K-dependent carboxylation domain-containing proteins is involved.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 292 protein includes an approximately 17 (i.e., 15, 16, 17, 18, or 19) amino acid residue signal peptide (amino acid residues 1 to 17 of SEQ ID NO: 40; SEQ ID NO: 41) preceding the mature TANGO 292 protein (i.e., approximately amino acid residues 18 to 226 of SEQ ID NO: 40; SEQ ID NO: 42). In one embodiment, human TANGO 292 protein includes an extracellular domain (amino acid residues 18 to 113 of SEQ ID NO: 40; SEQ ID NO: 43); a transmembrane domain (amino acid residues 114 to 138 of SEQ ID NO: 40; SEQ ID NO: 44); and a cytoplasmic domain (amino acid residues 139 to 225 of SEQ ID NO: 40; SEQ ID NO: 45). In an alternative embodiment, human TANGO 292 protein includes a cytoplasmic domain (amino acid residues 18 to 113 of SEQ ID NO: 40; SEQ ID NO: 43); a transmembrane domain (amino acid residues 114 to 138 of SEQ ID NO: 40; SEQ ID NO: 44); and an extracellular domain (amino acid residues 139 to 225 of SEQ ID NO: 40; SEQ ID NO: 45).

The SignalP program predicted that gerbil TANGO 292 protein includes an approximately 17 (i.e., 15, 16, 17, 18, or 19) amino acid residue amino acid signal peptide (amino acid residues 1 to 17 of SEQ ID NO: 83; SEQ ID NO: 84) preceding the mature TANGO 292 protein (i.e., approximately amino acid residues 18 to 225 of

SEQ ID NO: 83; SEQ ID NO: 85). In one embodiment, gerbil TANGO 292 protein includes an extracellular domain (amino acid residues 18 to 112 of SEQ ID NO: 83; SEQ ID NO: 86); a transmembrane domain (amino acid residues 113 to 137 of SEQ ID NO: 83; SEQ ID NO: 87); and a cytoplasmic domain (amino acid residues 138 to 225 of SEQ ID NO: 83; SEQ ID NO: 88). In an alternative embodiment, gerbil TANGO 292 protein includes a cytoplasmic domain (amino acid residues 18 to 112 of SEQ ID NO: 83; SEQ ID NO: 86); a transmembrane domain (amino acid residues 113 to 137 of SEQ ID NO: 83; SEQ ID NO: 87); and an extracellular domain (amino acid residues 138 to 225 of SEQ ID NO: 83; SEQ ID NO: 88).

Figure 4E depicts a hydrophilicity plot of human TANGO 292 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 17 of SEQ ID NO: 40 is the signal sequence of human TANGO 292. The hydrophobic region which corresponds to amino acid residues 114 to 138 of SEQ ID NO: 40 is the transmembrane domain of human TANGO 292. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 292 protein from about amino acid residue 90 to about amino acid residue 110 appears to be located at or near the surface of the protein, while the region from about amino acid residue 190 to about amino acid residue 195 appears not to be located at or near the surface.

Figure 4M depicts a hydrophilicity plot of gerbil TANGO 292 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 17 of SEQ ID NO: 83 is the signal sequence of gerbil TANGO 292. The hydrophobic region which corresponds to amino acid residues 113 to 137 of SEQ ID NO: 40 is the transmembrane domain of gerbil TANGO 292. As described elsewhere herein, relatively hydrophilic regions are

generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of gerbil TANGO 292 protein from about amino acid residue 90 to about amino acid residue 110 appears to be located at or near the surface of the protein.

5 An alignment of the human (H) and gerbil (G) ORF sequences encoding TANGO 292 protein is shown in Figures 4I-4K. This alignment was made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), and indicates about 64.1% identity between these two cDNA sequences. An alignment of the amino acid
10 sequences of gerbil (G) and human (H) TANGO 292 proteins is shown in Figure 4L. In this alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are about 77.7% identical and about 80% similar.

 The predicted molecular weight of human TANGO 292 protein without
15 modification and prior to cleavage of the signal sequence is about 25.4 kilodaltons. The predicted molecular weight of the mature human TANGO 292 protein without modification and after cleavage of the signal sequence is about 23.6 kilodaltons. The predicted molecular weight of gerbil TANGO 292 protein without modification and prior to cleavage of the signal sequence is about 25.4 kilodaltons. The predicted
20 molecular weight of the mature human TANGO 292 protein without modification and after cleavage of the signal sequence is about 23.5 kilodaltons.

 Northern analysis experiments indicated that human mRNA
corresponding to the cDNA encoding TANGO 292 is expressed in the tissues listed in Table VIc, wherein "++" indicates strong expression, "+" indicates lower expression,
25 "+/-" indicates still lower expression, and "-" indicates that expression could not be detected in the corresponding tissue.

Table VIc

Animal	Tissue	Relative Level of Expression
Human	placenta	++
	liver	++
	kidney	++
	lung	+
	pancreas	+
	heart	+/-
	brain	-
	skeletal muscle	-

Biological function of TANGO 292 proteins, nucleic acids encoding them, and modulators of these molecules

- 5 TANGO 292 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 292 is expressed in human embryonic keratinocytes, and in placenta, liver, kidney, lung, pancreas, and heart tissues, TANGO 292 protein is involved in one or more biological processes which
- 10 occur in these tissues. In particular, TANGO 292 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, keratinocytes and cells with which keratinocytes interact in the animal in which TANGO 292 is normally expressed. TANGO 292 is also involved in modulating growth, proliferation, survival, differentiation, and activity of placenta, liver, kidney,
- 15 lung, pancreas, and heart cells. Thus, TANGO 292 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 292 polypeptides, nucleic acids, and

modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

5 In another example, TANGO 292 polypeptides, nucleic acids, and modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbiliruinemias (e.g., Gilbert's syndrome, Crigler-Naijar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis
10 (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

15 In another example, TANGO 292 polypeptides, nucleic acids, or modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus
20 erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal diseasemedullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial
25 nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). TANGO 292 polypeptides, nucleic acids, and

modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

5 TANGO 292 polypeptides, nucleic acids, and modulators thereof can be associated with pulmonary (i.e., lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion, pulmonary edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), and tumors (e.g., bronchogenic carcinoma, bronchioloalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). TANGO 292 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Pancreatic disorders in which TANGO 292 can be involved include pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). TANGO 292 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

25 Because TANGO 292 exhibits expression in the heart, TANGO 292 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 292 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 292 polypeptides, nucleic

acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

5 Presence in TANGO 292 of a vitamin K-dependent carboxylation (Gla) domain indicates that TANGO 292 is involved in physiological functions identical or analogous to the functions performed by other proteins having such domains. For example, like other Gla domain-containing proteins, TANGO 292 modulates binding and uptake of calcium and other metal ions by cells which express it and the response of those cells to the presence and uptake of such ions. Human matrix Gla protein, for example, is involved in Keutel syndrome, an autosomal recessive disorder

10 characterized by abnormal cartilage calcification, peripheral pulmonary stenosis, and midfacial hypoplasia (Munroe et al. (1999) *Nat. Genet.* 21:142-144). Other proteins containing a Gla domain include, for example, two human proline-rich Gla proteins designated PRGP1 and PRGP2, human G domain-containing protein Gas6, and several human blood coagulation factors (Kulman et al. (1997) *Proc. Natl. Acad. Sci. USA*

15 94:9058-9062; Mark et al., (1996) *J. Biol. Chem.* 271:9785-9786; Cancela et al. (1990) *J. Biol. Chem.* 265:15040-15048). These proteins are involved in binding of mineral ions such as calcium, phosphate, and hydroxyapatite, binding of proteins, binding of vitamins and small molecules, and mediation of blood coagulation. Thus, TANGO 292 is involved in numerous physiological processes which are influenced by levels of

20 calcium and other metal ions in body fluids or by the presence of proteins, vitamins, or small molecules. Such processes include, for example, bone uptake, maintenance, and deposition, formation, maintenance, and repair of cartilage, formation and maintenance of extracellular matrices, movement of cells through extracellular matrices, coagulation and dissolution of blood components (e.g., blood cells and proteins), and deposition of

25 materials (e.g., lipids, cells, calcium, and the like) in arterial walls. TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 292 is involved in disorders which affect the tissues in which it is normally expressed and upon which it normally acts. Thus, TANGO 292 is involved

in disorders which involve aberrant binding or aberrant failure to bind of keratinocytes or similar cells with a tissue affected by the disorder. Such disorders include, by way of example and not limitation, osteoporosis, (repair of) traumatic bone injuries, rickets, osteomalacia, Paget's disease, and other bone disorders, osteoarthritis, rheumatoid
5 arthritis, ankylosing spondylitis, Keutel syndrome, and other disorders of the joints and cartilage, iron deficiency anemia, hemophilia, inappropriate blood coagulation, stroke, arteriosclerosis, atherosclerosis, aneurysm, and other disorders related to blood and blood vessels, metastasis and other disorders related to inappropriate movement of cells through extracellular matrices, and the like. TANGO 292 polypeptides, nucleic acids,
10 and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 325

A cDNA clone (designated jthdc071a12) encoding at least a portion of
15 human TANGO 325 protein was isolated from a human aortic endothelial cell cDNA library. The human TANGO 325 protein is predicted by structural analysis to be a transmembrane protein.

The full length of the cDNA encoding human TANGO 325 protein (Figure 5; SEQ ID NO: 46) is 2169 nucleotide residues. The ORF of this cDNA,
20 nucleotide residues 135 to 2000 of SEQ ID NO: 46 (i.e., SEQ ID NO: 47), encodes a 622-amino acid transmembrane protein (Figure 5; SEQ ID NO: 48).

The invention thus includes purified human TANGO 325 protein, both in the form of the immature 622 amino acid residue protein (SEQ ID NO: 48) and in the form of the mature, approximately 591 amino acid residue protein (SEQ ID NO:
25 50). Mature human TANGO 325 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 325 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human TANGO 325 proteins, the invention includes fragments, derivatives, and variants of these TANGO

325 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 325 polypeptides of the invention or TANGO 325 proteins of the invention.

The invention also includes nucleic acid molecules which encode a
5 TANGO 325 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 46 or some portion thereof, such as the portion which encodes mature TANGO 325 protein, immature TANGO 325 protein, or a domain of TANGO 325 protein. These nucleic acids are collectively referred to as TANGO 325 nucleic acids of the invention.

10 TANGO 325 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.

A common domain present in TANGO 325 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10
15 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-
20 60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 325 protein contains a signal sequence corresponding to about amino acid residues 1 to 31 of SEQ ID NO: 48 (SEQ ID NO: 49). The signal sequence is cleaved during processing of the mature protein.

25 TANGO 325 proteins can include an extracellular domain. The human TANGO 325 protein extracellular domain is located from about amino acid residue 32 to about amino acid residue 529 of SEQ ID NO: 48 (SEQ ID NO: 51).

In addition, TANGO 325 include a transmembrane domain. In one embodiment, a TANGO 325 protein of the invention contains a transmembrane domain

corresponding to about amino acid residues 530 to 547 of SEQ ID NO: 48 (SEQ ID NO: 52).

The present invention includes TANGO 325 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal
5 cytoplasmic domain. The human TANGO 325 cytoplasmic domain is located from about amino acid residue 548 to amino acid residue 622 of SEQ ID NO: 48 (SEQ ID NO: 53).

TANGO 325 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those
10 described herein in Table VII, as predicted by computerized sequence analysis of TANGO 325 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 325 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In
certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or
15 more of the post-translational modification sites listed in Table VII.

Table VII

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 48	Amino Acid Sequence
N-glycosylation site	71 to 74	NISY
	76 to 79	NESE
	215 to 218	NLTK
	266 to 269	NVTR
	317 to 320	NDTF
	331 to 334	NLSF
	336 to 339	NLTA
	400 to 403	NITN
	410 to 413	NVSR
	451 to 454	NITF
	579 to 582	NVTA
cAMP- or cGMP-dependent protein kinase phosphorylation site	231 to 234	RRLS
Protein kinase C phosphorylation site	40 to 42	TGR
	229 to 231	SLR
	326 to 328	SLK
	390 to 392	SMR
	510 to 512	SGK
	575 to 577	SAR
Casein kinase II phosphorylation site	284 to 287	SHND
	442 to 445	SPLE
	447 to 450	TETE
	453 to 456	TFWE

Table VII (Continued)

N-myristoylation site	3 to 8	GLQFSL
	69 to 74	GNNISY
	126 to 131	GIFKGL
	174 to 179	GTFVGM
ATP/GTP-binding site motif A (P-loop)	506 to 513	AASMSGKT
Leucine rich repeat amino terminal domain (LLRNT)	32 to 60	See Fig. 5
Leucine rich repeat (LRR) domain	61 to 84	See Fig. 5
	85 to 108	See Fig. 5
	109 to 132	See Fig. 5
	133 to 156	See Fig. 5
	157 to 180	See Fig. 5
	181 to 204	See Fig. 5
	205 to 228	See Fig. 5
	229 to 252	See Fig. 5
	253 to 276	See Fig. 5
	277 to 300	See Fig. 5
	301 to 324	See Fig. 5
	326 to 349	See Fig. 5
Leucine rich repeat carboxyl terminal domain (LRRCT)	359 to 405	See Fig. 5

Among the domains that occur in TANGO 325 protein are leucine rich repeat (LRR) domains, including amino terminal and carboxyl terminal LRR domains, and a P-loop domain. In one embodiment, the protein of the invention has at least one

domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains. In another embodiment, the protein has at least one amino terminal LRR domain, at least one carboxyl terminal LRR domain, and a plurality of LRR domains interposed therebetween. In yet another embodiment, the protein has at least one P-loop domain, and a plurality (e.g., 2, 3, 4, or more) of the LRR domains described herein in Table VII.

One or more LRR domains is present in a variety of proteins involved in protein-protein interactions. Such proteins include, for example, proteins involved in signal transduction, cell-to-cell adhesion, cell-to-extracellular matrix adhesion, cell development, DNA repair, RNA processing, and cellular molecular recognition processes. Specialized LRR domains, designated LRR amino terminal (LRRNT) domains and LRR carboxyl terminal (LRRCT) domains often occur near the amino and carboxyl, respectively, ends of a series of LRR domains. TANGO 325 protein has fourteen clustered LRR domains, including (from the amino terminus toward the carboxyl terminus of TANGO 325) an LRRNT domain, twelve LRR domains, and an LRRCT domain. TANGO 325 is thus involved in one or more physiological processes in which these other LRR domain-containing proteins are involved, namely binding of cells with extracellular proteins such as soluble extracellular proteins and cell surface proteins of other cells.

The fact that TANGO 325 has an ATP/GTP-binding domain (i.e., a P-loop domain) within the extracellular domain of the protein indicates that this protein is involved in transmembrane signaling events. Considered in combination with the protein-binding LRR domains present in the extracellular domain of the, the presence of the ATP/GTP-binding domain indicates that TANGO 325 protein is capable of sensing extracellular proteins, including ATP-binding proteins and GTP-binding proteins, and extracellular nucleotides (e.g., ATP, ADP, and AMP). Thus, TANGO 325 protein is involved in translating information (e.g., environmental conditions or signaling molecules provided to the environment by other cells) from the extracellular

environment of the cell in which it is expressed to one or more intracellular biochemical systems.

TANGO 325 exhibits amino acid sequence and nucleic acid sequence homology with human Slit-1 protein. An alignment of the amino acid sequences of TANGO 325 and human Slit-1 protein is shown in Figures 5G to 5L. In this alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 35.4% identical (i.e., 35.4% of the residues of TANGO 325 correspond to identical residues in Slit-1). An alignment of the nucleotide sequences of the ORFs encoding TANGO 325 and human Slit-1 protein is shown in Figures 5Mi through 5Mxviii. The two ORFs are 65.7% identical, as assessed using the same software and parameters.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 325 protein includes an approximately 31 (i.e., 29, 30, 31, 32, or 33) amino acid residue signal peptide (amino acid residues 1 to 31 of SEQ ID NO: 48; SEQ ID NO: 49) preceding the mature TANGO 325 protein (i.e., approximately amino acid residues 42 to 622 of SEQ ID NO: 48; SEQ ID NO: 50). In one embodiment, human TANGO 325 protein includes an extracellular domain (amino acid residues 32 to 529 of SEQ ID NO: 48; SEQ ID NO: 51); a transmembrane domain (amino acid residues 530 to 547 of SEQ ID NO: 48; SEQ ID NO: 52); and a cytoplasmic domain (amino acid residues 548 to 622 of SEQ ID NO: 48; SEQ ID NO: 53). In an alternative embodiment, human TANGO 325 protein includes a cytoplasmic domain (amino acid residues 32 to 529 of SEQ ID NO: 48; SEQ ID NO: 51); a transmembrane domain (amino acid residues 530 to 547 of SEQ ID NO: 48; SEQ ID NO: 52); and an extracellular domain (amino acid residues 548 to 622 of SEQ ID NO: 48; SEQ ID NO: 53).

Figure 5F depicts a hydrophilicity plot of human TANGO 325 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region

which corresponds to amino acid residues 1 to 31 of SEQ ID NO: 48 is the signal sequence of human TANGO 325 (SEQ ID NO: 49). The hydrophobic region which corresponds to amino acid residues 530 to 547 of SEQ ID NO: 48 is the transmembrane domain of human TANGO 325 (SEQ ID NO: 52). As described elsewhere herein,

5 relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 325 protein from about amino acid residue 550 to about amino acid residue 565 appears to be located at or near the surface of the protein, while the region from about amino acid residue 168

10 to about amino acid residue 185 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 325 protein without modification and prior to cleavage of the signal sequence is about 70.3 kilodaltons. The predicted molecular weight of the mature human TANGO 325 protein without modification and after cleavage of the signal sequence is about 66.8 kilodaltons.

15 Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding TANGO 325 is expressed in the tissues listed in Table VIIA, wherein "+" indicates expression and "-" indicates that expression could not be detected in the corresponding tissue.

Table VIIA

Animal	Tissue	Relative Level of Expression
Human	placenta	+
	liver	+
	kidney	+
	pancreas	+
	heart	+
	brain	-
	skeletal muscle	-
	lung	-

Biological function of TANGO 325 proteins, nucleic acids encoding them, and modulators of these molecules

TANGO 325 proteins are involved in disorders which affect both tissues
5 in which they are normally expressed and tissues in which they are normally not
expressed. Based on the observation that TANGO 325 is expressed in human aortic
endothelial tissue and in placenta, liver, kidney, pancreas, and heart tissues, TANGO
325 protein is involved in one or more biological processes which occur in these
tissues. In particular, TANGO 325 is involved in modulating growth, proliferation,
10 survival, differentiation, and activity of endothelial cells including, but not limited to,
vascular and cardiac (including valvular) endothelial cells of the animal in which it is
normally expressed. TANGO 325 also modulates growth, proliferation, survival,
differentiation, and activity of placenta, liver, kidney, and pancreas cells. Thus,
TANGO 325 has a role in disorders which affect these cells and their growth,
15 proliferation, survival, differentiation, and activity. TANGO 325 polypeptides, nucleic
acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or
alleviate one or more of these disorders.

In one example, TANGO 325 polypeptides, nucleic acids, and
modulators thereof can be used to treat placental disorders, such as toxemia of
20 pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion.
TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to
prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 325 polypeptides, nucleic acids, and
modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice,
25 hepatic failure, hereditary hyperbiliruinemias (e.g., Gilbert's syndrome, Crigler-Naijar
syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders
(e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis
(e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced
hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis),

and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 325 polypeptides, nucleic acids, or
5 modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle
10 cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly
15 progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate
20 one or more of these disorders.

Pancreatic disorders in which TANGO 325 can be involved include pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g.,
25 insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because TANGO 325 exhibits expression in the heart, TANGO 325 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 325 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

It is known that serum nucleotide levels (e.g., ATP) affect cardiac contractility and vasomotor tone. Presence in TANGO 325 of an ATP/GTP binding domain in the extracellular portion thereof implicates this transmembrane protein in sensing of serum nucleotide levels and transmission of the sensed level by mechanisms not yet fully understood to myocytes underlying the epithelium. Thus, TANGO 325 is involved in disorders such as cardiovascular insufficiency, hypertension, hypotension, shock, and the like.

Leukocytes are known to bind with vascular endothelial surfaces in a reversible manner prior to penetrating the vascular endothelium in route to an underlying tissue. Although a few proteins have previously been implicated in the leukocyte-endothelium binding process, the identities of all of the proteins involved remain unknown. The presence of numerous LRR domains on the exterior portion of TANGO 325 protein implicates this protein in reversible binding of leukocytes to vascular endothelium. Thus, TANGO 325 is involved in physiological processes and disorders which involve leukocyte-endothelium binding. Such processes and disorders include, by way of example, cellular aspects of immune responses, autoimmune responses and disorders, and migration of leukocytes to lymph nodes.

The aortic endothelium, as well as other vascular endothelia, are known to be involved in detection of signals (e.g., metabolites, proteins, and the like) in the blood stream. Mammalian Slit-1 protein is known to be involved in the human endocrine system (Itoh et al. (1998) *Brain Res. Mol. Brain Res.* 62:175-186). Amino acid and nucleic acid sequence similarity of TANGO 325 with human Slit-1 protein, as

described herein, indicates that TANGO 325 is involved in sensing physiological signals by the endocrine system. Thus, TANGO 325 is involved in one or more human endocrine disorders such as pituitary disorders (e.g., diabetes insipidus), thyroid disorders (e.g., hyperthyroidism, hypothyroidism, diabetes, goiter, and growth and developmental disorders), adrenal disorders (e.g., Addison's disease, Cushing's syndrome, hyperaldosteronism, and pheochromocytoma), and the like.

Human Slit-1 protein is also known to be involved in guidance of neuronal growth. The sequence similarity of TANGO 325 with Slit-1, as described herein, implicates TANGO 325 in growth, development, maintenance, and regeneration of neurons. TANGO 325 can thus be used to prevent, diagnose, and treat a variety of neurological disorders.

TANGO 331

A cDNA clone (designated jthvb042g08) encoding at least a portion of human TANGO 331 protein was isolated from a human mammary epithelium cDNA library. A corresponding cDNA clone (designated jchrc045a03) was isolated from a human heart library. The human TANGO 331 protein is predicted by structural analysis to be a secreted protein.

The full length of the cDNA encoding human TANGO 331 protein (Figure 6; SEQ ID NO: 54) is 1432 nucleotide residues. The ORF of this cDNA, nucleotide residues 114 to 1172 of SEQ ID NO: 54 (i.e., SEQ ID NO: 55), encodes a 353-amino acid secreted protein (Figure 6; SEQ ID NO: 56).

The invention thus includes purified human TANGO 331 protein, both in the form of the immature 353 amino acid residue protein (SEQ ID NO: 56) and in the form of the mature, approximately 329 amino acid residue protein (SEQ ID NO: 58). Mature human TANGO 331 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 331 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human TANGO 331 proteins, the invention includes fragments, derivatives, and variants of these TANGO 331 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 331 polypeptides of the invention or
5 TANGO 331 proteins of the invention.

The invention also includes nucleic acid molecules which encode a TANGO 331 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 54 or some portion thereof, such as the portion which encodes mature TANGO 331 protein,
10 immature TANGO 331 protein, or a domain of TANGO 331 protein. These nucleic acids are collectively referred to as TANGO 331 nucleic acids of the invention.

TANGO 331 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human
15 TANGO 331 protein and the Chinese hamster (*Cricetulus griseus*) protein designated HT and having GenBank Accession number U48852, as shown in Figure 6E, and the conservation of nucleotide sequence between the ORFs encoding human TANGO 331 protein and Chinese hamster protein HT, as shown in Figures 6F through 6J.

A common domain present in TANGO 331 proteins is a signal
20 sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino
25 acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 331 protein contains a signal

sequence corresponding to about amino acid residues 1 to 24 of SEQ ID NO: 56 (SEQ ID NO: 57). The signal sequence is cleaved during processing of the mature protein.

TANGO 331 proteins can include an extracellular domain. The human TANGO 331 protein is a secreted protein, and thus includes an 'extracellular domain' consisting of the entire mature protein (i.e., approximately residues 25 to 353 of SEQ ID NO: 56; SEQ ID NO: 58).

TANGO 331 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VIII, as predicted by computerized sequence analysis of TANGO 331 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 331 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table VIII.

Table VIII

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 56	Amino Acid Sequence
N-glycosylation site	190 to 193	NETH
	251 to 254	NGSY
cAMP- or cGMP-dependent protein kinase phosphorylation site	26 to 29	KKPT
Protein kinase C phosphorylation site	48 to 50	TAK
	123 to 125	TLK
	144 to 146	SQR
	165 to 167	SCR
	187 to 189	SLR
	202 to 204	SCK
	210 to 212	TNR
Casein kinase II phosphorylation site	58 to 61	Tawe
	66 to 69	SKYE
	86 to 89	SDFE
	197 to 200	TACD
	210 to 213	TNRD
	255 to 258	TCEE
	295 to 298	SLAE
	339 to 342	TEGE
	349 to 352	SRED

Table VIII (Continued)

Tyrosine kinase phosphorylation site	303 to 309	RKNENCY
N-myristoylation site	44 to 49	GMVDTA
	54 to 59	GGGNTA
	81 to 86	GLCESS
	150 to 155	GNGHCS
	158 to 163	GSRQGD
	164 to 169	GSCRCH
	252 to 257	GSYTCE
	313 to 318	GSYVCV
Aspartic acid and asparagine hydroxylation site	308 to 319	See Fig. 6
EGF-like domain cystein pattern signature	166 to 177	See Fig. 6
EGF domain	140 to 177	See Fig. 6
	234 to 263	See Fig. 6
	301 to 330	See Fig. 6
Laminin-like EGF domain	153 to 199	See Fig. 6
TNFR/NGFR cysteine-rich region domain	180 to 214	See Fig. 6
Vertebrate metallothionein-like domain	229 to 298	See Fig. 6
Leucine Zipper domain	94 to 115	See Fig. 6

Among the domains that occur in TANGO 331 protein are EGF domains, including a laminin-like EGF domain, a TNFR/NGFR cysteine-rich domain, a metallothionein-like domain, and a leucine zipper domain.

- EGF-like domains are about 30 to 40 amino acid residues in length and
- 5 comprise several conserved cysteine residues in one of several patterns. EGF-like domains occur in a large number of proteins including, for example, human epidermal growth factor (EGF), murine adipocyte differentiation inhibitor, human agrin, human growth factor amphiregulin, human growth factor betacellulin, sea urchin blastula tissue patterning proteins BP10 and Span, cattle tick glycoprotein BM86, human bone
 - 10 morphogenic protein 1, sea urchin suBMP, *Drosophila* tolloid protein, *Caenorhabditis elegans* developmental proteins lin-12 and glp-1, *C. elegans* tissue patterning protein APX-1, human calcium-dependent serine proteinase, human cartilage matrix protein, human cartilage oligomeric matrix protein, human cell surface antigen 114/A10, rat cell surface glycoprotein complex transmembrane subunit ASGP-2, human coagulation
 - 15 associated proteins C, Z, and S, human coagulation factors VII, IX, X, and XII, human complement components C1r, C1s, C6, C7, C8 α , C8 β , and C9, human complement-activating components of Ra-reactive factor, *Drosophila* epithelial development protein Crumbs, sea urchin exogastrula-inducing peptides A, C, D, and X, *Drosophila* cadherin-related tumor suppressor protein Fat, human fetal antigen 1 (a neuroendocrine
 - 20 differentiation protein derived from the delta-like protein), human fibrillins 1 and 2, sea urchin fibropellins IA, IB, IC, II, and III, human extracellular matrix proteins fibulin-1 and -2, *Drosophila* cell determination/axon guidance protein Argos, various poxvirus growth factor-related proteins, *Drosophila* developmental protein Gurken, human heparin-binding EGF-like growth factor, human transforming growth factor- α , human
 - 25 growth factors Lin-3 and Spitz, human hepatocyte growth factor activator, human LDL and VLDL receptors, human LDL receptor-related protein, human leukocyte antigen CD97, human cell surface glycoprotein EMR1, human cell surface glycoprotein F4/80, Japanese horseshoe crab limulus clotting factor C, mammalian membrane-bound endopeptidase Meprin A α subunit, murine milk fat globule-EGF factor 8, human glial

growth factors neuregulin GGF-I and GGF-II, mammalian neurexins, human
 neurogenic proteins Notch, Xotch, Tan-1, and Delta, *C. elegans* differentiation protein
 Lag-2, *Drosophila* differentiation proteins Serrate and Slit, chordate basement
 membrane protein Nidogen, *Plasmodium* ookinete 24, 25, and 28 kilodalton surface
 5 proteins, human pancreatic secretory granule membrane glycoprotein GP2, human non-
 specific cell lysis protein Perforin, human proteoglycans aggrecan, versican, perlecan,
 brevican, and chondroitin sulfate, human endoplasmic reticulum prostaglandin G/H
 synthases 1 and 2, human extracellular protein S1-5, human autocrine growth factor
 Schwannoma-derived growth factor, human E-, P-, and L-selectins, *Arabidopsis*
 10 *thaliana* chlorophyll complex assembly protein serine/threonine-protein kinase
 homolog, guinea pig sperm-egg fusion proteins PH-30 α and β , murine stromal cell
 derived protein-1, human teratocarcinoma-derived growth factor, mammalian
 extracellular protein tenascin, chicken extracellular protein TEN-A, human tenascin-X,
Drosophila tenascin-like proteins TEN-A and TEN-M, human protein C activator
 15 thrombomodulin, human adhesive glycoproteins thrombospondins 1, 2, 3, and 4,
 human thyroid peroxidases 1 and 2, human transforming growth factor β -1 binding
 protein, human tyrosine-protein kinase receptors Tek and Tie, human urokinase-type
 plasminogen activator, human tissue plasminogen activator, human uromodulin, human
 vitamin K-dependent anticoagulant proteins C and S (and the related human single-
 20 chain plasma glycoprotein Z), the sea urchin 63 kilodalton sperm flagellar membrane
 protein, chicken Nel protein, and the hypothetical *C. Elegans* protein T20G5.3.
 Although these proteins have a variety of activities and sites of expression, a common
 characteristic of most of them is that they are involved in protein-to-protein binding in
 the extracellular space - either to a secreted protein, a component of the extracellular
 25 matrix, or to an extracellular portion of an integral membrane protein. Based on this
 shared characteristic, the presence of multiple EGF-like domains in TANGO 331
 indicates that TANGO 331 is involved in binding to proteins extracellularly.

Post-translational hydroxylation of aspartic acid or asparagine to form
 erythro- β -hydroxyaspartic acid or erythro- β -hydroxyasparagine occurs in various

proteins having one or more EGF-like domains (e.g., blood coagulation protein factors VII, IX, and X, blood coagulation proteins C, S, and Z, the LDL receptor, thrombomodulin, and the like). TANGO 331 has a signature sequence which is characteristic of hydroxylation of the asparagine residue at amino acid residue 310.

- 5 The invention thus includes TANGO 331 proteins having a hydroxylated asparagine residue at position 310 of SEQ ID NO: 56.

- TNFR/NGFR (tumor necrosis factor receptor/nerve growth factor receptor) cysteine-rich region domains are about 30 to 40 amino acid residues in length, and generally exhibit a conserved pattern of six or more cysteine residues. These
- 10 domains occur in several soluble and transmembrane proteins which are known to be receptors for growth factors or for cytokines. Examples of TNFR/NGFR cysteine-rich region domain-containing proteins are human tumor necrosis factor (TNF) cysteine-rich region domains type I and type II receptors, Shope fibroma virus soluble TNF receptor, human lymphotoxin α/β , human low-affinity nerve growth factor receptor,
- 15 human CD40L (cytokine) receptor CD40, human CD27L (cytokine) receptor CD27, human CD30L (cytokine) receptor CD30, human T-cell cytokine receptor 4-1BB, human apoptotic FASL protein receptor FAS, human T-cell OX40L (cytokine) receptor OX40, human apoptosis-related receptor Wsl-1, and *Vaccinia* protein A53. Presence of a TNFR/NGFR cysteine-rich region domain in TANGO 331 is an indication that
- 20 TANGO 331 is involved in one or more physiological processes involving extracellular binding with a cytokine or growth factor. Such processes include, for example, growth, homeostasis, regeneration, and proliferation of cells and tissues, immune (including autoimmune) responses, host defenses against infection, and the like.

- Metallothioneins are cysteine-rich proteins which are capable of binding
- 25 heavy metals such as calcium, zinc, copper, cadmium, cobalt, nickel, and the like. Proteins which have a domain which resembles a metal-binding domain of a metallothionein are also capable of binding such metals. TANGO 331 comprises a metallothionein-like domain, and is capable of binding one or more heavy metals. This is an indication that TANGO 331 is involved in one or more physiological processes

which involve metal binding. Such processes include, by way of example and not limitation, nutritional supply of metals to cells on a controlled basis, removal of toxic metal species from body tissues, storage of metals, and the like.

TANGO 331 comprises a leucine zipper region at about amino acid
5 residue 94 to about amino acid residue 115 (i.e., 94 LeaqeehLeawwlqLkseypdL 115).
Leucine zipper regions are known to be involved in dimerization of proteins. Leucine
zipper regions interact with one another, leading to formation of homo- or hetero-
dimers between proteins, depending on their identity. The presence in TANGO 331 of
a leucine zipper region is a further indication that this protein is involved in protein-
10 protein interactions.

TANGO 331 shares amino acid and nucleic acid homology with a
Chinese hamster protein designated HT, and thus is involved in corresponding
physiological processes in humans. An alignment of the amino acid sequences of
(human) TANGO 331 and Chinese hamster protein HT is shown in Figure 6E. In this
15 alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver.
2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty =
4), the proteins are 71.9% identical. An alignment of the nucleotide sequences of the
ORFs encoding (human) TANGO 331 and Chinese hamster protein HT is shown in
Figures 6F through 6J. The two ORFs are 74.5% identical, as assessed using the same
20 software and parameters.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997)
Protein Engineering 10:1-6) predicted that human TANGO 331 protein includes an
approximately 24 (i.e., 22, 23, 24, 25, or 26) amino acid residue signal peptide (amino
acid residues 1 to 24 of SEQ ID NO: 56; SEQ ID NO: 57) preceding the mature
25 TANGO 331 protein (i.e., approximately amino acid residues 25 to 353 of SEQ ID NO:
56; SEQ ID NO: 58). Mature human TANGO 331 is a secreted protein.

Figure 6D depicts a hydrophilicity plot of human TANGO 331 protein.
Relatively hydrophobic regions are above the dashed horizontal line, and relatively
hydrophilic regions are below the dashed horizontal line. The hydrophobic region

which corresponds to amino acid residues 1 to 24 of SEQ ID NO: 56 is the signal sequence of human TANGO 331 (SEQ ID NO: 57). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively

- 5 hydrophobic regions. For example, the region of human TANGO 331 protein from about amino acid residue 140 to about amino acid residue 170 appears to be located at or near the surface of the protein, while the region from about amino acid residue 115 to about amino acid residue 130 appears not to be located at or near the surface.

- The predicted molecular weight of human TANGO 331 protein without
10 modification and prior to cleavage of the signal sequence is about 38.2 kilodaltons. The predicted molecular weight of the mature human TANGO 331 protein without modification and after cleavage of the signal sequence is about 35.6 kilodaltons.

- Tissue distribution of TANGO 331 mRNA was determined by Northern blot hybridization. Northern blot hybridizations with the various RNA samples were
15 performed using standard Northern blotting conditions and washing under stringent conditions (i.e., $0.2\times$ SSC at 65°C). The DNA probe used in the Northern Blot experiments was radioactively labeled with ^{32}P -dCTP using the PRIME-IT™ kit (Stratagene, La Jolla, CA) according to the instructions of the supplier. Filters having human mRNA disposed thereon (MULTITISSUE™ Northern I and MULTITISSUE™
20 Northern II obtained from Clontech, Palo Alto, CA) were probed in EXPRESSHYB™ hybridization solution (Clontech) and washed at high stringency according to the manufacturer's recommendations.

- Two isoforms of human TANGO 331 were identified using this Northern blot analysis, indicating that TANGO 331 can have a splice variant. One
25 isoform (corresponding to the larger message) can be a transmembrane protein (frizzled-like) and the other (i.e., smaller) isoform can be a secreted form. The two isoforms exhibit a clear pattern of tissue specificity. On the multiple tissue blot from Clontech, the large transcript is found in almost all tissues, whereas the smaller message is expressed mainly in heart, skeletal muscle, placenta, and pancreas tissues.

TANGO 331 can be expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide is isolated and characterized. Specifically, TANGO 331 can be fused with GST and this fusion polypeptide can be expressed in *E. coli*, e.g., in strain PEB199. Expression of the GST-TANGO 331 fusion protein in PEB199 is induced with IPTG. The recombinant fusion polypeptide can be purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography, e.g., using glutathione-substituted beads. Using polyacrylamide gel electrophoretic analysis of the polypeptide purified from the bacterial lysates, the molecular weight of the resultant fusion polypeptide can be determined.

To express the TANGO 331 gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) can be used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire TANGO 331 protein and an HA tag (Wilson et al. (1984) Cell 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment can be cloned into the polylinker region of the vector, thereby placing the expression of the recombinant protein under the control of the CMV promoter.

To construct the plasmid, the TANGO 331 DNA sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the TANGO 331 coding sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag or FLAG tag and the last 20 nucleotides of the TANGO 331 coding sequence. The PCR amplified fragment and the pcDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so that the TANGO 331 gene is inserted in the correct orientation. The ligation mixture is transformed into *E. coli* cells (e.g., one or more of strains HB101,

DH5a, SURE, available from Stratagene Cloning Systems, La Jolla, CA), the transformed culture is plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.

- 5 COS cells are subsequently transfected using the TANGO 331-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride coprecipitation methods, DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods of transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory
- 10 Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the TANGO 331 polypeptide can be detected by radiolabelling (^{35}S -methionine or ^{35}S -cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring
- 15 Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labelled for 8 hours with ^{35}S -methionine (or ^{35}S -cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 millimolar NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 millimolar Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody.
- 20 Precipitated polypeptides are then analyzed by SDS-PAGE.

- Alternatively, DNA containing the TANGO 331 coding sequence can be cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the TANGO 331 polypeptide can be detected by
- 25 radiolabelling and immunoprecipitation using an TANGO 331 specific monoclonal antibody.

The human TANGO 331 gene was mapped using the Genebridge 4 Human Radiation hybrid mapping panel with ATTATTCAGAAGGATGTCCCGTGG (SEQ ID NO: 99) as the forward primer and CCTCCTGATTACCTACAATGGTC

(SEQ ID NO: 100) as the reverse primer. The human TANGO 331 gene maps to human 22q11-q13. Flanking markers for this region are WI-4572 and WI-8917. The schizophrenia 4 (sczd4) locus also maps to this region of the human chromosome.

Also mapping to this region of the human chromosome are the following genes:

- 5 transcription factor 20 (tcf20), Benzodiazepine receptor, peripheral type (bzip), Arylsulfatase A (arsa), diaphorase (NADH); cytochrome b-5 reductase (dia1), and Solute carrier family 5 (sodium/glucose transporter), member 1 (slca1). This region is syntenic to mouse chromosome 15. The stargazer (stg), gray tremor (gt), brachyury modifier 2 (Brm2), bronchial hyperresponsiveness 2 (Bhr2), loss of righting induced by ethanol 5 (Lore5), fluctuating asymmetry QTL 8 (Faq8), jerky (Jrk), belted (bt), and koala (Koa) loci also map to this region of the mouse chromosome, several of which are neuromuscular related.
- 10

Biological function of TANGO 331 proteins, nucleic acids encoding them, and
15 modulators of these molecules

TANGO 331 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 331 is expressed in human mammary epithelial tissue and human heart tissue, TANGO 331 protein is involved in one or more biological processes which occur in mammary epithelial tissue, in other epithelial tissues, and in heart tissue. In particular, TANGO 331 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, epithelial cells (e.g., mammary epithelial cells) of the animal in which it is normally expressed. Thus, TANGO 331 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. TANGO 331 is therefore involved in physiological processes such as maintenance of epithelia, carcinogenesis, modulation and storage of protein factors and metals, and lactation. Furthermore, because TANGO 331 is expressed in human mammary epithelial cells, it also has a role in nutrition of human infants (e.g.,

20

25

providing nutrients such as minerals to infants and providing protein factors not synthesized by infants) and in disorders which affect them. Thus, TANGO 331 is involved in a number of disorders such as breast cancer, insufficient lactation, infant nutritional and growth disorders, and the like. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because TANGO 331 exhibits expression in the heart, TANGO 331 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 331 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 331 polypeptides, nucleic acids, and modulators thereof, can be involved in normal and aberrant functioning of skeletal muscle tissue, and can thus be involved in disorders of such tissue. Examples of skeletal muscle disorders include muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and congenital muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), myopathies (e.g., inflammatory myopathies (e.g., dermatomyositis and polymyositis), myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (e.g., phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, carnitine deficiency, carnitine palmitoyl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate

mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency). TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

5 In another example, TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

10 In another example, TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion.

 Presence in TANGO 331 of numerous EGF-like domains, including the laminin-like EGF-like domain indicates that TANGO 331 is involved in extracellular
15 binding of proteins, including both other secreted proteins (e.g., growth factors and cytokines) and cell-surface proteins. Binding of TANGO 331 to other secreted proteins modulates their activity, their rate of uptake by cells, and their rate of degradation. Binding of TANGO 331 to cell surface proteins modulates their activity, including, for example, their ability to bind with other secreted proteins, and transmits a signal to the
20 cell expressing the cell-surface protein. Presence in TANGO 331 of a TNFR/NGFR cysteine-rich region domain is further indicative of the ability of TANGO 331 to bind with growth factors and cytokines. Thus, TANGO 331 is involved in a number of proliferative and immune disorders including, but not limited to, cancers (e.g., breast cancer), autoimmune disorders, insufficient or inappropriate host responses to
25 infection, acquired immune deficiency syndrome, and the like. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

 The fact that TANGO 331 has a metallothionein-like region is indicative of the ability of TANGO 331 to bind with metal ions, including nutritionally required

metal ions (e.g., calcium, magnesium, zinc, manganese, cobalt, iron, and the like). Thus, TANGO 331 is involved in binding with essential minerals and in delivering them to their proper body locations. TANGO 331 is also involved in binding excess or toxic metal ions so that they can be excreted. TANGO 331 is thus involved in

5 disorders involving insufficient or inappropriate localization of metal ions. Such disorders include, but are not limited to, malnutrition and mineral deficiency disorders, hemochromatosis, inappropriate calcification of body tissues, bone disorders such as osteoporosis, and the like. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more
10 of these disorders.

Mapping of the human TANGO 331 gene to chromosomal region 22q11-q13 is an indication of disorders with which its expression (or non- or aberrant-expression) can be associated. For example, arylsulfatase A is associated with Metachromatic leukodystrophy. Diaphorase (NADH:cytochrome b-5 reductase) is
15 associated with methemoglobinemia, types I and II. Solute carrier family 5 (sodium/glucose transporter), member 1 is associated with glucose/galactose malabsorption. The gene designated schizophrenia 4 is associated with schizophrenia and velocardiofacial syndrome, as described in Online Mendelian Inheritance in Man, Johns Hopkins University, Baltimore, MD. MIM Number: 600850:12/7/98. (World
20 Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). These mapping data indicate that TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 332

25 A cDNA clone (designated jlhbab463g12) encoding at least a portion of human TANGO 332 protein was isolated from a human adult brain cDNA library. The human TANGO 332 protein is predicted by structural analysis to be a secreted protein.

The full length of the cDNA encoding human TANGO 332 protein (Figure 7; SEQ ID NO: 59) is 2730 nucleotide residues. The ORF of this cDNA,

nucleotide residues 173 to 2185 of SEQ ID NO: 59 (i.e., SEQ ID NO: 60), encodes a 671-amino acid transmembrane protein (Figure 7; SEQ ID NO: 61).

The invention thus includes purified human TANGO 332 protein, both in the form of the immature 671 amino acid residue protein (SEQ ID NO: 61) and in the form of the mature, approximately 649 amino acid residue protein (SEQ ID NO: 63). Mature human TANGO 332 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 332 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human TANGO 332 proteins, the invention includes fragments, derivatives, and variants of these TANGO 332 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 332 polypeptides of the invention or TANGO 332 proteins of the invention.

The invention also includes nucleic acid molecules which encode a TANGO 332 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 59 or some portion thereof, such as the portion which encodes mature TANGO 332 protein, immature TANGO 332 protein, or a domain of TANGO 332 protein. These nucleic acids are collectively referred to as TANGO 332 nucleic acids of the invention.

TANGO 332 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human TANGO 332 protein, human brain-enriched hyaluronan-binding factor (BEF), as shown in Figures 7G and 7H, and murine brevican protein, as shown in Figures 7I to 7K. This conservation is further indicated by conservation of nucleotide sequence between the ORFs encoding human TANGO 332 protein and murine brevican protein, as shown in Figures 7L through 7U.

A common domain present in TANGO 332 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10

amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 332 protein contains a signal sequence corresponding to about amino acid residues 1 to 22 of SEQ ID NO: 61 (SEQ ID NO: 62). The signal sequence is cleaved during processing of the mature protein.

TANGO 332 proteins are secreted proteins. The mature form of human TANGO 332 protein has the amino acid sequence of approximately amino acid residues 23 to 671 of SEQ ID NO: 61.

TANGO 332 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IX, as predicted by computerized sequence analysis of TANGO 332 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 332 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table IX.

Table IX

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 61	Amino Acid Sequence
N-glycosylation site	130 to 133	NDSG
	337 to 340	NQTG
Protein kinase C phosphorylation site	67 to 69	SRR
	74 to 76	SPR
	165 to 167	SAR
	212 to 214	TVR
	219 to 221	TPR
	310 to 312	SVR
	319 to 321	SQR
	545 to 547	TPR
	615 to 617	SGR
Casein kinase II phosphorylation site	29 to 32	SSSED
	116 to 119	SLTD
	219 to 222	TPRE
	269 to 272	TLEE
	382 to 385	TVTE
	386 to 389	TLEE
	397 to 400	TESE
	419 to 422	STPE
	430 to 433	TLLE
	446 to 449	SEEE
	545 to 548	TPRE
	558 to 561	TLVE
Tyrosine kinase phosphorylation site	128 to 135	RPNDSGIY
	451 to 459	KALEEEEEKY

Table IX (Continued)

N-myristoylation site	47 to 52	GVLGGA
	133 to 138	GIYRCE
	142 to 147	GIDDSS
	174 to 179	GAQEAC
	183 to 188	GAHIAT
	281 to 286	GAEIAT
	288 to 293	GQLYAA
	297 to 302	GLDHCS
	324 to 329	GGLPGV
	403 to 408	GAIYSI
	414 to 419	GGGGSS
	576 to 581	GVPRGE
	586 to 591	GSSEGA
Immunoglobulin-/major histocompatibility protein-like (Ig-/MHC-like) domain	50 to 141	See Fig. 7
Extracellular link domain	156 to 251	See Fig. 7
	257 to 353	See Fig. 7

Among the domains that occur in TANGO 332 protein are an Ig-/MHC-like domain and a pair of extracellular link domains. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains. In other embodiments, the protein has at least one Ig-/MHC-like domain and one extracellular link domain described herein in Table IX. In other embodiments, the protein has at least one Ig-/MHC-like domain and at least two extracellular link domains.

Ig-/MHC-like domains are conserved among immunoglobulin (Ig) constant (CL) regions and one of the three extracellular domains of major histocompatibility proteins (MHC). The presence in TANGO 332 of an Ig-/MHC-like domain indicates that the corresponding region of TANGO 332 is structurally similar to this conserved extracellular region.

Extracellular link domains occur in hyaluronan- (HA-)binding proteins. Proteins having this domain include cartilage link protein, proteoglycans such as aggrecan, brevican, neurocan, and versican, CD44 antigen (the primary cell surface receptor for HA), and tumor necrosis factor-inducible protein TSG-6. Presence of a pair of extracellular link domains in TANGO 332 indicates that this protein is also involved in HA-binding, and therefore is involved in physiological processes such as cartilage (and other tissue) organization, extracellular matrix organization, neural growth and branching, and cell-to-cell and cell-to-matrix interactions. Involvement of TANGO 332 in these processes implicates this protein in disorders such as tumor growth and metastasis, movement of cells (e.g., leukocytes) through extracellular matrix, inappropriate inflammation, and the like.

Brevican is a murine nervous system-specific chondroitin sulfate proteoglycan which binds in a calcium-dependent manner with two classes of sulfated glycolipids, namely sulfatides and HNK-1-reactive sulfoglucuronylglycolipids (Miura et al. (1999) *J. Biol. Chem.* 274:11431-11438). A human orthologue, designated BEF ('Brain-Enriched hyaluronan-binding Factor'), of murine brevican is expressed by human glioma cells, but not by brain tumors of non-glial origin (P.C.T. application publication number WO98/31800; Zhang et al. (1998) *J. Neurosci.* 18:2370-2376). Those authors suggested that cleavage of that human orthologue mediates glioma cell invasion *in vivo*.

An alignment of the amino acid sequences of TANGO 332 and BEF protein is shown in Figures 7G and 7H. In this alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 75.7% identical,

although it is seen that TANGO 332 includes two domains (one from about amino acid residue 152 to about residue 208, and the other near the carboxyl terminus of TANGO 332) which do not occur in BEF protein. It is likely that these two regions account for the differences between the physiological roles of TANGO 332 and BEF.

5 An alignment of the amino acid sequences of (human) TANGO 332 and murine brevican protein is shown in Figures 7I through 7K. In this alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 75.5% identical, although it is seen that murine brevican protein includes a domain
10 which does not occur in TANGO 332 protein, this domain is present from about amino acid residue 626 to the carboxyl terminus of murine brevican protein. An alignment of the nucleotide sequences of the ORFs encoding (human) TANGO 332 and murine brevican protein is shown in Figures 7L through 7U. The two ORFs are 62.6% identical, as assessed using the same software and parameters.

15 TANGO 332 exhibits many of the same properties as BEF. TANGO 332 is also related to murine brevican protein, and thus is involved with corresponding physiological processes (i.e., such as those described above) in humans. For example, TANGO 332 modulates intracellular binding and migration of cells in a tissue or extracellular matrix. However, the absence from BEF of one of the two extracellular
20 link domains present in TANGO 332 indicates that one or more of the subunit structure, the tissue specificity, and the binding specificity of TANGO 332 and BEF proteins differ. Thus, TANGO 332 is involved in many of the physiological processes and disorders in which BEF protein is involved. Like murine brevican and other
25 proteoglycans, TANGO 332 acts *in vivo* as a tissue organizing protein, influences growth and maturation of tissues in which it is expressed, modulates growth factor-mediated activities, modulates structural features of tissues (e.g., collagen fibrillogenesis), modulates tumor cell growth and invasivity, and influences neurite growth and branching.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 332 protein includes an approximately 22 (i.e., 20, 21, 22, 23, or 24) amino acid residue signal peptide (amino acid residues 1 to 22 of SEQ ID NO: 61; SEQ ID NO: 62) preceding the mature

5 TANGO 332 protein (i.e., approximately amino acid residues 23 to 671 of SEQ ID NO: 61; SEQ ID NO: 63). Human TANGO 332 protein is a secreted protein, as assessed using the secretion assay described herein. Secreted TANGO 332 proteins having approximate sizes of 148 kilodaltons and 100 kilodaltons could be detected using this assay.

10 Figure 7F depicts a hydrophilicity plot of human TANGO 332 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 22 of SEQ ID NO: 61 is the signal sequence of human TANGO 332 (SEQ ID NO: 62). As described elsewhere herein,
15 relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 332 protein from about amino acid residue 445 to about amino acid residue 475 appears to be located at or near the surface of the protein, while the region from about amino acid residue 45 to
20 about amino acid residue 62 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 332 protein without modification and prior to cleavage of the signal sequence is about 71.7 kilodaltons. The predicted molecular weight of the mature human TANGO 332 protein without modification and after cleavage of the signal sequence is about 69.5 kilodaltons.

25

Biological function of TANGO 332 proteins, nucleic acids encoding them, and modulators of these molecules

TANGO 332 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not

expressed. Based on the observation that TANGO 332 is expressed in human adult brain tissue, TANGO 332 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 332 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, adult brain cells of the animal in which it is normally expressed. Thus, TANGO 332 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, interaction, and activity. Examples of such disorders include, by way of example and not limitation, disorders of neural connection establishment or maintenance, impaired cognitive function, dementia, senility, Alzheimer's disease, mental retardation, brain tumors (e.g., gliomas such as astrocytomas, endophytic and exophytic retinoblastomas, ependymomas, gangliogliomas, mixed gliomas, nasal gliomas, optic gliomas, and Schwannomas, and other brain cell tumors such as medulloblastomas, pituitary adenomas, teratomas, etc.), and the like.

Homology of human TANGO 332 with murine brevican protein and with human brevican homolog BEF indicates that TANGO 332 has physiological functions in humans analogous to the functions of these proteins. Brevican is a member of the aggrecan/versican family of proteoglycans, and has a hyaluronic acid-binding domain in its amino terminal region and a lectin-like domain in its carboxyl terminal region. Expression of brevican is highly specific to brain tissue, and increases as the mammalian brain develops. Thus, brevican is involved in maintaining the extracellular environment of mature brain tissue and is a constituent of adult brain extracellular matrix. TANGO 332 is involved in modulating cell-to-cell adhesion, tissue and extracellular matrix invasivity of cells, and the like. Thus, TANGO 332 is involved in disorders in which these physiological processes are relevant. Such disorders include, for example, loss of control of cell growth, tumor metastasis, malformation of neurological connections, inflammation, immune and autoimmune responses, and the like.

In addition, presence in TANGO 332 of extracellular link domains indicates that this protein is involved in physiological processes involving structure and function of extracellular matrices and interaction of cells with such matrices and with each other. This is further evidence that TANGO 332 is involved in disorders such as

5 inappropriate inflammation, tumor metastasis, inappropriate leukocyte extravasation, localization, and reactivity, and the like.

TANGO 332-related molecules can be used to modulate one or more of the activities in which TANGO 332 is involved and can also be used to prevent, diagnose, or treat one or more of the disorders in which TANGO 332 is involved.

10 Tables A and B summarize sequence data corresponding to the human proteins herein designated INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332.

Table A

Protein Designation	SEQ ID NOs			Depicted in Figure #	ATCC® Accession #
	cDNA	ORF	Protein		
INTERCEPT 217	1	2	3	1	PTA-147
INTERCEPT 297	9	10	11	2	PTA-147
TANGO 276	33	34	35	3	PTA-150
TANGO 292	38	39	40	4	207230
TANGO 325	46	47	48	5	PTA-147
TANGO 331	54	55	56	6	PTA-147
TANGO 332	59	60	61	7	PTA-151

[illegible]

Various aspects of the invention are described in further detail in the following subsections.

I. Isolated Nucleic Acid Molecules

- 5 One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a biologically active portion thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or
- 10 mutation of nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
- 15 An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the
- 20 organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kilobases, 4 kilobases, 3 kilobases, 2 kilobases, 1 kilobases, 0.5 kilobases, or 0.1 kilobases of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an
- 25 "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of all or a portion of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a complement thereof, or which has a nucleotide sequence comprising one of these sequences, can be isolated using
5 standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequences of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92 as a hybridization probe, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., *Molecular Cloning: A*
10 *Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989*).

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can
15 be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In another preferred embodiment, an isolated nucleic acid molecule of
20 the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or a portion thereof. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby
25 forming a stable duplex.

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding a full length polypeptide of the invention for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a polypeptide of the invention. The nucleotide sequence

determined from the cloning one gene allows for the generation of probes and primers designed for use in identifying and/or cloning homologs in other cell types, e.g., from other tissues, as well as homologs from other mammals. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically

5 comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 15, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of the sense or anti-sense sequence of one of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or of a naturally occurring mutant of one of SEQ ID NO: 1, 2, 9,

10 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences encoding the same protein molecule encoded by a selected nucleic acid molecule. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme,

15 or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

20 A nucleic acid fragment encoding a biologically active portion of a polypeptide of the invention can be prepared by isolating a portion of one of SEQ ID NO: 2, 10, 34, 39, 47, 55, 60, 82, and 92, expressing the encoded portion of the polypeptide protein (e.g., by recombinant expression *in vitro*), and assessing the activity of the encoded portion of the polypeptide.

25 The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence of SEQ ID NO: 2, 10, 34, 39, 47, 55, 60, 82, or 92.

In addition to the nucleotide sequences of SEQ ID NOs: 2, 10, 34, 39, 47, 55, 60, 82, and 92, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus.

As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding proteins of the invention from other species (homologs), which have a nucleotide sequence which differs from that of the specific proteins described herein are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologs of a cDNA of the invention can be isolated based on their identity to human nucleic acid molecules using the cDNAs described herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a cDNA encoding a soluble form of a membrane-bound protein of the invention isolated based on its hybridization to a nucleic acid molecule encoding all or part of the membrane-bound form. Likewise, a

cDNA encoding a membrane-bound form can be isolated based on its hybridization to a nucleic acid molecule encoding all or part of the soluble form.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or a complement thereof. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or a complement thereof, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention sequence that can exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type

sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively,
5 amino acid residues that are conserved among the homologs of various species (e.g., murine and human) may be essential for activity and thus would not be likely targets for alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid
10 residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98%
15 identical to the amino acid sequence of one of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98.

An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60,
20 81, 82, or 92, such that one or more amino acid residue substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.

Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in
25 which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine,

tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all
5 or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant polypeptide that is a variant of a
10 polypeptide of the invention can be assayed for: (1) the ability to form protein:protein interactions with the polypeptide of the invention; (2) the ability to bind a ligand of the polypeptide of the invention (e.g., another protein identified herein); (3) the ability to bind to a modulator or substrate of the polypeptide of the invention; or (4) the ability to modulate a physiological activity of the protein, such as one of those disclosed herein.

15 The present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a polypeptide of the invention, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense
20 nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions ("5' and 3' un-translated regions") are the 5' and 3' sequences
25 which flank the coding region and are not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an

antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and

5 acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine,

10 N₆-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N₆-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N₆-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine,

15 pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an

20 antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to

25 cellular mRNA and/or genomic DNA encoding a selected polypeptide of the invention to thereby inhibit expression, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.

An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such
5 that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the
10 antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the invention can be an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual
15 beta-units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-O-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

The invention also encompasses ribozymes. Ribozymes are catalytic
20 RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach (1988) *Nature* 334:585-591) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of the protein encoded by the mRNA. A ribozyme having
25 specificity for a nucleic acid molecule encoding a polypeptide of the invention can be designed based upon the nucleotide sequence of a cDNA disclosed herein. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent

No. 5,116,742. Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g.,* Bartel and Szostak (1993) *Science* 261:1411-1418.

The invention also encompasses nucleic acid molecules which form
5 triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (e.g., the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells. *See generally* Helene (1991) *Anticancer Drug Des.* 6(6):569-84; Helene (1992) *Ann. N.Y. Acad. Sci.*
10 660:27-36; and Maher (1992) *Bioassays* 14(12):807-15.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic
15 acids (*see* Hyrup et al. (1996) *Bioorganic & Medicinal Chemistry* 4(1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA
20 and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 14670-675.

PNAs can be used in therapeutic and diagnostic applications. For
25 example, PNAs can be used as antisense or anti-gene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup

(1996), *supra*; or as probes or primers for DNA sequence and hybridization (Hyrup (1996), *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 14670-675).

In another embodiment, PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996), *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*, and Finn et al. (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA (Mag et al. (1989) *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) *Nucleic Acids Res.* 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser et al. (1975) *Bioorganic Med. Chem. Lett.* 5:1119-11124).

In other embodiments, the oligonucleotide can include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (*see, e.g.*, Krol et al. (1988)

Bio/Techniques 6:958-976) or intercalating agents (*see, e.g., Zon (1988) Pharm. Res.* 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

5

II. Isolated Proteins and Antibodies

One aspect of the invention pertains to isolated proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide of the invention. In one
10 embodiment, the native polypeptide can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide of the invention can be synthesized chemically using standard peptide synthesis techniques.

15 An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of protein in which the
20 protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is
25 also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such

preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

Biologically active portions of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein (e.g., the amino acid sequence shown in any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98), which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

Preferred polypeptides have the amino acid sequence of one of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98. Other useful proteins are substantially identical (e.g., at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two

sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions) \times 100). In one embodiment the two sequences are the same length.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. *Id.* When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) *CABIOS* 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a polypeptide of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same polypeptide of the invention). Within the
5 fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention.

One useful fusion protein is a GST fusion protein in which the
10 polypeptide of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a
15 polypeptide of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human
20 placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

In yet another embodiment, the fusion protein is an immunoglobulin
25 fusion protein in which all or part of a polypeptide of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell

(receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g.,
5 promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

Chimeric and fusion proteins of the invention can be produced by
10 standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric
15 gene sequence (*see, e.g.,* Ausubel et al., *supra*). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.

20 A signal sequence of a polypeptide of the invention (e.g., the signal sequence in one of SEQ ID NO: 3, 4, 11, 12, 35, 36, 40, 41, 48, 49, 56, 57, 61, 62, 83, 84, 93, and 94) can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during
25 secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a signal sequence, as well as to the signal sequence itself and to the polypeptide in the absence of the signal sequence (i.e., the cleavage products). In

one embodiment, a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

In another embodiment, the signal sequences of the present invention can be used to identify regulatory sequences, e.g., promoters, enhancers, repressors. Since signal sequences are the most amino-terminal sequences of a peptide, the nucleic acids which flank the signal sequence on its amino-terminal side are likely regulatory sequences which affect transcription. Thus, a nucleotide sequence which encodes all or a portion of a signal sequence can be used as a probe to identify and isolate signal sequences and their flanking regions, and these flanking regions can be studied to identify regulatory elements therein.

The present invention also pertains to variants of the polypeptides of the invention. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants can be generated by mutagenesis, e.g., discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side

effects in a subject relative to treatment with the naturally occurring form of the protein.

5 Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such
10 that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art
15 (see, e.g., Narang (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of
20 polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, re-naturing the DNA to form double stranded DNA which can include sense/antisense
25 pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

An isolated polypeptide of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of one of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.

Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. Figures 1F, 1M, 2D, 3E, 4E, 4M, 5F, 6D, and 7F are hydrophobicity plots of the proteins of the invention. These plots or similar analyses can be used to identify hydrophilic regions.

An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for

example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies
5 directed against a polypeptide of the invention. The terms "antibody" and "antibody substance" as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention. A molecule which specifically binds to a given
10 polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides
15 polyclonal and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope.

Polyclonal antibodies can be prepared as described above by
20 immunizing a suitable subject with a polypeptide of the invention as an immunogen. Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against (i.e., which bind specifically with) one or more polypeptides of the invention. Particularly preferred polyclonal antibody preparations are ones that contain only antibodies directed against one or more polypeptides of the invention.
25 Particularly preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions

raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.

The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies which bind specifically with a protein or polypeptide of the invention can be selected (e.g., partially purified) or purified using chromatographic methods, such as affinity chromatography. For example, a recombinantly expressed and purified (or partially purified) protein of the invention can be produced as described herein, and covalently or non-covalently coupled with a solid support such as, for example, a chromatography column. The column thus exhibits specific affinity for antibody substances which bind specifically with the protein of the invention, and these antibody substances can be purified from a sample containing antibody substances directed against a large number of different epitopes, thereby generating a substantially purified antibody substance composition, i.e., one that is substantially free of antibody substances which do not bind specifically with the protein. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those on the desired protein or polypeptide of the invention, preferably at most 20%, more preferably at most 10%, most preferably at most 5% (by dry weight), of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

At an appropriate time after immunization, e.g., when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature*

256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) *Immunol. Today* 4:72), the EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology* (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, NY).
5 Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a
10 monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene
15 *SURFZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO
20 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

Additionally, recombinant antibodies, such as chimeric and humanized
25 monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions of the antibody amino acid sequence are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a constant

region derived from a human immunoglobulin. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No. 4,816,397). Humanized antibodies are antibody molecules which are obtained from non-human species, which have one or more complementarity-determining regions (CDRs) derived from the non-human species, and which have a framework region derived from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Patent No. 5,585,089). Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-1043; Liu et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura et al. (1987) *Cancer Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559); Morrison (1985) *Science* 229:1202-1207; Oi et al. (1986) *Bio/Techniques* 4:214; U.S. Patent 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeyan et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies,

see Lonberg and Huszar (1995, *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, *see, e.g.*, U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, *e.g.*, a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al., 1994, *Bio/technology* 12:899-903).

An antibody directed against a polypeptide of the invention (*e.g.*, monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of

bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Further, an antibody substance can be conjugated with a therapeutic moiety such as a cytotoxin, a therapeutic agent, or a radioactive metal ion. Cytotoxins and cytotoxic agents include any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs of these compounds. Therapeutic agents include, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, and decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine {BSNU}, lomustine {CCNU}, cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin {formerly daunomycin} and doxorubicin), antibiotics (e.g., dactinomycin {formerly actinomycin}, bleomycin, mithramycin, and anthramycin {AMC}), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used to modify a biological response; the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety can be a protein or polypeptide which exhibits a desired biological activity. Such proteins include, for example, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; and biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and other growth factors.

Techniques for conjugating a therapeutic moiety with an antibody substance are well known (see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al., eds., pp. 243-256, Alan R. Liss, Inc., 1985; Hellstrom et al.,
5 "Antibodies For Drug Delivery", in Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., pp. 623-653, Marcel Dekker, Inc., 1987; Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological and Clinical Applications, Pinchera et al., eds., pp. 475-506, 1985; "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled
10 Antibody In Cancer Therapy", in Monoclonal Antibodies for Cancer Detection and Therapy, Baldwin et al., eds., pp. 303-316, Academic Press, 1985; and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58, 1982). Alternatively, an antibody can be conjugated with a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No.
15 4,676,980.

Accordingly, in one aspect, the invention provides substantially purified antibodies or fragment thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of
20 (i) SEQ ID NOS: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;
(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;
(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of
25 SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;
(iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG

software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:

(i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

(iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C. Such non-human antibodies can be goat,

mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

5 In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:

10 (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

15 (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

20 (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and
25 washing in 0.2× SSC, 0.1% SDS at 65°C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

The substantially purified antibodies or fragments thereof can specifically bind with a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain cytoplasmic membrane of a polypeptide of the

invention. In a particularly preferred embodiment, the substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind with a secreted sequence or with an extracellular domain of one of INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. Preferably, the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 14-18, 37, 43, 51, 58, or 63.

Any of the antibody substances of the invention can be conjugated with a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated with the antibody substances of the invention include an enzyme, a prosthetic group, a fluorescent material (i.e., a fluorophore), a luminescent material, a bioluminescent material, and a radioactive material (e.g., a radionuclide or a substituent comprising a radionuclide).

The invention also provides a kit containing an antibody substance of the invention conjugated with a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody substance of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody substance of the invention, a therapeutic moiety (preferably conjugated with the antibody substance), and a pharmaceutically acceptable carrier.

Still another aspect of the invention is a method of making an antibody that specifically recognizes one of INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. This method comprises immunizing a vertebrate (e.g., a mammal such as a rabbit, goat, or pig) with a polypeptide. The polypeptide used as an immunogen has an amino acid sequence that comprises a sequence selected from the group consisting of:

(i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

5 (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

10 (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and
15 washing in 0.2× SSC, 0.1% SDS at 65°C.

After immunization, a sample is collected from the vertebrate that contains an antibody that specifically recognizes the polypeptide with which the vertebrate was immunized. Preferably, the polypeptide is recombinantly produced using a non-human host cell. Optionally, an antibody substance can be further purified
20 from the sample using techniques well known to those of skill in the art. The method can further comprise making a monoclonal antibody-producing cell from a cell of the vertebrate. Optionally, antibodies can be collected from the antibody-producing cell.

III. Recombinant Expression Vectors and Host Cells

25 Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide of the invention (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into

which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal
5 mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA
10 techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic
15 acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence
20 of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are
25 described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by

those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic (e.g., *E. coli*) or eukaryotic cells (e.g., insect cells (using baculovirus expression vectors), yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel, *supra*. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al.,

Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident lambda prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari et al. (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al. (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA).

Alternatively, the expression vector is a baculovirus expression vector. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC

(Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both
5 prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., *supra*.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of
10 suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific
15 promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example
20 the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory
25 sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to the mRNA encoding a polypeptide of the invention. Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral

promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub et al. (*Reviews - Trends in Genetics*, Vol. 1(1) 1986).

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic (e.g., *E. coli*) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells).

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*supra*), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., for resistance to

antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

In another embodiment, the expression characteristics of an endogenous nucleic acid within a cell, cell line, or microorganism (e.g., a INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 nucleic acid, as described herein) can be modified by inserting a heterologous DNA regulatory element (i.e., one that is heterologous with respect to the endogenous gene) into the genome of the cell, stable cell line, or cloned microorganism. The inserted regulatory element can be operatively linked with the endogenous gene (e.g., INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332) and thereby control, modulate, or activate the endogenous gene. For example, an endogenous INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene which is normally "transcriptionally silent" (i.e., a INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene which is normally not expressed, or is normally expressed only at only a very low level) can be activated by inserting a regulatory element which is capable of promoting expression of the gene in the cell, cell line, or microorganism. Alternatively, a transcriptionally silent, endogenous INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene can be activated by inserting a promiscuous regulatory element that works across cell types.

A heterologous regulatory element can be inserted into a stable cell line or cloned microorganism such that it is operatively linked with and activates expression of an endogenous INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art (described

e.g., in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide of the invention have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a polypeptide of the invention have been introduced into their genome or homologous recombinant animals in which endogenous encoding a polypeptide of the invention sequences have been altered. Such animals are useful for studying the function and/or activity of the polypeptide and for identifying and/or evaluating modulators of polypeptide activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the

endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing nucleic acid encoding a polypeptide of the invention (or a homologue thereof) into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986), and in Wakayama et al., 1999, Proc. Natl. Acad. Sci. USA 96:14984-14989. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a gene encoding a polypeptide of the invention into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein

(e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (*see, e.g., Thomas and Capecchi (1987) Cell 51:503 for a description of homologous recombination vectors*).

The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (*see, e.g., Li et al. (1992) Cell 69:915*). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (*see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152*). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Bio/Technology* 2:823-829 and in PCT Publication NOS. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, *see, e.g., Lakso et al. (1992) Proc. Natl. Acad. Sci. USA 89:6232-6236*. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991)

Science 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) *Nature* 385:810-813 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

IV. Pharmaceutical Compositions

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical

composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention and one or more additional active compounds.

The agent which modulates expression or activity can, for example, be a small molecule. For example, such small molecules include peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

It is understood that appropriate doses of small molecule agents and protein or polypeptide agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of these agents will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the agent to have upon the nucleic acid or polypeptide of the invention. Exemplary doses of a small molecule include milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram). It is furthermore understood that appropriate doses of one of these agents depend upon the

potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses can be determined using the assays described herein. When one or more of these agents is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a
5 physician, veterinarian, or researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the
10 time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral
15 (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens;
20 antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose
25 vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic

water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as

5 bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of

10 surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can

15 be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required,

20 followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a

25 powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with

excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials
5 can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal
10 silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

15 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be
20 accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or
25 retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl

acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes having one
5 or more monoclonal antibodies incorporated therein or thereon; e.g., liposomes comprising a monoclonal antibody which binds specifically with a virus antigen) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

10 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association
15 with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

20 For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is
25 often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al. ((1997) *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193).

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470), or by stereotactic injection (*see, e.g.,* Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologs, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology); c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic). For example, polypeptides of the invention can be used for all of the purposes identified herein in portions of the disclosure relating to individual types of protein of the invention (e.g., INTERCEPT 217 proteins, INTERCEPT 297 proteins, TANGO 276 proteins, TANGO 292 proteins, TANGO 325 proteins, TANGO 331 proteins, and TANGO 332 proteins). The isolated nucleic acid molecules of the invention can be used to express proteins (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect mRNA (e.g., in a biological sample) or a genetic lesion, and to modulate activity of a polypeptide of the invention. In addition, the polypeptides of the invention can be used to screen drugs or compounds which modulate activity or expression of a polypeptide of the invention as well as to treat

disorders characterized by insufficient or excessive production of a protein of the invention or production of a form of a protein of the invention which has decreased or aberrant activity compared to the wild type protein. In addition, the antibodies of the invention can be used to detect and isolate a protein of the and modulate activity of a protein of the invention.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

A. Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to polypeptide of the invention or have a stimulatory or inhibitory effect on, for example, expression or activity of a polypeptide of the invention.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a polypeptide of the invention or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann et al.

(1994). *J. Med. Chem.* 37:2678; Cho et al. (1993) *Science* 261:1303; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop et al. (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds can be presented in solution (e.g., Houghten
5 (1992) *Bio/Techniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips
(Fodor (1993) *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores
(Patent NOS. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al. (1992) *Proc.*
Natl. Acad. Sci. USA 89:1865-1869) or phage (Scott and Smith (1990) *Science*
249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla et al. (1990) *Proc. Natl.*
10 *Acad. Sci. USA* 87:6378-6382; and Felici (1991) *J. Mol. Biol.* 222:301-310).

In one embodiment, an assay is a cell-based assay in which a cell which
expresses a membrane-bound form of a polypeptide of the invention, or a biologically
active portion thereof, on the cell surface is contacted with a test compound and the
ability of the test compound to bind to the polypeptide determined. The cell, for
15 example, can be a yeast cell or a cell of mammalian origin. Determining the ability of
the test compound to bind to the polypeptide can be accomplished, for example, by
coupling the test compound with a radioisotope or enzymatic label such that binding of
the test compound to the polypeptide or biologically active portion thereof can be
determined by detecting the labeled compound in a complex. For example, test
20 compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the
radioisotope detected by direct counting of radio-emission or by scintillation counting.

Alternatively, test compounds can be enzymatically labeled with, for example,
horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label
detected by determination of conversion of an appropriate substrate to product. In a
25 preferred embodiment, the assay comprises contacting a cell which expresses a
membrane-bound form of a polypeptide of the invention, or a biologically active
portion thereof, on the cell surface with a known compound which binds the
polypeptide to form an assay mixture, contacting the assay mixture with a test
compound, and determining the ability of the test compound to interact with the

polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or a biologically active portion thereof as compared to the known compound.

5 In another embodiment, the assay involves assessment of an activity characteristic of the polypeptide, wherein binding of the test compound with the polypeptide or a biologically active portion thereof alters (i.e., increases or decreases) the activity of the polypeptide.

10 In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide or a
15 biologically active portion thereof can be accomplished, for example, by determining the ability of the polypeptide to bind to or interact with a target molecule or to transport molecules across the cytoplasmic membrane.

 Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by one of the methods described
20 above for determining direct binding. As used herein, a "target molecule" is a molecule with which a selected polypeptide (e.g., a polypeptide of the invention binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses the selected protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell
25 membrane or a cytoplasmic molecule. A target molecule can be a polypeptide of the invention or some other polypeptide or protein. For example, a target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a polypeptide of the invention) through the cell membrane and into the cell or a second intercellular

protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with a polypeptide of the invention. Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule. For example, the
5 activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., an mRNA, intracellular Ca^{2+} , diacylglycerol, IP3, and the like), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding
10 a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound
15 to bind to the polypeptide or biologically active portion thereof. Binding of the test compound to the polypeptide can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay
20 mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or biologically active portion thereof as compared to the known compound.

25 In another embodiment, an assay is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the

polypeptide can be accomplished, for example, by determining the ability of the polypeptide to bind to a target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished by
5 determining the ability of the polypeptide of the invention to further modulate the target molecule. For example, the catalytic activity, the enzymatic activity, or both, of the target molecule on an appropriate substrate can be determined as previously described.

In yet another embodiment, the cell-free assay comprises contacting a
10 polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the polypeptide to
15 preferentially bind to or modulate the activity of a target molecule.

The cell-free assays of the present invention are amenable to use of both a soluble form or the membrane-bound form of a polypeptide of the invention. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it can be desirable to utilize a solubilizing agent such that the membrane-bound form of the
20 polypeptide is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-octylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-
25 cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

In one or more embodiments of the above assay methods of the present invention, it can be desirable to immobilize either the polypeptide of the invention or its target molecule to facilitate separation of complexed from non-complexed forms of

one or both of the proteins, as well as to accommodate automation of the assay.

Binding of a test compound to the polypeptide, or interaction of the polypeptide with a target molecule in the presence and absence of a candidate compound, can be

accomplished in any vessel suitable for containing the reactants. Examples of such

5 vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one

embodiment, a fusion protein can be provided which adds a domain that allows one or

both of the proteins to be bound to a matrix. For example, glutathione-S-transferase

fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto

glutathione Sepharose beads (Sigma Chemical; St. Louis, MO) or glutathione

10 derivatized microtiter plates, which are then combined with the test compound or the

test compound and either the non-adsorbed target protein or A polypeptide of the

invention, and the mixture incubated under conditions conducive to complex formation

(e.g., at physiological conditions for salt and pH). Following incubation, the beads or

microtiter plate wells are washed to remove any unbound components and complex

15 formation is measured either directly or indirectly, for example, as described above.

Alternatively, the complexes can be dissociated from the matrix, and the level of

binding or activity of the polypeptide of the invention can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used

20 in the screening assays of the invention. For example, either the polypeptide of the

invention or its target molecule can be immobilized utilizing conjugation of biotin and

streptavidin. Biotinylated polypeptide of the invention or target molecules can be

prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in

the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, IL), and immobilized in the

25 wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies

reactive with the polypeptide of the invention or target molecules but which do not

interfere with binding of the polypeptide of the invention to its target molecule can be

derivatized to the wells of the plate, and unbound target or polypeptide of the invention

trapped in the wells by antibody conjugation. Methods for detecting such complexes,

in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the polypeptide of the invention or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the polypeptide of the invention or target molecule.

5 In another embodiment, modulators of expression of a polypeptide of the invention are identified in a method in which a cell is contacted with a candidate compound and the expression of the selected mRNA or protein (i.e., the mRNA or protein corresponding to a polypeptide or nucleic acid of the invention) in the cell is determined. The level of expression of the selected mRNA or protein in the presence of the candidate compound is compared to the level of expression of the selected mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of expression of the polypeptide of the invention based on this comparison. For example, when expression of the selected mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of the selected mRNA or protein expression. Alternatively, when expression of the selected mRNA or protein is less (i.e., statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of the selected mRNA or protein expression. The level of the selected mRNA or protein expression in the cells can be determined by methods described herein.

15 In yet another aspect of the invention, a polypeptide of the inventions can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Bio/Techniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and PCT Publication No. WO 94/10300), to identify other proteins, which bind to or interact with the polypeptide of the invention and modulate activity of the polypeptide of the invention. Such binding proteins are also likely to be involved in the propagation of signals by the polypeptide

of the inventions as, for example, upstream or downstream elements of a signaling pathway involving the polypeptide of the invention.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

5

B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their
10 respective genes on a chromosome and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

15 1. Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, nucleic acid molecules described herein or fragments thereof, can be used to map the location of the corresponding genes on a chromosome. The mapping of the
20 sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 base pairs in length) from the sequence of a gene of the invention. Computer analysis of the sequence of a gene of the invention can be used to
25 rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the gene sequences will

yield an amplified fragment. For a review of this technique, see D'Eustachio et al. ((1983) *Science* 220:919-924).

5 . PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the nucleic acid sequences of the invention to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a gene to its chromosome include *in situ* hybridization (described in Fan et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6223-27), pre-screening
10 with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries. Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. For a review of this technique, see Verma et al. (Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New
15 York, 1988)).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to non-coding regions of the genes actually are preferred for mapping purposes.
20 Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance
25 in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland et al. (1987) *Nature* 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with a gene of the invention can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Furthermore, the nucleic acid sequences disclosed herein can be used to perform searches against "mapping databases", e.g., BLAST-type search, such that the chromosome position of the gene is identified by sequence homology or identity with known sequence fragments which have been mapped to chromosomes.

A polypeptide and fragments and sequences thereof and antibodies which bind specifically with such polypeptides/fragments can be used to map the location of the gene encoding the polypeptide on a chromosome. This mapping can be performed by specifically detecting the presence of the polypeptide/fragments in members of a panel of somatic cell hybrids between cells obtained from a first species of animal from which the protein originates and cells obtained from a second species of animal, determining which somatic cell hybrid(s) expresses the polypeptide, and noting the chromosome(s) of the first species of animal that it contains. For examples of this technique (see Pajunen et al., 1988, Cytogenet. Cell Genet. 47:37-41 and Van Keuren et al., 1986, Hum. Genet. 74:34-40). Alternatively, the presence of the polypeptide in the somatic cell hybrids can be determined by assaying an activity or property of the polypeptide (e.g., enzymatic activity, as described in Bordelon-Riser et al., 1979, Som. Cell Genet. 5:597-613 and Owerbach et al., 1978, Proc. Natl. Acad. Sci. USA 75:5640-5644).

2. Tissue Typing

The nucleic acid sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the nucleic acid sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The nucleic acid sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the non-coding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the non-coding regions, fewer sequences are necessary to differentiate individuals. The

non-coding sequences of SEQ ID NO: 1, 9, 33, 38, 46, 54, 59, and 81 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a non-coding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO: 2, 10, 34, 39, 47, 55, 60, 82, and 92 are used,
5 a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from the nucleic acid sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique
10 identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

3. Use of Partial Gene Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic
15 biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The
20 amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by,
25 for example, providing another "identification marker" (i.e., another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to non-coding regions are particularly appropriate for this use as greater numbers of polymorphisms occur in

the non-coding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the nucleic acid sequences of the invention or portions thereof, e.g., fragments derived from non-coding regions having a length of at least 20 or 30 bases.

5 The nucleic acid sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such probes can be used to identify tissue by
10 species and/or by organ type.

C. Predictive Medicine

 The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring
15 clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining expression of a polypeptide or nucleic acid of the invention and/or activity of a polypeptide of the invention, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted
20 with a disease or disorder, or is at risk of developing a disorder, associated with aberrant expression or activity of a polypeptide of the invention. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, mutations in a gene of the invention can be
25 assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with aberrant expression or activity of a polypeptide of the invention.

As an alternative to making determinations based on the absolute expression level of a selected gene, determinations can be based on normalized expression levels of the gene. A gene expression level is normalized by correcting the absolute expression level of the gene (e.g., an INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene as described herein) by comparing its expression to expression of a gene for which expression is not believed to be co-regulated with the gene of interest, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene. Such normalization allows comparison of the expression level in one sample, e.g., a patient sample, with the expression level in another sample, e.g., a sample obtained from a patient known not to be afflicted with a disease or condition, or between samples obtained from different sources.

Alternatively, the expression level can be assessed as a relative expression level. To assess a relative expression level for a gene (e.g., an INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene, as described herein), the level of expression of the gene is determined for 10 or more samples (preferably 50 or more samples) of different isolates of cells in which the gene is believed to be expressed, prior to assessing the level of expression of the gene in the sample of interest. The mean expression level of the gene detected in the large number of samples is determined, and this value is used as a baseline expression level for the gene. The expression level of the gene assessed in the test sample (i.e., its absolute level of expression) is divided by the mean expression value to yield a relative expression level. Such a method can identify tissues or individuals which are afflicted with a disorder associated with aberrant expression of a gene of the invention.

Preferably, the samples used in the baseline determination are generated either using cells obtained from a tissue or individual known to be afflicted with a disorder (e.g., a disorder associated with aberrant expression of one of the

INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325,
TANGO 331, or TANGO 332 genes) or using cells obtained from a tissue or individual
known not to be afflicted with the disorder. Alternatively, levels of expression of these
genes in tissues or individuals known to be or not to be afflicted with the disorder can
5 be used to assess whether the aberrant expression of the gene is associated with the
disorder (e.g., with onset of the disorder, or as a symptom of the disorder over time).

Another aspect of the invention provides methods for expression of a
nucleic acid or polypeptide of the invention or activity of a polypeptide of the invention
in an individual to thereby select appropriate therapeutic or prophylactic agents for that
10 individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for
the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an
individual based on the genotype of the individual (e.g., the genotype of the individual
examined to determine the ability of the individual to respond to a particular agent).

Yet another aspect of the invention pertains to monitoring the influence
15 of agents (e.g., drugs or other compounds) on the expression or activity of a
polypeptide of the invention in clinical trials. These and other agents are described in
further detail in the following sections.

1. Diagnostic Assays

20 An exemplary method for detecting the presence or absence of a
polypeptide or nucleic acid of the invention in a biological sample involves obtaining a
biological sample from a test subject and contacting the biological sample with a
compound or an agent capable of detecting a polypeptide or nucleic acid (e.g., mRNA,
genomic DNA) of the invention such that the presence of a polypeptide or nucleic acid
25 of the invention is detected in the biological sample. A preferred agent for detecting
mRNA or genomic DNA encoding a polypeptide of the invention is a labeled nucleic
acid probe capable of hybridizing to mRNA or genomic DNA encoding a polypeptide
of the invention. The nucleic acid probe can be, for example, a full-length cDNA, such
as the nucleic acid of SEQ ID NO: 1, 9, 33, 38, 46, 54, 59, 62, or 81, or a portion

thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a polypeptide of the invention. Other suitable probes for use in the diagnostic assays of the invention are described herein.

5 A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct
10 labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be
15 detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of
20 mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of a polypeptide of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of a polypeptide of the invention include
25 introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

 In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA

molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting a polypeptide of the invention or mRNA or genomic DNA encoding a polypeptide of the invention, such that the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide is detected in the biological sample, and comparing the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the control sample with the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample (a test sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed). For example, the kit can comprise a labeled compound or agent capable of detecting the polypeptide or mRNA encoding the polypeptide in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide if the amount of the polypeptide or mRNA encoding the polypeptide is above or below a normal level.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule encoding a polypeptide of the invention.

- 5 The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual
- 10 container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide.

2. Prognostic Assays

- 15 The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of
- 20 developing a disorder associated with aberrant expression or activity of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed). Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder. Thus, the present invention provides a method in which a
- 25 test sample is obtained from a subject and a polypeptide or nucleic acid (e.g., mRNA, genomic DNA) of the invention is detected, wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant expression or activity of the polypeptide. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest.

For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease activity of the polypeptide). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant expression or activity of a polypeptide of the invention in which a test sample is obtained and the polypeptide or nucleic acid encoding the polypeptide is detected (e.g., wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant expression or activity of the polypeptide).

The methods of the invention can also be used to detect genetic lesions or mutations in a gene of the invention, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized aberrant expression or activity of a polypeptide of the invention. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding the polypeptide of the invention, or the mis-expression of the gene encoding the polypeptide of the invention. For example, such genetic lesions or mutations can be detected by ascertaining the existence of at least one of: 1) a deletion of one or more nucleotides from the gene; 2) an addition of one or more nucleotides to the gene; 3) a substitution of one or more nucleotides of the gene; 4) a chromosomal rearrangement of the gene; 5) an alteration in the level of a messenger RNA transcript of the gene; 6) an aberrant modification of the gene, such as of the methylation pattern

of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; 8) a non-wild type level of the protein encoded by the gene; 9) an allelic loss of the gene; and 10) an inappropriate post-translational modification of the protein encoded by the gene. As described herein, there are a large
5 number of assay techniques known in the art which can be used for detecting lesions in a gene.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a
10 ligation chain reaction (LCR) (*see, e.g.*, Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:360-364), the latter of which can be particularly useful for detecting point mutations in a gene (*see, e.g.*, Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*,
15 genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to the selected gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.
20 PCR and/or LCR can be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self-sustained sequence replication (Guatelli et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) *Proc. Natl. Acad. Sci. USA*
25 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) *Bio/Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a selected gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, (optionally) amplified, digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin et al. (1996) *Human Mutation* 7:244-255; Kozal et al. (1996) *Nature Medicine* 2:753-759). For example, genetic mutations can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al., *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the selected gene and detect mutations by comparing the sequence of the sample nucleic acids with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also

contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Bio/Techniques* 19:448), including sequencing by mass spectrometry (*see, e.g.*, PCT Publication No. WO 94/16101; Cohen et al. (1996) *Adv. Chromatogr.* 36:127-162; and Griffin et al. (1993) *Appl.*

5 *Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in a selected gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) *Science* 230:1242).

In general, the technique of mismatch cleavage entails providing heteroduplexes
10 formed by hybridizing (labeled) RNA or DNA containing the wild-type sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to base pair mismatches between the control and sample strands. RNA/DNA duplexes can be treated with RNase to digest mismatched regions,
15 and DNA/DNA hybrids can be treated with S1 nuclease to digest mismatched regions.

In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of
20 mutation. *See, e.g.*, Cotton et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:4397; Saleeba et al. (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so
25 called DNA mismatch repair enzymes) in defined systems for detecting and mapping point mutations in cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a selected

sequence, e.g., a wild-type sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

- 5 In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in genes. For example, single strand conformation polymorphism (SSCP) can be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:2766; see also Cotton (1993) *Mutat. Res.* 285:125-144; Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control
- 10 nucleic acids will be denatured and allowed to re-nature. The secondary structure of single-stranded nucleic acids varies according to sequence, and the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments can be labeled or detected with labeled probes. The sensitivity of the
- 15 assay can be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) *Trends Genet.* 7:5).
- 20 In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a 'GC clamp' of approximately 40
- 25 base pairs of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys. Chem.* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers can be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) *Nature* 324:163); Saiki et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification can be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification can carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; Gibbs et al. (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatching can prevent or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition, it can be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) *Mol. Cell Probes* 6:1). Amplification can also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein can be performed, for example, using pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which can be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a gene encoding a polypeptide of the invention. Furthermore, any cell type or tissue,

preferably peripheral blood leukocytes, in which the polypeptide of the invention is expressed can be utilized in the prognostic assays described herein.

3. Pharmacogenomics

5 Agents, or modulators which have a stimulatory or inhibitory effect on activity or expression of a polypeptide of the invention as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant activity of the polypeptide. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the
10 relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective
15 agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of a polypeptide of the invention, expression of a nucleic acid of the invention, or mutation content of a gene of the invention in an individual can be determined to thereby select
20 appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a
25 single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as "altered drug metabolism". These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in

which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The
5 discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the
10 population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and
15 side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to
20 be due to CYP2D6 gene amplification.

Thus, the activity of a polypeptide of the invention, expression of a nucleic acid encoding the polypeptide, or mutation content of a gene encoding the polypeptide in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition,
25 pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a modulator of activity or

expression of the polypeptide, such as a modulator identified by one of the exemplary screening assays described herein.

4. Monitoring of Effects During Clinical Trials

5 Monitoring the influence of agents (e.g., drug compounds) on the expression or activity of a polypeptide of the invention (e.g., the ability to modulate aberrant cell proliferation chemotaxis, and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent, as determined by a screening assay as described herein, to increase gene
10 expression, protein levels, or protein activity, can be monitored in clinical trials of subjects exhibiting decreased gene expression, protein levels, or protein activity. Alternatively, the effectiveness of an agent, as determined by a screening assay, to decrease gene expression, protein levels or protein activity, can be monitored in clinical trials of subjects exhibiting increased gene expression, protein levels, or protein
15 activity. In such clinical trials, expression or activity of a polypeptide of the invention and preferably, that of other polypeptide that have been implicated in for example, a cellular proliferation disorder, can be used as a marker of the immune responsiveness of a particular cell.

 For example, and not by way of limitation, genes, including those of the
20 invention, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates activity or expression of a polypeptide of the invention (e.g., as identified in a screening assay described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of
25 expression of a gene of the invention and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of a gene of the invention or other genes. In this way, the gene

expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state can be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for
5 monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of the polypeptide or nucleic acid of the invention
10 in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level the of the polypeptide or nucleic acid of the invention in the post-administration samples; (v) comparing the level of the polypeptide or nucleic acid of the invention in the pre-administration sample with the level of the polypeptide or nucleic acid of the invention in the post-administration
15 sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent can be desirable to increase the expression or activity of the polypeptide to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent can be desirable to decrease expression or activity of the polypeptide to lower
20 levels than detected, i.e., to decrease the effectiveness of the agent.

D. Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a
25 disorder associated with aberrant expression or activity of a polypeptide of the invention and/or in which the polypeptide of the invention is involved. Disorders characterized by aberrant expression or activity of the polypeptides of the invention are described elsewhere in this disclosure.

1. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a polypeptide of the invention, by administering to the subject an agent which modulates expression or at least one activity of the polypeptide. Subjects at risk for a disease which is caused or contributed to by aberrant expression or activity of a polypeptide of the invention can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of aberrance, for example, an agonist or antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating expression or activity of a polypeptide of the invention for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of the polypeptide. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of the polypeptide. Examples of such stimulatory agents include the active polypeptide of the invention and a nucleic acid molecule encoding the polypeptide of the invention that has been introduced into the cell. In another embodiment, the agent inhibits one or more of the biological activities of the polypeptide of the invention. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by

administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a polypeptide of the invention. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay
5 described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) expression or activity. In another embodiment, the method involves administering a polypeptide of the invention or a nucleic acid molecule of the invention as therapy to compensate for reduced or aberrant expression or activity of the polypeptide.

10 Stimulation of activity is desirable in situations in which activity or expression is abnormally low or down-regulated and/or in which increased activity is likely to have a beneficial effect, e.g., in wound healing. Conversely, inhibition of activity is desirable in situations in which activity or expression is abnormally high or up-regulated and/or in which decreased activity is likely to have a beneficial effect.

15 The contents of all references, patents, and published patent applications cited throughout this application are hereby incorporated by reference.

Deposits of Clones

20 Clones encoding the proteins of the invention were deposited with the American Type Culture Collection (ATCC®, 10801 University Boulevard, Manassas, VA 20110-2209) on April 27, 1999 and May 27, 1999. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Each of these deposits was made merely as a convenience to those of skill in the art. These deposits
25 are not an admission that a deposit is required under 35 U.S.C. §112.

Clones comprising cDNA molecules encoding human INTERCEPT 217, human INTERCEPT 297, human TANGO 325, and human TANGO 331 were deposited with ATCC® on May 28, 1999, as part of a composite deposit representing a

mixture of five strains, each carrying one recombinant plasmid harboring a particular cDNA clone. This deposit was assigned Accession Number PTA-147

To distinguish the strains and isolate a strain harboring a particular cDNA clone, an aliquot of the mixture is streaked out to single colonies on nutrient medium
5 (e.g., Luria broth plates) supplemented with 100 micrograms per milliliter ampicillin, single colonies grown, and then plasmid DNA is extracted using a standard mini-preparation procedure. Next, a sample of the DNA mini-preparation is digested using a combination of the restriction enzymes *SalI*, *NotI*, and *SmaI*, and the resultant products are resolved on a 0.8% agarose gel using standard DNA electrophoresis conditions.

10 The digest liberates fragments as follows:

1. human INTERCEPT 217 (clone EpT217): 2.9 kilobases
2. human INTERCEPT 297 (clone EpT297): 1.2 kilobases and 0.3 kilobases
(human INTERCEPT 297 has a *SmaI* cut site at about base pair 1183).
3. human TANGO 325 (clone EpT325): 2.2 kilobases
- 15 4. human TANGO 331 (clone EpT331): 1.4 kilobases

The identity of the strains can be inferred from the fragments liberated.

Human TANGO 276, human TANGO 292, and human TANGO 332 were each deposited as single deposits. Their clone names, deposit dates, and accession numbers are as follows:

- 20 1. human TANGO 276: clone EpT276 was deposited with ATCC® on May 28, 1999, and was assigned Accession Number PTA-150.
2. human TANGO 292: clone EpT292 was deposited with ATCC® on April 28, 1999, and was assigned Accession Number 207230.
3. human TANGO 332: clone EpT332 was deposited with ATCC® on May
25 28, 1999, and was assigned Accession Number PTA-151.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by

5 the following claims.

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule having a nucleotide sequence which is at least 40% identical to the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92 or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

b) a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98 or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, wherein the fragment comprises at least 8 consecutive amino acid residues of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151; and

e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, wherein the nucleic acid

molecule hybridizes to a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof under stringent conditions.

2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

a) a nucleic acid having the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof; and

b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof.

3. The nucleic acid molecule of claim 1, further comprising vector nucleic acid sequences.

4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

5. A host cell which contains the nucleic acid molecule of claim 1.

6. The host cell of claim 5 which is a mammalian host cell.

7. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.

8. An isolated polypeptide selected from the group consisting of:

a) a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, wherein the fragment comprises at least 8 contiguous amino acids of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151;

b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof under stringent conditions; and

c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 40% identical to a nucleic acid consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof.

9. The isolated polypeptide of claim 8 having the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof.

10. The polypeptide of claim 8, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

11. An antibody which selectively binds with the polypeptide of claim 8.

12. A method for producing a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

b) a polypeptide comprising a fragment of the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof, wherein the fragment comprises at least 8 contiguous amino acids of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof; and

c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63,

83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof under stringent conditions;

the method comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:

- a) contacting the sample with a compound which selectively binds with a polypeptide of claim 8; and
- b) determining whether the compound binds with the polypeptide in the sample.

14. The method of claim 13, wherein the compound which binds with the polypeptide is an antibody.

15. A kit comprising a compound which selectively binds with a polypeptide of claim 8 and instructions for use.

16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:

- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes with the nucleic acid molecule; and

b) determining whether the nucleic acid probe or primer binds with a nucleic acid molecule in the sample.

17. The method of claim 16, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

18. A kit comprising a compound which selectively hybridizes with a nucleic acid molecule of claim 1 and instructions for use.

19. A method for identifying a compound which binds with a polypeptide of claim 8 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
- b) determining whether the polypeptide binds with the test compound.

20. The method of claim 19, wherein the binding of the test compound with the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- c) detection of binding using an assay for an activity characteristic of the polypeptide.

21. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds with the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

22. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:

- a) contacting a polypeptide of claim 8 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

23. An antibody substance which selectively binds with the polypeptide of claim 8, wherein the antibody substance is made by providing the polypeptide to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.

NOVEL GENES ENCODING PROTEINS HAVING
DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES

Abstract of the Disclosure

5 The invention provides isolated nucleic acids encoding a variety of
proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses.
These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a
number of human and other animal disorders. The invention also provides antisense
nucleic acid molecules, expression vectors containing the nucleic acid molecules of the
10 invention, host cells into which the expression vectors have been introduced, and non-
human transgenic animals in which a nucleic acid molecule of the invention has been
introduced or disrupted. The invention still further provides isolated polypeptides,
fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and
therapeutic methods utilizing compositions of the invention are also provided. The
15 nucleic acids and polypeptides of the present invention are useful as modulating agents
in regulating a variety of cellular processes.

GTCGACCCACGCGTCCGGGAGCGCGCTAAGAGTGCCGCACCGCCTCACAAACCTGGGAACCGGAGAGTAGGGGCCGTC	79
GGCTGGCAAGAACCCCGCGTCCCTCCTCGCAAGGGCCATCCGGTGCCACCCCATGTCCGACTAGACGAGAAGAGGGTGA	158
GTCCCTGAACTGCAACCTGCACAGAGCTGCTCTGTACTGTCCCTGGTGGTGGCCGCC	229
ATG ACC TGG TTG GTG	5
ATG ACC TGG TTG GTG	229
GTCCCTGAACTGCAACCTGCACAGAGCTGCTCTGTACTGTCCCTGGTGGTGGCCGCC	25
ATG ACC TGG TTG GTG	289
ATG ACC TGG TTG GTG	45
ATG ACC TGG TTG GTG	349
ATG ACC TGG TTG GTG	65
ATG ACC TGG TTG GTG	409
ATG ACC TGG TTG GTG	85
ATG ACC TGG TTG GTG	469
ATG ACC TGG TTG GTG	105
ATG ACC TGG TTG GTG	529
ATG ACC TGG TTG GTG	125
ATG ACC TGG TTG GTG	589

Fig. 1A

R H D L D G L G A L E K L L L L F N N R L 145
 CGC CAC GAC CTC GAC GGG CTG GGG GCG CTG GAG AAG CTG CTT CTG TTC AAT AAC CGC TTG 649

 V H L D E H A F H G L R A L S H L Y L G 165
 GTG CAC TTG GAC GAG CAT GCC TTC CAC GGC CTG CGC GCG CTC AGC CAT CTC TAC CTG GGC 709

 C N E L A S F S F D H L L H G L S A T H L 185
 TGC AAC GAA CTC GCC TCG TCC TTC TCC TCC GAC CAC CTG CAC GGT CTG AGC GCC ACC CAC CTG 769

 L T L D L S S N R L G H I S V P E L A A 205
 CTT ACT CTG GAC CTC TCC TCC AAC CGG CTG GGA CAC ATC TCC GTA CCT GAG CTG GCC GCG 829

 L P A F L L K N G L Y L L H N N P L P C D C 225
 CTG CCG GCC TTC CTC AAG AAC AAC GGC CTC TAC TTG CAC AAC AAC CCT TTG CCT TGC GAC TGC 889

 R L Y H L L L Q R W H Q R G L S A V R D F 245
 CGC CTC TAC CAC CTG CTA CAG CGC TGG CAC CAG CGG GGC CTG AGC GCC GTG CGC GAC TTT 949

 A R E Y V C L A F K V P A S R V R F Q 265
 GCG CGC GAG TAC GTA TGC TTG GCC TTC AAG GTA CCC GCG TCC CGC GTG CGC TTC TTC CAG 1009

 H S R V F E N C S S A P A L G L K R P E 285
 CAC AGC CGC GTC TTT GAG AAC TGC TCG TCG GCC CCA GCT CTT GGC CTA AAG CGG CCG GAA 1069

Fig. 1B

E H L Y A L V G R S L R L Y C N T S V P 305
 GAG CAC CTG TAC GCG CTG GTG GGT TCC CTG AGG CTT TAC TGC AAC ACC AGC GTC CCG 1129

 A M R I A W V S P Q Q Q E L L R A P G S R 325
 GCC ATG CGC ATT GCC TGG GTT TCG CCG CAG CAG GAG CTT CTC AGG GCG CCA GGA TCC CGC 1189

 D G S I A V L A D G S L A I G N V Q E Q 345
 GAT GGC AGC ATC GCG GTG CTG GCC GGC AGC TTG GCC ATA GGC AAC GTA CAG GAG CAG 1249

 H A G L F V C L A T G P R L H H N Q T H 365
 CAT GCG GGA CTC TTC GTG TGC CTG GCC ACT GGG CCC CGC CTG CAC CAC AAC CAG ACG CAC 1309

 E Y N V S V H F P R P E P E A F N T G F 385
 GAG TAC AAC GTG AGC GTG CAC TTT CCG CGC CCA GAG CCC GAG GCT TTC AAC ACA GGC TTC 1369

 T T L L G C A V G L V L V L L Y L F A P 405
 ACC ACA CTG CTG GGC TGT GCC GTG GGC CTT GTG CTC GTG CTC TAC CTG TTC GCC CCA 1429

 P C R C C R A C P L P P L A P N T Q P 425
 CCC TGC CGC TGC TGC CGC CGT GCC TGC CCG CTG CCG CTG GGC CCA AAC ACC CAG CCC 1489

 A P R A E P H K S S V L S T T P P D A P 445
 GCT CCA AGA GCT GAG CCG CAC AAG TCC TCA GTA CTC AGC ACC ACA CCG CCA GAC GCA CCC 1549

Fig. 1C

S	P	Q	G	Q	A	S	T	S	T	*	456																								
AGC	CCG	CAA	GGC	CAA	GCG	TCC	ACA	AGC	ACG	TAG	1582																								
TCT	TTCT	GGAG	CCAG	CCGG	AGGG	CCCT	CAAT	GGCCCC	GGGT	GCAG	CTGC	AGCT	GAG	GAAT	TCG	ATCT	CTACA	ACC	1661																
CTG	AGG	CCCT	GCAG	CTGA	AGG	CTGG	CTCT	GAGT	CCGCC	CAGCT	CCAT	AGG	CTCC	GAGG	TCCC	ATG	ACA	ACC	TAG	ACT	GC	1740													
CAG	GGCT	CCCC	ACCC	AGG	CCCC	ACCC	CTCT	TGCT	GTCT	CGCCC	TGCT	CCCT	GTCT	CCCT	GTCT	CGG	TCC	AG	AACT	GGC	AG	ATA	CT	1819											
GGT	GG	AAG	CAC	TGT	GC	CT	GG	CCCC	CCAG	CTT	CC	TGT	ATG	GG	CT	CG	AA	CACA	AT	GGG	CC	TCT	CG	CT	CAC	TG	GT	GA	1898						
GAC	AGG	GT	TGT	GGT	CCCC	CAAC	CTG	CTCT	GTCCC	CTGC	AC	AGG	ACCC	AAAG	GGCCCC	AGG	CCCT	GC	AA	GGT	GTG	1977													
CTAG	TCC	TGCT	TT	CCCC	GGG	ACTT	CC	TAGT	GCC	CAAT	GCCC	CTGT	GAGG	CTG	AG	AG	ACCC	AGG	CCCC	CTGT	GG	CTT	TCA	2056											
AC	AC	AG	CAC	AG	CTGT	GAAG	TGG	CTGT	GTCT	TCT	TAC	AG	CCCT	GTG	GA	AA	CCCC	CTGT	AG	AG	CCCT	CCCC	AT	CC	ACCC	2135									
TC	AGG	GGCT	GAG	GCAG	CTCT	CG	AGG	AGTGG	TGCT	CA	AG	AGCTG	AC	GC	AGG	CCAC	CTCCCC	T	CCCC	AA	GGGG	TGG	GAG	2214											
GG	AGT	GGG	CCCC	AC	AGG	AA	AGG	CGG	CTCT	GA	AG	GAAG	ATC	TG	CC	CC	AC	ACCC	CCAG	GC	AG	AA	AG	AG	CA	AAG	2293								
CCG	CCCC	CT	GTG	AA	TGG	ACT	CCCC	TCC	ATCC	AC	CA	CCCA	CA	CCCT	CT	CC	TG	AA	AGCTT	C	AC	CA	ACT	T	C	AC	GC	AG	AGT	CC	2372				
GGT	GG	CAG	GC	AC	CG	CA	GG	AA	AGG	CTC	CT	CA	AG	AGG	T	CT	CT	GG	GTCT	GG	CT	TA	AG	CCCC	CC	AG	CC	AG	AG	GG	CC	CT	GT	CTC	2451

Fig. 1D

TCTCTGGCCTGGGGCATCCACCCGTTGTTCTGAAGGCAGAGCCCATTCTGTGGGCTCACAAAGACACAGTGAAGGGGATC 2530
ATGGCCTGCACCCCTGCTTTTCAGCAGTAAAAAGCCCTGGCGAGCATGGCCGAGCTGGGAGGGCCGAGCCG 2609
GAACTCCACGTCCCTCGAGAGCAGGAGCCCTTAAGGGCTGGCACTGGTCTCAGCCCTAATGGCTGAGGGCGGTACCCCTGG 2688
CTTCATATGCATCTCACTGCTCCCACTGCAGGGGGCAGGGAAGGGGGTCTGGGAGCCCCTTCATGTGTGGGGCCGAG 2767
CTGGGGGCCCCCATGGCCATCCTGGACCTCGCTGCCAGAGTTTAATAAAGGTAGCACATGCTTATTGCTAGAAAAAA 2846
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGCGGCCGC 2895

Fig. 1E




Fig. 1F

```

      10      20      30      40      50      60      70
H MTWLVLGTLMLRVGLGTPDSEGFPPRALHNCYPKICAADLLSCTGLGLQDVPAELPAATADLDLSH
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
P MN-LDIHCEQLSDARWTELLPQLQYEVVRLLDDCGLTEEHCKDIGS--ALRANPSLTCLRTNEL--GD
  10      20      30      40      50      60

      80      90      100      110      120      130
H NALQRLRPGWLAPLFQLRALHLDHNELDALGRGVFNA---SGLRLDLLSSNTLRALGRHDL-DGLGA-
  .... :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
P AGVHLVLQGLQSPCKIQKLSLQNCSLTEAGCVLPSTLRSPTLREHLSDNPLGDAGRLLCGLLDP
  70      80      90      100      110      120      130

      140      150      160      170      180      190      200
H ---LEKLLLFNNRLVHLD-EHAFHGLRALSHLYLGCNELASFDFDHLHGLSATHLLTLDLSSNRLGHISV
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
P QCHLEKLQLEYCRLTAASCEPLASVLRATRAL---KELTVSNND--IGEAGARVLGQGLAD-----SA
  140      150      160      170      180      190

      210      220      230      240      250      260
H PELAALPAFLKN-GLYLHNNPLPCDCRLYHLLQRWHQRLSAVRDFAREYVCLAFKVPASRVR---FFQH
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
P CQLETLR--LENCGLTPANCKDLCGIVASQASLRELDLGSNGLGDAGIAELCPGLLSPASRLKTLWLWEC
  200      210      220      230      240      250      260

```

Fig. 1G

```

270      280      290      300      310      320
H SRVFENCSSA-PALGLKRPEEHLIALVGRSL-----RLYCNTSV-PAMRIAWVSPQQELLRAPGSRDGS
. . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P DITASGCRDLCRVLQAKETLKEI-SLAGNKLGDGEGARILLCEILLQPGCQLESILWVKSCSLTAACQHVSL
270      280      290      300      310      320      330

330      340      350      360      370      380      390
H AVLADGSLAIGNVQEQHAGLFVCLATGPRLLHHNQTHEYNVSVHFFRPEPEAFNTGFTLLGCAVGLVLVL
. . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P MLTQNKHL-----LELQLSSNKLGDSGIQELCQALSQPGTTLRVLCIGDCEVTNSGCSSLAS--LLLANRS
340      350      360      370      380      390

400      410      420      430      440      450
H LYLFAPPCRRACPLPPIAPNTQPAPRAEPHK-SSVLSTTPPDAPSPQGQASTS-----T
: . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P LRELDLSNNCVGDPGVLIQLIGSLEQPGCALEQLVLDYTYWTEEVEDRLQALEGSKPGLRVIS
400      410      420      430      440      450

```

Fig. 1H

ccg ttt ctc ttt aac cac ttg cac ggt ctg ggg tta acc cgc ctg cgg 48
 Pro Phe Leu Phe Asn 5 His Leu His Gly Leu Thr Arg Leu Arg 15
 1
 act ctg gac ctc tcc tcc aac tgg ctg aaa cat atc tcc atc cct gag 96
 Thr Leu Asp Leu Ser 20 Ser Ser Asn Trp Leu Lys His Ile Ser 30
 25
 ttg gct gca ctg cca act act tat ctc aag aac agg ctc tac ctg cac aac 144
 Leu Ala Ala Leu Pro Thr Tyr Leu Leu Lys Asn Arg Leu Tyr Leu His Asn 45
 35
 aac ccg ctg ccc tgt gac ggc tgc agc ctc tac cac ctg cgc cgg tgg 192
 Asn Pro Leu Pro Cys Asp 50 Ser Cys Ser Leu Tyr His Leu Arg Arg Trp 60
 55
 cac cag cgg ggc ctg agt agt ggc ctg cat gat ttt gaa cgc gag tac aca 240
 His Gln Arg Gly Leu Ser 70 Ala Leu His Asp Phe Glu Arg Glu Tyr Thr 80
 65
 tgc ttg gtc ttt aag gtg tca gag tcc cga gtg cgc ttt gag cac 288
 Cys Leu Val Phe Lys 85 Val Ser Arg Val Arg Phe Phe Glu His 95
 90
 agc cgg gtc ttc aag aac tgc tct gtg gct gca gct cca ggc tta gag 336
 Ser Arg Val Phe Lys Asn Cys Ser Val Ala Ala Ala Pro Gly Leu Glu 100
 105
 110

Fig. 11

ctg cct gaa gag cag ctg cac gcg cag gtg ggc cag tcc ctg agg ctc 384
 Leu Pro 115 Glu Glu His 120 Gln Val Gly Gln Ser 125 Leu Arg Leu
 ttc tgc aac acc agt gtg cct gcc act cgg gtg gcc tgg gtc tcc ccg 432
 Phe Cys Asn Thr Ser Val 135 Pro Ala Thr Arg Val Ala Trp Val Ser Pro
 aag aat gag ctg ctt gtg gcg cca gcc tct cag gat ggt agc atc gct 480
 Lys Asn Glu Leu 150 Val Val Ala Pro Ala Ser Gln Asp Gly Ser Ile Ala
 145
 gtg ttg gct gat ggc agc tta gcc ata ggc agg gtg caa gag cag cac 528
 Val Leu Ala Asp 165 Gly Ser Leu Ala Ile Gly Arg Val Gln Glu Gln His
 170
 gca ggc gtc ttt gtg tgc ctg gcc agt ggg ccc cgc ctg cac cag aac 576
 Ala Gly Val Phe Val Cys Leu Ala Ser Gly Pro Arg Leu His His Asn
 180 185 190
 cag aca ctt gag tac aat gtg agt gtg caa aag gct cgc ccc gag cca 624
 Gln Thr Leu Glu Tyr Asn Val 200 Ser Val Gln Lys Ala Arg Pro Glu Pro
 195 205
 gag act ttc aac aca ggc ttt acc acc ctg ggc tgt att gtg ggc 672
 Glu Thr Phe Asn Thr Gly Phe Thr Thr Leu Leu Gly Cys Ile Val Gly
 210 215 220

Fig. 1J


```

ctg gtg ctg gtg ttg ctc tac ttg ttt gca cca ccc tgt cgt ggc tgc      720
Leu Val Leu Val Leu Leu Leu Tyr Leu Phe Ala Pro Pro Cys Arg Gly Cys
225                               230
tgt cac tgc tgt cag cgg gcc tgc tgc cgc aac cgt tgg ccc cgg gca      768
Cys His Cys Cys Gln Arg Ala Cys Arg Asn Arg Cys Trp Pro Arg Ala
                               245      250      255
tcc agt cca ctc cag gag ctg agc gca cag tcc tcc atg ctt agc act      816
Ser Ser Pro Leu Leu Gln Ser Ala Gln Ser Ser Met Leu Ser Thr
                               260      265
acg cca cca gat gca cca ccc agc cgc aag gcc agt gtc cac aag cat gtg      864
Thr Pro Pro Asp Ala Pro Ser Arg Lys Ala Ser Val His Lys His Val
                               275      280      285
gtc ttc ctg gag ccg ggc gag aag aag ggc ctc aat ggc cgt gtg cag ctc      912
Val Phe Leu Glu Pro Gly Lys Lys Gly Leu Asn Asn Gly Arg Val Gln Leu
                               290      295      300
gca gta cct cca gac tcc gat ctg tgc aac ccc atg ggc ttg caa ctc      960
Ala Val Pro Pro Asp Ser Asp Leu Cys Asn Pro Met Gly Leu Gln Leu
305                               310      315      320
aa
962

```

Fig. 1K




Fig. 1L

```

M      1 .....PFLFNHLHGIGLTRLRLDLDSSNWLKHISI      30
      | | | | | | | | | | | | | | | | | | | | | |
H    151 HAFHGLRALSHLYIGCNELASFDFHLHGLSATHLLTLDLSSNRLGHISV 200

M      31 PELAALPTYIKNRLYLHNPNLPDCSCLYHLLRRWHQRGLSALHDFEREY 80
      | | | | | : | | | | | | | | | | | | | | | | | | | | | |
H    201 PELAALPAFLKNGLYLHNPNLPDCRCRLYHLLQRWHQRGLSAVRDFAREYV 250

M      81 CLVFKVSESRVRFEEHSRVFKNCVAAAPGLELPEEQHQAQVGSRLRFC 130
      | | | | | : | | | | | | | | | | | | | | | | | | | | | |
H    251 CLAFKVPASRVRFHQHSRVFENCSSAPALGLKRPEEHLYALVGRSLRLYC 300

M     131 NTSVPATRVAVWSPKNEILLVAPASQDGSIAVLADGSLAIGRVQEQHAGVF 180
      | | | | | : | | | | | | | | | | | | | | | | | | | | | |
H    301 NTSVPAMRIAWVSPQQLLRAFGSRDGSIAVLADGSLAIGNVQEQHAGLF 350

M     181 VCLASGPRLHHNQTL EYNVSQKARPEPETFNTGFTLLGCIVGLVLVLL 230
      | | | | | . | | | | | | | | | | | | | | | | | | | | | |
H    351 VCLATGPRLHHNQTHEYNVSVHFPRPEAFNTGFTLLGCAVGLVLVLL 400

M     231 YLFAPPCRGCHCCQACRNRCWPRASSPLQELSA.QSSMLSTTTPPDAPS 279
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
H    401 YLFAPPCR...CCRRACPLPPLAPNTQAPAPRAEPHKSSVLSTTTPPDAPS 446

M     280 RKASVHKHVVFLEPGKKGLNGRVQLAVPPDSDL CNP MGLQL 320

H    447 PQQASTST..... 455

```

Fig. 1M

Fig. 2A

T	I	A	G	L	V	V	G	L	A	D	L	L	S	K	H	D	S	Q	170	
ACC	ATC	GCG	GGG	CTG	GTG	GTC	GTG	GGC	CTG	GCT	GAC	CTC	CTG	AGC	AAG	CAC	GAC	AGT	CAG	549
H	K	L	S	E	V	I	T	G	D	L	L	I	I	M	A	Q	I	I	V	190
CAC	AAG	CTC	AGC	GAA	GTG	ATC	ACA	GGG	GAC	CTG	TTG	ATC	ATC	ATG	GCC	CAG	ATC	ATC	GTT	609
A	I	Q	M	V	L	E	E	K	F	V	Y	K	H	N	V	H	P	L	R	210
GCC	ATC	CAG	ATG	GTG	CTA	GAG	GAG	AAG	TTC	GTC	TAC	AAA	CAC	AAT	GTG	CAC	CCA	CTG	CGG	669
A	V	G	T	E	G	L	F	G	F	V	I	L	S	L	L	L	V	P	M	230
GCA	GTT	GGC	ACT	GAG	GGC	CTC	TTT	GGC	TTT	GTG	ATC	CTC	TCC	CTG	CTG	CTG	GTG	CCC	ATG	729
Y	Y	I	P	A	G	S	F	S	G	N	P	R	G	T	L	E	D	A	L	250
TAC	TAC	ATC	CCC	GCC	GGC	TCC	TTC	AGC	GGA	AAC	CCT	CGT	GGG	ACA	CTG	GAG	GAT	GCA	TTG	789
D	A	F	C	Q	V	G	Q	Q	P	L	I	A	V	A	L	L	G	N	I	270
GAC	GCC	TTC	TGC	CAG	GTG	GGC	CAG	CAG	CCG	CTC	ATT	GCC	GTG	GCA	CTG	CTG	GGC	AAC	ATC	849
S	S	I	A	F	F	N	F	A	G	I	S	V	T	K	E	L	S	A	T	290
AGC	AGC	ATT	GCC	TTC	TTC	AAC	TTC	GCA	GGC	ATC	AGC	GTC	ACC	AAG	GAA	CTG	AGC	GCC	ACC	909
T	R	M	V	L	D	S	L	R	T	V	V	I	W	A	L	S	L	A	L	310
ACC	CGC	ATG	GTG	TTG	GAC	AGC	TTG	CGC	ACC	GTT	GTC	ATC	TGG	GCA	CTG	AGC	CTG	GCA	CTG	969

Fig. 2B

Fig. 2C




Fig. 2D

GTCGACCCACGCGTCCGCGGACAGCTGGCCTGAAGCTCAGAGCCGGCGGTGGCC																ATG	GCC	CCA	CAC	TGG	5
A	V	W	L	L	A	A	R	L	W	G	L	G	I	G	A	E	V	W	W	72	
GCT	GTC	TGG	CTG	CTG	GCA	GCA	AGG	CTG	TGG	GGC	CTG	GGC	ATT	GGG	GCT	GAG	GTG	TGG	TGG		
N	L	V	P	R	K	T	V	S	S	G	E	L	A	T	V	V	R	R	F	25	
AAC	CTT	GTG	CCG	CGT	AAG	ACA	GTG	TCT	TCT	GGG	GAG	CTG	GCC	ACG	GTA	GTA	CGG	CGG	TTC	132	
S	Q	T	G	I	Q	D	F	L	T	L	T	L	T	E	P	T	G	L	L	45	
TCC	CAG	ACC	GGC	ATC	CAG	GAC	TTC	CTG	ACA	CTG	ACG	CTG	ACG	GAG	CCC	ACT	GGG	CTT	CTG	192	
Y	V	G	A	R	E	A	L	F	A	F	S	M	E	A	L	E	L	Q	G	65	
TAC	GTG	GGC	GCC	CGA	GAG	GCC	CTG	TTT	GCC	TTC	AGC	ATG	GAG	GCC	CTG	GAG	CTG	CAA	GGA	252	
A	I	S	W	E	A	P	V	E	K	K	T	E	C	I	Q	K	G	K	N	85	
GCG	ATC	TCC	TGG	GAG	GCC	CCC	GTG	GAG	AAG	AAG	ACT	GAG	TGT	ATC	CAG	AAA	GGG	AAG	AAC	312	
N	Q	T	E	C	F	N	F	I	R	F	L	Q	P	Y	N	A	S	H	L	105	
AAC	CAG	ACC	GAG	TGC	TTC	AAC	TTC	ATC	CGC	TTC	CTG	CAG	CCC	TAC	AAT	GCC	TCC	CAC	CTG	372	
Y	V	C	G	T	Y	A	F	Q	P	K	C	T	Y	V	V	S	A	A	L	125	
TAC	GTC	TGT	GGC	ACC	TAC	GCC	TTC	CAG	CCC	AAG	TGC	ACC	TAC	GTC	GTG	AGT	GCT	GCC	CTC	432	
																				492	

Fig. 3A

L P R C P Q P P A L L T L L L W T R G C G 165
 CTA CCT CGG TGT CCC CAG CCC CCC GCC CTC CTC CTT CTC TGG ACT CGT GGA TGT GGC 552

 P Q S P A L K H L L I T S L S V L R T C 185
 CCA CAG AGC CCT GCC CTT AAG CAT CTC CTC ATC ACC TCT CTC TCT GTC CTT AGA ACA TGC 612

 S P S L W S M E S L K M G R A S V P M T 205
 TCA CCT TCA CTT TGG AGC ATG GAG AGT TTG AAG ATG GGA AGG GCA AGT GTC CCT ATG ACC 672

 Q L R A M L A F L W M V S C T R P H S T 225
 CAG CTA AGG GCC ATG CTG GCC TTC TTG TGG ATG GTG AGC TGT ACT CGG CCA CAC TCA ACA 732

 T S W A R N P L S C V T W G P T P * 244
 ACT TCC TGG GCA CGG AAC CCA TTA TCC TGC GTA ACA TGG GGC CCC ACC ACT CCA TGA 789

 AGACAGAGTACCTGGCCCTTTTGGCTCAACGAACCTCACTTTGTAGGCTCTGCCCTATGTACCTGAGAGTGTGGCAGCTT 868

 CACGGGGACGACGACAAGGTCTACTTCTTTCAGGGAGCGGGCAGTGGAGTCCGACTGCTATGCCGAGCAGGTGGTG 947

 GCTCGTGTGGCCCGTGTCTGCAAGGGCGATATGGGGGGCGACGCCCTGCAGAGGAAGTGGACCACGTTCCCTGAAGG 1026

 CGCGGCTGGCATGCTCTGCCCCGAACTGGCAGCTCTACTTCAACCAGCTGCAGGCGATGCACACCCCTGCAGGACACCTC 1105

Fig. 3B

Fig. 3C

Fig. 3C

GACAGATACTGCCCCAGCACCCACCCGGCCATGAGGACCTGCTCTGCTCAGCACGGGCACCTGCCACTTGGTGTGGCTCAC 2132
 CAGGGCACCGCCTCGCAGAAGGCATCTTCCTCCTCTCTGTGAATCACAGACACGGGGACCCAGCCGCCAAAACCTTT 2211
 TCAAGGCAGAAGTTCAAGATGTGTGTTTGTCTGTATTTGCACATGTGTGTTGTGTGTGTGTGTGTGTGTGTGTGCACGC 2290
 GCGTGGCGCCTTGTCGATAGCCCTTCCTGTTTCTGTCAAGTCCTCCCTGGCCTGGGTCCCTGGTGAGTCATTGGAG 2369
 CTATGAAGGGAAGGGTCCGTATCACTTTGTCTCTCCTACCCCCACTGCCCCGAGTGTCCGGCAGCGATGTACATATGG 2448
 AGGTGGGTGGACAGGTGCTGTGCCCCCTTCAGAGGAGTGCAGGGCTTGGGGTGGGCCCTAGTCCTCCTAGGGCTG 2527
 TGAATGTTTTCAGGGTGGGGGAGGAGATGGAGCCCTCCTGTGTGTTTGGGGGGAAGGGTGGTGGGGCCTCCCACCTG 2606
 GCCCCGGGTTCAGTGGTATTTTATACTTGCCCTTCTCCTGTACAGGGCTGGGAAGGCTGTGTGAGGGGAGAGAAAGGG 2685
 AGAGGTGGGCCCTGCTGTGGACAATGGCATACTCTCTTCCAGCCCCTAGGAGGAGGGCTCCTAACAGTGTAACCTTATGT 2764
 GTCCCCCGGTATTTATTTGTTGTAATAATTTTGAGATTTTATATATGA 2811

Fig. 3D




Fig. 3E

Fig. 3F

```

360      370      380      390      400      410      420
M QAQWARYTDPVSPRPGSCINNWHRDNGYTSSLELPDNTLFIKKHPLMEDQVKPRLGRPLLVKKNTNF
H ---WTR-----GCGPQ-----SPAL-----KH-----LLI-----TSL
160

430      440      450      460      470      480      490
M THVVADRVPGLDGATYTVLFIGTGDGWLKAVSLGPWIHMVEELQVDFQEPVESLVLSQSKKVLFAGSRS
H S-----VLRTCSPSLW-----SMESLKMGRA-----SVPMT
180      190      200

500      510      520      530      540      550      560
M QLVQLSLADCTKYRFCVDCVLARDPYCAWNVTSRCVATTSGRSGSFLVQHVANLDTSKMCNQYGIKKVR
H QLRAM-LA-----F-----L-----WMVSCTRPHSTTS-----
210      220

570      580      590      600      610      620      630
M SIPKNI TVVSGTDLVLPCHLSSNLAAHAWTFGSQDLPAEQPGSFLYDTGLQALVMAAQSRHSGPYRCYS
H -----W-----

640      650      660      670      680      690      700
M EEQTRLAESYLVA VVAGSSVTLEARAPLENIGLVWLAVVALGAVCLVLLLVLSLRRRLREELEKGAK
H -----ARNPLS-----CVT-----
230

```

Fig. 3G

```

710      720      730      740      750      760      770
M ASERTLVYPLELPKEPASPPFRPGPETDEKLWDVPVGYYSDSLKI VPGHARCQPGGGPPSPPPGIPGQP
      :
H -----W-----GPTTP-----
                                240

780      790      800      810      820      830
M LPSPTRLHLGGGRNSNANGYVRLQLGGEDRGGSGHPLPELADELRRKLQQRQPLPDSNPPESSV
H -----

```

Fig. 3H

```

10      20      30      40      50      60      70
M GGCACGAGGTGCCCGGAGTCAAACGCCGAGGCCAGGCCAGGATTGGAGCTGCACGAAAGAGGGCTGCTG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTC-----GACC-----CACG-----CGTC-----CGCG-----GGACAGCTG
10      20
80      90      100     110     120     130     140
M GACTGAAGTTTAGACCCCTGGGTGTCTGCCATGGCCCCACACTGGGCTGTCTGGCTGCTGGCAGCAGGGCT
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GCCTGAAGCTCAGAGCCCGGGCGTGCGCCATGGCCCCACACTGGGCTGTCTGGCTGCTGGCAGCAAGGCT
30      40      50      60      70      80      90
150     160     170     180     190     200     210
M GTGGGCGCTGGGCATCGGGCTGAGATGTGGTGAACCTTGTGCCCGGAAAGACAGTATCTTCTGGGGAG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTGGGCGCTGGGCATTGGGCTGAGGTGTGGTGAACCTTGTGCCCGGTAAGACAGTGTCTTCTGGGGAG
100     110     120     130     140     150     160
220     230     240     250     260     270     280
M CTGGTCACAGTAGTGAGGCGGTTCTCCCCAGACAGGCATCCAGGACTTCCTGACACTGACCCCTGACAGAAC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H CTGGCCACGGTAGTACGGCGGTTCTCCCCAGACCGGCATCCAGGACTTCCTGACACTGACGCTGACGGAGC
170     180     190     200     210     220     230
290     300     310     320     330     340     350
M ATTCTGGCCTTTTATATGTGGGGGCCCCGAGAGGCGCTGTTGCCCTTCACTGTAGAGGCTCTGGAGCTGCA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H CCACTGGGCTTCTGTACGTGGGCGCCCCGAGAGGCCCTGTTTGCCTTTCAGCATGGAGGCCCTTGGAGCTGCA
240     250     260     270     280     290     300

```

Fig. 3I

Fig. 3J

Fig. 3J

```

710      720      730      740      750      760      770
M TCAAGACAGAGTACCTGGCTTTTGGCTGAATGAACCCCACTTTGTAGGCTCTGCCTTTGTCCCTGAGAG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----AGAGCCCTGCCCTTAAGC-----ATCTCCTCATCAC---CTCTCTCTGTCTCC-TTAGA-
560      570      580      590      600

780      790      800      810      820      830      840
M TGTGGGAAGCTTCACGGGAGACGATGACAAGATCTACTTCTTCTTCAGTGAGCGGGCAGTGGAGTATGAC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----ACATGCTCACCTTCA-CTT-TG-GAGCA---TGGAGAGTTTGA-
610      620      630      640

850      860      870      880      890      900      910
M TGTCTATCCGAGCAGGTGGTGGCTCGTGTGGCGAGAGTCTGTAAAGGTGACATGGGGGAGCAGGACGC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----AGATGG-----GAAGGGCAAGTGTCT-----C-----CTATGACCCC
650      660      670

920      930      940      950      960      970      980
M TGCAGAAGAAATGGACGACGTTCCCTGAAGGCTCGGTTGGTGTGCTCAGCCCCCTGACTGGAAGGTCTACTT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H AGCTAAGGGCCCATGCTGGCCTTCTTGT-GGATGGTGAGCTGTACTCGGCCAC--ACT-----CAACAA
680      690      700      710      720      730

990      1000      1010      1020      1030      1040      1050
M CAACCAGCTGAAGGCGGTGCACACCCTGCGGGGCGCCTCTTGGCACAAACACCACCTTCTTCGGGGTTTTT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H CTTCCCTG-----GGCA-----CGGAAC-CCA-TTATC-----CTGCG-----TAA
740      750      760      770

```

Fig. 3K

```

1060      1070      1080      1090      1100      1110      1120
M CAAGCGGATGGGGCGATATGGACCTGTCTGCAGTTTGTGAGTACCAGTTGGAACAGATCCAGCAAGTGT
::      :::::      ::      ::::      ::::      :      ::::
H CA-----TGGGGC-----CC-----C-----ACCA-----C-----TCCA-----
770

1130      1140      1150      1160      1170      1180      1190
M TTGAGGGTCCCTACAAGGAGTACAGTGAGCAAGCCAGAAAGTGGGCCCCGTATACTGACCCGGTACCCAG
:::      ::      :::::      :::::      ::      ::      ::      ::
H -TGAAG-----ACA--GAGTAC-----CTGGCC---T---TTTGGCTCAACGAACCTCACTTTGTA---GG
790      800      810      820      830

1200      1210      1220      1230      1240      1250      1260
M CCCTCGGCCTGGTTCTGTATCAACAACCTGGCACCCGAGACAATGGCTACACCAGTTCCCTGGAACCTGCCG
:      ::      :::::      :::::      :::::      ::      ::      ::      ::
H C--TCTGCCTA-----TGTA-C-----CTGA-----GAGT-GTGGGCAGCTTCA---CGGGGGACGAC--
840      850      860      870      880

1270      1280      1290      1300      1310      1320      1330
M GACAACACCCCTCAACTTCATCAAGAAGCACCCCTGTATGGAGGACCAGGTGAAGCCTCGGTGGGGCCGCC
:::      :      :::::      :::::      :::::      ::      ::      ::
H GACAAGGTCTACTTCTTCTCAGGGAGC-----GGGC--AGTGGAGTC-CGA-----
890      900      910      920

1340      1350      1360      1370      1380      1390      1400
M CCCTACTTGTGAAGAAGAACACTAATTCAACACACGTGGTGGCCGACAGGGTCCAGGGCTTGATGTGC
:::      ::      ::      :::::      :::::      ::      ::      ::
H --CTGCTA-----TGC--CGAGCAGGTGGTGGC-----TC-----GTGTGGC
930      940      950

```

Fig. 3L

```

1410      1420      1430      1440      1450      1460      1470
M CACCTATACAGTGTGTTTCATTGGTACAGGAGATGGCTGGCTGCTGAAGGCTGTGAGCCCTGGGGCCCTGG
: . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H C--CGTGTCTG-----CAAGGG--C--GATATGGGGGGC-----GCA-----C--GGACCCCTG--
960      970      980      990

1480      1490      1500      1510      1520      1530      1540
M ATCCACATGGTGGAGGAACTGCAGGTGTTTGACCAAGGAGCCAGTGGAAAGTCTGGTGTCTCAGAGCA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----CA-----GAGGAA-----GTG---GACCACGTTCCCTG---AAGGC---GCGG---CTG-GCA
1000      1010      1020      1030

1550      1560      1570      1580      1590      1600      1610
M AGAAGGTGCTCTTTGCTGGCTCCCGCTCTCAGCTGTTTCAGCTGTCTCTGCGCGACTGCACAAAGTACCG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----TGCTCT-----GC-CCCGAACT-GGCAG-CTCTACT-TCA---ACCAGCTGCA---GG---CG
1040      1050      1060      1070      1080

1620      1630      1640      1650      1660      1670      1680
M TTTCTGTAGACTGTGTCCCTGGCCAGGGACCCCTTACTGTGCCCTGGAATGTCAACACCAGCCGCTGTGTG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H ATGC-----ACA---CCCTG--CAGGACACCT-----CCTGGCA---CAACACCACCTTCTTTGGG
1090      1100      1110      1120      1130

1690      1700      1710      1720      1730      1740      1750
M GCCACCACAGTGTGCTCGGCTCGGGTCCCTTTCTGGTCCAACATGTGGCGAACTTGGACACTTCAAAGATGT
: . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTTT--TTCAA-----GCACAGTGG-----GGT--GACATGTACCTGTC---GGC-CATCTG---TGA
1140      1150      1160      1170

```

Fig. 3M

```

1760      1770      1780      1790      1800      1810      1820
M GTAACCAAGTATGGCATTAATAAAGTCAGATCTATTCCCAAGAACATCACCGTTGTGTACGGCACAGACCT
::: ::::: :::      ::: :::::      ::: ::: : ::: : :::
H GTA-CCAGT-TGG-----AAG--AGATC-----CAGCG--GGTGTTTGAGG-----
1180      1190      1200      1210
M GGTCCCTACCCCTGCCACCTCTCGTCCAATTGGCCCATGCCCACTGGACCTTCGGAAGCCAGGACCTGCCT
1830      1840      1850      1860      1870      1880      1890
H -----GCC-----CCTATAAGGA--GTACC--ATGA-----GGAAGC-----CCA
1220      1230      1240

1900      1910      1920      1930      1940      1950      1960
M GCAGAACAACTGGCTCCTTTCTTTATGACACGGGACTCCAGGCGTGGTGGTATGCCCGCACAGTCCC
: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
H GAAGTGGGACC--GCTAC--ACT----GACCCCTGTAC--CCAGGCCCTGGTTGTGATGGCTGCCCAGCCCC
1250      1260      1270      1280      1290      1300

1970      1980      1990      2000      2010      2020      2030
M GTCACCTCTGGACCCCTATCGTTGCTATTTCAGAGGAGCAGGGACAAAGACTGGCTGCAGAAAGCTACCTTGT
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GCCATGCCGGGGCCCTACCACTGCTTTTCAGAGGAGCAGGGGCGCGGCTGGCTGCTGAAGGCTACCTTGT
1310      1320      1330      1340      1350      1360      1370

2040      2050      2060      2070      2080      2090      2100
M TGCTGTCTGGCCGGCTCGTCGGTGACACTGGAGGCACGGGCTCCCTTGGAACCTGGGGCTCGTGTGG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GGCTGTCTGGCAGGCCCGTCTGGTGACCTTGGAGGCCCGGGCCCCCTGGAAACCTGGGGCTGGTGTGG
1380      1390      1400      1410      1420      1430      1440

```

Fig. 3N

Fig. 30

Fig. 3P

```

2800      2810      2820      2830      2840      2850      2860
M ACTTCAGCCTCACAGGAGACA-CACCCCTCCTCT--GTGAATTGAGACATGTGGACCCAGCAGCCAAA
.. : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GCACCAGCCTCGCAGAAGGCATCTTCCTCCTCTCTGTGAATCACAGACGCGGGACCCAGCCGCCAAA
2140      2150      2160      2170      2180      2190      2200

2870      2880      2890      2900      2910      2920
M ACTTTGCAAGGAAGAGGTTTCAAGATGTGGCGGTGTTTGTGCAT--ATATGTGTGGTATGCATGTGGAA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H ACTTTTCAAGGCAGAGATTTCAGATGTGTGTTTGTCTGTATTGACACATGTGTTTGTGTGTGTAT
2210      2220      2230      2240      2250      2260      2270

2930      2940      2950      2960      2970      2980      2990
M GAATGTGTGTGTGTGTGTG---TGTGTTGTAACCTTCCCTGTCTCTATCACGTCTTCCCTTGGCCTGG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTGTGTGTGCACGCGCGTGGCGCCTTGTGGCATAGCCTTCCCTGTTCTGTCAAGTCTTCCCTTGGCCTGG
2280      2290      2300      2310      2320      2330      2340

3000      3010      3020      3030      3040      3050      3060
M GGTCCCTCCTGGTTGAGTCCTTTGGAGCTATGAAGGGGAAGGGGTCAATAGCACTTTGCTTCTCCTACCCCC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H G-TCCCTCCTGGT-GAGTCATTGGAGCTATGAAGGGGAAGGGG-TCGTATCACTTTGTCTCTCCTACCCCC
2350      2360      2370      2380      2390      2400      2410

3070      3080      3090      3100      3110      3120      3130
M AGCTGTCCCAAGCTTTGGGCAGTGATGTACATACGGGGGAAGGAAGGACAGGGTGTGTACCCCTTTTG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H A-CTGCCCCCGAG-TGTCGGGCAGCGATGTACATATGGAGGTGGGTGGACAGGGTGTGTGCCCTTCAG
2420      2430      2440      2450      2460      2470      2480

```

Fig. 3Q


```

3140      3150      3160      3170      3180      3190      3200
M GGGAGTGGGACTCGGGGTGGGCTAGCCCTGCTCCTAGGGCTGTGAATGTTTTCAGGGCGGGGTT
. . . . .
H AGGAGTGCAGGGCT-TGGGGTGGGCTAGTCCCTGCTCCTAGGGCTGTGAATGTTTTCAGGGTGGGGGA
2490      2500      2510      2520      2530      2540      2550

3210      3220      3230      3240      3250      3260      3270
M GGGGTGGAGATGGAACCTCCTGC--TTCAGGGGAGGGGTGGCAGGCCCTCCACTTGCCCTCCGGG
. . . . .
H GGG-----AGATGGAGCCCTCCTGTGTGTTTGGGGGAAGGGTGGTGGGCCCTCCACTTGCCCCCGGG
2560      2570      2580      2590      2600      2610

3280      3290      3300      3310      3320      3330
M TTCGGTGGTATTTTATATTTGCGCTCTTC-TG-ACAGGGCTGGGAAGG--TTGTTGGGGAGGAAGG
. . . . .
H TTCAGTGGTATTTTATACTTGCCCTTCTTCCCTGTACAGGGCTGGGAAGGCTGTGTGAGGGAGAGAAGG
2620      2630      2640      2650      2660      2670      2680

3340      3350      3360      3370      3380      3390      3400
M AGGAGGTGGGCATGCTATGGATACTGGCCCTATCCTCTCCCTGCTCTGGGAAAGGGCT--AACAGTGTA
. . . . .
H AGAGGGTGGGCCTGCTGTGGACAAATGGCATACTCTCTCCAGCCCTAGGAGGAGGGCTCCTAACAGTGT
2690      2700      2710      2720      2730      2740      2750

3410      3420      3430      3440      3450      3460      3470
M ACTTATTGTGTCGCCACATATTTATTGTTGTAAATAATTGAGTATTTTATATTGACAAATAAAATGGA
. . . . .
H ACTTATTGTGTCGCCGATTTATTGTTGTAAATAATTGAG-ATTTTATATTGA-----
2760      2770      2780      2790      2800      2810

```

Fig. 3R

GTCGACCCACGGTCCGCGACGGTGGGCGCGGGGCCCATCCAGACCTCGGGAGAGCGAGGCCCGGAGCGTCCGCC 79
 GAGGTTTGAGGGCGCGGAGACCGAGGGCCCTGGCGGCCGAAGAACCGCCCCCAAGAAAGAGCCCTCTGGCCCCGGGGGCTGC 158
 TGGAACATGTGCGGGGGACACAGTTTGTGACAGTTGCCAGACT ATG TTT ACG CTT CTG GTT CTA CTC 8
 228
 S Q L P T V T L G F P H C A R G P K A S 28
 AGC CAA CTG CCC ACA GTT ACC CTG GGG TTT CCT CAT TGC GCA AGA GGT CCA AAG GCT TCT 288
 K H A G E E V F T S K E E A N F F I H R 48
 AAG CAT GCG GGA GAA GAA GTG TTT ACA TCA AAA GAA GAA AAC TTT TTC ATA CAT AGA 348
 R L L Y N R F D L E L F T P G N L E R E 68
 CGC CTT CTG TAT AAT AGA TTT GAT CTG GAG CTC TTC ACT CCC GGC AAC CTA GAA AGA GAG 408
 C N E E L C N Y E E A R E I F V D E D K 88
 TGC AAT GAA GAA CTT TGC AAT TAT GAG GAA GCC AGA GAG ATT TTT GTG GAT GAA GAT AAA 468
 T I A F W Q E Y S A K G P T T K S D G N 108
 ACG ATT GCA TTT TGG CAG GAA TAT TCA GCT AAA GGA CCA ACC ACA AAA TCA GAT GGC AAC 528

Fig. 4A

R E K I D V M G L L L T G L I A A G V F L 128
 AGA GAG AAA ATA GAT GTT ATG GGC CTT CTG ACT GGA TTA ATT GCT GCT GGA GTA TTT TTG 588

 V I F G L L L G Y Y L C I T K C N R L Q H 148
 GTT ATT TTT GGA TTA CTT GGC TAC TAT CTT TGT TGT ATC ACT AAG TGT AAT AGG CTA CAA CAT 648

 P C S S A V Y E R G R H T P S I I F R R 168
 CCA TGC TCT TCA GCC GTC TAT GAA AGG GGC AGG CAC ACT CCC TCC ATC ATT TTC AGA AGA 708

 P E E A A L S P L P P S V E D A G L P S 188
 CCT GAG GAG GCT GCC TTG TCT CCA TTG CCG CCT TCT TCT GTG GAG GAT GCA GGA TTA CCT TCT 768

 Y E Q A V A L S P L T R K H S V S P P P Y P 208
 TAT GAA CAG GCA GTG GCG CTG ACC AGA AAA CAC AGT GTT TCA CCA CCA CCA CCA TAT CCT 828

 G H T K G F R V F K K S M S L P S H * 227
 GGG CAC ACA AAA GGA TTT AGG GTA TTT AAA AAA TCT ATG TCT CTC CCA TCT CAC TGA 885

 CTACCTTGTCATTTTGGTATAAGAAATTTGTGTTATTGTATAGCCGGGCATGGTGGCTCATGCCCTGTAAATCCCAGCAC 964

 TTTGGGAGGCCAGGAGTTCGAGACCAGCCCTGGCCAAACATGGTGAAACCCGGTCTCTACTAAAAAATTCAAAAATTACCTA 1043

 GCGTCATGGGGCATGCCTGTAGTCCACCTACTTGGAGGCTGAAGCAGGAGAAATTGCTCGAACCTGGGAGGCAGAGG 1122

Fig. 4B

Fig. 4C

Fig. 4C




Fig. 40

GTCGACCCAC	CGTCCGCTG	CGTTCTCACC	CCTGGACCAC	CCTGGGAGAA	CAGTTGACCG	60
AAGTTTGTTT	GGCAGTTGCT	GCTGGACT	ATG TTT CTG	CTT CTG	GTG GTA CTC	112
			Met Phe Leu	Leu Val	Val Leu	
			1	5		
AGC CAG CTG	CCC AGA CTT	ACC CTC	GCG GTT	CCT CAT	ACA AGA AGC CTA	160
Ser Gln Leu	Pro Arg Leu	Thr Leu	Ala Val	Pro His	Thr Arg Ser Leu	
			15	20		
			10			
AAG AAT TCT	GAA CAT GCC	CCA GAA	GGA GTC	TTT GCA	TCA AAA AAA GCA	208
Lys Asn Ser	Glu His Ala	Pro Glu	Gly Val	Phe Ala	Ser Lys Lys Ala	
			30	35	40	
			25			
GCA AGC ATC	TTT ATG CAC	CGT CGC	CTC CTA	TAC AAT	AGA TTT GAT TTA	256
Ala Ser Ile	Phe Met His	Arg Arg	Leu Leu	Tyr Asn	Arg Phe Asp Leu	
			45	50	55	
GAA CTC TTC	ACT CCC	GGG AAC	CTG GAG	AGA GAG	TGC TAT GAG GAG TTC	304
Glu Leu Phe	Thr Pro	Gly Asn	Leu Leu	Glu Arg	Glu Cys Tyr Glu Phe	
			60	65	70	
TGT AGT TAT	GAA GAA GCC	AGA GAG	ATC CTC	GGG GAC	AAC GAA GAA ATG	352
Cys Ser Tyr	Glu Glu Ala	Arg Arg	Glu Ile	Leu Gly	Asn Asp Glu Met	
			75	80	85	

Fig. 4E

ATC ACA TTC TGG CGG GAA TAT TCA GTC AAA GGA CCA ACC ACA AGA TCA	400
Ile Thr Phe Trp Arg Glu Tyr Ser Val Lys Gly Pro Thr Arg Ser	
90	
95	
GAT GTC AAC AAA GAG AAA ATT GAT GTT ATG GGC CTT CTG ACT GGC TTA	448
Asp Val Asn Lys Glu Lys Ile Asp Val Met Gly Leu Thr Gly Leu	
105	
110	
115	
ATT GCG GCT GGA GTA TTC TTG GTT TTT GGC TTA CTT GGT TAC TAT	496
Ile Ala Ala Gly Val Phe Leu Val Val Phe Gly Leu Leu Gly Tyr Tyr	
125	
130	
CTG TGT ATC ACC AAG TGT AAT AGG CAG CCA TAT CAA GGT TCT TCA GCT	544
Leu Cys Ile Thr Lys Cys Asn Arg Gln Pro Tyr Gln Gly Ser Ser Ala	
140	
145	
GTC TAC ACA AGA AGG ACC AGG CAC ACA CCG TCC ATC ATC TTC AGA ACC	592
Val Tyr Thr Arg Arg Thr Arg His Thr Pro Ser Ile Ile Phe Arg Thr	
155	
160	
165	
CAT GAG GAA GCT GTC TTC TCT CCA TCG TCA TCC TCA GAG GAC GCG GGA	640
His Glu Glu Ala Val Leu Ser Pro Ser Ser Ser Ser Glu Asp Ala Gly	
170	
175	
180	

Fig. 4F

CTA CCT TCC TAT GAA CAG GCA GTA GCT CTG ACC AGA AAA CAC AGT GTC	688
Leu Pro Ser Tyr Glu Gln Ala Val Ala Leu Thr Arg Lys His Ser Val	200
185	
TCA CCA CCA CCT CCA TAT CCT GGG CCA GCA AAA GGA TTT AGG GTA TTT	736
Ser Pro Pro Pro Tyr Pro Gly Pro Ala Lys Gly Phe Arg Val Phe	215
205	
AAA AAG TCA ATG TCA CTC CCA TCT CAC TAAGCCCACC TTGCCGCGCTT	783
Lys Lys Ser Met Ser Leu Pro Ser His	225
220	
GCTGTGGTCT GAATAATATG TTCTTCCTGA AACAAACAACA ACAAAAAAAT TTGCCTGTTC	843
AGCTTTTAT GACAAAGCAC AAGGAATAAA GGAACACTAT ATACAGAACA GAATTCACCA	903
CAGCCCCGCT TTCAGCTCTG CCCCCAACTG GATTGCTGTC TTGGTAAGAG ACTTCTACCG	963
TGCTTCCTCG AAGTTAAGAA GAAAGTGCCT TTTTGCAATG TAAACTGTAC TGGTTCAAAC	1023
ATTCTTGCTA CAGCTAGGTA CCTATAATCC CCACCTTCAG GAGACTTAGG CGGAGGGAT	1083
GAGAGTTCAA GGCCAGCCTG GGCCCTGTCA GGACGCTGC TCAAAACAACA GTTTGTTATC	1143
AATAGAATAA TTAGAATTAA CAAACTAGGA TTTTCAGTCT TAAGTCATGA TATTGGATCT	1203
TCTCTTCAGT AAGGTTTCTT TTTGGCTAGA AATACTTCAT AGAATTTGAC ATTTTGGTAT	1263
ACATCTGTGG CCTTGATACA ATGACTTGAT TTTCTGTTTT AATTAGTGCA GAGGATTCAG	1323
CAAAATTGCA GGTCCTTCAAT TTGTTCCCTC GCTATCCATC GATCATGTTT CAGTGTATTA	1383
AGAGGAGTCA GCCAGGCGTG GTGGCCCCACA CCTGTGATCC CAGCACTTAG GGGGGCATAG	1443
GCAGGCAGAT CTCTGTGAGC TGAAGGACAG CCTGGCCTAC AAAGTCCAGG ACAACCCAGA	1503
CCACACAGAG AAACCTTGTC TTGAAAAACA AAACAAAAAC AAGAGAGAGA GAGAGAGAGA	1563

Fig. 4G


```
GAGAAAAGAG ATGTCAAGAG GTTTTGTGTT TTTTTTTTTT AAATTACTAT TTATGGGCCT 1623
CACTTGGAAA AGTGCTTGCC ATGCAAAATAG AAGGACAGGA GTTCAATCCT CATTACCCAC 1683
ATTGAAACA AATAACAAGA AAAACAAACC AAAAACCAA AACAAACAA ATCTTGAGAA 1743
CTTGAGTGAA TACCGGTAA CTCAGGGCTA GGCACGTAA CTGAATCAGG AGCCTCCAGA 1803
TCCAGGGAAA CGCTGTCTCA ACAAATAAAT AAATAAGTAA GTCAGTGAGG TGGTCTTAA 1863
ACCCAGCACT TGAGAGCCAA AGGCAGGCAG AGCTCAGTGA GTTGGAGACC AGCCTGGTCT 1923
ACAAAGCAAG TTCTAAGGGA GCCAGGGCAC AGAGAAACCC TGTCTGAAGG AAAAAAATAA 1983
AAAAAAAAG GCGGCCCGC 2002
```

Fig. 4H

```

G      1  ATGTTTCTGCTTCTGGTGCTACTCAGCCAGCTGCCCAGACTTACCCCTCGC  50
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
H      1  ATGTTTACGCTTCTGGTTCTACTCAGCCAACTGCCACAGTTACCCCTGGG  50

G     51  GGTTCCCTCAT...ACAAGAGCCCTAAAGAAATCTGAACATGCCCCAGAAAG  97
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
H     51  GTTTCCTCATTGCGCAAGAGGTCCTCAAGGCTTCTAAGCATGCGGAGAAG  100

G     98  GAGTCTTTGCATCAAAAAAGCAGCAAGCATCTTTATGCACCGTCGCCCTC  147
      ||| ||| ||||| ||| ||||| ||| ||| ||| ||| ||| ||| |||
H    101  AAGTGTTTACATCAAAAGAGCAAGCAAACTTTTTCATACATAGACGCCTT  150

G    148  CTATACAATAGATTTGATTTAGAACTCTTCACTCCCGGGAACCTGGAGAG  197
      || || ||||| ||||| || ||||| ||||| ||||| ||||| ||| ||
H    151  CTGTATAATAGATTTGATCTGGAGCTCTTCACTCCCGGCAACCTAGAAAAG  200

G    198  AGAGTGCTATGAGGAGTTCGTAGTTATGAAGAAAGCCAGAGAGATCCTCG  247
      ||||| |||| || || || ||||| ||||| ||||| ||||| ||| ||
H    201  AGAGTGCAATGAAGAACTTTGCAATTATGAGGAAGCCAGAGAGATTTTTC  250

```

Fig. 4I

Fig. 4J


```

G   1 MELLVVLSQLPRLTLAVPH.TRSLKNSEHAPEGVFASKKAASIFMHRRL 49
    || |||.|||||.|| || | | | | | | | | | | | | | | | | | | |
H   1 MFTLLVLSQLPTVTLGFPHCARGPKASKHAGEEVFTSKEEANFFIHRRL 50

G   50 LYNRFDELFTPGNLERECYEEFFCSYEEAREILGDNEEMITFWREYSVKG 99
    || |||.|||||.|||| | | | | | | | | | | | | | | | | | | |
H   51 LYNRFDELFTPGNLERECNEELCNYYEEAREIFVDEDKTIAFWQEYSAG 100

G   100 PTTRSDVNKEKIDVMGLLTGLIAAGVFLVFGLLGYLGCITKCNRQPYQG 149
    || | : || | | | | | | | | | | | | | | | | | | | | | | :
H   101 PTTKSDGNREKIDVMGLLTGLIAAGVFLVIFGLLGYLGCITKCNRLQHPC 150

G   150 SSAVYTRRTRHTPSIIFRTHEEAVLSP.SSSSEDAGLPSYEQAVALTRKH 198
    || || | | | | | | | | | | | | | | | | | | | | | | | |
H   151 SSAVY.ERGRHTPSIIFRRPEEAALSPLPPSVEDAGLPSYEQAVALTRKH 199

G   199 SVSPPPPPYPGPAKGFRVFKKMSMLPSH 225
    || |||.|||||.|||| | | | | | | | | | | | | | | | | | | |
H   200 SVSPPPPPYPGHTKGFRVFKKMSMLPSH 226

```

Fig. 4L




Fig. 4M

GTCCGACCCACGGTCCGGAATGTCGTCTTCAGATTAAAAAGAAACCTTTACTGAATCAGCTGAGTGTTAATAA	79
CGAATTTCCTTTCTTGCCAAATTCGATCTGAACAGAAAAATCCAAGAACAGGGAT ATG TGT GGA TTA CAG TTT	6 152
S L P C L R L F L V V T C Y L L L L L L H	26
TCT CTG CCT TGC CTA CGA CTG TTT CTG GTT ACC TGT TAT CTT TTA TTA CTC CAC	212
K E I L G C S S V C Q L C T G R Q I N C	46
AAA GAA ATA CTT GGA TGT TCG TCT GTT TGT CAG CTC TGC ACT GGG AGA CAA ATT AAC TGC	272
R N L G L S S I P K N F P E S T V F L Y	66
CGT AAC TTA GGC CTT TCG AGT ATT CCT AAG AAT TTT CCT GAA AGT ACA GTT TTT CTG TAT	332
L T G N N I S Y I N E S E L T G L H S L	86
CTG ACT GGG AAT AAT ATA TCT TAT ATA AAT GAA AGT GAA TTA ACA GGA CTT CAT TCT CTT	392
V A L Y L D N S N I L Y V Y P K A F V Q	106
GTA GCA TTG TAT TTG GAT AAT TCT AAC ATT CTG TAT GTA TAT CCA AAA GCC TTT GTT CAA	452
L R H L Y F L F L N N N F I K R L D P G	126
TTG AGG CAT CTA TAT TTT CTA AAT AAT AAT TTC ATC AAA CGC TTA GAT CCT GGA	512

49 / 109

Fig. 5A

I	F	K	G	L	L	N	L	R	N	L	Y	L	Q	Y	N	Q	V	S	F	146
ATA	TTT	AAG	GGA	CTT	TTA	AAT	CTT	CGT	AAT	TTA	TAT	TTA	CAG	TAT	AAT	CAG	GTA	TCT	TTT	572
V	P	R	G	V	F	N	D	L	V	S	V	Q	Y	L	N	L	Q	R	N	166
GTT	CCG	AGA	GGA	GTA	TTT	AAT	GAT	CTA	GTT	TCA	GTT	CAG	TAC	TTA	AAT	CTA	CAA	AGG	AAT	632
R	L	T	V	L	G	S	G	T	F	V	G	M	V	A	L	R	I	L	D	186
CGC	CTC	ACT	GTC	CTT	GGG	AGT	GGT	ACC	TTT	GTT	GGT	ATG	GTT	GCT	CTT	CGG	ATA	CTT	GAT	692
L	S	N	N	N	I	L	R	I	S	E	S	G	F	Q	H	L	E	N	L	206
TTA	TCA	AAC	AAT	AAC	ATT	TTG	AGG	ATA	TCA	GAA	TCA	GGC	TTT	CAA	CAT	CTT	GAA	AAC	CTT	752
A	C	L	Y	L	G	S	N	N	L	T	K	V	P	S	N	A	F	E	V	226
GCT	TGT	TTG	TAT	TTA	GGA	AGT	AAT	AAT	TTA	ACA	AAA	GTA	CCA	TCA	AAT	GCC	TTT	GAA	GTA	812
L	K	S	L	R	R	L	S	L	S	H	N	P	I	E	A	I	Q	P	F	246
CTT	AAA	AGT	CTT	AGA	AGA	CTT	TCT	TTG	TCT	TCT	CAT	AAT	CCT	ATT	GAA	GCA	ATA	CAG	CCC	872
A	F	K	G	L	A	N	L	E	Y	L	L	L	K	N	S	R	I	R	N	266
GCA	TTT	AAA	GGA	CTT	GCC	AAT	CTG	GAA	TAC	CTC	CTC	CTG	AAA	AAT	TCA	AGA	ATT	AGG	AAT	932
V	T	R	D	G	F	S	G	I	N	N	L	K	H	L	I	L	S	H	N	286
GTT	ACT	AGG	GAT	GGG	TTT	AGT	GGA	ATT	AAT	AAT	CTT	AAA	CAT	TTG	ATC	TTA	AGT	CAT	AAT	992

Fig. 5B

D	L	E	N	L	N	S	D	T	F	S	L	L	L	K	N	L	I	Y	L	K	306
GAT	TTA	GAG	AAT	TTA	AAT	TCT	GAC	ACA	TTC	AGT	TTG	TTA	AAG	AAT	TTA	ATT	TAC	CTT	AAG	1052	
L	D	R	N	R	I	I	S	I	D	N	D	T	F	E	N	M	G	A	S	326	
TTA	GAT	AGA	AAC	AGA	ATA	ATT	AGC	ATT	GAT	AAT	GAT	ACA	TTT	GAA	AAT	ATG	GGA	GCA	TCT	1112	
L	K	I	L	N	L	S	F	N	N	L	T	A	L	H	P	R	V	L	K	346	
TTG	AAG	ATC	CTT	AAT	CTG	TCA	TTT	AAT	AAT	CTT	ACA	GCC	TTG	CAT	CCA	AGG	GTC	CTT	AAG	1172	
P	L	S	S	L	I	H	L	Q	A	N	S	N	P	W	E	C	N	C	K	366	
CCG	TTG	TCT	TCA	TTG	ATT	CAT	CTT	CAG	GCA	AAT	TCT	AAT	CCT	TGG	GAA	TGT	AAC	TGC	AAA	1232	
L	L	G	L	R	D	W	L	A	S	S	A	I	T	L	N	I	Y	C	Q	386	
CTT	TTG	GGC	CTT	CGA	GAC	TGG	CTA	GCA	TCT	TCA	GCC	ATT	ACT	CTA	AAC	ATC	TAT	TGT	CAG	1292	
N	P	P	S	M	R	G	R	A	L	R	Y	I	N	I	T	N	C	V	T	406	
AAT	CCC	CCA	TCC	ATG	CGT	GGC	AGA	GCA	TTA	CGT	TAT	ATT	AAC	ATT	ACA	AAT	TGT	GTT	ACA	1352	
S	S	I	N	V	S	R	A	W	A	V	V	K	S	P	H	I	H	H	K	426	
TCT	TCA	ATA	AAT	GTA	TCC	AGA	GCT	TGG	GCT	GTT	GTA	AAA	TCT	CCT	CAT	ATT	CAT	CAC	AAG	1412	
T	T	A	L	M	M	A	W	H	K	V	T	T	N	G	S	P	L	E	N	446	
ACT	ACT	GCG	CTA	ATG	ATG	GCC	TGG	CAT	AAA	GTA	ACC	ACA	AAT	GGC	AGT	CCT	CTG	GAA	AAT	1472	

Fig. 5C

T	E	T	E	N	I	T	F	W	E	R	I	P	T	S	P	A	G	R	F	466
ACT	GAG	ACT	GAG	AAC	ATT	ACT	TTC	TGG	GAA	CGA	ATT	CCT	ACT	TCA	CCT	GCT	GGT	AGA	TTT	1532
F	Q	E	N	A	F	G	N	P	L	E	T	T	A	V	L	P	V	Q	I	486
TTT	CAA	GAG	AAT	GCC	TTT	GGT	AAT	CCA	TTA	GAG	ACT	ACA	GCA	GTG	TTA	CCT	GTG	CAA	ATA	1592
Q	L	T	T	S	V	T	L	N	L	E	K	N	S	A	L	P	N	D	A	506
CAA	CTT	ACT	ACT	TCT	GTT	ACC	TTG	AAC	TTG	GAA	AAA	AAC	AGT	GCT	CTA	CCG	AAT	GAT	GCT	1652
A	S	M	S	G	K	T	S	L	I	C	T	Q	E	V	E	K	L	N	E	526
GCT	TCA	ATG	TCA	GGG	AAA	ACA	TCT	CTA	ATT	TGT	ACA	CAA	GAA	GTT	GAG	AAG	TTG	AAT	GAG	1712
A	F	D	I	L	L	A	F	F	I	L	A	C	V	L	I	I	F	L	I	546
GCT	TTT	GAC	ATT	TTG	CTA	GCT	TTT	TTC	ATC	TTA	GCT	TGT	GTT	TTA	ATC	ATT	TTT	TTG	ATC	1772
Y	K	V	V	Q	F	K	Q	K	L	K	A	S	E	N	S	R	E	N	R	566
TAC	AAA	GTT	GTT	CAG	TTT	AAA	CAA	AAA	CTA	AAG	GCA	TCA	GAA	AAC	TCA	AGG	GAA	AAT	AGA	1832
L	E	Y	Y	S	F	Y	Q	S	A	R	Y	N	V	T	A	S	I	C	N	586
CTT	GAA	TAC	TAC	AGC	TTT	TAT	CAG	TCA	GCA	AGG	TAT	AAT	GTA	ACT	GCC	TCA	ATT	TGT	AAC	1892
T	S	P	N	S	L	E	S	P	G	L	E	Q	I	R	L	H	K	Q	I	606
ACT	TCC	CCA	AAT	TCT	CTA	GAA	AGT	CCT	GGC	TTG	GAG	CAG	ATT	CGA	CTT	CAT	AAA	CAA	ATT	1952

Fig. 5D




Fig. 5F

Fig. 5G

Fig. 5G

```

280      290      300      310      320      330      340
slit AACTCSNNIVDCRGKGLTEIPTNLPEITTEIRLEQNTIKVIPPGAFSPYKKLRRIDLNNQISELAPDAF
325 -----LRILDSNNNI-----190

350      360      370      380      390      400      410
slit QGLRSINSLVLYGNKITELPKSLFEGFLSLQLLLNANKINCLRVDAFQDLHNLNLLSLYDNKLQTIAGK
325 --LR-----ISE-----SGFHLENLACL-----200

420      430      440      450      460      470      480
slit TFSPLRAIQTMHLAQNPFCIDCHLKWLDYLTNPIETSGARCTSPRRLANKRIGQIKSKKFRCSAKEQY
325 -----YLGSN-----210

490      500      510      520      530      540      550
slit FIPGTEDYRSKLSGDCFCADLACPEKRCCEGTVDCSNQKLNKIPEHIPQYTAELRLNNNEFTVLEATGIF
325 -----NLTKVP-----SNAFEVLKS-----220

```

Fig. 5H

Fig. 51

```

      840      850      860      870      880      890      900
Slit  GNDISVVPEGA FNDSLALSHLAIGANPLYCDCNMQLSDWVKSEYKEPGIARCAGPGEMADKLLLTTPSK
      325  -----SSLIHLQANSNPWECNCKLLGLRDWLAS-----
            350      360      370

      910      920      930      940      950      960      970
Slit  KFTCQGPVDVNILAKCNPCLSNPCKNDGTCNSDPVDFYRCTCPYGFKGQDCDVPIHACISNPCKHGGTCH
            ... ..:
      325  ----SAITLNI-----Y-----CQNP-----PSMRG-----
            380                                390

      980      990      1000      1010      1020      1030      1040
Slit  LKEGEEDGFWCICADGFEGENCEVNVDDCEDNDCENNSTCVDGINNYTCLCPPEYTGELCEEKLD FCAQD
            ... :
      325  ----RALRYI-----NITNCV-----
            400

      1050      1060      1070      1080      1090      1100      1110
Slit  LNPCQHDSKCILTPKGFKCDCTPGYVGEHC DIDFDDCQDNKCKNGAHCTDAVNGYTCICPEGYSGLFCEE
            :...:
      325  ----TSSIN-----
            410

```

Fig. 5J


```

1120      1130      1140      1150      1160      1170      1180
slit SPPMVLPRTSPCDNFDCQNGAQCIVRINEPICQCLPGYQGEKCEKLVSVNFINKESYLIQIPSAKVRPQTN
      :.:. .      :.:.      :.:.      :.:.      :.:.      :.:.
325 ----V$RAWA-----VVK-----SPHIHHKTTALMMAWHKV-----
      420      430

1190      1200      1210      1220      1230      1240      1250
slit ITLQIATDEDSGILLYKGDKDHIAVELYRGRVRASYDTGSHPASAIYSVETINDGNFHVIVELLALDQSL$
      :.:. .      :.:. .      :.:. .      :.:. .      :.:. .      :.:. .
325 ----TTNGSP----LENTETENIT----FWERIP$T$-----PAGRFFQENAFGNP-LETTAVL$PVQIQILT
      440      450      460      470      480

1260      1270      1280      1290      1300      1310      1320
slit L$VDG$NPKIITNLSKQ$TLNFD$PLYVGGMPGK$NVASL$RQAPGQNGTSFHGCIRNLYINSELQDFQKV
      :.:. .      :.:. .      :.:. .      :.:. .      :.:. .      :.:. .
325 TSV-----TLNLEKNSALPNDA$-----SM$GKTSLI-----CT-----QEVEKL
      490      500      510      520

1330      1340      1350      1360      1370      1380      1390
slit PMQTGILPGCEPCHKKVC$AHGTCQPS$QAGFTCECQEGW$MGPLCDORTNDPCLGNKCVHGTCLPINAF$Y
      :.:. .      :.:. .      :.:. .      :.:. .      :.:. .      :.:. .
325 NEAFDILLA-----F-----FIL
      530

```

Fig. 5K

```

1400      1410      1420      1430      1440      1450      1460
Slit  SCKLEGGHGGVLCDEEEDLFNPCQAICKKHGKCRLSGLGQPYCECSSGYTGDSCDREISCRGERIRDYYQ
      ::      ::      ::      ::      ::      ::      ::      ::      ::
325 AC-----VL-----IIFLIYKVVQFKQ---KLKA-----SENS-----RENRL-EYY-
      540      550      560      570

1470      1480      1490      1500      1510      1520
Slit  KQQGYAACQTTK-KVSRLECRGGCAGGCCGGLRSKRRKYSFECTDGSSFVDEVEKVVKCGCTRCVS
      ::      ::      ::      ::      ::      ::      ::      ::      ::
325 ---SF--YQSARYNVTASICNTSPNSLESPLGQIRLHK-----QIVPENEAQVI-LFEHSAL
      580      590      600      610      620

```

Fig. 5L

```

10      20      30      40      50      60      70
Slit  CAGAGCAGGTGGAGAGGGCGGTGGAGGCGTGTGCTGAGTGGGCTCTACTGCCCTTGTTCATATTATT
325  -----

80      90      100     110     120     130     140
Slit  TTGTGCACATTTCCCTGGCACTCTGGGTGCTAGCCCCCGGGGCACTGGGCCTCAGACACTGCGCGGT
325  -----

150     160     170     180     190     200     210
Slit  TCCCTCGGAGCAGCAAGCTAAAGAAAGCCCCCAGTGCCCGCGAGGAAGAGGCGGCGGGAAGATGCGC
325  -----

220     230     240     250     260     270     280
Slit  GCGGTTGGCTGGCAGATGCTGCCCTGCTCGCTGGGTTAGTGTGCTGGCGATCCTGAACAAGGTGGCACC GC
      ::::
325  -----GTCG-----ACC--

```

Fig. 5Mi

```

290      300      310      320      330      340      350
Slit AGCGTGCCCGGCAGTGCTCTTGCTCGGCAGCACAGTGGACTGTACGGGCTGGCGTGCGCAGCGT
325 -----CACG-----CGT
                               10

360      370      380      390      400      410      420
Slit GCCAGGAATATCCCCGCAACCCGAGAGACTGGATTAAATGGAAATAACATCACAGAATTACGAAG
                               :.:.:.:.:.:
325 --CCGGAATGTC-----
                               20

430      440      450      460      470      480      490
Slit ACAGATTTTGCTGGTCTTAGACATCTAAGAGTTCTTCAGCTTATGGAGAATAAGATTAGCACCATTGAAA
                               :.:.:.:.:.:
325 -----GTTCTTCAGATTAAAGAAAA-----CCTTTA---
                               30      40      50

500      510      520      530      540      550      560
Slit GAGGAGCATTCAGGATCTTAAAGAACTAGAGAGACTGCGTTTAAACAGAAAATCACCTTCAGCTGTTCC
                               :.:.:.:.:.:
325 -----CTGAATC-----AGCT-GAGTG-----TTAAT---AATACG-----AATTTC
                               60      70      80

```

Fig. 5Mii

```

570      580      590      600      610      620      630
Slit  TGAGTTGCTGTTCTTGGGACTGCGAAGCTATACAGGCTTGATCTCAGTGAACCAAAATTCAGGCAATC
:      :::::      :      :::::      :      :::::      :      :::::      :
325  T-----TTTCTTG---C---CAATTCTGATCTGA-----ACAGA-AAATCCAAGAACAGG-----
          90          100          110          120          130

640      650      660      670      680      690      700
Slit  CCAAGGAAAGCTTCCGTGGGGCAGTTGACATAAAAAAATTGCAACTGGATTACAACCATCAGCTGTA
:      :::::      :      :::::      :      :::::      :      :::::      :
325  -----GATATGTG-----TGGATTACA-----GTT
          140          150

710      720      730      740      750      760      770
Slit  TTGAAGATGGGGCATTTCAGGGCTCTCCGGGACCTGGAAGTGCTCACTCTCAACAATAACAATTACTAG
:      ::      :::::      :      :::::      :      :::::      :
325  TT-----CTCT-----GCCT-----TGC-----CTACGA-----
          160          170

780      790      800      810      820      830      840
Slit  ACTTCTGTGGCAAGTTTCAACCATATGCCCTAAACTTAGGACTTTTCGACTGCATTCAAAACAACCTGTAT
:      :::::      :::::      :      :::::      :      :::::      :
325  -----CTGTTTCTGGTTGTTACCTGTTA-----TCITTT-----AT
          180          190          200

```

Fig. 5Miii

```

      850      860      870      880      890      900      910
Slit  TGTGACTGCCACCTGGCCTGGCTCTCCGACTGGCTTCGCCAAAGGCCTCGGGTTGGTCTGTACACTCAGT
      :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
325  TATTACT-CCACAAAG-----AAATAC-----TTGGA-TGTTGCG-TC--T
      210      220      230

      920      930      940      950      960      970      980
Slit  GTATGGCCCCCTCCACCTGAGAGGCCATAATGTAGCCGAGGTTCAAAAACGAGAATTGTCTGCAGTGG
      :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
325  GTTTG-----TC-----AGC-----TCTGCACTGG
      240      250

      990      1000      1010      1020      1030      1040      1050
Slit  TCACCAGTCATTATGGCTCCTTCTGTAGTGTTTGCACTGCCCTGCCGCCCTGTACCTGTAGCAACAAT
      :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
325  G-----AGACAAATTA-----ACTGCC-----GTAACCTAGGC-----
      260      270      280

      1060      1070      1080      1090      1100      1110      1120
Slit  ATCGTAGACTGTCGTGGGAAAGGTCTCACTGAGATCCCCACAAATCTCCAGAGACCATCACAGAAATAC
      :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
325  -----CTTTCGAG-----TATTC-----CTAAGA-----ATTTCCCTGAAA--GT-ACAGTTTTC
      290      300      310      320
```

Fig. 5Miv

Fig. 5Mv


```

1690      1700      1710      1720      1730      1740      1750
Slit  CGATCAAAATTAAAGTGGAGACTGCTTTGCGGATCTGGCTTGGCCCTGAAAAGTGTGCGCTGTGAAGGAACCA
      :::::::::::
      -GATCTAGTTT-----CAGTTTCAG-----
      600      610

1760      1770      1780      1790      1800      1810      1820
Slit  CAGTAGATTGCTCTAATCAAAAAGCTCAACAAAATCCGGAGCACATTCCTCCAGTACACTGCAGAGTTGCG
      :::::::::::
      -TACTTAAATCTA-----CAAA-----GAA-----TCGCCT---CACTG-----
      620      630      640

1830      1840      1850      1860      1870      1880      1890
Slit  TCTCAATAATAATGAATTTACCGTGTGGAAGCCACAGGAATCTTTAAGAAACTTCCTCAATTACGTAAA
      :::::::::::
      -TCC-----TTGGGAG-----TGG-----TACCT-----
      650      660

1900      1910      1920      1930      1940      1950      1960
Slit  ATAAACTTTAGCAACAATAAGATCACAGATATTGAGGAGGAGCATTTGAAGGAGCATCTGGTGTAATG
      :::::::::::
      -TTGTTGGTATGGTTGCT-----CTTCGG-----
      670      680

```

Fig. 5Mvii

```

1970      1980      1990      2000      2010      2020      2030
Slit AAATACTTCTTACGAGTAATCGTTTGGAAAATGTCAGCATAAGATGTTCAAGGGATTGAAAGCCTCAA
      :::::      :: :::::
325 --ATACTT-----GATTATC-----A
      690

      2040      2050      2060      2070      2080      2090      2100
Slit AACTTTGATGTTGAGAAGCAATCGAATAACCTGTGTGGGAATGACAGTTTCATAGGACTCAGTTCTGTG
      :::      ::: :::::      ::: :::::
325 AAC-----AATAAC--ATTTGAGGATATCAGAATCAG-----
      700      710      720

      2110      2120      2130      2140      2150      2160      2170
Slit CGTTTGCTTCTTGTATGATAATCAAAATTACTACAGTTGCACCAGGGCATTTGATACTCTCCATTCTT
      :::::      :::::
325 -----GCTTTC-----
      730

      2180      2190      2200      2210      2220      2230      2240
Slit TATCTACTCTAAACCTCTTGGCCCAATCCTTTTAACTGTAACCTGCTACCTGGCTTGGTTGGGAGAGTGGCT
      ::: :::::      :::::      ::::: :::::
325 -----AACATCTTGA--AAACCTT-----GCTTGTGTGTAT-----T
      740      750      760

```

Fig. 5Mviii

```

2250      2260      2270      2280      2290      2300      2310
Slit  GAGAAAGAGAGAAATTGTCACGGGAAATCCTAGATGTCAAAAACCATACTTCTGAAAGAAAATACCCATC
      :::::::::::::: :::::::::::::: :::::::::::::: ::::::::::::::
325  TAGGAAGTAATAATTAA--ACAAAAGTACC-----ATCAAATGCCTTT-----GAAGTAC-----
      770      780      790      800      810

2320      2330      2340      2350      2360      2370      2380
Slit  CAGGATGTGGCCATTTCAGGACTTCACCTTGATGACGGAAATGATGACAATAGTTGCTCCCCACTTTCTC
      :::::::::::::: :::::::::::::: :::::::::::::: ::::::::::::::
325  -----TTAAAAGTCTT-----AGAAAGACTTT-----CTTTGTCTC
      820      830      840

2390      2400      2410      2420      2430      2440      2450
Slit  GCTGTCCTACTGAATGTACTTGTGCTTGGATACAGTCGTCGATGTAGCAACAAGGTTTGAAAGGTCTTGCC
      . . . . . :::: :::: :::: :::: :::: ::::
325  ATAATCCTATTGAA-----GCA---ATACAG-C--CCTTTG---CA-----TTTAAAGGACTTGCC
      850      860      870      880      890

2460      2470      2480      2490      2500      2510      2520
Slit  GAAAGGTATTCCAAGAGATGTCACAGAGTTGTATCTGGATGGAAACCAATTACACTGGTTCCCAAGGAA
      .: :::::::::: :::::::::: :::::::::: ::::::::::
325  AA-----TCTGGA---ATACC-----TCC-----
      900

```

Fig. 5Mix

```

2530      2540      2550      2560      2570      2580      2590
Slit CTCTCCAACACAAACATTTAACACTTATAGACTTAAGTAACAACAGAAATAAGCACGCTTTCTAATCAGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 ---TCCTGAAAAAATCAAGAA-----TTAGGA---ATGTTACTA-GGGATGGG-----TTTAGT--GG
      910      920      930      940      950

2600      2610      2620      2630      2640      2650      2660
Slit GCTTCAGCAACATGACCCAGCTCCTCACCTTAATTCTTAGTTACAACCGTCTGAGATGTATTCCTCCTCG
      . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 AATTAATAATCTTAA-----ACATTGATCTTAA-----GTCA-TAATGA-----
      960      970      980      990

2670      2680      2690      2700      2710      2720      2730
Slit CACCTTTGATGGATTAAAGTCTCTTCGATTACTTTCTCTACATGGAATGACATTTCTGTGTGCTGAA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 ----TTAGAGAAATTTAAAT-----TCTGACACATTCAGT--TTGTTAAAGA-ATT--TAATTTACCTTAA
      1000      1010      1020      1030      1040      1050

2740      2750      2760      2770      2780      2790      2800
Slit GGTGCTTTCAATGATCTTTCTGCATTATCACATCTAGCAATTGGAGCCAACCCCTCTTACTGTGATTGTA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 G-----TTAGATAGAA---ACAGAATAAT-----TAGCATT-----GATAATGAT
      1060      1070      1080

```

Fig. 5Mx

```

2810      2820      2830      2840      2850      2860      2870
Slit ACATGCAGTGGTTATCCGACTGGGTGAAGTCGGAATATAAGGAGCCTGGAATTGCTCGTTGTGCTGGTCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 ACAT-----TTGAAAATATGGGAGCAT-----CTTGAA--GATCC
1090      1100      1110

2880      2890      2900      2910      2920      2930      2940
Slit TGGAGAAATGGCAGATAAACTTTTACTCACAACTCCCTCCAAAAAATTTACCTGTCAAGGTCCTGTGGAT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 T-----TAATCTGTCAT-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
1130

2950      2960      2970      2980      2990      3000      3010
Slit GTCAATATCTAGCTAAGTGTAAACCCCTGCCCTATCAAATCCGTGTAAATAATGATGGCACATGTAATAGTG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 -TTAATAATCTTACA-----GCCTTGC--ATCCAAG-----G
1140      1150      1160

3020      3030      3040      3050      3060      3070      3080
Slit ATCCAGTTGACTTTTACCGATGCACCTGTCCATAATGGTTTCAAGGGCAGGACTGTGATGTCCCAATTCA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 GTCC-----TTAAGCCCGT-----TGTC-----TTCATTG-----ATTCA
1170      1180      1190

```

Fig. 5Mxi

Fig. 5Mxii

```

3370      3380      3390      3400      3410      3420      3430
Slit  TGCA TCCTAACTCCAAAGGGATTCAAATGTGACTGCACACCCAGGGTACGTAGTGAACACTGGGACATCG
      :::::
325  --CATCCATGC-----GTGGCAGAGCA---TTACGTT-----
      1300      1310      1320

3440      3450      3460      3470      3480      3490      3500
Slit  ATTTGACGACTGCCAAGACAAAGTGTA AAAACGGAGCCCACTGCACAGATGCAGTGAACGGCTATAC
      :::::
325  ATATTAAAC-----ATTACAAATTGTGTTA-----CATCTTCA-----ATAA
      1330      1340      1350      1360

3510      3520      3530      3540      3550      3560      3570
Slit  GTGCATATGCCCCGAAGGTTACAGTGGCTTGTCTGTGAGTTTCTCCACCCCATGGTCCCTCCCTCGTACC
      :::
325  ATGTAT-----CCAGAG-----CTTGGGCT-GTT-----GTAAAATCTCCTC--ATATTCAACACAAGA--C
      1370      1380      1390      1400      1410

3580      3590      3600      3610      3620      3630      3640
Slit  AGCCCCCTGTGATAATTTTGATTGTCAGAAATGGAGCTCAGTGTATCGTCAGAAATAAATGAGCCCAATATGTC
      :::
325  TAC---TGCGCTAAT---GATGGCCTG-----GCATAAAGTAAC--CA-----CAA-ATGGC
      1420      1430      1440      1450

```

Fig. 5Mxiii

```

3650      3660      3670      3680      3690      3700      3710
Slit AGTGTTCCTGGCTATCAGGGAGAAAAGTGTAATAATTGGTTAGTGTAATTTTATAAACAAGAGTC
    ::      ::      ::      ::      ::      ::      ::
325 AGT-----CCT--CT-----GGAAAATACTGAGAC-----TGAGAACATTACTTTCTGGGAA--
1460      1470      1480      1490      1500

3720      3730      3740      3750      3760      3770      3780
Slit TTATCTTCAGATTCCCTCAGCCCAAGGTTCCGGCCTCAGACGAACATAACACTTCAGATTGCCACAGATGAA
    ::      ::      ::      ::      ::      ::      ::
325 -----CGAATTCCTAC-----TTCACCTGCTGGTAGA-TTTTTCAGAGAGAATGCCCTTGGTAA-
1510      1520      1530      1540      1550

3790      3800      3810      3820      3830      3840      3850
Slit GACAGCGGAATCCTCCTGTATAAGGGTGACAAAGACCATATCGCGGTAGAACTCTATCGGGGGCGGTTC
    ::      ::      ::      ::      ::      ::      ::
325 -----TCCATT-----GAGACTA-----CA----GCAGTGTAC-CTGT-----GCAAATAC
1560      1570      1580      1590

3860      3870      3880      3890      3900      3910      3920
Slit GTGCCAGCTATGACACCGGCTCTCATCCAGCTTCTGCCATTACAGTGTGGAGACAATCAATGATGAA
    ::      ::      ::      ::      ::      ::      ::
325 AA-CTTACTA-----CTTCTGTTACCTTGAAC--TGGAATAAACACAGTCT-----
1600      1610      1620      1630

```

Fig. 5Mxiv

Fig. 5M_{xv}

```

4210      4220      4230      4240      4250      4260      4270
Slit  TGTGAGCCATGCCACAAGGTGTGTGCCCATGGCACATGCCAGCCCAGCAGCCAGGCTTACCT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  TTTGATC--TAC-----AAAGTTGTT-----CAGTTTA----A
      1770      1780      1790

4280      4290      4300      4310      4320      4330      4340
Slit  GCGAGTGCCAGGAAGGATGGATGGGGCCCCTCTGTGACCAACGGACCAATGACCCTTGCCCTTGGAAATAA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  ACAAAACTA--AAG-----CATCAGAAAACT-----CAAGGGAAAAAT
      1800      1810      1820

4350      4360      4370      4380      4390      4400      4410
Slit  ATGCGTACATGGCACCTGCTTGCCCATCAATGCGTTCTCCTACAGCTGTAAGTGCTTGGAGGGCCATGGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  AGACTTGAATA-CTACAGCTT-----TTATCAGTCAGCAAGGTATA-----ATGTA
      1830      1840      1850      1860      1870

4420      4430      4440      4450      4460      4470      4480
Slit  GGTGTCCTCTGTGATGAAGAGGAGGATCTGTTTAACCCATGCCAGGCGATCAAGTGCAAGCACGGGAAGT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  ACTG-CCTCAAT-TTG-----TAACACTTCCC-----CAAATTCT--CT-AGAAAGT
      1880      1890      1900      1910

```

Fig. 5Mxvi

```

4490      4500      4510      4520      4530      4540      4550
Slit GCAGGCTTTCAGGTCTGGGCAGCCCTACTGTGAATGCAGCAGTGGATACACGGGGACAGCTGTGATCG
      :.:.:.:.:      :.:.:.:.:      :.:.:.:.:      :.:.:.:.:      :.:.:.:.:
325 CCTGGCTT-----GGAGCAG-----ATTC-----GACTTCA-TAAACA
      1920      1930      1940

4560      4570      4580      4590      4600      4610      4620
Slit AGAAATCTCTTGTGAGGGGAAAGGATAAGAGATTATTACCAAAAGCAGCAGGGCTATGCTGCTTGCCAA
      :.:.:.:.:      :.:.:.:.:      :.:.:.:.:      :.:.:.:.:      :.:.:.:.:
325 AATTGT-TC-----C-----TGAAAATGAG-----GCA-CAGGTC-ATTCTTTTGTG---A
      1950      1960      1970      1980

4630      4640      4650      4660      4670      4680      4690
Slit ACAACCAAGAAGGTGTCCCGATTAGAGTGCAGAGGTGGGTGTGCAGGAGGGCAGTGTGTGGACCGCTGA
      :.:.:.:      :.:.:.:      :.:.:.:      :.:.:.:      :.:.:.:
325 ACATTC-----TGCTTTATAACTC---
      1990      2000

4700      4710      4720      4730      4740      4750      4760
Slit GGAGCAAGCGGCGGAAATACTCTTTTCGAATGCACGTGACGGCTCCTCCTTTGTGGACGAGGTTGAGAAAGT
      :.:.:.:      :.:.:.:      :.:.:.:      :.:.:.:      :.:.:.:
325 --AACTAA-----ATATTGTCTATAAGAAACT---TCAGTGCCA-----TGACATGATTTAAA-----
      2010      2020      2030      2040      2050

```

Fig. 5Mxvii

```

4770      4780      4790      4800      4810      4820      4830
Slit GGTGAAGTGGGGCTGTACGAGGTGTGTGTCCTAAACACACTCCCGGCAGCTCTGTCTTTGGAAAAGGTTG
      ::::      ::::      ::::      ::::      ::::      ::::
325 -----CTG-----AAAC---CTC-----CTT---ATATAATTA
      2060      2070

4840      4850      4860      4870      4880      4890      4900
Slit TATACTTCCTTGACCATGTGGGACTAATGAATGCTTCATAGTGGAATAATTTGAAATATATTTGTAAATAC
      :::::      :::::      :::::      :::::      :::::      :::::
325 TATACTT-TAGT---TGGAAATATAATGAATTATATGAGGTTAGCATTATTTAAATATGTTTTTAA----
      2080      2090      2100      2110      2120      2130

4910      4920      4930      4940      4950
Slit AGAACAGACTTATTTTATTATGAGAAATAAAGACTTTTCTTCGCATTG
      :::::      :::::      :::::      :::::
325 -----TAAAAA-----GCGC-----
      2140      2150      2160

```

Fig. 5Mxviii


Fig. 6A

Fig. 6A

Fig. 6B

D	E	C	S	L	A	E	K	T	C	V	R	K	N	E	N	C	Y	N	T	311
GAC	GAG	TGC	TCA	CTA	GCA	GAA	AAA	ACC	TGT	GTG	AGG	AAA	AAC	GAA	AAC	TGC	TAC	AAT	ACT	1046
P	G	S	Y	V	C	V	C	P	D	G	F	E	E	T	E	D	A	C	V	331
CCA	GGG	AGC	TAC	GTC	TGT	GTG	TGT	CCT	GAC	GGC	TTC	GAA	GAA	ACG	GAA	GAT	GCC	TGT	GTG	1106
P	P	A	E	A	E	A	T	E	G	E	S	P	T	Q	L	P	S	R	E	351
CCG	CCG	GCA	GAG	GCT	GAA	GCC	ACA	GAA	GGA	GAA	AGC	CCG	ACA	CAG	CTG	CCC	TCC	CGC	GAA	1166
D	L	*																	354	
GAC	CTG	TAA																	1175	
TGT	GCC	GACTT	ACCC	TTT	AAAT	TAT	T	CAG	AAG	GAT	GT	CCCC	GT	G	AAAA	ATG	TGG	CCCC	TGAG	1254
GGAC	AGCG	GGG	GAG	AGCT	GC	TCT	CTA	ACGG	TTG	ATT	CT	CA	TTT	GT	CCCC	TTA	AA	CAG	CTGC	1333
TTCT	TAA	CAG	ACT	TG	TAT	TTT	TG	ATAC	AGT	TC	TTT	TG	TA	AAAA	ATT	TG	AC	CAT	TGTAG	1412
AAAA	AGG	CGCG	CGCT	AGAC																1432

Fig. 6C



Cys
N919
out
TH
ins

Fig. 6D

Fig. 6F

```

260      270      280      290      300      310      320
C GGCAACACGGCGTGGGAGGAGAGAGTCTGTCCAAGTACGAATTCAAGTGGCTCCTGGAGATTA
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H GGGAAACACGGCTTGGGAGGAAAAGACGCTGTCCAAGTACGAGTCCAGCGAGATTGCGCTGCTGGAGATCC
280      290      300      310      320      330      340

330      340      350      360      370      380      390
C TGGAGGGCCTGTGTGACAGCAACGACTTTGAATGCAACCAACT-CTTGGAAACAGCATGAGGAGCAGCTAG
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H TGGAGGGCCTGTGCGAGAGCAGCGACTTCGAATGCAATCAGATGCTAGAGGC-GCAGGAGGAGCACCTGG
350      360      370      380      390      400      410

400      410      420      430      440      450      460
C AGGCCTGGTGGCAGACACTGAAGAAGGAGTGCCCTAACCTATTTGAGTGGTTCTGTGTACACACACTGAA
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H AGGCCTGGTGGCTGCAGCTGAAGAGCGGAATATCCTGACTTATTCGAGTGGTTTGTGTGAAGACACTGAA
420      430      440      450      460      470      480

470      480      490      500      510      520      530
C AGCATGCTGTCTTCCAGGCACCTATGGGCCAGACTGTCAGGAATGCCAGGGTGGTCTCAGAGGCCCTTGT
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H AGTGTGCTGCTCTCCAGGAACCTACGGTCCCAGCTGTCTCGCATGCCAGGCGGATCCCAGAGGCCCTGC
490      500      510      520      530      540      550

```

Fig. 6G

```

540      550      560      570      580      590      600
C AGCGGGAATGCCACTGCGACGGAGATGGCAGCAGACAGGGCGACGGGTCTTGCAGTGTACGTAGGAT
  ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H AGCGGGAATGCCACTGCGACGGAGATGGGAGCAGACAGGGCGACGGGTCTTGCCTGCCGGTGCCACATGGGGT
560      570      580      590      600      610      620

610      620      630      640      650      660      670
C ACAAGGGCCGCTGTGTATCGACTGCATGGATGGCTACTTCAGCTTGTCTGAGGAACGAGACCCACAGCTT
  ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H ACCAGGGCCGCTGTGCACTGACTGCATGGACGGCTACTTCAGCTCGCTCCGGAACGAGACCCACAGCAT
630      640      650      660      670      680      690

680      690      700      710      720      730      740
C CTGCACAGCCTGTGATGAGTCCTGCAAGACATGCTCAGGTCCAACCAAAAGGCTGTGTGGAGTCCGAA
  ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H CTGCACAGCCTGTGACGAGTCCTGCAAGACGTGCTCGGGCCTGACCAACACAGAGACTGCGGCGAGTGTGAA
700      710      720      730      740      750      760

750      760      770      780      790      800      810
C GTGGGCTGGACACGTGTGGAGGATGCCCTGTGTGGATGTTGACGAGTGTGCAGCAGAGACCCACCCCTGCA
  ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H GTGGGCTGGGTGCTGGACGAGGGCGCCCTGTGTGGATGTGGACGAGTGTGCGGCCGAGCCGCTCCCTGCA
770      780      790      800      810      820      830

```

Fig. 6H

Fig. 61

```

1100      1110      1120      1130      1140      1150
C AAGCGAAGTGGCAGAGGAAAGT--CCC-ACACAGCCACCCTCCCATGAGGATTTGTGACGGGCAATCCAG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H AGGCTGAAGCCACAGAGGAGAAAGCCCGACACAGCTGCCCTCCCGCGAAGA-----CCTG
1120      1130      1140      1150      1160      1170
1160      1170      1180      1190      1200      1210      1220
C GTTCAGAAAGCTGGACTCTCACCCCTTTTAAGTTATTGAGAGGACATCCTATAGAAAAATGTGGCCCATGAC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H --TAATGTGCGCGACTT--ACCCCTTAAATATTTCAGAAAGGATGTCCCCTGGAAAAATGTGGCCCTGAGGA
1180      1190      1200      1210      1220      1230

1230      1240      1250      1260      1270      1280      1290
C ATCAACCCCATTTCTCCAGGAAGTTTGG-AGGAAGAAGCTGCCCTGCTTTGAAACAGTAGATACTCACTT
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H TGCCGTCTC---CTGCAGTGGACAGCGGGGAGAGGCTGCCCTGCTCTCTAAACGGTTGATTCTCATTT
1240      1250      1260      1270      1280      1290      1300
1300      1310      1320      1330      1340      1350      1360
C GGCCCTTTAAACGCTGCATTTCTTGGTGGTTCTTAAACAGATTTCGTATATTTTGATACTGTTCTTTATA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTCCCTTAAACA-GCTGCATTTCTTGGTGTCTTAAACAGACTTGTATATTTTGATACAGTCTTTGTGA
1310      1320      1330      1340      1350      1360      1370

1370      1380      1390
C ATAAAATTGATCATTTGAAGGTCACCAGGAA-----CA-----
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H ATAAAATTGACCATTTGTAGGTAATCAAAAAAAGGCGGCGCGCTAGAC
1380      1390      1400      1410      1420      1430

```

Fig. 6J

Fig. 7A

C	E	V	Q	H	G	I	D	D	S	S	D	A	V	E	V	K	V	K	G	156
TGT	GAG	GTC	CAG	CAC	GGC	ATC	GAT	GAC	AGC	AGC	GAC	GCT	GTG	GAG	GTC	AAG	GTC	AAA	GGG	640
V	V	F	L	Y	R	E	G	S	A	R	Y	A	F	S	F	S	G	A	Q	176
GTC	GTC	TTT	CTC	TAC	CGA	GAG	GGC	TCT	GCC	CGC	TAT	GCT	TTC	TCC	TTT	TCT	GGG	GCC	CAG	700
E	A	C	A	R	I	G	A	H	I	A	T	P	E	Q	L	Y	A	A	Y	196
GAG	GCC	TGT	GCC	CGC	ATT	GGA	GCC	CAC	ATC	GCC	ACC	CCG	GAG	CAG	CTC	TAT	GCC	GCC	TAC	760
L	G	G	Y	E	Q	C	D	A	G	W	L	S	D	Q	T	V	R	Y	P	216
CTT	GGG	GGC	TAT	GAG	CAA	TGT	GAT	GCT	GGC	TGG	CTG	TCG	GAT	CAG	ACC	GTG	AGG	TAT	CCC	820
I	Q	T	P	R	E	A	C	Y	G	D	M	D	G	F	P	G	V	R	N	236
ATC	CAG	ACC	CCA	CGA	GAG	GCC	TGT	TAC	GGA	GAC	ATG	GAT	GGC	TTC	CCC	GGG	GTC	CGG	AAC	880
Y	G	V	V	D	P	D	D	L	Y	D	V	Y	C	Y	A	E	D	L	N	256
TAT	GGT	GTG	GTG	GAC	CCG	GAT	GAC	CTC	TAT	GAT	GTG	TAC	TGT	TAT	GCT	GAA	GAC	CTA	AAT	940
G	E	L	F	L	G	D	P	P	E	K	L	T	L	E	E	A	R	A	Y	276
GGA	GAA	CTG	TTC	CTG	GGT	GAC	CCT	CCA	GAG	AAG	CTG	ACA	TTG	GAG	GAA	GCA	CGG	GCG	TAC	1000
C	Q	E	R	G	A	E	I	A	T	T	G	Q	L	Y	A	A	W	D	G	296
TGC	CAG	GAG	CGG	GGT	GCA	GAG	ATT	GCC	ACC	ACG	GGC	CAA	CTG	TAT	GCA	GCC	TGG	GAT	GGT	1060

90 / 109

Fig. 7B

Fig. 7C

Fig. 7C

Fig. 7D

Fig. 7E




Fig.7F

Fig. 7G

Fig. 7H

Fig. 7I

Fig. 7J

Fig. 7J


```

680      690      700      710      720      730      740
M GACYKHFSTRSWEAAEQCRALGAHLTSICTPEEQDFVNDRYEQWIGLNDRTIEGDFLWSDGAPLLY
H -----SI-----L-----LLF
      660

750      760      770      780      790      800      810
M ENWNPQPDSYFLSGENCVMVWHQGWSDVPCNYHLSYCKMGLVSCGPPQLPLAQIFGRPRLRYAV
H -----F-----PLQ-----
      :
      :
      :

820      830      840      850      860      870      880
M DTVLRYCRDGLAQRNLPLIRCQENGLWEAPQISCVPRRPGRALRSMDAPEGPRGQLSRHRKAPLTPPSS
H -----LWVT-----
      670

```

M L

H -

Fig. 7K

```

10      20      30      40      50
H  GTCG-ACCCA-CG-----CGTCC-----GTCCCTGGGGCCCCAGCCCTCTCCTCAGGCTCGCGCAGTC
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  GAGGCTCCCGCGAGCTGGCGCCCTGTCTGGGTCCCGCGCGCCCGGCC-CTGCTCGCGCCCGCGCA-TC
   10      20      30      40      50      60

60      70      80      90      100     110     120
H  TCCGCCGAGTCTCAG-CTGCAGCTGCAGGACTGAGCCGTGCACCCGGAGGAGACCCCGGAGAGGCGGA
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  GC-GCCGAGTCTCGGTCTCGGCTGCGGACGTGACGCGCTGCGCGGAGGGGACCTC-----GCAA
   70      80      90      100     110     120

130     140     150     160     170     180     190
H  CAAACTTCGCAGTGCCCGGACCCCAACCCAGCCCTGGTAGCCTGCAGCATGGCCCCAGCTGTTCTGCCC
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  -GTTCTTC-----CATC-----AGTG---TGCAGAATGATACCACCTGCTTCTGTCC
   130     140     150     160     170

200     210     220     230     240     250     260
H  CTGCTGGCAGCCCTGGTCCTGGCCAGGCTCCTGCAGCTTTAGCAGATGTTCTGGAAGGAGACAGCTCAG
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  CTGCTGGCCGCTCTGGTCCTGACCCCAAGCCCTGCCGCCCTCGCTGATGACCTGAAAGAACAGACAGCTCGG
   180     190     200     210     220     230     240

270     280     290     300     310     320     330
H  AGGACCGCGCTTTTCGCGTGCGCATCGCGGGCGACGCGCCACTGCAGGGCGTGTCTGGCGGGCCCCCTCAC
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  AGGATCGAGCCTTCCGCGTGCGCATCG-GTGC--CGCGCAGCTGCGGGCGGTGCTGGCGGGTGCCTGGC
   250     260     270     280     290     300

```

Fig. 7L

Fig. 7M

```

690      700      710      720      730      740      750
H CCTTTCTGGGGCCAGGAGGCTGTGCCCGCATTTGGAGCCCCACATCGCCACCCGGAGCAGCTCTATGC
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M CCTTCGCTGGAGCCCAAGGAAAGCCCTGCGCTCGCATAGGAGCCCCGAATCGCCACCCGGAGCAGCTCTATGC
660      670      680      690      700      710      720

760      770      780      790      800      810      820
H CGCCTACCTTGGGGCTATGAGCAATGTGATGCTGGCTGGCTGTCGGATCAGACCGTGAGGTATCCCATC
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M TGCCTACCTCGGGGCTATGAGCAGTGTGATGCAGGCTGGCTGTCCGACCAAACTGTGAGGTACCCCATC
730      740      750      760      770      780      790

830      840      850      860      870      880      890
H CAGACCCACGAGAGGCCCTGTTACGGAGACATGGATGGCTTCCCCGGGTCCGGAACATATGGTGTGGTGG
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M CAGAACCCACGAGAGGCCCTGCTCTGAGACATGGATGGCTATCCTGGCGTGCGGAACACTACGGAGTGGTGG
800      810      820      830      840      850      860

900      910      920      930      940      950      960
H ACCCGGATGACCTCTATGATGTGTACTGTGTTATGCTGAAGACCTAAATGGAGAACTGTTCCCTGGTGACCC
   .: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M GTCCCTGATGATCTCTATGATGTCTACTGTTATGCCGAAGACCTAAATGGAGAACTGTTCCTAGCGCCCCC
870      880      890      900      910      920      930

970      980      990      1000      1010      1020      1030
H TCCAGAGAAGCTGACATTGGAGGAAGCACGGGCGTACTGCCAGAGCGGGGTGCAGAGATTGCCACACAG
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M TCCCAGCAAGCTGACATGGGAGGAGGCTCGGGACTACTGTCTGGAACGTGGTGCACAGATCGCTAGCACA
940      950      960      970      980      990      1000

```

Fig. 7N

Fig. 70

Fig. 7P

Fig. 7Q

Fig. 7R


```

2280      2290      2300      2310      2320
H  --CAATCTCGGATATCCAC-----CTTGTGG-GTATCTCAGCTCTCCGGT-CTT-TACCCCTGTG-AT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  GACCATCGAGGGTGACTTCTTGTGGTCAGATGGTGCCCTCTGCTCTATGAAAACTGGAACCCCTGGGCAG
2330      2340      2350      2360      2370      2380      2390
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
2330      2340
H  CC---CAGC-----CCCGCC-----ACTG-----ACCA---TCTGTGA---
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  CCTGACAGCTACTTCCTGTCTGGGGAGAACTGTGTGGTCATGGTGTGGCATGACCAAGGACAGTGGAGTG
2400      2410      2420      2430      2440      2450      2460
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
2360      2370      2380
H  -----CCCTTCC-CTGCCATTGGGC---CTCCA-----CCTGTGG---CTCACATCTC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  ATGTGCCCTGCAACTACCATCTATCCTACACCTGCAAGATGGGGCTTGTGTCTCTGTGGCCCTC-CACCCAC
2470      2480      2490      2500      2510      2520      2530
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
2400      2410      2420      2430      2440      2450
H  GCCAGCCCCA---CA-----GAGCATCCTCAG---GCCCTCCAAGGGTCCCTCATCACCTATTGCA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  AGCTACCCCTGGCTCAAAATATTGGTCGCCCTCGGCTGCGCTACGCGGTGGATACTGTGCTTCGATATCG
2540      2550      2560      2570      2580      2590      2600
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
2460      2470      2480
H  --GCCTT--CAGG---GCTCGGC-----CTATTTTCCACTAC-----TCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M  ATGCCGAGACGGGCTGGCTCAGCGCAACCTGCCGTTGATCCGCTGCCAGGAGAAATGGGCTTTGGAGGCC
2610      2620      2630      2640      2650      2660      2670

```

Fig. 7S

```

2490      2500      2510      2520      2530
H CTTCA-TCCGCCCTGTGTGCC-----GTCC--CCTTTAGCTGC-CTCCT-----ATTGATCTC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M CCTCAGATTTCCTGTGTACCCCGGAGGCCCTGGCCGTGCTCTGCGCTCCATGGACGCCCCCAGAGACCAC
2680      2690      2700      2710      2720      2730      2740

2540      2550      2560      2570      2580
H AGGA-AGC-----CTGGGAGTC-CC-TTCTCACC--CCTC-AACCTCCGGAGT-CCAGGAGAAC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M GGGACAGCTCTCGAGGCACAGGAAGGCACCGTTGACACCGCCCTCCAGTCTCTAGGAGCCTGGAAGAC
2750      2760      2770      2780      2790      2800      2810

2590      2600      2610      2620      2630
H CCGTACCCCCA-CAGAGCCTTAA-GCAACTACT-----TCT-----GTGAAGTATTT
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M TGCTGCCCCCAGCAGGACCCCTCTCACATCAACTGCCAGTGCTCTTCCCCATGATAGGGGTGACGTGAGA
2820      2830      2840      2850      2860      2870      2880

2640      2650
H ---TTTGACTGT--TTCA-----TGGAAAAACA-----
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M GGGGTGGGACTGAAATTTCAGAGGACAGCGCTCGAAGGGGTTTCTGGGAAACACTTGGGTGGCTCCGCCCC
2890      2900      2910      2920      2930      2940      2950

2660      2670      2680
H -----AGCCTTGGAAT-----AAATCTCTATTA-----AC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M CTCACACAAGGGCCTCAGGTTTATACCCGGTAAGTCCCTAAGTGCCTCAACTGCCCTCTCATGTCAAGTGC
2960      2970      2980      2990      3000      3010      3020

```

Fig. 7T

```

      2690                                2700
H CGCTTTGT-----AAC-----CAAAAAAAAAAAAAAA
: : : : :                               : : : : :
M CTCCTTGTCCCTCGATNTCGTNAGGGGACACTGTGCTATTCGATCTTGATTGTCGAAGAGTTTTTAGGAT
3030 3040 3050 3060 3070 3080 3090

      2710                                2730
H AAA-----AAAAAAAGGGCGG--CC-----GC
: : : : :                               : : : : :
M GGAGTACCAGCAAAACCAGGTGGAATATAAGTTGTCTGAACCCCAAGAAAAAA
3100 3110 3120 3130 3140 3150

```

Fig. 7U

DECLARATION AND POWER OF ATTORNEY
(Related Application)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**Novel Genes Encoding Proteins Having Diagnostic,
Preventive, Therapeutic, and Other Uses**

the specification of which is attached hereto and/or was filed on June 26, 2000 as Application No. _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d), of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

FOREIGN PRIORITY APPLICATION(S)

			<u>Priority Claimed</u>
			<input type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/month/year filed)	
			<u>Priority Claimed</u>
			<input type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/month/year field)	

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional patent application(s) listed below and have also identified below any United States provisional patent application(s) having a filing date before that of the application on which priority is claimed.

PROVISIONAL PRIORITY PATENT APPLICATION

		<u>Priority Claimed</u>
		<input type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Application No.)	_____ (Filing Date)	
		<input type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Application No.)	_____ (Filing Date)	

I hereby claim the benefit under Title 35, United States Code, Section 120, of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or in the prior U.S. provisional application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09/342,364 June 29, 2000 Pending
(Application Serial No.) (Filing Date) (Status)--(patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status)--(patented, pending, abandoned)

And I hereby appoint the registered attorneys and agents associated with **AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., Customer No. 000570**, as my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to **Customer No. 000570, namely, AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**, One Commerce Square, 2005 Market Street, Suite 2200, Philadelphia, Pennsylvania 19103. Please direct all communications and telephone calls to **Gary D. Colby** at (215) 965-1285.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole
inventor, if any **Susan J. Kirst**

Inventor's Signature _____

Date _____

Residence Brookline, Massachusetts

Citizenship United States of America

Post Office Address 12 Dana Street; Brookline, MA 02445

Full name of second joint

inventor, if any **Douglas A. Holtzman**

Inventor's Signature _____

Date _____

Residence Jamaica Plain, Massachusetts

Citizenship United States of America

Post Office Address 821 Centre Street, No. 6; Jamaica Plain, MA 02130

Full name of third joint

inventor, if any **Christopher C. Fraser**

Inventor's Signature _____

Date _____

Residence Lexington, Massachusetts

Citizenship United States of America

Post Office Address 52 Grassland Street; Lexington, MA 02421

Full name of fourth joint

inventor, if any **John D. Sharp**

Inventor's Signature _____

Date _____

Residence Arlington, Massachusetts

Citizenship United States of America

Post Office Address 245 Parke Avenue; Arlington, MA 02476

Full name of fifth joint
inventor, if any Thomas S. Barnes

Inventor's Signature _____

Date _____

Residence Boston, Massachusetts

Citizenship Australia

Post Office Address 22 Hanson Street # 2; Boston, MA 02118

SEQUENCE LISTING

<110> KIRST, Susan
SHARP, John
HOLTZMAN, Douglas
BARNES, Tom
FRASER, Christopher

<120> Novel Genes Encoding Proteins Having Diagnostic,
Preventive, Therapeutic, and Other Uses

<130> 210147.0025/11U1

<140> Not Yet Assigned

<141> 2000-06-16

<150> US 09/342,364

<151> 1999-06-29

<160> 100

<170> PatentIn Ver. 2.1

<210> 1

<211> 2895

<212> DNA

<213> Homo sapiens

<400> 1

```
gtcgaccac ggcgtccggg agcgcggtc agagtgccgc accgcctcac aacctgggaa 60
ccggagagta ggggcccgtc gctggcaaga accgcctgc cctcctcggc aagggccatc 120
cggtgccacc catgtcgcac tagagcagaa gaggttgagt cctgaactgc aacctgcaca 180
gagctgctct gtactgtccc tgggtggtgc cgccatgacc tggttggtgc tgctggggac 240
actgctctgc atgctgcgcg ttgggttagg caccgccgac tccgagggtt tccgcgcccg 300
tgcgtccac aactgcccct acaaagtat ctgcgctgcc gacctgctaa gctgcactgg 360
cctagggctg caggacgtgc cagccgagtt acctgccgt actgcggacc tcgacctgag 420
ccacaacgcg ctccagcgcc tgcgcccccg ctggttggcg cccctcttcc agctgcgcgc 480
cctgcaccta gaccacaacg aactagatgc gctgggtcgc ggcgtcttcg tcaacgccag 540
cggcctgagg ctgctcgatc tatcatctaa caggttgccg gcgcttgcc gccacgacct 600
cgacgggctg ggggcgctgg agaagctgct tctgttcaat aaccgcttg tgcaacttga 660
cgagcatgcc ttccacggcc tgcgcgcgct cagccatctc tacctgggct gcaacgaact 720
cgcctcgttc tccttcgacc acctgcacgg tctgagcgcc acccacctgc ttactctgga 780
cctctcctcc aaccggctgg gacacatctc cgtacctgag ctggccgcgc tgccggcctt 840
cctcaagaac ggctctact tgcacaacaa ccctttgcct tgcgactgcc gcctctacca 900
cctgctacag cgctggcacc agcggggcct gagcgccgtg cgcgacttg cgcgcgagta 960
cgtatgcttg gocttcaagg taccgcgctc ccgcgtgcgc ttcttcagc acagccgcgt 1020
ctttgagaac tgctcgtcgg cccagctct tggcctaaag cggccggaag agcaacctga 1080
cgcgctggtg ggtcgggtccc tgaggcttta ctgcaacacc agcgtcccg ccatgcgcac 1140
```

tgcttgggtt	tcgccgcagc	aggagcttct	cagggcgcca	ggatcccgcg	atggcagcat	1200
cgcggtgctg	gccgacggca	gcttggccat	aggcaacgta	caggagcagc	atgcgggact	1260
cttcgtgtgc	ctggccactg	ggccccgcct	gcaccacaac	cagacgcacg	agtacaacgt	1320
gagcgtgcac	tttccgcgcc	cagagcccga	ggctttcaac	acaggcttca	ccacactgct	1380
gggctgtgcc	gtgggccttg	tgctcgtgct	gctctacctg	ttcgccccac	cctgccgctg	1440
ctgccgcctg	gcttgccccg	tgccgcctgt	ggccccaaac	acccagcccc	ctccaagagc	1500
tgagccgcac	aagtccctcag	tactcagcac	cacaccgcca	gacgcaccca	gcccgcgaag	1560
ccaagcgtcc	acaagcacgt	agtctttctg	gagccaggcc	ggaggggcct	caatggcccc	1620
cgtgcagctg	gcagtagctg	aggaattcga	tctctacaac	cctggaggcc	tgcagctgaa	1680
ggctggctct	gagtcgcgca	gctccatagg	ctccgagggt	cccatgacaa	cctagactgc	1740
cagggctccc	ccaccaggc	ccccaccctc	ttgctgctcg	ccctgctccc	tgtttcggtc	1800
cagagaactg	gcagatactg	gtgggaagca	ctgtgcctgg	ccccccagct	tcctgtatgg	1860
gcctcgaaac	acaatgggcc	ttctcgctca	ctggtagaga	caggggttgt	ggccccaac	1920
ctgccttctg	ctctgcccc	gcacaggacc	caaaggcccc	aggccctgca	aggtgtgcta	1980
gttcctgctt	tcccgcggac	ttcctagtgc	ccaaatgccc	tgtgaggctg	agagaccag	2040
gcccctgtgg	ctttcaacac	agcacagctg	tggaaagtgg	tgtgttcttc	tacagcctgt	2100
ggaagaaccc	ctgtagcaga	gcctcccatc	caccctcagg	ggctgaggca	gctctcgagg	2160
agtgggtgct	aagagctgac	gcagggccac	ctccccttcc	caagggggtg	ggagggagtg	2220
ggccacaggg	gaaaagaagg	cggctctgaa	ggaagatctc	gccacacccc	caggacagaa	2280
agaggaaaca	agcccgccct	ctggtgaaat	gggactccct	ccatccacca	acacccaacc	2340
tcctgaaagc	ttcacaactt	cacgcagagt	ccggtggcag	gcaccaggca	ggaaaggctc	2400
ctcaagaggt	tcctggtggt	ctggcctaag	cccagccag	aggccctgct	ctctctggcc	2460
tggggcatcc	accggttggt	ctgaaggcag	agccattctt	gtgggctcac	aagacacagt	2520
gaaggggatc	atggcctgca	ccctgctttt	tcagcagtaa	aaagcccga	aagcctggcg	2580
agcatggccg	agctgggagg	gccgagcccg	aactccacgt	ccctcgagag	caggagcctc	2640
ttaagggctg	gcactggtct	cagcctaata	gctgaggcgg	tacctggctt	tcatatgcat	2700
ctcactgctc	ccactgcagg	ggggcaggga	aggggggtct	gggagccctt	catgtgtggg	2760
ggccgagctg	ggggccccc	tggccatcct	ggacctcgct	gctccagagt	ttaataaagg	2820
tagcacatgc	ttattgctag	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	2880
aaaaagggcg	gccgc					2895

<210> 2

<211> 1365

<212> DNA

<213> Homo sapiens

<400> 2

atgacctggt	tgggtgctgct	ggggacactg	ctctgcatgc	tgcgcgttgg	gttaggcacc	60
ccggactccg	agggtttccc	gccccgtgcg	ctccacaact	gcccctacaa	atgtatctgc	120
gctgccgacc	tgctaagctg	cactggccta	gggctgcagg	acgtgccagc	cgagttacct	180
gccgctactg	cggacctcga	cctgagccac	aacgcgctcc	agcgctcgcg	ccccggctgg	240
ttggcgcccc	tcttccagct	gcgcgcctcg	cacctagacc	acaacgaact	agatgcgctg	300
ggtcgcggcg	tcttcgtcaa	cgcagcggc	ctgaggctgc	tcgatctatc	atctaacacg	360
ttgcgggcgc	ttggccgcca	cgacctcgac	gggctggggg	cgctggagaa	gctgcttctg	420
ttcaataacc	gcttgggtgca	cttggacgag	catgccttcc	acggcctgcg	cgcgctcagc	480
catctctacc	tgggctgcaa	cgaactcgcc	tcgttctcct	tcgaccacct	gcacgggtctg	540
agcgccaccc	acctgcttac	tctggacctc	tcctccaacc	ggctgggaca	catctccgta	600

```

cctgagctgg ccgcgctgcc ggcttctc aagaacggcc tctacttgca caacaaccct 660
ttgcttgcg actgccgcct ctaccacctg ctacagcgct ggcaccagcg gggcctgagc 720
gcggtgcgag actttgcgag cgagtagta tgcttgccct tcaaggtagc cgcgccccgc 780
gtgcgcttct tccagcacag ccgcgtcttt gagaactgct cgtcgccccc agctcttggc 840
ctaaagcggc cggaagagca cctgtacgag ctgggtgggtc ggtccctgag gctttactgc 900
aacaccagcg tcccggccat gcgcattgcc tgggtttcgc cgcagcagga gcttctcagg 960
gcgccaggat cccgcgatgg cagcatcgcg gtgctggcgg acggcagctt ggccataggc 1020
aacgtacagg agcagcatgc gggactcttc gtgtgcctgg ccaactgggccc ccgcctgcac 1080
cacaaccaga cgcacgagta caacgtgagc gtgcactttc cgcgccagga gcccgaggct 1140
ttcaacacag gcttcaccac actgctgggc tgtgccgtgg gccttggtgt cgtgctgctc 1200
tacctgttcg cccaccctg ccgctgctgc cgcgctgcct gcccgctgcc gccgctggcc 1260
ccaaacaccc agcccgctcc aagagctgag ccgcacaagt cctcagtact cagcaccaca 1320
ccgccagacg caccagccc gcaaggccaa gcgtccacaa gcacg 1365

```

<210> 3

<211> 455

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg Val
  1                      5                      10                      15

```

```

Gly Leu Gly Thr Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His
          20                      25                      30

```

```

Asn Cys Pro Tyr Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr
          35                      40                      45

```

```

Gly Leu Gly Leu Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala
          50                      55                      60

```

```

Asp Leu Asp Leu Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp
          65                      70                      75                      80

```

```

Leu Ala Pro Leu Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu
          85                      90                      95

```

```

Leu Asp Ala Leu Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg
          100                      105                      110

```

```

Leu Leu Asp Leu Ser Ser Asn Thr Leu Arg Ala Leu Gly Arg His Asp
          115                      120                      125

```

```

Leu Asp Gly Leu Gly Ala Leu Glu Lys Leu Leu Leu Phe Asn Asn Arg
          130                      135                      140

```

Leu Val His Leu Asp Glu His Ala Phe His Gly Leu Arg Ala Leu Ser
 145 150 155 160

His Leu Tyr Leu Gly Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His
 165 170 175

Leu His Gly Leu Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser
 180 185 190

Asn Arg Leu Gly His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala
 195 200 205

Phe Leu Lys Asn Gly Leu Tyr Leu His Asn Asn Pro Leu Pro Cys Asp
 210 215 220

Cys Arg Leu Tyr His Leu Leu Gln Arg Trp His Gln Arg Gly Leu Ser
 225 230 235 240

Ala Val Arg Asp Phe Ala Arg Glu Tyr Val Cys Leu Ala Phe Lys Val
 245 250 255

Pro Ala Ser Arg Val Arg Phe Phe Gln His Ser Arg Val Phe Glu Asn
 260 265 270

Cys Ser Ser Ala Pro Ala Leu Gly Leu Lys Arg Pro Glu Glu His Leu
 275 280 285

Tyr Ala Leu Val Gly Arg Ser Leu Arg Leu Tyr Cys Asn Thr Ser Val
 290 295 300

Pro Ala Met Arg Ile Ala Trp Val Ser Pro Gln Gln Glu Leu Leu Arg
 305 310 315 320

Ala Pro Gly Ser Arg Asp Gly Ser Ile Ala Val Leu Ala Asp Gly Ser
 325 330 335

Leu Ala Ile Gly Asn Val Gln Glu Gln His Ala Gly Leu Phe Val Cys
 340 345 350

Leu Ala Thr Gly Pro Arg Leu His His Asn Gln Thr His Glu Tyr Asn
 355 360 365

Val Ser Val His Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr Gly
 370 375 380

Phe Thr Thr Leu Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu Leu
 385 390 395 400

Tyr Leu Phe Ala Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Pro Leu
 405 410 415

Pro Pro Leu Ala Pro Asn Thr Gln Pro Ala Pro Arg Ala Glu Pro His
 420 425 430

Lys Ser Ser Val Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Pro Gln
 435 440 445

Gly Gln Ala Ser Thr Ser Thr
 450 455

<210> 4
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg Val
 1 5 10 15

Gly Leu Gly Thr
 20

<210> 5
 <211> 435
 <212> PRT
 <213> Homo sapiens

<400> 5
 Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His Asn Cys Pro Tyr
 1 5 10 15

Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr Gly Leu Gly Leu
 20 25 30

Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala Asp Leu Asp Leu
 35 40 45

Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp Leu Ala Pro Leu
 50 55 60

Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu Leu Asp Ala Leu
 65 70 75 80

Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg Leu Leu Asp Leu

					85						90						95
Ser	Ser	Asn	Thr	Leu	Arg	Ala	Leu	Gly	Arg	His	Asp	Leu	Asp	Gly	Leu		
			100					105					110				
Gly	Ala	Leu	Glu	Lys	Leu	Leu	Leu	Phe	Asn	Asn	Arg	Leu	Val	His	Leu		
		115					120					125					
Asp	Glu	His	Ala	Phe	His	Gly	Leu	Arg	Ala	Leu	Ser	His	Leu	Tyr	Leu		
		130				135					140						
Gly	Cys	Asn	Glu	Leu	Ala	Ser	Phe	Ser	Phe	Asp	His	Leu	His	Gly	Leu		
145					150					155					160		
Ser	Ala	Thr	His	Leu	Leu	Thr	Leu	Asp	Leu	Ser	Ser	Asn	Arg	Leu	Gly		
				165				170						175			
His	Ile	Ser	Val	Pro	Glu	Leu	Ala	Ala	Leu	Pro	Ala	Phe	Leu	Lys	Asn		
			180					185					190				
Gly	Leu	Tyr	Leu	His	Asn	Asn	Pro	Leu	Pro	Cys	Asp	Cys	Arg	Leu	Tyr		
		195					200					205					
His	Leu	Leu	Gln	Arg	Trp	His	Gln	Arg	Gly	Leu	Ser	Ala	Val	Arg	Asp		
		210				215					220						
Phe	Ala	Arg	Glu	Tyr	Val	Cys	Leu	Ala	Phe	Lys	Val	Pro	Ala	Ser	Arg		
225					230					235					240		
Val	Arg	Phe	Phe	Gln	His	Ser	Arg	Val	Phe	Glu	Asn	Cys	Ser	Ser	Ala		
				245					250						255		
Pro	Ala	Leu	Gly	Leu	Lys	Arg	Pro	Glu	Glu	His	Leu	Tyr	Ala	Leu	Val		
			260					265					270				
Gly	Arg	Ser	Leu	Arg	Leu	Tyr	Cys	Asn	Thr	Ser	Val	Pro	Ala	Met	Arg		
		275					280					285					
Ile	Ala	Trp	Val	Ser	Pro	Gln	Gln	Glu	Leu	Leu	Arg	Ala	Pro	Gly	Ser		
		290				295					300						
Arg	Asp	Gly	Ser	Ile	Ala	Val	Leu	Ala	Asp	Gly	Ser	Leu	Ala	Ile	Gly		
305					310					315					320		
Asn	Val	Gln	Glu	Gln	His	Ala	Gly	Leu	Phe	Val	Cys	Leu	Ala	Thr	Gly		
				325				330						335			
Pro	Arg	Leu	His	His	Asn	Gln	Thr	His	Glu	Tyr	Asn	Val	Ser	Val	His		

340	345	350
Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr Gly Phe Thr Thr Leu		
355	360	365
Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu Leu Tyr Leu Phe Ala		
370	375	380
Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Pro Leu Pro Pro Leu Ala		
385	390	395
Pro Asn Thr Gln Pro Ala Pro Arg Ala Glu Pro His Lys Ser Ser Val		
405	410	415
Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Pro Gln Gly Gln Ala Ser		
420	425	430
Thr Ser Thr		
435		

<210> 6
 <211> 363
 <212> PRT
 <213> Homo sapiens

<400> 6
Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His Asn Cys Pro Tyr
1 5 10 15
Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr Gly Leu Gly Leu
20 25 30
Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala Asp Leu Asp Leu
35 40 45
Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp Leu Ala Pro Leu
50 55 60
Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu Leu Asp Ala Leu
65 70 75 80
Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg Leu Leu Asp Leu
85 90 95
Ser Ser Asn Thr Leu Arg Ala Leu Gly Arg His Asp Leu Asp Gly Leu
100 105 110

Gly Ala Leu Glu Lys Leu Leu Leu Phe Asn Asn Arg Leu Val His Leu
115 120 125

Asp Glu His Ala Phe His Gly Leu Arg Ala Leu Ser His Leu Tyr Leu
130 135 140

Gly Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His Leu His Gly Leu
145 150 155 160

Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser Asn Arg Leu Gly
165 170 175

His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala Phe Leu Lys Asn
180 185 190

Gly Leu Tyr Leu His Asn Asn Pro Leu Pro Cys Asp Cys Arg Leu Tyr
195 200 205

His Leu Leu Gln Arg Trp His Gln Arg Gly Leu Ser Ala Val Arg Asp
210 215 220

Phe Ala Arg Glu Tyr Val Cys Leu Ala Phe Lys Val Pro Ala Ser Arg
225 230 235 240

Val Arg Phe Phe Gln His Ser Arg Val Phe Glu Asn Cys Ser Ser Ala
245 250 255

Pro Ala Leu Gly Leu Lys Arg Pro Glu Glu His Leu Tyr Ala Leu Val
260 265 270

Gly Arg Ser Leu Arg Leu Tyr Cys Asn Thr Ser Val Pro Ala Met Arg
275 280 285

Ile Ala Trp Val Ser Pro Gln Gln Glu Leu Leu Arg Ala Pro Gly Ser
290 295 300

Arg Asp Gly Ser Ile Ala Val Leu Ala Asp Gly Ser Leu Ala Ile Gly
305 310 315 320

Asn Val Gln Glu Gln His Ala Gly Leu Phe Val Cys Leu Ala Thr Gly
325 330 335

Pro Arg Leu His His Asn Gln Thr His Glu Tyr Asn Val Ser Val His
340 345 350

Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr
355 360

<210> 7
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 7
 Gly Phe Thr Thr Leu Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu
 1 5 10 15
 Leu Tyr Leu Phe
 20

<210> 8
 <211> 52
 <212> PRT
 <213> Homo sapiens

<400> 8
 Ala Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Pro Leu Pro Pro Leu
 1 5 10 15
 Ala Pro Asn Thr Gln Pro Ala Pro Arg Ala Glu Pro His Lys Ser Ser
 20 25 30
 Val Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Pro Gln Gly Gln Ala
 35 40 45
 Ser Thr Ser Thr
 50

<210> 9
 <211> 1518
 <212> DNA
 <213> Homo sapiens

<400> 9
 gtgcacccac gcggtccggcg aaccccagcg tccgccgaca tggcctggac caagtaccag 60
 ctgttctctgg cggggtcat gcttggtacc ggctccatca acacgctctc ggcaaaatgg 120
 gcggacaatt tcatggccga gggctgtgga gggagcaagg agcacagctt ccagcatccc 180
 ttctccagg cagtgggcat gttcctggga gaattctcct gcctggctgc cttctacctc 240
 ctccgatgca gagctgcagg gcaatcagac tccagcgtag acccccagca gcccttcaac 300
 cctcttcttt tctgcccc agcgctctgt gacatgacag ggaccagcct catgtatgtg 360
 gctctgaaca tgaccagtgc ctccagcttc cagatgctgc ggggtgcagt gatcatattc 420
 actggcctgt tctcggtggc cttcctgggc cggaggctgg tgctgagcca gtggctgggc 480
 atcctagcca ccacgcggg gctggtggtc gtgggcctgg ctgacctcct gagcaagcac 540

```

gacagtcagc acaagctcag cgaagtgatc acaggggacc tgttgatcat catggcccag 600
atcatcgttg ccatccagat ggtgctagag gagaagttcg tctacaaaca caatgtgcac 660
ccactgcggg cagttggcac tgagggcctc tttggctttg tgatcctctc cctgctgctg 720
gtgcccattg actacatccc cgccggctcc ttcagcggaa accctcgtgg gacactggag 780
gatgcattgg acgccttctg ccaggtgggc cagcagccgc tcattgccgt ggactgctg 840
ggcaacatca gcagcattgc cttcttcaac ttgcagggca tcagcgtcac caaggaaactg 900
agcgccacca ccgcgatggt gttggacagc ttgcgcaccg ttgtcatctg ggactgagc 960
ctggcactgg gctgggaggc cttccatgca ctgcagatcc ttggcttcct catactcctt 1020
ataggcactg ccctctacaa tgggctacac cgtccgctgc tgggcccgcct gtccaggggc 1080
cggcccctgg cagaggagag cgagcaggag agactgctgg gtggcaccgc cactcccatc 1140
aatgatgcca gctgaggttc cctggaggct tctactgcca ccgggtgct ccttctccct 1200
gagactgagg ccacacaggc tgggtgggcc cgaatgccct atccccaagg cctcaccctg 1260
tccccctcct gcagaacccc cagggcagct gctgccacag aagataacaa caccgaagtc 1320
ctctttttct cactaccacc tgcagggtgg tgttaccag ccccccacag cctgagtgc 1380
gtggcagacc tcagctctct ggaccctcc tacagcata gagctaaatc atgaagtga 1440
attgtaggaa tttaccaccg tagtgtatct gaatcataaa ctagattatc ataaaaaaaa 1500
aaaaaaaaag ggcggcgc                                     1518

```

<210> 10

<211> 1113

<212> DNA

<213> Homo sapiens

<400> 10

```

atggcctgga ccaagtacca gctgttcctg gccgggctca tgettgttac cggctccatc 60
aacacgctct cggcaaaatg ggcggaacaat ttcattggcg agggctgtgg agggagcaag 120
gagcacagct tcagcatcc cttcctccag gcagtgggca tgttcctggg agaattctcc 180
tgcttgctg cttctacct cctccgatgc agagctgcag ggcaatcaga ctccagcgta 240
gacccccagc agcccttcaa cctcttctt ttctgcccc cagcgctctg tgacatgaca 300
gggaccagcc tcattgatgt ggctctgaac atgaccagtg cctccagctt ccagatgctg 360
cggggtgcag tgatcatatt cactggcctg ttctcggtgg ccttcctggg ccggaggctg 420
gtgctgagcc agtggctggg catcctagcc accatcgcg ggctggtgg cgtgggcctg 480
gctgacctcc tgagcaagca cgacagtcag cacaagctca gcgaagtgat cacaggggac 540
ctgttgatca tcattggcca gatcatcgtt gccatccaga tgggtgctaga ggagaagttc 600
gtctacaaac acaatgtgca ccactgcgg gcagttggca ctgagggcct ctttggcttt 660
tgatcctct ccctgctgct ggtgcccatg tactacatcc ccgcccgtc cttcagcgga 720
aaccctcgtg ggacactgga ggatgcattg gacgccttct gccaggtggg ccagcagccg 780
ctcattgccg tggcactgct gggcaacatc agcagcattg cttcttcaa cttcgcaggc 840
atcagcgta ccaaggaaact gagcgccacc acccgcatgg tgttgacag cttgcgcacc 900
gttgtcatct gggcactgag cctggcactg ggctgggagg ccttccatgc actgcagatc 960
cttggcttcc tcatactcct tataggcact gccctctaca atgggctaca ccgtccgctg 1020
ctgggcccgc tgtccagggg ccggcccctg gcagaggaga gcgagcagga gagactgctg 1080
ggtggcacc gcactcccat caatgatgcc agc                                     1113

```

<210> 11

<211> 371

<212> PRT

<213> Homo sapiens

<400> 11

Met Ala Trp Thr Lys Tyr Gln Leu Phe Leu Ala Gly Leu Met Leu Val
1 5 10 15

Thr Gly Ser Ile Asn Thr Leu Ser Ala Lys Trp Ala Asp Asn Phe Met
20 25 30

Ala Glu Gly Cys Gly Gly Ser Lys Glu His Ser Phe Gln His Pro Phe
35 40 45

Leu Gln Ala Val Gly Met Phe Leu Gly Glu Phe Ser Cys Leu Ala Ala
50 55 60

Phe Tyr Leu Leu Arg Cys Arg Ala Ala Gly Gln Ser Asp Ser Ser Val
65 70 75 80

Asp Pro Gln Gln Pro Phe Asn Pro Leu Leu Phe Leu Pro Pro Ala Leu
85 90 95

Cys Asp Met Thr Gly Thr Ser Leu Met Tyr Val Ala Leu Asn Met Thr
100 105 110

Ser Ala Ser Ser Phe Gln Met Leu Arg Gly Ala Val Ile Ile Phe Thr
115 120 125

Gly Leu Phe Ser Val Ala Phe Leu Gly Arg Arg Leu Val Leu Ser Gln
130 135 140

Trp Leu Gly Ile Leu Ala Thr Ile Ala Gly Leu Val Val Val Gly Leu
145 150 155 160

Ala Asp Leu Leu Ser Lys His Asp Ser Gln His Lys Leu Ser Glu Val
165 170 175

Ile Thr Gly Asp Leu Leu Ile Ile Met Ala Gln Ile Ile Val Ala Ile
180 185 190

Gln Met Val Leu Glu Glu Lys Phe Val Tyr Lys His Asn Val His Pro
195 200 205

Leu Arg Ala Val Gly Thr Glu Gly Leu Phe Gly Phe Val Ile Leu Ser
210 215 220

Leu Leu Leu Val Pro Met Tyr Tyr Ile Pro Ala Gly Ser Phe Ser Gly
225 230 235 240

Asn Pro Arg Gly Thr Leu Glu Asp Ala Leu Asp Ala Phe Cys Gln Val
245 250 255

Gly Gln Gln Pro Leu Ile Ala Val Ala Leu Leu Gly Asn Ile Ser Ser
260 265 270

Ile Ala Phe Phe Asn Phe Ala Gly Ile Ser Val Thr Lys Glu Leu Ser
275 280 285

Ala Thr Thr Arg Met Val Leu Asp Ser Leu Arg Thr Val Val Ile Trp
290 295 300

Ala Leu Ser Leu Ala Leu Gly Trp Glu Ala Phe His Ala Leu Gln Ile
305 310 315 320

Leu Gly Phe Leu Ile Leu Leu Ile Gly Thr Ala Leu Tyr Asn Gly Leu
325 330 335

His Arg Pro Leu Leu Gly Arg Leu Ser Arg Gly Arg Pro Leu Ala Glu
340 345 350

Glu Ser Glu Gln Glu Arg Leu Leu Gly Gly Thr Arg Thr Pro Ile Asn
355 360 365

Asp Ala Ser
370

<210> 12

<211> 18

<212> PRT

<213> Homo sapiens

<400> 12

Met Ala Trp Thr Lys Tyr Gln Leu Phe Leu Ala Gly Leu Met Leu Val
1 5 10 15

Thr Gly

<210> 13

<211> 353

<212> PRT

<213> Homo sapiens

<400> 13

Ser Ile Asn Thr Leu Ser Ala Lys Trp Ala Asp Asn Phe Met Ala Glu
 1 5 10 15
 Gly Cys Gly Gly Ser Lys Glu His Ser Phe Gln His Pro Phe Leu Gln
 20 25 30
 Ala Val Gly Met Phe Leu Gly Glu Phe Ser Cys Leu Ala Ala Phe Tyr
 35 40 45
 Leu Leu Arg Cys Arg Ala Ala Gly Gln Ser Asp Ser Ser Val Asp Pro
 50 55 60
 Gln Gln Pro Phe Asn Pro Leu Leu Phe Leu Pro Pro Ala Leu Cys Asp
 65 70 75 80
 Met Thr Gly Thr Ser Leu Met Tyr Val Ala Leu Asn Met Thr Ser Ala
 85 90 95
 Ser Ser Phe Gln Met Leu Arg Gly Ala Val Ile Ile Phe Thr Gly Leu
 100 105 110
 Phe Ser Val Ala Phe Leu Gly Arg Arg Leu Val Leu Ser Gln Trp Leu
 115 120 125
 Gly Ile Leu Ala Thr Ile Ala Gly Leu Val Val Val Gly Leu Ala Asp
 130 135 140
 Leu Leu Ser Lys His Asp Ser Gln His Lys Leu Ser Glu Val Ile Thr
 145 150 155 160
 Gly Asp Leu Leu Ile Ile Met Ala Gln Ile Ile Val Ala Ile Gln Met
 165 170 175
 Val Leu Glu Glu Lys Phe Val Tyr Lys His Asn Val His Pro Leu Arg
 180 185 190
 Ala Val Gly Thr Glu Gly Leu Phe Gly Phe Val Ile Leu Ser Leu Leu
 195 200 205
 Leu Val Pro Met Tyr Tyr Ile Pro Ala Gly Ser Phe Ser Gly Asn Pro
 210 215 220
 Arg Gly Thr Leu Glu Asp Ala Leu Asp Ala Phe Cys Gln Val Gly Gln
 225 230 235 240
 Gln Pro Leu Ile Ala Val Ala Leu Leu Gly Asn Ile Ser Ser Ile Ala
 245 250 255

Phe Phe Asn Phe Ala Gly Ile Ser Val Thr Lys Glu Leu Ser Ala Thr
 260 265 270

Thr Arg Met Val Leu Asp Ser Leu Arg Thr Val Val Ile Trp Ala Leu
 275 280 285

Ser Leu Ala Leu Gly Trp Glu Ala Phe His Ala Leu Gln Ile Leu Gly
 290 295 300

Phe Leu Ile Leu Leu Ile Gly Thr Ala Leu Tyr Asn Gly Leu His Arg
 305 310 315 320

Pro Leu Leu Gly Arg Leu Ser Arg Gly Arg Pro Leu Ala Glu Glu Ser
 325 330 335

Glu Gln Glu Arg Leu Leu Gly Gly Thr Arg Thr Pro Ile Asn Asp Ala
 340 345 350

Ser

<210> 14

<211> 29

<212> PRT

<213> Homo sapiens

<400> 14

Ser Ile Asn Thr Leu Ser Ala Lys Trp Ala Asp Asn Phe Met Ala Glu
 1 5 10 15

Gly Cys Gly Gly Ser Lys Glu His Ser Phe Gln His Pro
 20 25

<210> 15

<211> 9

<212> PRT

<213> Homo sapiens

<400> 15

Asn Met Thr Ser Ala Ser Ser Phe Gln
 1 5

<210> 16

<211> 14

<212> PRT

<213> Homo sapiens

<400> 16

Asp Leu Leu Ser Lys His Asp Ser Gln His Lys Leu Ser Glu
1 5 10

<210> 17

<211> 27

<212> PRT

<213> Homo sapiens

<400> 17

Pro Ala Gly Ser Phe Ser Gly Asn Pro Arg Gly Thr Leu Glu Asp Ala
1 5 10 15

Leu Asp Ala Phe Cys Gln Val Gly Gln Gln Pro
20 25

<210> 18

<211> 7

<212> PRT

<213> Homo sapiens

<400> 18

Glu Ala Phe His Ala Leu Gln
1 5

<210> 19

<211> 21

<212> PRT

<213> Homo sapiens

<400> 19

Phe Leu Gln Ala Val Gly Met Phe Leu Gly Glu Phe Ser Cys Leu Ala
1 5 10 15

Ala Phe Tyr Leu Leu
20

<210> 20

<211> 21

<212> PRT

<213> Homo sapiens

<400> 20

Leu Leu Phe Leu Pro Pro Ala Leu Cys Asp Met Thr Gly Thr Ser Leu
1 5 10 15

Met Tyr Val Ala Leu
20

<210> 21

<211> 19

<212> PRT

<213> Homo sapiens

<400> 21

Met Leu Arg Gly Ala Val Ile Ile Phe Thr Gly Leu Phe Ser Val Ala
1 5 10 15

Phe Leu Gly

<210> 22

<211> 17

<212> PRT

<213> Homo sapiens

<400> 22

Trp Leu Gly Ile Leu Ala Thr Ile Ala Gly Leu Val Val Val Gly Leu
1 5 10 15

Ala

<210> 23

<211> 17

<212> PRT

<213> Homo sapiens

<400> 23

Val Ile Thr Gly Asp Leu Leu Ile Ile Met Ala Gln Ile Ile Val Ala
1 5 10 15

Ile

<210> 24

<211> 18
<212> PRT
<213> Homo sapiens

<400> 24
Gly Leu Phe Gly Phe Val Ile Leu Ser Leu Leu Leu Val Pro Met Tyr
1 5 10 15
Tyr Ile

<210> 25
<211> 23
<212> PRT
<213> Homo sapiens

<400> 25
Leu Ile Ala Val Ala Leu Leu Gly Asn Ile Ser Ser Ile Ala Phe Phe
1 5 10 15
Asn Phe Ala Gly Ile Ser Val
20

<210> 26
<211> 20
<212> PRT
<213> Homo sapiens

<400> 26
Met Val Leu Asp Ser Leu Arg Thr Val Val Ile Trp Ala Leu Ser Leu
1 5 10 15
Ala Leu Gly Trp
20

<210> 27
<211> 17
<212> PRT
<213> Homo sapiens

<400> 27
Ile Leu Gly Phe Leu Ile Leu Leu Ile Gly Thr Ala Leu Tyr Asn Gly
1 5 10 15
Leu

<210> 28
<211> 20
<212> PRT
<213> Homo sapiens

<400> 28
Arg Cys Arg Ala Ala Gly Gln Ser Asp Ser Ser Val Asp Pro Gln Gln
1 5 10 15

Pro Phe Asn Pro
20

<210> 29
<211> 7
<212> PRT
<213> Homo sapiens

<400> 29
Arg Arg Leu Val Leu Ser Gln
1 5

<210> 30
<211> 23
<212> PRT
<213> Homo sapiens

<400> 30
Gln Met Val Leu Glu Glu Lys Phe Val Tyr Lys His Asn Val His Pro
1 5 10 15

Leu Arg Ala Val Gly Thr Glu
20

<210> 31
<211> 9
<212> PRT
<213> Homo sapiens

<400> 31
Thr Lys Glu Leu Ser Ala Thr Thr Arg
1 5

<210> 32
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 32
 His Arg Pro Leu Leu Gly Arg Leu Ser Arg Gly Arg Pro Leu Ala Glu
 1 5 10 15
 Glu Ser Glu Gln Glu Arg Leu Leu Gly Gly Thr Arg Thr Pro Ile Asn
 20 25 30
 Asp Ala Ser
 35

<210> 33
 <211> 2811
 <212> DNA
 <213> Homo sapiens

<400> 33
 gtcgacccac gcgctccgcgg gacagctggc ctgaagctca gagccggggc gtgcgccatg 60
 gcccacact gggctgtctg gctgctggca gcaaggctgt ggggcctggg cattggggct 120
 gaggtgtggt ggaaccttgt gccgcgtaag acagtgtctt ctggggagct ggccacggta 180
 gtacggcggt tctcccagac cggcatccag gacttcctga cactgacgct gacggagccc 240
 actgggcttc tgtacgtggg cgcccagag gccctgtttg ccttcagcat ggaggccctg 300
 gagctgcaag gagcgatctc ctgggaggcc cccgtggaga agaagactga gtgtatccag 360
 aaagggaaga acaaccagac cgagtgttc aacttcattc gcttcctgca gccctacaat 420
 gcctcccacc tgtacgtctg tggcacctac gccttcagc ccaagtgcac ctaogtcgtg 480
 agtgcctgcc tctacctcg gtgtccccag ccccccggc tctcaccct tctctggact 540
 cgtggatgtg gccacagag ccctgccctt aagcatctcc tcatcacctc tctctctgtc 600
 cttagaacat gctcaccttc actttggagc atggagagtt tgaagatggg aagggaagt 660
 gtccctatga ccagctaag ggccatgctg gccttcttgt ggatggtgag ctgtactcgg 720
 ccacactcaa caacttcctg ggcacggaac ccattatcct gcgtaacatg gggccccacc 780
 actccatgaa gacagagtac ctggcctttt ggctcaacga acctcacttt gtaggctctg 840
 cctatgtacc tgagagtgtg ggcagcttca cgggggacga cgacaaggtc tactttcttct 900
 tcagggagcg ggcagtggag tccgactgct atgccgagca ggtggtggct cgtgtggccc 960
 gtgtctgcaa gggcgatatg gggggcgcac ggaccctgca gaggaagtgg accacgttcc 1020
 tgaaggcgcg gctggcatgc tctgccccga actggcagct ctacttcaac cagctgcagg 1080
 cgatgcacac cctgcaggac acctcctggc acaacaccac cttctttggg gtttttcaag 1140
 cacagtgggg tgacatgtac ctgtcggcca tctgtgagta ccagttggaa gagatccagc 1200
 ggggtgtttga gggcccctat aaggagtacc atgaggaagc ccagaagtgg gaccgctaca 1260
 ctgacctgt acccaggccc tggttgtgat ggctgccag ccccgccatg ccggggccta 1320
 ccaactgcttt tcagaggagc agggggcgcg gctggctgct gaaggctacc ttgtggctgt 1380
 cgtggcagcg cgtcggtga ccttgaggc cggggccccc ctggaaaacc tggggctggt 1440
 gtggctggcg gtggtggccc tgggggctgt gtgcctggtg ctgctgctgc tgggtgctgc 1500

```

attgcgccgg cggctgcggg aagagctgga gaaagggggc aaggctactg agaggacctt 1560
ggtgtacccc ctggagctgc ccaaggagcc caccagtcce cccttcgggc cctgtcctga 1620
accagatgag aaactttggg atcctgtcgg ttactactat tcagatggct cccttaagat 1680
agtacctggg catgcccggt gccagcccg tggggggccc ccttcggcac ctccaggcat 1740
cccaggccag cctctgcctt ctccaactcg gcttcacctg gggggtgggc ggaactcaaa 1800
tgccaatggt tacgtgcgct tacaactagg aggggaggac cggggagggc tcgggcaccc 1860
cctgcctgag ctgcgcatg aactgagacg caaactgcag caacgccagc cactgcccga 1920
ctccaacccc gaggagtcag cagtatgagg ggaaccccc aacgctcggc gggaagcgtg 1980
ggaggtgtag ctccactatt tgcacaggca ccagctacct caggacatg gcacgggcac 2040
ctgctctgtc tgggacagat actgccacg acccaccggc ccatgaggac ctgctctgct 2100
cagcacgggc actgccactt ggtgtggctc accagggcac cagcctcgca gaaggcatct 2160
tcctcctctc tgtgaatcac agacacgagg gacccagcc gccaaaactt ttcaaggcag 2220
aagtttcaag atgtgtgttt gtctgtatct gcacatgtgt ttgtgtgtgt gtgtatgtgt 2280
gtgtgcacgc gcgtgcgcgc ttgtggcata gccttcctgt ttctgtcaag tcttccttg 2340
gcctgggtcc tcctggtgag tcattggagc tatgaagggg aagggtcgt atcactttgt 2400
ctctcctacc cccactgccc cgagtgtcgg gcagcgatgt acatatggag gtggggtgga 2460
cagggtgctg tgccccttca gagggagtgc agggcttggg gtgggcctag tcctgctcct 2520
agggctgtga atgttttcag ggtgggggga gggagatgga gcctcctgtg tgtttggggg 2580
gaagggtggg tggggcctcc cacttggccc cggggttcag tgggtattta tacttgcctt 2640
cttctgtac agggctggga aaggctgtgt gaggggagag aaggagagg gtgggcctgc 2700
tgtggacaat ggcatactct ctccagccc taggaggagg gtcctaaca gtgtaactta 2760
ttgtgtcccc gcgtatttat ttgttgtaaa ttttgagat ttttatattg a 2811

```

<210> 34

<211> 729

<212> DNA

<213> Homo sapiens

<400> 34

```

atggccccac actgggctgt ctggctgctg gcagcaaggc tgtggggcct gggcattggg 60
gctgaggtgt ggtggaacct tgtgccgct aagacagtgt cttctgggga gctggccacg 120
gtagtacggc ggttctccca gaccggcatc caggacttcc tgacactgac gctgacggag 180
cccactgggc ttctgtacgt gggcgcccga gaggcctgt ttgccttcag catggaggcc 240
ctggagctgc aaggagcgat ctctgggag gccccctgg agaagaagac tgagtgtatc 300
cagaaaggga agaacaacca gaccgagtgc ttcaacttca tccgcttcct gcagccctac 360
aatgcctccc acctgtacgt ctgtggcacc tacgccttcc agcccaagtg cacctacgtc 420
gtgagtgtgt cctcctacc tcgggtgtcc cagcccccg cctcctcac cttctctgtg 480
actcgtggat gtggccacac gagccctgcc cttaagcatc tcctcatcac ctctctctct 540
gtccttagaa catgctcacc ttacttttgg agcatggaga gtttgaagat gggaagggca 600
agtgtcccta tgaccagct aagggccatg ctggccttct tgtggtggt gagctgtact 660
cggccacact caacaacttc ctgggcacgg aaccattat cctgcgtaac atggggcccc 720
accactcca
729

```

<210> 35

<211> 243

<212> PRT

<213> Homo sapiens

<400> 35

Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Arg Leu Trp Gly
1 5 10 15

Leu Gly Ile Gly Ala Glu Val Trp Trp Asn Leu Val Pro Arg Lys Thr
20 25 30

Val Ser Ser Gly Glu Leu Ala Thr Val Val Arg Arg Phe Ser Gln Thr
35 40 45

Gly Ile Gln Asp Phe Leu Thr Leu Thr Leu Thr Glu Pro Thr Gly Leu
50 55 60

Leu Tyr Val Gly Ala Arg Glu Ala Leu Phe Ala Phe Ser Met Glu Ala
65 70 75 80

Leu Glu Leu Gln Gly Ala Ile Ser Trp Glu Ala Pro Val Glu Lys Lys
85 90 95

Thr Glu Cys Ile Gln Lys Gly Lys Asn Asn Gln Thr Glu Cys Phe Asn
100 105 110

Phe Ile Arg Phe Leu Gln Pro Tyr Asn Ala Ser His Leu Tyr Val Cys
115 120 125

Gly Thr Tyr Ala Phe Gln Pro Lys Cys Thr Tyr Val Val Ser Ala Ala
130 135 140

Leu Leu Pro Arg Cys Pro Gln Pro Pro Ala Leu Leu Thr Leu Leu Trp
145 150 155 160

Thr Arg Gly Cys Gly Pro Gln Ser Pro Ala Leu Lys His Leu Leu Ile
165 170 175

Thr Ser Leu Ser Val Leu Arg Thr Cys Ser Pro Ser Leu Trp Ser Met
180 185 190

Glu Ser Leu Lys Met Gly Arg Ala Ser Val Pro Met Thr Gln Leu Arg
195 200 205

Ala Met Leu Ala Phe Leu Trp Met Val Ser Cys Thr Arg Pro His Ser
210 215 220

Thr Thr Ser Trp Ala Arg Asn Pro Leu Ser Cys Val Thr Trp Gly Pro
225 230 235 240

Thr Thr Pro

<210> 36

<211> 20

<212> PRT

<213> Homo sapiens

<400> 36

Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Arg Leu Trp Gly
1 5 10 15

Leu Gly Ile Gly
20

<210> 37

<211> 223

<212> PRT

<213> Homo sapiens

<400> 37

Ala Glu Val Trp Trp Asn Leu Val Pro Arg Lys Thr Val Ser Ser Gly
1 5 10 15

Glu Leu Ala Thr Val Val Arg Arg Phe Ser Gln Thr Gly Ile Gln Asp
20 25 30

Phe Leu Thr Leu Thr Leu Thr Glu Pro Thr Gly Leu Leu Tyr Val Gly
35 40 45

Ala Arg Glu Ala Leu Phe Ala Phe Ser Met Glu Ala Leu Glu Leu Gln
50 55 60

Gly Ala Ile Ser Trp Glu Ala Pro Val Glu Lys Lys Thr Glu Cys Ile
65 70 75 80

Gln Lys Gly Lys Asn Asn Gln Thr Glu Cys Phe Asn Phe Ile Arg Phe
85 90 95

Leu Gln Pro Tyr Asn Ala Ser His Leu Tyr Val Cys Gly Thr Tyr Ala
100 105 110

Phe Gln Pro Lys Cys Thr Tyr Val Val Ser Ala Ala Leu Leu Pro Arg
115 120 125

Cys Pro Gln Pro Pro Ala Leu Leu Thr Leu Leu Trp Thr Arg Gly Cys

130 135 140
 Gly Pro Gln Ser Pro Ala Leu Lys His Leu Leu Ile Thr Ser Leu Ser
 145 150 155 160
 Val Leu Arg Thr Cys Ser Pro Ser Leu Trp Ser Met Glu Ser Leu Lys
 165 170 175
 Met Gly Arg Ala Ser Val Pro Met Thr Gln Leu Arg Ala Met Leu Ala
 180 185 190
 Phe Leu Trp Met Val Ser Cys Thr Arg Pro His Ser Thr Thr Ser Trp
 195 200 205
 Ala Arg Asn Pro Leu Ser Cys Val Thr Trp Gly Pro Thr Thr Pro
 210 215 220

<210> 38

<211> 2498

<212> DNA

<213> Homo sapiens

<400> 38

gtgcagccac ggcgtccgcgg acgcgtgggc gcgcgggggc catccagacc ctgcggagag 60
 cgaggcccg agcgtcgccg aggtttgagg gcgccggaga ccgagggcct ggcggccgaa 120
 ggaaccgccc caagaagagc ctctggcccc ggggctgctg gaacatgtgc ggggggacac 180
 agtttgtttg acagttgcc aactatgttt acgcttcttg ttctactcag ccaactgccc 240
 acagttaccc tggggtttcc tcattgcgca agaggtccaa aggcttctaa gcatgcggga 300
 gaagaagtgt ttacatcaaa agaagaagca aactttttca tacatagacg ccttctgtat 360
 aatagatttg atctggagct cttcactccc ggcaacctag aaagagagtg caatgaagaa 420
 ctttgcaatt atgaggaagc cagagagatt tttgtggatg aagataaaac gattgcattt 480
 tggcaggaat attcagctaa aggaccaacc acaaaatcag atggcaacag agagaaaata 540
 gatgttatgg gccttctgac tggattaatt gctgctggag tatttttggg tatttttggg 600
 ttacttggct actatctttg taccactaag tgtaataggc tacaacatcc atgctcttca 660
 gccgtctatg aaagggggag gcacactccc tccatcattt tcagaagacc tgaggaggct 720
 gccttgtctc cattgccgcc ttctgtggag gatgcaggat taccttctta tgaacaggca 780
 gtggcgctga ccagaaaaca cagtgtttca ccaccaccac catatcctgg gcacacaaaa 840
 ggatttaggg tatttaaaaa atctatgtct ctcccatctc actgactacc ttgtcatttt 900
 ggtataagaa atttgtgtta tttgataggc cgggcatggg ggctcatgcc tgtaatccca 960
 gcactttggg aggccaggag ttcgagacca gcctggccaa catggtgaaa cccggtctct 1020
 actaaaaatt caaaaattac ctaggcgtca tggggcatgc ctgtagtccc acctacttgg 1080
 gaggtgaag caggagaatt gctcgaacct gggaggcaga ggttgagta agctgagatc 1140
 acgccactgc attccagcct gggcgacaga gcaagactcc atctcaaaaa taaaataaaa 1200
 aaagaaagaa agaaaagaag aagaaaagag aagaaggaga aggagatgaa ggaggaggag 1260
 gaggagaagg agaagaagaa gaagaagaag accacaaaag acatgactat ccaacttttt 1320
 atgacaaact gcaaggaata aaggaagaat aagtccatgt actgtaccac agaagttctg 1380
 tctgcatctt ggacctgaac ttgatcatta tcagcttgat aagagacttt ttgactctat 1440

```

atccttgcag ttaagaagaa agcaactttt tgtaatgttt gttttaatgg ttcaaaaaaa 1500
atctttctta taaagagcat aggtagaatt agtgaactct ttggatcctt tgtacagata 1560
aaggttatag atttcttgtg ttgaatatta aaaaagcaag gatgtctaac cattaagatt 1620
atccaaagtc aggctgggcg cagtggctca cgctgtaat ccagcactt tgggagggat 1680
aggctgggagg atcacctgag gtcaggagtt tgagaccagc ctggccaaca tggcaaaacc 1740
ccgtctctac aaaaatacaa aagaaattag ccagacatga tggcggtgct ctctaattcc 1800
agctactggg gaggctgagg tgggagaatc gcttgaactc gggagggtga ggttgtagt 1860
aggcgagatt gtgccattgc actccaacct gggcgacaga gtgagactcc atctcaaaaa 1920
aaaaaaaaaa aaaaagatta tccaaaaaga tattggacct actctttctt aggatTTTTT 1980
tggcgggggg ttagaaatac ttcacagaat ttgacatttc agtataaata tgtgacctta 2040
atataatcac ttggttttat atgttaaatt attgcacagc agtcatcata ttttgagag 2100
tttagttctt aactcttgct gtcagtcatt ttttattata ggtagtgggg tcagtagttt 2160
tcttcttcta aaaaatacta tttgctatga agttagttct tcagaagata caagtttgca 2220
atgaaaagga tttgcaaggg ttgttatgct atcaaataaa cagacctaaa atctaggaga 2280
cactagaact taatgaagtt gccctgtta ctgattagta aatactccca tcttcgttg 2340
aaaattatct ctctgtataa ctacatatga ttattttgaa atttgttaaa cttcataagt 2400
aatagtttga gaatgtggaa aaagtaattt gcttttctgc tcttaaaata atattgatta 2460
atgttaccag aaaaaaaaaa aaaaaaaagg gcggccgc 2498

```

<210> 39

<211> 678

<212> DNA

<213> Homo sapiens

<400> 39

```

atgtttacgc ttctggttct actcagccaa ctgccacag ttaccctggg gtttcctcat 60
tgcgcaagag gtccaaaggc ttctaagcat gcgggagaag aagtgtttac atcaaaagaa 120
gaagcaaact ttttcataca tagacgcctt ctgtataata gatttgatct ggagctcttc 180
actcccgga acctagaaag agagtgaat gaagaacttt gcaattatga ggaagccaga 240
gagatttttg tggatgaaga taaaacgatt gcattttggc aggaatattc agctaaagga 300
ccaaccacaa aatcagatgg caacagagag aaaatagatg ttatgggcct tctgactgga 360
ttaattgctg ctggagtatt tttggttatt tttggattac ttggctacta tctttgtatc 420
actaagtgtg ataggctaca acatccatgc tcttcagccg tctatgaaag ggggaggcac 480
actccctcca tcattttcag aagacctgag gaggtgcct tgtctccatt gccgccttct 540
gtggaggatg caggattacc ttcttatgaa caggcagtgg cgctgaccag aaaacacagt 600
gtttcaccac caccaccata tcttgggcac acaaaaggat ttaggttatt taaaaaatct 660
atgtctctcc catctcac 678

```

<210> 40

<211> 226

<212> PRT

<213> Homo sapiens

<400> 40

Met Phe Thr Leu Leu Val Leu Leu Ser Gln Leu Pro Thr Val Thr Leu

1

5

10

15

Gly Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His Ala Gly
 20 25 30

Glu Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe Ile His Arg
 35 40 45

Arg Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn
 50 55 60

Leu Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn Tyr Glu Glu Ala Arg
 65 70 75 80

Glu Ile Phe Val Asp Glu Asp Lys Thr Ile Ala Phe Trp Gln Glu Tyr
 85 90 95

Ser Ala Lys Gly Pro Thr Thr Lys Ser Asp Gly Asn Arg Glu Lys Ile
 100 105 110

Asp Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu
 115 120 125

Val Ile Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn
 130 135 140

Arg Leu Gln His Pro Cys Ser Ser Ala Val Tyr Glu Arg Gly Arg His
 145 150 155 160

Thr Pro Ser Ile Ile Phe Arg Arg Pro Glu Glu Ala Ala Leu Ser Pro
 165 170 175

Leu Pro Pro Ser Val Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala
 180 185 190

Val Ala Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Pro Tyr Pro
 195 200 205

Gly His Thr Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro
 210 215 220

Ser His
 225

<210> 41

<211> 17

<212> PRT

<213> Homo sapiens

<400> 41

Met Phe Thr Leu Leu Val Leu Leu Ser Gln Leu Pro Thr Val Thr Leu
1 5 10 15

Gly

<210> 42

<211> 209

<212> PRT

<213> Homo sapiens

<400> 42

Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His Ala Gly Glu
1 5 10 15

Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe Ile His Arg Arg
20 25 30

Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu
35 40 45

Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn Tyr Glu Glu Ala Arg Glu
50 55 60

Ile Phe Val Asp Glu Asp Lys Thr Ile Ala Phe Trp Gln Glu Tyr Ser
65 70 75 80

Ala Lys Gly Pro Thr Thr Lys Ser Asp Gly Asn Arg Glu Lys Ile Asp
85 90 95

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val
100 105 110

Ile Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn Arg
115 120 125

Leu Gln His Pro Cys Ser Ser Ala Val Tyr Glu Arg Gly Arg His Thr
130 135 140

Pro Ser Ile Ile Phe Arg Arg Pro Glu Glu Ala Ala Leu Ser Pro Leu
145 150 155 160

Pro Pro Ser Val Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala Val
165 170 175

Ala Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Pro Tyr Pro Gly
 180 185 190

His Thr Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro Ser
 195 200 205

His

<210> 43

<211> 96

<212> PRT

<213> Homo sapiens

<400> 43

Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His Ala Gly Glu
 1 5 10 15

Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe Ile His Arg Arg
 20 25 30

Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu
 35 40 45

Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn Tyr Glu Glu Ala Arg Glu
 50 55 60

Ile Phe Val Asp Glu Asp Lys Thr Ile Ala Phe Trp Gln Glu Tyr Ser
 65 70 75 80

Ala Lys Gly Pro Thr Thr Lys Ser Asp Gly Asn Arg Glu Lys Ile Asp
 85 90 95

<210> 44

<211> 25

<212> PRT

<213> Homo sapiens

<400> 44

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val
 1 5 10 15

Ile Phe Gly Leu Leu Gly Tyr Tyr Leu

<210> 45
 <211> 88
 <212> PRT
 <213> Homo sapiens

<400> 45
 Cys Ile Thr Lys Cys Asn Arg Leu Gln His Pro Cys Ser Ser Ala Val
 1 5 10 15
 Tyr Glu Arg Gly Arg His Thr Pro Ser Ile Ile Phe Arg Arg Pro Glu
 20 25 30
 Glu Ala Ala Leu Ser Pro Leu Pro Pro Ser Val Glu Asp Ala Gly Leu
 35 40 45
 Pro Ser Tyr Glu Gln Ala Val Ala Leu Thr Arg Lys His Ser Val Ser
 50 55 60
 Pro Pro Pro Pro Tyr Pro Gly His Thr Lys Gly Phe Arg Val Phe Lys
 65 70 75 80
 Lys Ser Met Ser Leu Pro Ser His
 85

<210> 46
 <211> 2169
 <212> DNA
 <213> Homo sapiens

<400> 46
 gtcgacccac gcgtccggaa atgtcgttct tcagatttaa aaagaaaacc tttactgaat 60
 cagctgagtg ttaataatac gaatttcctt ttcttgccaa ttctgatctg aacagaaaat 120
 ccaagaacag ggatatgtgt ggattacagt tttctctgcc ttgcctacga ctgtttcttg 180
 ttgttacctg ttatctttta ttattactcc acaaagaaat acttgatgt tcgtctgttt 240
 gtcagctctg cactgggaga caaattaact gccgtaactt aggcttttcg agtattccta 300
 agaattttcc tgaaagtaca gtttttctgt atctgactgg gaataatata tcttatataa 360
 atgaaagtga attaacagga cttcattctc ttgtagcatt gtatttgat aattctaaca 420
 ttctgtatgt atatccaaaa gcctttgttc aattgaggca tctatatttt ctatttctaa 480
 ataataattt catcaaacgc ttagatcctg gaatatttaa gggactttta aatcttcgta 540
 atttatattt acagtataat caggatatctt ttgttccgag aggagtattt aatgatctag 600
 tttcagttca gtacttaaat ctacaaagga atgcgcctcac tgtccttggg agtggtacct 660
 ttgttggtat ggttgctctt cggatacttg atttatcaaa caataacatt ttgaggatat 720
 cagaatcagg ctttcaacat cttgaaaacc ttgcttgttt gtatttagga agtaataatt 780
 taacaaaagt accatcaaat gcctttgaag tacttaaaag tcttagaaga ctttctttgt 840

```

ctcataatcc tattgaagca atacagccct ttgcatttaa aggacttgcc aatctggaat 900
acctcctcct gaaaaattca agaattagga atgttactag ggatggggtt agtggaatta 960
ataatcttaa acatttgatc ttaagtcata atgatttaga gaatttaa atctgacacat 1020
tcagtttggt aaagaattta atttacctta agttagatag aaacagaata attagcattg 1080
ataatgatac atttgaaaat atgggagcat ctttgaagat ccttaatctg tcatttaata 1140
atcttacagc cttgcatcca agggctccta agccgttggtc ttcattgatt catcttcagg 1200
caaattctaa tccttgggaa tgtaactgca aacttttggg ccttcgagac tggctagcat 1260
cttcagccat tactctaaac atctattgtc agaatcccc atccatgctg ggcagagcat 1320
tacgttatat taacattaca aattgtgtta catcttcaat aaatgtatcc agagcttggg 1380
ctgttgtaaa atctcctcat attcatcaca agactactgc gctaataatg gcctggcata 1440
aagtaaccac aaatggcagt cctctggaaa atactgagac tgagaacatt actttctggg 1500
aacgaattcc tacttcacct gctggtagat tttttcaaga gaatgccttt ggtaatccat 1560
tagagactac agcagtgtta cctgtgcaaa tacaacttac tacttctgtt accttgaact 1620
tggaaaaaaa cagtgtctta ccgaatgatg ctgcttcaat gtcagggaaa acatctctaa 1680
tttgtacaca agaagttgag aagttgaatg aggcttttga ctttttgcta gcttttttca 1740
tcttagcttg tgttttaatc atttttttga tctacaaagt tgttcagttt aaacaaaaac 1800
taaaggcatc agaaaactca agggaaaata gacttgaata ctacagcttt tatcagtcag 1860
caaggtataa tgtaactgcc tcaatttgta acacttcccc aaattctcta gaaagtctg 1920
gcttgagaca gattcgactt cataaaciaa ttgttctga aaatgaggca caggctcattc 1980
tttttgaaca ttctgcttta taactcaact aaatattgtc tataagaaac ttcagtgcca 2040
tggaatgat ttaaactgaa acctccttat ataattatat acttttagttg gaaatataat 2100
gaattatatg aggttagcat tattaaaata tgtttttaat aaaaaaaaaa aaaaaaaaaa 2160
ggcgccgc 2169

```

<210> 47

<211> 1866

<212> DNA

<213> Homo sapiens

<400> 47

```

atgtgtggat tacagttttc tctgccttgc ctacgactgt ttctggttgt tacctgttat 60
cttttattat tactccacaa agaaatactt ggatgttctg ctgtttgtca gctctgcact 120
gggagacaaa ttaactgcog taacttaggc ctttcgagta ttctaagaa ttttcctgaa 180
agtacagttt ttctgtatct gactgggaat aatatatctt atataaatga aagtgaatta 240
acaggacttc attctcttgt agcattgtat ttggataatt ctaacattct gtatgtatat 300
ccaaaagcct ttgttcaatt gaggcattct tttttctat ttctaaataa taatttcattc 360
aaacgcttag atcctggaat atttaaggga cttttaaatc ttctgaattt atatttacag 420
tataatcagg tatcttttgt tccgagagga gtatttaatg atctagtttc agttcagtac 480
ttaaactctac aaaggaatcg cctcactgtc cttgggagtg gtaccttctg tggatgggtt 540
gctcttcgga tacttgattt atcaaacaat aacattttga ggatatcaga atcaggcttt 600
caacatcttg aaaaccttgc ttgtttgtat ttaggaagta ataatttaac aaaagtacca 660
tcaaatgcct ttgaagtact taaaagtctt agaagacttt ctttgtctca taatcctatt 720
gaagcaatac agccctttgc atttaaggga cttgccaatc tggaataacct cctcctgaaa 780
aattcaagaa ttaggaatgt tactagggat ggggttagtg gaattaataa tcttaaacat 840
ttgatcttaa gtcataatga ttagagaat ttaaattctg acacattcag tttgttaaag 900
aatttaattt accttaagtt agatagaaac agaataatta gcattgataa tgatacattt 960
gaaaatatgg gagcatcttt gaagatcctt aatctgtcat ttaataatct tacagccttg 1020

```

```

catccaaggg tccttaagcc gttgtcttca ttgattcatc ttcaggcaaa ttctaattct 1080
tggaatgta actgcaaact tttgggcctt cgagactggc tagcatcttc agccattact 1140
ctaaacatct attgtcagaa tccccatcc atgcgtggca gagcattacg ttatattaac 1200
attacaaatt gtgttacatc ttcaataaat gtatccagag cttgggctgt tgtaaaatct 1260
cctcatattc atcacaagac tactgcgcta atgatggcct ggcataaagt aaccacaaat 1320
ggcagtcctc tggaaaatac tgagactgag aacattactt tctgggaacg aatttact 1380
tcacctgctg gtagattttt tcaagagaat gcctttggta atccattaga gactacagca 1440
gtgttacctg tgcaaatata acttactact tctgttacct tgaacttga aaaaaacagt 1500
gctctaccga atgatgctgc ttcaatgtca gggaaaacat ctctaatttg tacacaagaa 1560
gttgagaagt tgaatgaggc ttttgacatt ttgctagctt ttttcatctt agcttgtgtt 1620
ttaatcattt ttttgatcta caaagtgtgt cagttaaacc aaaaactaaa ggcacagaa 1680
aactcaaggg aaaatagact tgaatactac agcttttata agtcagcaag gtataatgta 1740
actgcctcaa tttgtaacac ttcccaaat tctctagaaa gtcctggctt ggagcagatt 1800
cgacttcata aacaaattgt tcctgaaaat gaggcacagg tcattctttt tgaacattct 1860
gcttta

```

<210> 48

<211> 622

<212> PRT

<213> Homo sapiens

<400> 48

Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu Val

1 5 10 15

Val Thr Cys Tyr Leu Leu Leu Leu Leu His Lys Glu Ile Leu Gly Cys

20 25 30

Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg Asn

35 40 45

Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val Phe

50 55 60

Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu Leu

65 70 75 80

Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn Ile

85 90 95

Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr Phe

100 105 110

Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile Phe

115 120 125

Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln Val

130	135	140
Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln Tyr		
145	150	155 160
Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr Phe		
	165	170 175
Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn Ile		
	180	185 190
Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala Cys		
	195	200 205
Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala Phe		
	210	215 220
Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro Ile		
	225	230 235 240
Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu Tyr		
	245	250 255
Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly Phe		
	260	265 270
Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp Leu		
	275	280 285
Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile Tyr		
	290	295 300
Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr Phe		
	305	310 315 320
Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn Asn		
	325	330 335
Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu Ile		
	340	345 350
His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu Leu		
	355	360 365
Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile Tyr		
	370	375 380
Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile Asn		

385		390		395		400
Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp Ala						
	405		410		415	
Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met Met						
	420		425		430	
Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr Glu						
	435		440		445	
Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala Gly						
	450		455		460	
Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr Ala						
465		470		475		480
Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn Leu						
	485		490		495	
Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly Lys						
	500		505		510	
Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala Phe						
	515		520		525	
Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile Phe						
	530		535		540	
Leu Ile Tyr Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser Glu						
545		550		555		560
Asn Ser Arg Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser Ala						
	565		570		575	
Arg Tyr Asn Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser Leu						
	580		585		590	
Glu Ser Pro Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val Pro						
	595		600		605	
Glu Asn Glu Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu						
	610		615		620	

<210> 49
 <211> 31
 <212> PRT

<213> Homo sapiens

<400> 49

Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu Val
1 5 10 15

Val Thr Cys Tyr Leu Leu Leu Leu Leu His Lys Glu Ile Leu Gly
20 25 30

<210> 50

<211> 591

<212> PRT

<213> Homo sapiens

<400> 50

Cys Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg
1 5 10 15

Asn Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val
20 25 30

Phe Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu
35 40 45

Leu Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn
50 55 60

Ile Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr
65 70 75 80

Phe Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile
85 90 95

Phe Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln
100 105 110

Val Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln
115 120 125

Tyr Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr
130 135 140

Phe Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn
145 150 155 160

Ile Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala
165 170 175

Cys Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala
 180 185 190

Phe Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro
 195 200 205

Ile Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu
 210 215 220

Tyr Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly
 225 230 235 240

Phe Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp
 245 250 255

Leu Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile
 260 265 270

Tyr Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr
 275 280 285

Phe Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn
 290 295 300

Asn Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu
 305 310 315 320

Ile His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu
 325 330 335

Leu Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile
 340 345 350

Tyr Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile
 355 360 365

Asn Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp
 370 375 380

Ala Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met
 385 390 395 400

Met Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr
 405 410 415

Glu Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala
 420 425 430

Gly Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr
 435 440 445

Ala Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn
 450 455 460

Leu Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly
 465 470 475 480

Lys Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala
 485 490 495

Phe Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile
 500 505 510

Phe Leu Ile Tyr Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser
 515 520 525

Glu Asn Ser Arg Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser
 530 535 540

Ala Arg Tyr Asn Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser
 545 550 555 560

Leu Glu Ser Pro Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val
 565 570 575

Pro Glu Asn Glu Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu
 580 585 590

<210> 51

<211> 498

<212> PRT

<213> Homo sapiens

<400> 51

Cys Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg
 1 5 10 15

Asn Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val
 20 25 30

Phe Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu
 35 40 45

Leu Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn

50	55	60
Ile Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr		
65	70	75 80
Phe Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile		
	85	90 95
Phe Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln		
	100	105 110
Val Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln		
	115	120 125
Tyr Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr		
	130	135 140
Phe Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn		
	145	150 155 160
Ile Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala		
	165	170 175
Cys Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala		
	180	185 190
Phe Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro		
	195	200 205
Ile Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu		
	210	215 220
Tyr Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly		
	225	230 235 240
Phe Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp		
	245	250 255
Leu Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile		
	260	265 270
Tyr Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr		
	275	280 285
Phe Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn		
	290	295 300
Asn Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu		

305 310 315 320
 Ile His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu
 325 330 335
 Leu Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile
 340 345 350
 Tyr Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile
 355 360 365
 Asn Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp
 370 375 380
 Ala Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met
 385 390 395 400
 Met Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr
 405 410 415
 Glu Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala
 420 425 430
 Gly Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr
 435 440 445
 Ala Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn
 450 455 460
 Leu Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly
 465 470 475 480
 Lys Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala
 485 490 495
 Phe Asp

<210> 52
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 52
 Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile Phe Leu
 1 5 10 15

Ile Tyr

<210> 53

<211> 75

<212> PRT

<213> Homo sapiens

<400> 53

Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser Glu Asn Ser Arg
1 5 10 15

Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser Ala Arg Tyr Asn
20 25 30

Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser Leu Glu Ser Pro
35 40 45

Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val Pro Glu Asn Glu
50 55 60

Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu
65 70 75

<210> 54

<211> 1432

<212> DNA

<213> Homo sapiens

<400> 54

acgcgtccgc acanggccgg cgcggctggg agcgggtggg cggccgggag gccggagcag 60
cacggccgca ggacctggag ctccggctgc gtcttcccgc agcgctaccc gccatgcgcc 120
tgccgcgccg ggccgcgctg gggctcctgc cgcttctgct gctgctgccg ccgcgcgccg 180
aggccgccaa gaagccgacg cctgccacc ggtgccgggg gctggtggac aagttaacc 240
aggggatggt ggacaccgca aagaagaact ttggcgccgg gaacacggct tgggaggaaa 300
agacgctgtc caagtacgag tccagcgaga ttcgctgct ggagatcctg gaggggctgt 360
gcgagagcag cgacttcgaa tgcaatcaga tgctagaggc gcaggaggag cacctggagg 420
cctggtggct gcagctgaag agcgaatata ctgacttatt cgagtgggtt tgtgtgaaga 480
cactgaaagt gtgctgctct ccaggaacct acggtcccga ctgtctcgca tgccagggcg 540
gatcccagag gccctgcagc gggaatggcc actgcagcgg agatgggagc agacagggcg 600
acgggtcctg ccggtgccac atgggggtacc agggcccgcgt gtgcactgac tgcattggacg 660
gctacttcag ctgcgtccgg aacgagacct acagcatctg cacagcctgt gacgagtcct 720
gcaagacgtg ctcgggcctg accaaccagag actgcggcga gtgtgaagtg ggctgggtgc 780
tggacgaggg cgctgtgtg gatgtggacg agtgtgcggc cgagccgcct ccctgcagcg 840
ctgcgcagtt ctgtaagaac gccaacggct cctacacgtg cgaagagtgt gactccagct 900
gtgtgggctg cacaggggaa ggcccaggaa actgtaaaga gtgtatctct ggctacgcga 960

```

gggagcacgg acagtgtgca gatgtggacg agtgcctact agcagaaaaa acctgtgtga 1020
ggaaaaacga aaactgctac aatactccag ggagctacgt ctgtgtgtgt cctgacggct 1080
tcgaagaaac ggaagatgcc tgtgtgccgc cggcagaggc tgaagccaca gaaggagaaa 1140
ccccgacaca gctgccctcc cgcgaagacc tgtaatgtgc cggacttacc ctttaaatta 1200
ttcagaagga tgtcccgtgg aaaatgtggc cctgaggatg cctgtctctg cagtggacag 1260
cggcggggag aggctgcctg ctctctaacg gttgattctc atttgtccct taaacagctg 1320
catttcttgg ttgttcttaa acagacttgt atattttgat acagttcttt gtaataaaat 1380
tgaccattgt aggtaatcaa aaaaaaaaaa aaaaaaaggg cggccgctag ac 1432

```

<210> 55

<211> 1059

<212> DNA

<213> Homo sapiens

<400> 55

```

atgcgcctgc cgcgcggggc cgcgctgggg ctccctgccgc ttctgctgct gctgccgccc 60
gcgcgggagg ccgccaagaa gccgacgccc tgccaccggt gccgggggct ggtggacaag 120
tttaaccagg ggatggtgga caccgcaaag aagaactttg gcggcgggaa cacggcttgg 180
gaggaaaaga cgctgtccaa gtacgagtcc agcgagattc gcctgctgga gatcctggag 240
gggctgtgcg agagcagcga cttcgaatgc aatcagatgc tagaggcgca ggaggagcac 300
ctggaggcct ggtggctgca gctgaagagc gaatatcctg acttattcga gtggttttgt 360
gtgaagacac tgaaagtgtg ctgctctcca ggaacctacg gtcccgaactg tctcgcatgc 420
cagggcggat cccagaggcc ctgcagcggg aatggccact gcagcggaga tgggagcaga 480
cagggcgacg ggtcctgccc gtgccacatg ggggtaccag gcccgctgtg cactgactgc 540
atggacggct acttcagctc gctccggaac gagaccaca gcctctgcac agcctgtgac 600
gagtcctgca agacgtgctc gggcctgacc aacagagact gcggcgagtg tgaagtgggc 660
tgggtgctgg acgagggcgc ctgtgtggat gtggacgagt gtgcggccga gccgcctccc 720
tgcagcgtg cgcagttctg taagaacgcc aacggctcct acacgtgcga agagtgtgac 780
tccagctgtg tgggctgcac aggggaaggc ccaggaaact gtaaagagtg tatctctggc 840
tacgcgaggg agcacggaca gtgtgcagat gtggacgagt gctcactagc agaaaaaacc 900
tgtgtgagga aaaacgaaaa ctgctacaat actccaggga gctacgtctg tgtgtgtcct 960
gacggcttcg aagaaacgga agatgcctgt gtgccgcccg cagaggctga agccacagaa 1020
ggagaaagcc cgacacagct gccctcccgc gaagacctg 1059

```

<210> 56

<211> 353

<212> PRT

<213> Homo sapiens

<400> 56

```

Met Arg Leu Pro Arg Arg Ala Ala Leu Gly Leu Leu Pro Leu Leu
  1                      5                      10          15

```

```

Leu Leu Pro Pro Ala Pro Glu Ala Ala Lys Lys Pro Thr Pro Cys His
          20                      25          30

```

Arg Cys Arg Gly Leu Val Asp Lys Phe Asn Gln Gly Met Val Asp Thr
 35 40 45

Ala Lys Lys Asn Phe Gly Gly Gly Asn Thr Ala Trp Glu Glu Lys Thr
 50 55 60

Leu Ser Lys Tyr Glu Ser Ser Glu Ile Arg Leu Leu Glu Ile Leu Glu
 65 70 75 80

Gly Leu Cys Glu Ser Ser Asp Phe Glu Cys Asn Gln Met Leu Glu Ala
 85 90 95

Gln Glu Glu His Leu Glu Ala Trp Trp Leu Gln Leu Lys Ser Glu Tyr
 100 105 110

Pro Asp Leu Phe Glu Trp Phe Cys Val Lys Thr Leu Lys Val Cys Cys
 115 120 125

Ser Pro Gly Thr Tyr Gly Pro Asp Cys Leu Ala Cys Gln Gly Gly Ser
 130 135 140

Gln Arg Pro Cys Ser Gly Asn Gly His Cys Ser Gly Asp Gly Ser Arg
 145 150 155 160

Gln Gly Asp Gly Ser Cys Arg Cys His Met Gly Tyr Gln Gly Pro Leu
 165 170 175

Cys Thr Asp Cys Met Asp Gly Tyr Phe Ser Ser Leu Arg Asn Glu Thr
 180 185 190

His Ser Ile Cys Thr Ala Cys Asp Glu Ser Cys Lys Thr Cys Ser Gly
 195 200 205

Leu Thr Asn Arg Asp Cys Gly Glu Cys Glu Val Gly Trp Val Leu Asp
 210 215 220

Glu Gly Ala Cys Val Asp Val Asp Glu Cys Ala Ala Glu Pro Pro Pro
 225 230 235 240

Cys Ser Ala Ala Gln Phe Cys Lys Asn Ala Asn Gly Ser Tyr Thr Cys
 245 250 255

Glu Glu Cys Asp Ser Ser Cys Val Gly Cys Thr Gly Glu Gly Pro Gly
 260 265 270

Asn Cys Lys Glu Cys Ile Ser Gly Tyr Ala Arg Glu His Gly Gln Cys
 275 280 285

Ala Asp Val Asp Glu Cys Ser Leu Ala Glu Lys Thr Cys Val Arg Lys
 290 295 300

Asn Glu Asn Cys Tyr Asn Thr Pro Gly Ser Tyr Val Cys Val Cys Pro
 305 310 315 320

Asp Gly Phe Glu Glu Thr Glu Asp Ala Cys Val Pro Pro Ala Glu Ala
 325 330 335

Glu Ala Thr Glu Gly Glu Ser Pro Thr Gln Leu Pro Ser Arg Glu Asp
 340 345 350

Leu

<210> 57

<211> 24

<212> PRT

<213> Homo sapiens

<400> 57

Met Arg Leu Pro Arg Arg Ala Ala Leu Gly Leu Leu Pro Leu Leu Leu
 1 5 10 15

Leu Leu Pro Pro Ala Pro Glu Ala
 20

<210> 58

<211> 329

<212> PRT

<213> Homo sapiens

<400> 58

Ala Lys Lys Pro Thr Pro Cys His Arg Cys Arg Gly Leu Val Asp Lys
 1 5 10 15

Phe Asn Gln Gly Met Val Asp Thr Ala Lys Lys Asn Phe Gly Gly Gly
 20 25 30

Asn Thr Ala Trp Glu Glu Lys Thr Leu Ser Lys Tyr Glu Ser Ser Glu
 35 40 45

Ile Arg Leu Leu Glu Ile Leu Glu Gly Leu Cys Glu Ser Ser Asp Phe
 50 55 60

Glu Cys Asn Gln Met Leu Glu Ala Gln Glu Glu His Leu Glu Ala Trp

<210> 59

<211> 2730

<212> DNA

<213> Homo sapiens

<400> 59

```

gtcgacccac gcggtccgtcc tgcggcccca gcctctcctc acgctcgcgc agtctccgcc 60
gcagtctcag ctgcagctgc aggactgagc cgtgcacccg gaggagaccc ccggaggagg 120
cgacaaactt cgcagtgccg cgacccaacc ccagccctgg gtagcctgca gcatggccca 180
gctgttcctg cccctgctgg cagccctggg cctggcccag gctcctgcag ctttagcaga 240
tgtttctgaa ggagacagct cagaggaccg cgcttttcgc gtgcgcacgc cggggcgacgc 300
gccactgcag ggcgtgctcg gcggcgccct caccatccct tgccacgtcc actacctgcg 360
gccaccgccg agccgccggg ctgtgctggg ctctccgcgg gtcaagtggg ctttcctgtc 420
ccggggccgg gaggcagagg tgctgggtgg gcggggagtg cgcgtcaagg tgaacgaggc 480
ctaccggttc cgcgtggcac tgctgctgta cccagcgtcg ctaccgcagc tctccctggc 540
gctgagcgag ctgcgcccc aacactcagg tatctatcgc tgtgaggtcc agcacggcat 600
cgatgacagc agcgacgctg tggaggtcaa ggtcaaaggg gtctgtcttc tctaccgaga 660
gggctctgcc cgctatgctt tctccttttc tggggcccag gaggcctgtg cccgcattgg 720
agccacatc gccaccccg agcagctcta tgccgcctac cttggggggt atgagcaatg 780
tgatgctggc tggctgtcgg atcagaccgt gaggtatccc atccagaccc caccagaggc 840
ctgttacgga gacatggatg gcttcccccg ggtccggaac tatggtgtgg tggaccggga 900
tgacctctat gatgtgtact gttatgctga agacctaat ggagaactgt tctgggtga 960
ccctccagag aagctgacat tggaggaagc acgggcgtac tgccaggagc ggggtgcaga 1020
gattgccacc acgggccaac tgtatgcagc ctgggatggg ggcttgacc actgcagccc 1080
aggggtggta gctgatggca gtgtgcgcta cccatcgtc acaccagcc agcgtgtgg 1140
tgggggcttg cctggtgtca agactctctt cctcttcccc aaccagactg gcttcccaa 1200
taagcacagc cgcttcaacg tctactgctt ccgagactcg gccagcctt ctgccatccc 1260
tgaggcctcc aaccagcct ccaaccagc ctctgatgga cttagaggta tcgtcacagt 1320
gacagagacc ctggaggaac tgcagctgcc tcaggaagcc acagagagt aatcccgtgg 1380
ggccatctac tccatcccca tcatggagga cggaggaggt ggaagctcca ctccagaaga 1440
cccagcagag gcccttagga cgctcctaga atttgaaaca caatccatgg taccgcccac 1500
ggggttctca gaagaggaag gtaaggcatt ggaggaagaa gagaaatat aagatgaaga 1560
agagaaagag gaggaagaag aagaggagga ggtggaggat gaggctctgt gggcatggcc 1620
cagcgagctc agcagcccg gccctgaggg ctctctcccc actgagccag cagcccagga 1680
gaagtactc tcccaggcgc cagcaagggc agtcctgcag cctggtgcat caccacttcc 1740
tgatggagag tcagaagctt ccaggcctcc aagggtccat ggaccaccta ctgagactct 1800
gcccactccc agggagagga acctagcct cccatcacct tccactctgg ttgaggcaag 1860
agaggtgggg gaggcaactg gtggtcctga gctatctggg gtccctcgag gagagagcga 1920
ggagacagga agctccgagg gtgccccttc cctgcttcca gccacacggg cccctgaggg 1980
taccagggag ctggaggccc cctctgaaga taattctgga agaactgccc cagcagggac 2040
ctcagtgcag gccagccag tgctgcccac tgacagcgcc agccgagggt gagtggccgt 2100
ggtccccgca tcaggtaat ctgcccagg ctcaactgcc ctctctatcc tactcctttt 2160
cttccccctg cagctctggg tcacctgacc tgtagtctt taaccacca tcatccaaa 2220
ctctcctgtc ctttgccctt attctcttac ccacctctac ctatgggtct ccaatctcgg 2280
atatccacct tgtgggtatc tcagctctcc gcgtctttac cctgtgatcc cagccccgcc 2340

```

actgaccatc	tgtgaccott	ccctgccatt	gggcoctcca	cctgtggctc	acatctcgcc	2400
agccccacag	agcatcctca	ggcctctcca	agggtcctca	tcacctattg	cagccttcag	2460
ggctcggcct	attttccact	actcccttca	tccgcctgtg	tgccgtcccc	tttagctgcc	2520
tcctattgat	ctcaggggaag	cctgggagtc	ccttctcacc	cctcaacctc	cggagtccag	2580
gagaaccctg	acccccacag	agccttaagc	aactacttct	gtgaagtatt	ttttgactgt	2640
ttcatggaaa	acaagccttg	gaaataaatc	tctattaaac	cgctttgtaa	ccaaaaaaaa	2700
aaaaaaaaaa	aaaaaaaaaa	gggcggccgc				2730

<210> 60

<211> 2013

<212> DNA

<213> Homo sapiens

<400> 60

atggcccagc	tgttctgcc	cctgctggca	gccctggctc	tggcccaggc	tctgcagct	60
ttagcagatg	ttctggaagg	agacagctca	gaggaccgcg	cttttcgcgt	gcgcacgcgc	120
ggcgacgcgc	cactgcaggg	cgtgctcggc	ggcgccctca	ccatcccttg	ccacgtccac	180
tacctgcggc	caccgccgag	ccgccgggct	gtgctgggct	ctccgcgggt	caagtggact	240
ttctgttccc	ggggccggga	ggcagagggt	ctggtggcgc	ggggagtgcg	cgtcaagggtg	300
aacgaggcct	accggttccg	cgtggcactg	cctgcgtacc	cagcgtcgc	caccgacgtc	360
tccctggcgc	tgagcgagct	gcgcccac	gactcaggta	tctatcgcgtg	tgagggtccag	420
cacggcatcg	atgacagcag	cgacgctgtg	gagggtcaagg	tcaaaggggt	cgtctttctc	480
taccgagagg	gctctgccc	ctatgcttcc	tcttttctg	gggcccagga	ggcctgtgcc	540
cgatttgag	cccacatcgc	caccgccgag	cagctctatg	ccgcctacct	tgggggctat	600
gagcaatgtg	atgctggctg	gctgtcggat	cagaccgtga	ggtatcccat	ccagacccca	660
cgagaggcct	gttacggaga	catggatggc	ttcccgggg	tccggaacta	tggtgtggtg	720
gaccgggatg	acctctatga	tgtgtactgt	tatgctgaag	acctaaatgg	agaactgttc	780
ctgggtgacc	ctccagagaa	gctgacattg	gaggaagcac	gggcgtactg	ccaggagcgcg	840
ggtgcagaga	ttgccaccac	gggccaaactg	tatgcagcct	gggatgggtg	cctggaccac	900
tgcagcccag	ggtggctagc	tgatggcagt	gtgcgtacc	ccatcgtcac	accagcccag	960
cgctgtgggtg	ggggcttgcc	tggtgtcaag	actctcttcc	tcttcccaa	ccagactggc	1020
ttccccaata	agcacagccg	cttcaacgtc	tactgcttcc	gagactcggc	ccagccttct	1080
gccatccctg	aggcctccaa	cccagcctcc	aaccagcct	ctgatggact	agaggctatc	1140
gtcacagtga	cagagaccct	ggaggaactg	cagctgcctc	aggaagccac	agagagtga	1200
tcccgtaggg	ccatctactc	catccccatc	atggaggacg	gaggaggtgg	aagctccact	1260
ccagaagacc	cagcagaggc	ccctaggacg	ctcctagaat	ttgaaacaca	atccatggta	1320
ccgcccacgc	ggttctcaga	agaggaaggt	aaggcattgg	aggaagaaga	gaaatatgaa	1380
gatgaagaag	agaaagagga	ggaagaagaa	gaggaggagg	tggaggatga	ggctctgtgg	1440
gcattggccc	gcgagctcag	cagcccgggc	cctgaggcct	ctctccccc	tgagccagca	1500
gccaggaga	agtcactctc	ccaggcgcca	gcaagggcag	tctgcagcc	tggtgcatca	1560
ccacttcctg	atggagagtc	agaagcttcc	aggcctccaa	gggtccatgg	accacctact	1620
gagactctgc	ccactcccag	ggagaggaac	ctagcatccc	catcaccttc	cactctggtt	1680
gaggcaagag	aggtggggga	ggcaactggt	ggtcctgagc	tatctgggg	ccctcgagga	1740
gagagcgagg	agacaggaag	ctccgagggt	gccccttccc	tgcttcacgc	cacacggggc	1800
cctgagggtg	ccaggagact	ggaggccccc	tctgaagata	attctggaag	aactgcccga	1860
gcagggacct	cagtgcaggc	ccagccagtg	ctgccactg	acagcgccag	ccgagggtgga	1920
gtggccgtgg	tccccgcac	aggtaattct	gcccaggct	caactgcct	ctctatccta	1980

ctccttttct tccccctgca gctctgggtc acc

2013

<210> 61

<211> 671

<212> PRT

<213> Homo sapiens

<400> 61

Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln
1 5 10 15

Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser Glu Asp
20 25 30

Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu Gln Gly Val
35 40 45

Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His Tyr Leu Arg Pro
50 55 60

Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro Arg Val Lys Trp Thr
65 70 75 80

Phe Leu Ser Arg Gly Arg Glu Ala Glu Val Leu Val Ala Arg Gly Val
85 90 95

Arg Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala
100 105 110

Tyr Pro Ala Ser Leu Thr Asp Val Ser Leu Ala Leu Ser Glu Leu Arg
115 120 125

Pro Asn Asp Ser Gly Ile Tyr Arg Cys Glu Val Gln His Gly Ile Asp
130 135 140

Asp Ser Ser Asp Ala Val Glu Val Lys Val Lys Gly Val Val Phe Leu
145 150 155 160

Tyr Arg Glu Gly Ser Ala Arg Tyr Ala Phe Ser Phe Ser Gly Ala Gln
165 170 175

Glu Ala Cys Ala Arg Ile Gly Ala His Ile Ala Thr Pro Glu Gln Leu
180 185 190

Tyr Ala Ala Tyr Leu Gly Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu
195 200 205

Ser Asp Gln Thr Val Arg Tyr Pro Ile Gln Thr Pro Arg Glu Ala Cys
 210 215 220

Tyr Gly Asp Met Asp Gly Phe Pro Gly Val Arg Asn Tyr Gly Val Val
 225 230 235 240

Asp Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn
 245 250 255

Gly Glu Leu Phe Leu Gly Asp Pro Pro Glu Lys Leu Thr Leu Glu Glu
 260 265 270

Ala Arg Ala Tyr Cys Gln Glu Arg Gly Ala Glu Ile Ala Thr Thr Gly
 275 280 285

Gln Leu Tyr Ala Ala Trp Asp Gly Gly Leu Asp His Cys Ser Pro Gly
 290 295 300

Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile Val Thr Pro Ser Gln
 305 310 315 320

Arg Cys Gly Gly Gly Leu Pro Gly Val Lys Thr Leu Phe Leu Phe Pro
 325 330 335

Asn Gln Thr Gly Phe Pro Asn Lys His Ser Arg Phe Asn Val Tyr Cys
 340 345 350

Phe Arg Asp Ser Ala Gln Pro Ser Ala Ile Pro Glu Ala Ser Asn Pro
 355 360 365

Ala Ser Asn Pro Ala Ser Asp Gly Leu Glu Ala Ile Val Thr Val Thr
 370 375 380

Glu Thr Leu Glu Glu Leu Gln Leu Pro Gln Glu Ala Thr Glu Ser Glu
 385 390 395 400

Ser Arg Gly Ala Ile Tyr Ser Ile Pro Ile Met Glu Asp Gly Gly Gly
 405 410 415

Gly Ser Ser Thr Pro Glu Asp Pro Ala Glu Ala Pro Arg Thr Leu Leu
 420 425 430

Glu Phe Glu Thr Gln Ser Met Val Pro Pro Thr Gly Phe Ser Glu Glu
 435 440 445

Glu Gly Lys Ala Leu Glu Glu Glu Glu Lys Tyr Glu Asp Glu Glu Glu
 450 455 460

Lys Glu Glu Glu Glu Glu Glu Glu Glu Val Glu Asp Glu Ala Leu Trp
 465 470 475 480
 Ala Trp Pro Ser Glu Leu Ser Ser Pro Gly Pro Glu Ala Ser Leu Pro
 485 490 495
 Thr Glu Pro Ala Ala Gln Glu Lys Ser Leu Ser Gln Ala Pro Ala Arg
 500 505 510
 Ala Val Leu Gln Pro Gly Ala Ser Pro Leu Pro Asp Gly Glu Ser Glu
 515 520 525
 Ala Ser Arg Pro Pro Arg Val His Gly Pro Pro Thr Glu Thr Leu Pro
 530 535 540
 Thr Pro Arg Glu Arg Asn Leu Ala Ser Pro Ser Pro Ser Thr Leu Val
 545 550 555 560
 Glu Ala Arg Glu Val Gly Glu Ala Thr Gly Gly Pro Glu Leu Ser Gly
 565 570 575
 Val Pro Arg Gly Glu Ser Glu Glu Thr Gly Ser Ser Glu Gly Ala Pro
 580 585 590
 Ser Leu Leu Pro Ala Thr Arg Ala Pro Glu Gly Thr Arg Glu Leu Glu
 595 600 605
 Ala Pro Ser Glu Asp Asn Ser Gly Arg Thr Ala Pro Ala Gly Thr Ser
 610 615 620
 Val Gln Ala Gln Pro Val Leu Pro Thr Asp Ser Ala Ser Arg Gly Gly
 625 630 635 640
 Val Ala Val Val Pro Ala Ser Gly Asn Ser Ala Gln Gly Ser Thr Ala
 645 650 655
 Leu Ser Ile Leu Leu Leu Phe Phe Pro Leu Gln Leu Trp Val Thr
 660 665 670

<210> 62

<211> 22

<212> PRT

<213> Homo sapiens

<400> 62

Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln
 1 5 10 15

Ala Pro Ala Ala Leu Ala
20

<210> 63

<211> 649

<212> PRT

<213> Homo sapiens

<400> 63

Asp Val Leu Glu Gly Asp Ser Ser Glu Asp Arg Ala Phe Arg Val Arg
1 5 10 15

Ile Ala Gly Asp Ala Pro Leu Gln Gly Val Leu Gly Gly Ala Leu Thr
20 25 30

Ile Pro Cys His Val His Tyr Leu Arg Pro Pro Pro Ser Arg Arg Ala
35 40 45

Val Leu Gly Ser Pro Arg Val Lys Trp Thr Phe Leu Ser Arg Gly Arg
50 55 60

Glu Ala Glu Val Leu Val Ala Arg Gly Val Arg Val Lys Val Asn Glu
65 70 75 80

Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala Tyr Pro Ala Ser Leu Thr
85 90 95

Asp Val Ser Leu Ala Leu Ser Glu Leu Arg Pro Asn Asp Ser Gly Ile
100 105 110

Tyr Arg Cys Glu Val Gln His Gly Ile Asp Asp Ser Ser Asp Ala Val
115 120 125

Glu Val Lys Val Lys Gly Val Val Phe Leu Tyr Arg Glu Gly Ser Ala
130 135 140

Arg Tyr Ala Phe Ser Phe Ser Gly Ala Gln Glu Ala Cys Ala Arg Ile
145 150 155 160

Gly Ala His Ile Ala Thr Pro Glu Gln Leu Tyr Ala Ala Tyr Leu Gly
165 170 175

Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu Ser Asp Gln Thr Val Arg
180 185 190

Tyr Pro Ile Gln Thr Pro Arg Glu Ala Cys Tyr Gly Asp Met Asp Gly

195	200	205
Phe Pro Gly Val Arg Asn Tyr Gly Val Val Asp Pro Asp Asp Leu Tyr		
210	215	220
Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn Gly Glu Leu Phe Leu Gly		
225	230	235 240
Asp Pro Pro Glu Lys Leu Thr Leu Glu Glu Ala Arg Ala Tyr Cys Gln		
	245	250 255
Glu Arg Gly Ala Glu Ile Ala Thr Thr Gly Gln Leu Tyr Ala Ala Trp		
	260	265 270
Asp Gly Gly Leu Asp His Cys Ser Pro Gly Trp Leu Ala Asp Gly Ser		
	275	280 285
Val Arg Tyr Pro Ile Val Thr Pro Ser Gln Arg Cys Gly Gly Gly Leu		
	290	295 300
Pro Gly Val Lys Thr Leu Phe Leu Phe Pro Asn Gln Thr Gly Phe Pro		
305	310	315 320
Asn Lys His Ser Arg Phe Asn Val Tyr Cys Phe Arg Asp Ser Ala Gln		
	325	330 335
Pro Ser Ala Ile Pro Glu Ala Ser Asn Pro Ala Ser Asn Pro Ala Ser		
	340	345 350
Asp Gly Leu Glu Ala Ile Val Thr Val Thr Glu Thr Leu Glu Glu Leu		
	355	360 365
Gln Leu Pro Gln Glu Ala Thr Glu Ser Glu Ser Arg Gly Ala Ile Tyr		
	370	375 380
Ser Ile Pro Ile Met Glu Asp Gly Gly Gly Gly Ser Ser Thr Pro Glu		
385	390	395 400
Asp Pro Ala Glu Ala Pro Arg Thr Leu Leu Glu Phe Glu Thr Gln Ser		
	405	410 415
Met Val Pro Pro Thr Gly Phe Ser Glu Glu Glu Gly Lys Ala Leu Glu		
	420	425 430
Glu Glu Glu Lys Tyr Glu Asp Glu Glu Glu Lys Glu Glu Glu Glu Glu		
	435	440 445
Glu Glu Glu Val Glu Asp Glu Ala Leu Trp Ala Trp Pro Ser Glu Leu		

450	455	460
Ser Ser Pro Gly Pro Glu Ala Ser Leu Pro Thr Glu Pro Ala Ala Gln		
465	470	475 480
Glu Lys Ser Leu Ser Gln Ala Pro Ala Arg Ala Val Leu Gln Pro Gly		
	485	490 495
Ala Ser Pro Leu Pro Asp Gly Glu Ser Glu Ala Ser Arg Pro Pro Arg		
	500	505 510
Val His Gly Pro Pro Thr Glu Thr Leu Pro Thr Pro Arg Glu Arg Asn		
	515	520 525
Leu Ala Ser Pro Ser Pro Ser Thr Leu Val Glu Ala Arg Glu Val Gly		
	530	535 540
Glu Ala Thr Gly Gly Pro Glu Leu Ser Gly Val Pro Arg Gly Glu Ser		
545	550	555 560
Glu Glu Thr Gly Ser Ser Glu Gly Ala Pro Ser Leu Leu Pro Ala Thr		
	565	570 575
Arg Ala Pro Glu Gly Thr Arg Glu Leu Glu Ala Pro Ser Glu Asp Asn		
	580	585 590
Ser Gly Arg Thr Ala Pro Ala Gly Thr Ser Val Gln Ala Gln Pro Val		
	595	600 605
Leu Pro Thr Asp Ser Ala Ser Arg Gly Gly Val Ala Val Val Pro Ala		
	610	615 620
Ser Gly Asn Ser Ala Gln Gly Ser Thr Ala Leu Ser Ile Leu Leu Leu		
625	630	635 640
Phe Phe Pro Leu Gln Leu Trp Val Thr		
	645	

<210> 64
 <211> 456
 <212> PRT
 <213> Sus scrofa

<400> 64
 Met Asn Leu Asp Ile His Cys Glu Gln Leu Ser Asp Ala Arg Trp Thr
 1 5 10 15

Glu Leu Leu Pro Leu Leu Gln Gln Tyr Glu Val Val Arg Leu Asp Asp
 20 25 30

Cys Gly Leu Thr Glu Glu His Cys Lys Asp Ile Gly Ser Ala Leu Arg
 35 40 45

Ala Asn Pro Ser Leu Thr Glu Leu Cys Leu Arg Thr Asn Glu Leu Gly
 50 55 60

Asp Ala Gly Val His Leu Val Leu Gln Gly Leu Gln Ser Pro Thr Cys
 65 70 75 80

Lys Ile Gln Lys Leu Ser Leu Gln Asn Cys Ser Leu Thr Glu Ala Gly
 85 90 95

Cys Gly Val Leu Pro Ser Thr Leu Arg Ser Leu Pro Thr Leu Arg Glu
 100 105 110

Leu His Leu Ser Asp Asn Pro Leu Gly Asp Ala Gly Leu Arg Leu Leu
 115 120 125

Cys Glu Gly Leu Leu Asp Pro Gln Cys His Leu Glu Lys Leu Gln Leu
 130 135 140

Glu Tyr Cys Arg Leu Thr Ala Ala Ser Cys Glu Pro Leu Ala Ser Val
 145 150 155 160

Leu Arg Ala Thr Arg Ala Leu Lys Glu Leu Thr Val Ser Asn Asn Asp
 165 170 175

Ile Gly Glu Ala Gly Ala Arg Val Leu Gly Gln Gly Leu Ala Asp Ser
 180 185 190

Ala Cys Gln Leu Glu Thr Leu Arg Leu Glu Asn Cys Gly Leu Thr Pro
 195 200 205

Ala Asn Cys Lys Asp Leu Cys Gly Ile Val Ala Ser Gln Ala Ser Leu
 210 215 220

Arg Glu Leu Asp Leu Gly Ser Asn Gly Leu Gly Asp Ala Gly Ile Ala
 225 230 235 240

Glu Leu Cys Pro Gly Leu Leu Ser Pro Ala Ser Arg Leu Lys Thr Leu
 245 250 255

Trp Leu Trp Glu Cys Asp Ile Thr Ala Ser Gly Cys Arg Asp Leu Cys
 260 265 270

Arg Val Leu Gln Ala Lys Glu Thr Leu Lys Glu Leu Ser Leu Ala Gly
 275 280 285

Asn Lys Leu Gly Asp Glu Gly Ala Arg Leu Leu Cys Glu Ser Leu Leu
 290 295 300

Gln Pro Gly Cys Gln Leu Glu Ser Leu Trp Val Lys Ser Cys Ser Leu
 305 310 315 320

Thr Ala Ala Cys Cys Gln His Val Ser Leu Met Leu Thr Gln Asn Lys
 325 330 335

His Leu Leu Glu Leu Gln Leu Ser Ser Asn Lys Leu Gly Asp Ser Gly
 340 345 350

Ile Gln Glu Leu Cys Gln Ala Leu Ser Gln Pro Gly Thr Thr Leu Arg
 355 360 365

Val Leu Cys Leu Gly Asp Cys Glu Val Thr Asn Ser Gly Cys Ser Ser
 370 375 380

Leu Ala Ser Leu Leu Leu Ala Asn Arg Ser Leu Arg Glu Leu Asp Leu
 385 390 395 400

Ser Asn Asn Cys Val Gly Asp Pro Gly Val Leu Gln Leu Leu Gly Ser
 405 410 415

Leu Glu Gln Pro Gly Cys Ala Leu Glu Gln Leu Val Leu Tyr Asp Thr
 420 425 430

Tyr Trp Thr Glu Glu Val Glu Asp Arg Leu Gln Ala Leu Glu Gly Ser
 435 440 445

Lys Pro Gly Leu Arg Val Ile Ser
 450 455

<210> 65
 <211> 834
 <212> PRT
 <213> Mus sp.

<400> 65
 Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Gly Leu Trp Gly
 1 5 10 15

Leu Gly Ile Gly Ala Glu Met Trp Trp Asn Leu Val Pro Arg Lys Thr
 20 25 30

Val Ser Ser Gly Glu Leu Val Thr Val Val Arg Arg Phe Ser Gln Thr
 35 40 45
 Gly Ile Gln Asp Phe Leu Thr Leu Thr Leu Thr Glu His Ser Gly Leu
 50 55 60
 Leu Tyr Val Gly Ala Arg Glu Ala Leu Phe Ala Phe Ser Val Glu Ala
 65 70 75 80
 Leu Glu Leu Gln Gly Ala Ile Ser Trp Glu Ala Pro Ala Glu Lys Lys
 85 90 95
 Ile Glu Cys Thr Gln Lys Gly Lys Ser Asn Gln Thr Glu Cys Phe Asn
 100 105 110
 Phe Ile Arg Phe Leu Gln Pro Tyr Asn Ser Ser His Leu Tyr Val Cys
 115 120 125
 Gly Thr Tyr Ala Phe Gln Pro Lys Cys Thr Tyr Ile Asn Met Leu Thr
 130 135 140
 Phe Thr Leu Asp Arg Ala Glu Phe Glu Asp Gly Lys Gly Lys Cys Pro
 145 150 155 160
 Tyr Asp Pro Ala Lys Gly His Thr Gly Leu Leu Val Asp Gly Glu Leu
 165 170 175
 Tyr Ser Ala Thr Leu Asn Asn Phe Leu Gly Thr Glu Pro Val Ile Leu
 180 185 190
 Arg Tyr Met Gly Thr His His Ser Ile Lys Thr Glu Tyr Leu Ala Phe
 195 200 205
 Trp Leu Asn Glu Pro His Phe Val Gly Ser Ala Phe Val Pro Glu Ser
 210 215 220
 Val Gly Ser Phe Thr Gly Asp Asp Asp Lys Ile Tyr Phe Phe Phe Ser
 225 230 235 240
 Glu Arg Ala Val Glu Tyr Asp Cys Tyr Ser Glu Gln Val Val Ala Arg
 245 250 255
 Val Ala Arg Val Cys Lys Gly Asp Met Gly Gly Ala Arg Thr Leu Gln
 260 265 270
 Lys Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Val Cys Ser Ala Pro
 275 280 285

Asp	Trp	Lys	Val	Tyr	Phe	Asn	Gln	Leu	Lys	Ala	Val	His	Thr	Leu	Arg	290	295	300	
Gly	Ala	Ser	Trp	His	Asn	Thr	Thr	Phe	Phe	Gly	Val	Phe	Gln	Ala	Arg	305	310	315	320
Trp	Gly	Asp	Met	Asp	Leu	Ser	Ala	Val	Cys	Glu	Tyr	Gln	Leu	Glu	Gln	325	330	335	
Ile	Gln	Gln	Val	Phe	Glu	Gly	Pro	Tyr	Lys	Glu	Tyr	Ser	Glu	Gln	Ala	340	345	350	
Gln	Lys	Trp	Ala	Arg	Tyr	Thr	Asp	Pro	Val	Pro	Ser	Pro	Arg	Pro	Gly	355	360	365	
Ser	Cys	Ile	Asn	Asn	Trp	His	Arg	Asp	Asn	Gly	Tyr	Thr	Ser	Ser	Leu	370	375	380	
Glu	Leu	Pro	Asp	Asn	Thr	Leu	Asn	Phe	Ile	Lys	Lys	His	Pro	Leu	Met	385	390	395	400
Glu	Asp	Gln	Val	Lys	Pro	Arg	Leu	Gly	Arg	Pro	Leu	Leu	Val	Lys	Lys	405	410	415	
Asn	Thr	Asn	Phe	Thr	His	Val	Val	Ala	Asp	Arg	Val	Pro	Gly	Leu	Asp	420	425	430	
Gly	Ala	Thr	Tyr	Thr	Val	Leu	Phe	Ile	Gly	Thr	Gly	Asp	Gly	Trp	Leu	435	440	445	
Leu	Lys	Ala	Val	Ser	Leu	Gly	Pro	Trp	Ile	His	Met	Val	Glu	Glu	Leu	450	455	460	
Gln	Val	Phe	Asp	Gln	Glu	Pro	Val	Glu	Ser	Leu	Val	Leu	Ser	Gln	Ser	465	470	475	480
Lys	Lys	Val	Leu	Phe	Ala	Gly	Ser	Arg	Ser	Gln	Leu	Val	Gln	Leu	Ser	485	490	495	
Leu	Ala	Asp	Cys	Thr	Lys	Tyr	Arg	Phe	Cys	Val	Asp	Cys	Val	Leu	Ala	500	505	510	
Arg	Asp	Pro	Tyr	Cys	Ala	Trp	Asn	Val	Asn	Thr	Ser	Arg	Cys	Val	Ala	515	520	525	
Thr	Thr	Ser	Gly	Arg	Ser	Gly	Ser	Phe	Leu	Val	Gln	His	Val	Ala	Asn	530	535	540	

Leu Asp Thr Ser Lys Met Cys Asn Gln Tyr Gly Ile Lys Lys Val Arg
 545 550 555 560

Ser Ile Pro Lys Asn Ile Thr Val Val Ser Gly Thr Asp Leu Val Leu
 565 570 575

Pro Cys His Leu Ser Ser Asn Leu Ala His Ala His Trp Thr Phe Gly
 580 585 590

Ser Gln Asp Leu Pro Ala Glu Gln Pro Gly Ser Phe Leu Tyr Asp Thr
 595 600 605

Gly Leu Gln Ala Leu Val Val Met Ala Ala Gln Ser Arg His Ser Gly
 610 615 620

Pro Tyr Arg Cys Tyr Ser Glu Glu Gln Gly Thr Arg Leu Ala Ala Glu
 625 630 635 640

Ser Tyr Leu Val Ala Val Val Ala Gly Ser Ser Val Thr Leu Glu Ala
 645 650 655

Arg Ala Pro Leu Glu Asn Leu Gly Leu Val Trp Leu Ala Val Val Ala
 660 665 670

Leu Gly Ala Val Cys Leu Val Leu Leu Leu Val Leu Ser Leu Arg
 675 680 685

Arg Arg Leu Arg Glu Glu Leu Glu Lys Gly Ala Lys Ala Ser Glu Arg
 690 695 700

Thr Leu Val Tyr Pro Leu Glu Leu Pro Lys Glu Pro Ala Ser Pro Pro
 705 710 715 720

Phe Arg Pro Gly Pro Glu Thr Asp Glu Lys Leu Trp Asp Pro Val Gly
 725 730 735

Tyr Tyr Tyr Ser Asp Gly Ser Leu Lys Ile Val Pro Gly His Ala Arg
 740 745 750

Cys Gln Pro Gly Gly Gly Pro Pro Ser Pro Pro Pro Gly Ile Pro Gly
 755 760 765

Gln Pro Leu Pro Ser Pro Thr Arg Leu His Leu Gly Gly Gly Arg Asn
 770 775 780

Ser Asn Ala Asn Gly Tyr Val Arg Leu Gln Leu Gly Gly Glu Asp Arg
 785 790 795 800

Gly Gly Ser Gly His Pro Leu Pro Glu Leu Ala Asp Glu Leu Arg Arg
805 810 815

Lys Leu Gln Gln Arg Gln Pro Leu Pro Asp Ser Asn Pro Glu Glu Ser
820 825 830

Ser Val

<210> 66
<211> 3503
<212> DNA
<213> Mus sp.

<400> 66
ggcacgaggt ggccggagtc aaacgcgagg gcagcgccag ggattggagc tgcacgaaag 60
agggtctgtg gactgaagtt tagaccctgg gtgtctgcca tggccccaca ctgggctgtc 120
tggtctgtgg cagcagggct gtggggcctg ggcatcgggg ctgagatgtg gtggaacctt 180
gtgccccgga agacagtatc ttctggggag ctggtcacag tagtgaggcg gttctcccag 240
acaggcatcc aggacttcct gacactgacc ctgacagaac attctggcct tttatatgtg 300
ggggccccgag aggcgctgtt tgccttcagt gtagaggctc tggagctgca aggagcgate 360
tcttgggagg ctccagctga gaagaaaatt gaatgtacc agaaagggaa gagcaaccag 420
accgaatgct tcaacttcat ccgcttcctt cagccataca attcctccca tctgtatgtc 480
tgcggcacct atgccttcca gcccaagtgc acctacatca acatgctcac gttcaccttg 540
gaccgtgcag aatttgagga tgggaagggt aaatgcccat atgaccagc taagggtcac 600
accggactcc ttgtggacgg tgagctgtac tcagccacac tcaataactt cctgggcaca 660
gagccggtta tccttcgata catggggacc caccactcca tcaagacaga gtacctggct 720
ttttggctga atgaaccca cttttagagg tctgcctttg tccttgagag tgtgggaagc 780
ttcacgggag acgatgacaa gatctacttc ttcttcagt agcgggcagt ggagtatgac 840
tgctattccg agcaggtggt ggctcgtgtg gcgagagtct gtaagggtga catgggggga 900
gcacggacgc tgcagaagaa atggacgacg ttctgaagg ctcggttggg gtgctcagcc 960
cctgactgga aggtctactt caaccagctg aaggcgggtg acacctgcg gggcgctct 1020
tggcacaaca ccaccttctt cgggggtttt caagcgcgat ggggogatat ggacctgtct 1080
gcagtttgtg agtaccagtt ggaacagatc cagcaagtgt ttgagggtcc ctacaaggag 1140
tacagtgagc aagcccagaa gtggggccgc tatactgacc cggtaaccag ccctcggcct 1200
ggttcgtgta tcaacaactg gcaccgagac aatggctaca ccagttccct ggaactgccg 1260
gacaacaccc tcaacttcat caagaagcac cccctgatgg aggaccaggt gaagcctcgg 1320
ttgggcccgc ccctacttgt gaagaagaac actaacttca cacacgtggt ggccgacagg 1380
gtcccagggc ttgatggtgc cacctataca gtgttgttca ttggtacagg agatggctgg 1440
ctgctgaagg ctgtgagcct ggggccctgg atccacatgg tggaggaact gcaggtgttt 1500
gaccaggagc cagtggaaag tctggtgctg tctcagagca agaagggtgct ctttgcctggc 1560
tcccgtcttc agctggttca gctgtctctg gccgactgca caaagtaccg tttctgtgta 1620
gactgtgtcc tggccaggga cccttactgt gcctggaatg tcaacaccag ccgctgtgtg 1680
gccaccacca gtggtcgtc ggggtccttt ctggtccaac atgtggcgaa cttggacact 1740
tcaaagatgt gtaaccagta tggcattaaa aaagtacgat ctattcccaa gaacatcacc 1800
gttgtgtcag gcacagacct ggtcctaccc tgccacctct cgtccaattt ggcccatgcc 1860


```

cactggacct tcggaagcca ggacctgcct gcagaacaac ctggctcctt tctttatgac 1920
acgggactcc aggcgctggt ggtgatggcc gcacagtccc gtcactctgg accctatcgt 1980
tgctattcag aggagcagg gacaagactg gctgcagaaa gctaccttgt tgctgtcgtg 2040
gccggctcgt cggtgacact ggaggcacgg gctcccttgg aaaacctggg gctcgtgtgg 2100
ctcgtgtggg tggccctggg ggctgtgtgc ctgggtgtgc tgctgtggg cctatcgtc 2160
cgccggcgac ttcgagaaga gctagaaaag ggtgccaaag catctgagag gacactggtg 2220
tacctcttgg aactgcccac ggagcctgcc agtccccctt tccgtcctgg ccccgaaact 2280
gatgagaaac tttgggatcc tgtcgggtac tactattcgg atggctctct caagattgtg 2340
cctggtcacg cccggtgcca gcctgggggt gggccccctt ccccacctcc tggcatacct 2400
ggccagcctc tgccttctcc aactcggctc cacctaggag gtggtcggaa ctcaaatgcc 2460
aatggttatg tgcgtttaca gttgggcgga gaggaccgag gaggatctgg gcacccactg 2520
cctgagctcg cggatgaatt acgacggaac ctacaacagc gccagccgct gcctgactcc 2580
aaccagagg agtcttcagt atgaggggac ccccccacct cattggcggg ggggggtctc 2640
atgggaggtg cactcttaac ttttgacag gcaccagcta cctcagggac atggcagggg 2700
cacttgctct gcctgggaca gacactgcc atcatttgcc cggccgtgag gacctgctca 2760
gcatgggcac tgccacttgg tgtggctcac caggacttca gcctcacagg agacacaccc 2820
tcctctgtga atttgagaca tgtgggacct cagcagccaa aactttgcaa ggaagaggtt 2880
tcaagatgtg ggcgtgtttg tgcataatg tgttggtatg catgtggaag aatgtgtgtg 2940
tgtgtgtgtg tgtgttgtaa ctttcctgtc tctatcacgt cttcccttgg cctgggggtc 3000
tcctggttga gtctttggag ctatgaagg gaagggggtc atagcacttt gcttctccta 3060
ccccagctg tcccaagctt tggggcagt atgtacatac ggggaaggga aggacaggt 3120
gttgtaaccc ttttggggga gtgcgggact cgggggtggg cctagccctg ctctagggc 3180
tgtgaatgtt ttcagggcgg ggggtggggg tggagatgga acctcctgct tcagggggag 3240
gggtgggcag ggctccac ttgccctccg ggttcgtgg tattttatat ttgcgtctct 3300
ctgacagggc tgggaagggt tgttggggga ggggaaggag gaggtgggca tgctatggat 3360
actggcctat cctctccctg ctctgggaaa agggctaaca gtgtaactta ttgtgtcccc 3420
acatatttat ttgttgtaaa tatttgagta tttttatatt gacaaataaa atggagaaaa 3480
tgaaatttaa aaaaaaaaaa aaa 3503

```

<210> 67

<211> 1529

<212> PRT

<213> Homo sapiens

<400> 67

```

Met Arg Gly Val Gly Trp Gln Met Leu Ser Leu Ser Leu Gly Leu Val
  1               5               10              15

```

```

Leu Ala Ile Leu Asn Lys Val Ala Pro Gln Ala Cys Pro Ala Gln Cys
      20               25              30

```

```

Ser Cys Ser Gly Ser Thr Val Asp Cys His Gly Leu Ala Leu Arg Ser
    35               40              45

```

```

Val Pro Arg Asn Ile Pro Arg Asn Thr Glu Arg Leu Asp Leu Asn Gly
    50               55              60

```

Asn Asn Ile Thr Arg Ile Thr Lys Thr Asp Phe Ala Gly Leu Arg His
 65 70 75 80
 Leu Arg Val Leu Gln Leu Met Glu Asn Lys Ile Ser Thr Ile Glu Arg
 85 90 95
 Gly Ala Phe Gln Asp Leu Lys Glu Leu Glu Arg Leu Arg Leu Asn Arg
 100 105 110
 Asn His Leu Gln Leu Phe Pro Glu Leu Leu Phe Leu Gly Thr Ala Lys
 115 120 125
 Leu Tyr Arg Leu Asp Leu Ser Glu Asn Gln Ile Gln Ala Ile Pro Arg
 130 135 140
 Lys Ala Phe Arg Gly Ala Val Asp Ile Lys Asn Leu Gln Leu Asp Tyr
 145 150 155 160
 Asn Gln Ile Ser Cys Ile Glu Asp Gly Ala Phe Arg Ala Leu Arg Asp
 165 170 175
 Leu Glu Val Leu Thr Leu Asn Asn Asn Asn Ile Thr Arg Leu Ser Val
 180 185 190
 Ala Ser Phe Asn His Met Pro Lys Leu Arg Thr Phe Arg Leu His Ser
 195 200 205
 Asn Asn Leu Tyr Cys Asp Cys His Leu Ala Trp Leu Ser Asp Trp Leu
 210 215 220
 Arg Gln Arg Pro Arg Val Gly Leu Tyr Thr Gln Cys Met Gly Pro Ser
 225 230 235 240
 His Leu Arg Gly His Asn Val Ala Glu Val Gln Lys Arg Glu Phe Val
 245 250 255
 Cys Ser Gly His Gln Ser Phe Met Ala Pro Ser Cys Ser Val Leu His
 260 265 270
 Cys Pro Ala Ala Cys Thr Cys Ser Asn Asn Ile Val Asp Cys Arg Gly
 275 280 285
 Lys Gly Leu Thr Glu Ile Pro Thr Asn Leu Pro Glu Thr Ile Thr Glu
 290 295 300
 Ile Arg Leu Glu Gln Asn Thr Ile Lys Val Ile Pro Pro Gly Ala Phe
 305 310 315 320

Ser Pro Tyr Lys Lys Leu Arg Arg Ile Asp Leu Ser Asn Asn Gln Ile
325 330 335

Ser Glu Leu Ala Pro Asp Ala Phe Gln Gly Leu Arg Ser Leu Asn Ser
340 345 350

Leu Val Leu Tyr Gly Asn Lys Ile Thr Glu Leu Pro Lys Ser Leu Phe
355 360 365

Glu Gly Leu Phe Ser Leu Gln Leu Leu Leu Leu Asn Ala Asn Lys Ile
370 375 380

Asn Cys Leu Arg Val Asp Ala Phe Gln Asp Leu His Asn Leu Asn Leu
385 390 395 400

Leu Ser Leu Tyr Asp Asn Lys Leu Gln Thr Ile Ala Lys Gly Thr Phe
405 410 415

Ser Pro Leu Arg Ala Ile Gln Thr Met His Leu Ala Gln Asn Pro Phe
420 425 430

Ile Cys Asp Cys His Leu Lys Trp Leu Ala Asp Tyr Leu His Thr Asn
435 440 445

Pro Ile Glu Thr Ser Gly Ala Arg Cys Thr Ser Pro Arg Arg Leu Ala
450 455 460

Asn Lys Arg Ile Gly Gln Ile Lys Ser Lys Lys Phe Arg Cys Ser Ala
465 470 475 480

Lys Glu Gln Tyr Phe Ile Pro Gly Thr Glu Asp Tyr Arg Ser Lys Leu
485 490 495

Ser Gly Asp Cys Phe Ala Asp Leu Ala Cys Pro Glu Lys Cys Arg Cys
500 505 510

Glu Gly Thr Thr Val Asp Cys Ser Asn Gln Lys Leu Asn Lys Ile Pro
515 520 525

Glu His Ile Pro Gln Tyr Thr Ala Glu Leu Arg Leu Asn Asn Asn Glu
530 535 540

Phe Thr Val Leu Glu Ala Thr Gly Ile Phe Lys Lys Leu Pro Gln Leu
545 550 555 560

Arg Lys Ile Asn Phe Ser Asn Asn Lys Ile Thr Asp Ile Glu Glu Gly
565 570 575

Ala Phe Glu Gly Ala Ser Gly Val Asn Glu Ile Leu Leu Thr Ser Asn
 580 585 590

Arg Leu Glu Asn Val Gln His Lys Met Phe Lys Gly Leu Glu Ser Leu
 595 600 605

Lys Thr Leu Met Leu Arg Ser Asn Arg Ile Thr Cys Val Gly Asn Asp
 610 615 620

Ser Phe Ile Gly Leu Ser Ser Val Arg Leu Leu Ser Leu Tyr Asp Asn
 625 630 635 640

Gln Ile Thr Thr Val Ala Pro Gly Ala Phe Asp Thr Leu His Ser Leu
 645 650 655

Ser Thr Leu Asn Leu Leu Ala Asn Pro Phe Asn Cys Asn Cys Tyr Leu
 660 665 670

Ala Trp Leu Gly Glu Trp Leu Arg Lys Lys Arg Ile Val Thr Gly Asn
 675 680 685

Pro Arg Cys Gln Lys Pro Tyr Phe Leu Lys Glu Ile Pro Ile Gln Asp
 690 695 700

Val Ala Ile Gln Asp Phe Thr Cys Asp Asp Gly Asn Asp Asp Asn Ser
 705 710 715 720

Cys Ser Pro Leu Ser Arg Cys Pro Thr Glu Cys Thr Cys Leu Asp Thr
 725 730 735

Val Val Arg Cys Ser Asn Lys Gly Leu Lys Val Leu Pro Lys Gly Ile
 740 745 750

Pro Arg Asp Val Thr Glu Leu Tyr Leu Asp Gly Asn Gln Phe Thr Leu
 755 760 765

Val Pro Lys Glu Leu Ser Asn Tyr Lys His Leu Thr Leu Ile Asp Leu
 770 775 780

Ser Asn Asn Arg Ile Ser Thr Leu Ser Asn Gln Ser Phe Ser Asn Met
 785 790 795 800

Thr Gln Leu Leu Thr Leu Ile Leu Ser Tyr Asn Arg Leu Arg Cys Ile
 805 810 815

Pro Pro Arg Thr Phe Asp Gly Leu Lys Ser Leu Arg Leu Leu Ser Leu
 820 825 830

His Gly Asn Asp Ile Ser Val Val Pro Glu Gly Ala Phe Asn Asp Leu
 835 840 845
 Ser Ala Leu Ser His Leu Ala Ile Gly Ala Asn Pro Leu Tyr Cys Asp
 850 855 860
 Cys Asn Met Gln Trp Leu Ser Asp Trp Val Lys Ser Glu Tyr Lys Glu
 865 870 875 880
 Pro Gly Ile Ala Arg Cys Ala Gly Pro Gly Glu Met Ala Asp Lys Leu
 885 890 895
 Leu Leu Thr Thr Pro Ser Lys Lys Phe Thr Cys Gln Gly Pro Val Asp
 900 905 910
 Val Asn Ile Leu Ala Lys Cys Asn Pro Cys Leu Ser Asn Pro Cys Lys
 915 920 925
 Asn Asp Gly Thr Cys Asn Ser Asp Pro Val Asp Phe Tyr Arg Cys Thr
 930 935 940
 Cys Pro Tyr Gly Phe Lys Gly Gln Asp Cys Asp Val Pro Ile His Ala
 945 950 955 960
 Cys Ile Ser Asn Pro Cys Lys His Gly Gly Thr Cys His Leu Lys Glu
 965 970 975
 Gly Glu Glu Asp Gly Phe Trp Cys Ile Cys Ala Asp Gly Phe Glu Gly
 980 985 990
 Glu Asn Cys Glu Val Asn Val Asp Asp Cys Glu Asp Asn Asp Cys Glu
 995 1000 1005
 Asn Asn Ser Thr Cys Val Asp Gly Ile Asn Asn Tyr Thr Cys Leu Cys
 1010 1015 1020
 Pro Pro Glu Tyr Thr Gly Glu Leu Cys Glu Glu Lys Leu Asp Phe Cys
 1025 1030 1035 1040
 Ala Gln Asp Leu Asn Pro Cys Gln His Asp Ser Lys Cys Ile Leu Thr
 1045 1050 1055
 Pro Lys Gly Phe Lys Cys Asp Cys Thr Pro Gly Tyr Val Gly Glu His
 1060 1065 1070
 Cys Asp Ile Asp Phe Asp Asp Cys Gln Asp Asn Lys Cys Lys Asn Gly
 1075 1080 1085

Ala His Cys Thr Asp Ala Val Asn Gly Tyr Thr Cys Ile Cys Pro Glu
1090 1095 1100

Gly Tyr Ser Gly Leu Phe Cys Glu Phe Ser Pro Pro Met Val Leu Pro
1105 1110 1115 1120

Arg Thr Ser Pro Cys Asp Asn Phe Asp Cys Gln Asn Gly Ala Gln Cys
1125 1130 1135

Ile Val Arg Ile Asn Glu Pro Ile Cys Gln Cys Leu Pro Gly Tyr Gln
1140 1145 1150

Gly Glu Lys Cys Glu Lys Leu Val Ser Val Asn Phe Ile Asn Lys Glu
1155 1160 1165

Ser Tyr Leu Gln Ile Pro Ser Ala Lys Val Arg Pro Gln Thr Asn Ile
1170 1175 1180

Thr Leu Gln Ile Ala Thr Asp Glu Asp Ser Gly Ile Leu Leu Tyr Lys
1185 1190 1195 1200

Gly Asp Lys Asp His Ile Ala Val Glu Leu Tyr Arg Gly Arg Val Arg
1205 1210 1215

Ala Ser Tyr Asp Thr Gly Ser His Pro Ala Ser Ala Ile Tyr Ser Val
1220 1225 1230

Glu Thr Ile Asn Asp Gly Asn Phe His Ile Val Glu Leu Leu Ala Leu
1235 1240 1245

Asp Gln Ser Leu Ser Leu Ser Val Asp Gly Gly Asn Pro Lys Ile Ile
1250 1255 1260

Thr Asn Leu Ser Lys Gln Ser Thr Leu Asn Phe Asp Ser Pro Leu Tyr
1265 1270 1275 1280

Val Gly Gly Met Pro Gly Lys Ser Asn Val Ala Ser Leu Arg Gln Ala
1285 1290 1295

Pro Gly Gln Asn Gly Thr Ser Phe His Gly Cys Ile Arg Asn Leu Tyr
1300 1305 1310

Ile Asn Ser Glu Leu Gln Asp Phe Gln Lys Val Pro Met Gln Thr Gly
1315 1320 1325

Ile Leu Pro Gly Cys Glu Pro Cys His Lys Lys Val Cys Ala His Gly
1330 1335 1340

Thr Cys Gln Pro Ser Ser Gln Ala Gly Phe Thr Cys Glu Cys Gln Glu
1345 1350 1355 1360

Gly Trp Met Gly Pro Leu Cys Asp Gln Arg Thr Asn Asp Pro Cys Leu
1365 1370 1375

Gly Asn Lys Cys Val His Gly Thr Cys Leu Pro Ile Asn Ala Phe Ser
1380 1385 1390

Tyr Ser Cys Lys Cys Leu Glu Gly His Gly Gly Val Leu Cys Asp Glu
1395 1400 1405

Glu Glu Asp Leu Phe Asn Pro Cys Gln Ala Ile Lys Cys Lys His Gly
1410 1415 1420

Lys Cys Arg Leu Ser Gly Leu Gly Gln Pro Tyr Cys Glu Cys Ser Ser
1425 1430 1435 1440

Gly Tyr Thr Gly Asp Ser Cys Asp Arg Glu Ile Ser Cys Arg Gly Glu
1445 1450 1455

Arg Ile Arg Asp Tyr Tyr Gln Lys Gln Gln Gly Tyr Ala Ala Cys Gln
1460 1465 1470

Thr Thr Lys Lys Val Ser Arg Leu Glu Cys Arg Gly Gly Cys Ala Gly
1475 1480 1485

Gly Gln Cys Cys Gly Pro Leu Arg Ser Lys Arg Arg Lys Tyr Ser Phe
1490 1495 1500

Glu Cys Thr Asp Gly Ser Ser Phe Val Asp Glu Val Glu Lys Val Val
1505 1510 1515 1520

Lys Cys Gly Cys Thr Arg Cys Val Ser
1525

<210> 68

<211> 4900

<212> DNA

<213> Homo sapiens

<400> 68

cagagcaggg tggagagggc ggtgggaggc gtgtgcctga gtgggctcta ctgccttggt 60
ccatattatt ttgtgcacat ttccctggc actctgggtt gctagccccg ccgggcactg 120
ggcctcagac actgcgcggt tccctcggag cagcaagcta aagaaagccc ccagtgcccg 180
cgaggaagga ggcggcgggg aaagatgcgc ggcgttggtt ggcagatgct gtccctgtcg 240
ctgggggttag tgctggcgat cctgaacaag gtggcaccgc aggcgtgccc ggcgcagtgc 300

tcttgtctcg	gcagcacagt	ggactgtcac	gggctggcgc	tgcgcagcgt	gcccaggaat	360
atcccccgca	acaccgagag	actggattta	aatggaaata	acatcacaag	aattacgaag	420
acagattttg	ctggtcttag	acatctaaga	gttcttcagc	ttatggagaa	taagattagc	480
accattgaaa	gaggagcatt	ccaggatctt	aaagaactag	agagactgcg	tttaaacaga	540
aatcaccttc	agctgtttcc	tgagttgctg	tttcttggga	ctgcgaagct	atacaggctt	600
gatctcagtg	aaaaccaa	tcaggcaatc	ccaaggaaa	ctttccgtgg	ggcagttgac	660
ataaaaaatt	tgcaactgga	ttacaaccag	atcagctgta	ttgaagatgg	ggcattcagg	720
gctctccggg	acctggaagt	gctcactctc	aacaataaca	acattactag	actttctgtg	780
gcaagtttca	accatatgcc	taaacttagg	acttttcgac	tgcatcaca	caacctgtat	840
tgtgactgcc	acctggcctg	gctctccgac	tggcttcgcc	aaaggcctcg	ggttggtctg	900
tacactcagt	gtatgggccc	ctcccacctg	agaggccata	atgtagccga	ggttcaaaaa	960
cgagaatttg	tctgcagtg	tcaccagtca	tttatggctc	cttcttgtag	tgttttgcac	1020
tgccctgccg	cctgtacctg	tagcaacaat	atcgtagact	gtcgtgggaa	aggtctcact	1080
gagatcccca	caaactcttc	agagaccatc	acagaaatac	gtttggaaca	gaacacaatc	1140
aaagtcatcc	ctcctggagc	tttctcacca	tataaaaagc	ttagacgaat	tgacctgagc	1200
aataatcaga	tctctgaact	tgaccagatg	gctttccaag	gactacgctc	tctgaattca	1260
cttgtcctct	atggaaataa	aatcacagaa	ctccccaaaa	gtttatttga	aggactgttt	1320
tccttacagc	tcctattatt	gaatgccaac	aagataaact	gccttcgggt	agatgctttt	1380
caggatctcc	acaacttgaa	ccttctctcc	ctatatgaca	acaagcttca	gaccatcgcc	1440
aaggggacct	tttcacctct	tcggggccatt	caaactatgc	atttggccca	gaaccccttt	1500
atttgtgaact	gccatctcaa	gtggctagcg	gattatctcc	ataccaaccc	gattgagacc	1560
agtggtgccc	gttgcaccag	ccccgcgcgc	ctggcaca	aaagaattgg	acagatcaaa	1620
agcaagaaat	tccgttggtc	agctaaagaa	cagtatttca	ttccagggtac	agaagattat	1680
cgatcaaaat	taagtggaga	ctgctttgcg	gatctggctt	gccctgaaaa	gtgtcgctgt	1740
gaagggaacca	cagtagattg	ctctaataca	aagctcaaca	aaatcccggga	gcacattccc	1800
cagtagactg	cagagttg	tctcaataat	aatgaattta	ccgtgttgga	agccacagga	1860
atctttaaga	aacttcctca	attacgtaaa	ataaacttta	gcaacaataa	gatcacagat	1920
attgaggagg	gagcatttga	aggagcatct	ggtgtaaatg	aaatacttct	tacgagtaat	1980
cgtttgga	atgtgcagca	taagatgttc	aagggattgg	aaagcctcaa	aactttgatg	2040
ttgagaagca	atcgaataac	ctgtgtgggg	aatgacagtt	tcataaggact	cagttctgtg	2100
cgtttgcttt	ctttgtatga	taatcaaatt	actacagttg	caccaggggc	atttgatact	2160
ctocattctt	tatctactct	aaacctcttg	gccaatcctt	ttaactgtaa	ctgctacctg	2220
gcttggttgg	gagagtggct	gagaaagaag	agaattgtca	cgggaaatcc	tagatgtcaa	2280
aaaccatact	tcctgaaaga	aatacccatc	caggatgtgg	ccattcagga	cttcacttgt	2340
gatgacggaa	atgatgacaa	tagttgctcc	ccactttctc	gctgtcctac	tgaatgtact	2400
tgcttgata	cagtcgtccg	atgtagcaac	aagggtttga	aggtcttgcc	gaaaggtatt	2460
ccaagagatg	tcacagagtt	gtatctggat	ggaaaccaat	ttacactggg	tccaaggaa	2520
ctotccaact	acaaacattt	aacacttata	gacttaagta	acaacagaat	aagcacgctt	2580
tctaatacaga	gcttcagcaa	catgaccag	ctcctcacct	taattcttag	ttacaaccgt	2640
ctgagatgta	ttcctcctcg	cacctttgat	ggattaaagt	ctcttcgatt	actttctcta	2700
catggaaatg	acatttctgt	tgtgcctgaa	ggtgctttca	atgatctttc	tgcatatca	2760
catctagcaa	ttggagccaa	ccctctttac	tgtgattgta	acatgcagtg	gttatccgac	2820
tggttgaaagt	cggaatataa	ggagcctgga	attgctcggt	gtgctgggtcc	tgagaaatg	2880
gcagataaac	ttttactcac	aactccctcc	aaaaatttta	cctgtcaagg	tcctgtggat	2940
gtcaatatcc	tagctaagt	taaccctgc	ctatcaaatac	cgtgtaaaaa	tgatggcaca	3000
tgtaatatgt	atccagttga	cttttaccga	tgacactgtc	catatgggtt	caaggggcag	3060
gactgtgatg	tcccaattca	tgccctgcac	agtaacccat	gtaaacatgg	aggaacttgc	3120
cacttaaagg	aaggagaaga	agatggattc	tggtgtattt	gtgctgatgg	atttgaagga	3180

gaaaattgtg aagtcaacgt tgatgattgt gaagataatg actgtgaaaa taattctaca 3240
tgtgtcgatg gcattaataa ctacacatgc ctttgcccac ctgagtatac aggtgagttg 3300
tgtgaggaga agctggactt ctgtgccag gacctgaacc cctgccagca cgattcaaag 3360
tgcactctaa ctccaaaggg attcaaatgt gactgcacac cagggtacgt aggtgaacac 3420
tgcgacatcg attttgacga ctgccaagac aacaagtgtg aaaacggagc cactgcaca 3480
gatgcagtga acggctatac gtgcatatgc cccgaagggt acagtggctt gttctgtgag 3540
ttttctccac ccatggctct cctcgtacc agcccctgtg ataattttga ttgtcagaat 3600
ggagctcagt gtatcgtcag aataaatgag ccaatatgtc agtgtttgcc tggctatcag 3660
ggagaaaagt gtgaaaaatt ggttagtgtg aattttataa acaaagagtc ttatcttcag 3720
attccttcag ccaagggttcg gcctcagacg aacataacac ttcagattgc cacagatgaa 3780
gacagcggaa tcctcctgta taagggtgac aaagaccata tcgcggtaga actctatcgg 3840
gggcgtgttc gtgccagcta tgacaccggc tctcatccag cttctgccat ttacagtgtg 3900
gagacaatca atgatggaaa cttccacatt gtggaactac ttgccttgga tcagagtctc 3960
tctttgtcog tggatgggtg gaaccccaaa atcatcacta acttgtcaaa gcagtccact 4020
ctgaattttg actctccact ctatgtagga ggcatgccag ggaagagtaa cgtggcatct 4080
ctgcgccagg cccctgggca gaacggaacc agcttccacg gctgcatccg gaacctttac 4140
atcaacagtg agctgcagga cttccagaag gtgccgatgc aaacaggcat tttgcctggc 4200
tgtgagccat gccacaagaa ggtgtgtgcc catggcacat gccagcccag cagccaggca 4260
ggcttcacct gcgagtgcc ggaaggatgg atggggcccc tctgtgacca acggaccaat 4320
gaccttgcc ttggaaataa atgcgtacat ggcacctgct tgcccatcaa tgcgttctcc 4380
tacagctgta agtgcttgga gggccatgga ggtgtcctct gtgatgaaga ggaggatctg 4440
tttaacccat gccaggcgat caagtgaag cacgggaagt gcaggctttc aggtctgggg 4500
cagccctact gtgaatgcag cagtggatac acgggggaca gctgtgatcg agaaatctct 4560
tgtcgagggg aaaggataag agattattac caaaagcagc agggctatgc tgcttgccaa 4620
acaaccaaga aggtgtcccg attagagtgc agagggtggg gtgcaggagg gcagtgtgtg 4680
ggaccgctga ggagcaagcg gcggaaatac tctttcgaat gcactgacgg ctctcctttt 4740
gtggacgagg ttgagaaagt ggtgaagtgc ggctgtacga ggtgtgtgtc ctaaacacac 4800
tcccggcagc tctgtctttg gaaaagggtt tatacttctt gaccatgtgg gactaatgaa 4860
tgcttcatag tggaaatatt tgaaatatat tgtaaatac 4900

<210> 69

<211> 348

<212> PRT

<213> *Cricetulus griseus*

<400> 69

Met His Leu Pro Pro Ala Ala Ala Val Gly Leu Leu Leu Leu Leu Leu
1 5 10 15

Pro Pro Pro Ala Arg Val Ala Ser Arg Lys Pro Thr Met Cys Gln Arg
20 25 30

Cys Arg Ala Leu Val Asp Lys Phe Asn Gln Gly Met Ala Asn Thr Ala
35 40 45

Arg Lys Asn Phe Gly Gly Gly Asn Thr Ala Trp Glu Glu Lys Ser Leu
50 55 60

Ser Lys Tyr Glu Phe Ser Glu Ile Arg Leu Leu Glu Ile Met Glu Gly
 65 70 75 80
 Leu Cys Asp Ser Asn Asp Phe Glu Cys Asn Gln Leu Leu Glu Gln His
 85 90 95
 Glu Glu Gln Leu Glu Ala Trp Trp Gln Thr Leu Lys Lys Glu Cys Pro
 100 105 110
 Asn Leu Phe Glu Trp Phe Cys Val His Thr Leu Lys Ala Cys Cys Leu
 115 120 125
 Pro Gly Thr Tyr Gly Pro Asp Cys Gln Glu Cys Gln Gly Gly Ser Gln
 130 135 140
 Arg Pro Cys Ser Gly Asn Gly His Cys Asp Gly Asp Gly Ser Arg Gln
 145 150 155 160
 Gly Asp Gly Ser Cys Gln Cys His Val Gly Tyr Lys Gly Pro Leu Cys
 165 170 175
 Ile Asp Cys Met Asp Gly Tyr Phe Ser Leu Leu Arg Asn Glu Thr His
 180 185 190
 Ser Phe Cys Thr Ala Cys Asp Glu Ser Cys Lys Thr Cys Ser Gly Pro
 195 200 205
 Thr Asn Lys Gly Cys Val Glu Cys Glu Val Gly Trp Thr Arg Val Glu
 210 215 220
 Asp Ala Cys Val Asp Val Asp Glu Cys Ala Ala Glu Thr Pro Pro Cys
 225 230 235 240
 Ser Asn Val Gln Tyr Cys Glu Asn Val Asn Gly Ser Tyr Thr Cys Glu
 245 250 255
 Glu Cys Asp Ser Thr Cys Val Gly Cys Thr Gly Lys Gly Pro Ala Asn
 260 265 270
 Cys Lys Glu Cys Ile Ser Gly Tyr Ser Lys Gln Lys Gly Glu Cys Ala
 275 280 285
 Asp Ile Asp Glu Cys Ser Leu Glu Thr Lys Val Cys Lys Lys Glu Asn
 290 295 300
 Glu Asn Cys Tyr Asn Thr Pro Gly Ser Phe Val Cys Val Cys Pro Glu
 305 310 315 320

Gly Phe Glu Glu Asp Arg Arg Cys Leu Cys Thr Asp Ser Arg Arg Arg
 325 330 335

Ser Gly Arg Gly Lys Ser His Thr Ala Thr Leu Pro
 340 345

<210> 70
 <211> 1399
 <212> DNA
 <213> *Cricetulus griseus*

<400> 70
 gtagccggggg gaacggccgg cgcgcttgcc ggtgggcgga ggcgagactc cacagcagtt 60
 ctctgccggg cgcccgcgag tgcaccgcc atgcacctgc cgcccgctgc cgcagtcggg 120
 ctgctactgc tgetgctgcc gcctcccgg cgcggtggcct ccggaagcc gacaatgtgc 180
 cagaggtgcc gggcgctggg ggacaagttc aaccagggga tggccaacac ggccaggaag 240
 aatttcggcg gcggaacac ggcgtgggag gagaagagtc tgtccaagta cgaattcagt 300
 gagattcggc tcctggagat tatggagggc ctgtgtgaca gcaacgactt tgaatgcaac 360
 caactcttgg aacagcatga ggagcagcta gaggcctggg ggcagacact gaagaaggag 420
 tgccctaacc tatttgagtg gttctgtgta cacacactga aagcatgctg tcttccaggc 480
 acctatgggc cagactgtca ggaatgccag ggtgggtctc agaggccttg tagcgggaat 540
 ggccactgcg acggagatgg cagcagacag ggcgacgggt cctgccagtg tcacgtagga 600
 tacaaggggc cgctgtgtat cgactgcatg gatggctact tcagcttgct gaggaacgag 660
 acccacagct tctgcacagc ctgtgatgag tcctgcaaga catgctcagg tccaaccaac 720
 aaaggctgtg tggagtgcga agtgggctgg acacgtgtgg aggatgcctg tgtggatgtt 780
 gacgagtgtg cagcagagac cccaccctgc agcaatgtac agtactgtga aaatgtcaac 840
 ggctcctaca catgtgaaga gtgtgattct acctgtgtgg gctgcacagg aaaaggccca 900
 gccaatgtga aagagtgtat ctctggctac agcaagcaga aaggagagtg tgcagatata 960
 gatgaatgct cattagaaac aaagggtgtg aagaaggaaa atgagaactg ctacaatact 1020
 ccaggagact ttgtctgcgt gtgtccggaa ggtttcgagg aagacagaag atgcttgtgt 1080
 acagacagca gaaggcgaag tggcagagga aagtcccaca cagccaccct cccatgagga 1140
 tttgtgacgg gcatccaggt tcagaagctg gactctcacc cttttaagtt attgagagga 1200
 catcctatag aaaatgtggc ccatggacat caacccatt tctccaggaa gttttggagg 1260
 aagaagctgc ctgctttgaa acagtagata ctcaattggc cctttaaaac gctgcatttc 1320
 ttggtggttc ttaaacagat tcgtatattt tgatactgtt ctttataata aaattgatca 1380
 ttgaaggtca ccaggaaca 1399

<210> 71
 <211> 528
 <212> PRT
 <213> *Homo sapiens*

<400> 71
 Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln
 1 5 10 15

Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser Glu Asp
 20 25 30

Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu Gln Gly Val
 35 40 45

Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His Tyr Leu Arg Pro
 50 55 60

Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro Arg Val Lys Trp Thr
 65 70 75 80

Phe Leu Ser Arg Gly Arg Glu Ala Glu Val Leu Val Ala Arg Gly Val
 85 90 95

Arg Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala
 100 105 110

Tyr Pro Ala Ser Leu Thr Asp Val Ser Leu Ala Leu Ser Glu Leu Arg
 115 120 125

Pro Asn Asp Ser Gly Ile Tyr Arg Cys Glu Val Gln His Gly Ile Asp
 130 135 140

Asp Ser Ser Asp Ala Val Glu Ser Ser Gln Arg Tyr Pro Ile Gln Thr
 145 150 155 160

Pro Arg Glu Ala Cys Tyr Gly Asp Met Asp Gly Phe Pro Gly Val Arg
 165 170 175

Asn Tyr Gly Val Val Asp Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr
 180 185 190

Ala Glu Asp Leu Asn Gly Glu Leu Phe Leu Gly Asp Pro Pro Glu Lys
 195 200 205

Leu Thr Leu Glu Glu Ala Arg Ala Tyr Cys Gln Glu Arg Gly Ala Glu
 210 215 220

Ile Ala Thr Thr Gly Gln Leu Tyr Ala Ala Trp Asp Gly Gly Leu Asp
 225 230 235 240

His Cys Ser Pro Gly Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile
 245 250 255

Val Thr Pro Ser Gln Arg Cys Gly Gly Gly Leu Pro Gly Val Lys Thr
 260 265 270

Leu Phe Leu Phe Pro Asn Gln Thr Gly Phe Pro Asn Lys His Ser Arg
 275 280 285

Phe Asn Val Tyr Cys Phe Arg Asp Ser Ala Gln Leu Leu Pro Ser Leu
 290 295 300

Arg Pro Pro Thr Gln Pro Pro Thr Gln Leu Asp Gly Leu Glu Ala Ile
 305 310 315 320

Val Thr Val Thr Glu Thr Leu Glu Glu Leu Gln Leu Pro Gln Glu Ala
 325 330 335

Thr Glu Ser Glu Ser Arg Gly Ala Ile Tyr Ser Ile Pro Ile Met Glu
 340 345 350

Asp Gly Gly Gly Gly Ser Ser Thr Pro Glu Asp Pro Ala Glu Ala Pro
 355 360 365

Arg Thr Leu Leu Glu Phe Glu Thr Gln Ser Met Val Pro Pro Thr Gly
 370 375 380

Phe Ser Glu Glu Glu Gly Lys Ala Leu Glu Glu Glu Glu Lys Tyr Glu
 385 390 395 400

Asp Glu Glu Glu Lys Glu Glu Glu Glu Glu Glu Glu Val Glu Asp
 405 410 415

Glu Ala Leu Trp Ala Trp Pro Ser Glu Leu Ser Ser Pro Gly Pro Glu
 420 425 430

Ala Ser Leu Pro Thr Glu Pro Ala Ala Gln Glu Glu Ser Leu Ser Gln
 435 440 445

Ala Pro Ala Arg Ala Val Leu Gln Pro Gly Ala Ser Pro Leu Pro Asp
 450 455 460

Gly Glu Ser Glu Ala Ser Arg Pro Pro Arg Val His Gly Pro Pro Thr
 465 470 475 480

Glu Thr Leu Pro Thr Pro Arg Glu Arg Asn Leu Ala Ser Pro Ser Pro
 485 490 495

Ser Thr Leu Val Glu Ala Arg Glu Val Gly Glu Ala Thr Gly Gly Pro
 500 505 510

Glu Leu Ser Gly Val Pro Arg Gly Gly Ala Arg Thr Gln Phe Ala Leu
 515 520 525

<210> 72
<211> 883
<212> PRT
<213> Mus sp.

<400> 72

Met Ile Pro Leu Leu Leu Ser Leu Leu Ala Ala Leu Val Leu Thr Gln
1 5 10 15

Ala Pro Ala Ala Leu Ala Asp Asp Leu Lys Glu Asp Ser Ser Glu Asp
20 25 30

Arg Ala Phe Arg Val Arg Ile Gly Ala Ala Gln Leu Arg Gly Val Leu
35 40 45

Gly Gly Ala Leu Ala Ile Pro Cys His Val His His Leu Arg Pro Pro
50 55 60

Arg Ser Arg Arg Ala Ala Pro Gly Phe Pro Arg Val Lys Trp Thr Phe
65 70 75 80

Leu Ser Gly Asp Arg Glu Val Glu Val Leu Val Ala Arg Gly Leu Arg
85 90 95

Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala Tyr
100 105 110

Pro Ala Ser Leu Thr Asp Val Ser Leu Val Leu Ser Glu Leu Arg Pro
115 120 125

Asn Asp Ser Gly Val Tyr Arg Cys Glu Val Gln His Gly Ile Asp Asp
130 135 140

Ser Ser Asp Ala Val Glu Val Lys Val Lys Gly Val Val Phe Leu Tyr
145 150 155 160

Arg Glu Gly Ser Ala Arg Tyr Ala Phe Ser Phe Ala Gly Ala Gln Glu
165 170 175

Ala Cys Ala Arg Ile Gly Ala Arg Ile Ala Thr Pro Glu Gln Leu Tyr
180 185 190

Ala Ala Tyr Leu Gly Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu Ser

195		200		205
Asp Gln Thr Val Arg Tyr Pro Ile Gln Asn Pro Arg Glu Ala Cys Ser				
210		215		220
Gly Asp Met Asp Gly Tyr Pro Gly Val Arg Asn Tyr Gly Val Val Gly				
225		230		235
				240
Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn Gly				
	245		250	255
Glu Leu Phe Leu Gly Ala Pro Pro Ser Lys Leu Thr Trp Glu Glu Ala				
	260		265	270
Arg Asp Tyr Cys Leu Glu Arg Gly Ala Gln Ile Ala Ser Thr Gly Gln				
	275		280	285
Leu Tyr Ala Ala Trp Asn Gly Gly Leu Asp Arg Cys Ser Pro Gly Trp				
	290		295	300
Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile Ile Thr Pro Ser Gln Arg				
305		310		315
				320
Cys Gly Gly Gly Leu Pro Gly Val Lys Thr Leu Phe Leu Phe Pro Asn				
	325		330	335
Gln Thr Gly Phe Pro Ser Lys Gln Asn Arg Phe Asn Val Tyr Cys Phe				
	340		345	350
Arg Asp Ser Ala His Pro Ser Ala Ser Ser Glu Ala Ser Ser Pro Ala				
	355		360	365
Ser Asp Gly Leu Glu Ala Ile Val Thr Val Thr Glu Lys Leu Glu Glu				
	370		375	380
Leu Gln Leu Pro Gln Glu Ala Met Glu Ser Glu Ser Arg Gly Ala Ile				
385		390		395
				400
Tyr Ser Ile Pro Ile Ser Glu Asp Gly Gly Gly Gly Ser Ser Thr Pro				
	405		410	415
Glu Asp Pro Ala Glu Ala Pro Arg Thr Pro Leu Glu Ser Glu Thr Gln				
	420		425	430
Ser Ile Ala Pro Pro Thr Glu Ser Ser Glu Glu Glu Gly Val Ala Leu				
	435		440	445
Glu Glu Glu Glu Arg Phe Lys Asp Leu Glu Ala Leu Glu Glu Glu Lys				

450		455		460
Glu Gln Glu Asp Leu Trp Val Trp Pro Arg Glu Leu Ser Ser Pro Leu				
465		470		475 480
Pro Thr Gly Ser Glu Thr Glu His Ser Leu Ser Gln Val Ser Pro Pro				
	485		490	495
Ala Gln Ala Val Leu Gln Leu Asp Ala Ser Pro Ser Pro Gly Pro Pro				
	500		505	510
Arg Phe Arg Gly Pro Pro Ala Glu Thr Leu Leu Pro Pro Arg Glu Trp				
	515		520	525
Ser Ala Thr Ser Thr Pro Gly Gly Ala Arg Glu Val Gly Gly Glu Thr				
	530		535	540
Gly Ser Pro Glu Leu Ser Gly Val Pro Arg Glu Ser Glu Glu Ala Gly				
545		550		555 560
Ser Ser Ser Leu Glu Asp Gly Pro Ser Leu Leu Pro Ala Thr Trp Ala				
	565		570	575
Pro Val Gly Pro Arg Glu Leu Glu Thr Pro Ser Glu Glu Lys Ser Gly				
	580		585	590
Arg Thr Val Leu Ala Gly Thr Ser Val Gln Ala Gln Pro Val Leu Pro				
	595		600	605
Thr Asp Ser Ala Ser His Gly Gly Val Ala Val Ala Pro Ser Ser Gly				
610		615		620
Asp Cys Ile Pro Ser Pro Cys His Asn Gly Gly Thr Cys Leu Glu Glu				
625		630		635 640
Lys Glu Gly Phe Arg Cys Leu Cys Leu Pro Gly Tyr Gly Gly Asp Leu				
	645		650	655
Cys Asp Val Gly Leu His Phe Cys Ser Pro Gly Trp Glu Ala Phe Gln				
	660		665	670
Gly Ala Cys Tyr Lys His Phe Ser Thr Arg Arg Ser Trp Glu Glu Ala				
	675		680	685
Glu Ser Gln Cys Arg Ala Leu Gly Ala His Leu Thr Ser Ile Cys Thr				
	690		695	700
Pro Glu Glu Gln Asp Phe Val Asn Asp Arg Tyr Arg Glu Tyr Gln Trp				

705	710	715	720
Ile Gly Leu Asn Asp Arg Thr Ile Glu Gly Asp Phe Leu Trp Ser Asp			
725	730	735	
Gly Ala Pro Leu Leu Tyr Glu Asn Trp Asn Pro Gly Gln Pro Asp Ser			
740	745	750	
Tyr Phe Leu Ser Gly Glu Asn Cys Val Val Met Val Trp His Asp Gln			
755	760	765	
Gly Gln Trp Ser Asp Val Pro Cys Asn Tyr His Leu Ser Tyr Thr Cys			
770	775	780	
Lys Met Gly Leu Val Ser Cys Gly Pro Pro Pro Gln Leu Pro Leu Ala			
785	790	795	800
Gln Ile Phe Gly Arg Pro Arg Leu Arg Tyr Ala Val Asp Thr Val Leu			
805	810	815	
Arg Tyr Arg Cys Arg Asp Gly Leu Ala Gln Arg Asn Leu Pro Leu Ile			
820	825	830	
Arg Cys Gln Glu Asn Gly Leu Trp Glu Ala Pro Gln Ile Ser Cys Val			
835	840	845	
Pro Arg Arg Pro Gly Arg Ala Leu Arg Ser Met Asp Ala Pro Glu Gly			
850	855	860	
Pro Arg Gly Gln Leu Ser Arg His Arg Lys Ala Pro Leu Thr Pro Pro			
865	870	875	880
Ser Ser Leu			

<210> 73

<211> 3153

<212> DNA

<213> Mus sp.

<400> 73

```

gaggctcccc gcgagctggc gcccctgtct ggggtcccgcg cgcccggccc tgctcgcgcc 60
cgcgcatcgc gccgcagtct cggtctgcgg ctgcgggacg tgacggcgtg cgcgaggagg 120
acctcgcaag ttcttccatc agtgtgcaga atgataccac tgcttctgtc cctgctggcc 180
gctctgggtc tgacccaagc ccctgccgcc ctgctgatg acctgaaaga agacagctcg 240
gaggatcgag ccttccgcgt gcgcatcggt gccgcgcagc tgcggggcgt gctgggcggt 300
gccctggcca tcccatgcc agtccaccac ctgcggccgc cgcgagccg ccgggcccgcg 360

```

ccgggttttc cccgggtcaa gtggacettc ctgtccgggg accgggaggt agaggttctg 420
 gtggctcgcg ggctgcgcgt caaggtaaac gaagcctacc gggtccgcgt ggcgctgcct 480
 gcctaccccc catcgctcac ggatgtgtct ctagtattga gcgaactgog gcccaatgat 540
 tccgggggtct atcgctgcga ggtccagcac ggtatcgacg acagcagtga tgctgtggag 600
 gtcaagggtca aaggggtcgt ctctctctac agagaggggt ctgcgcgcta tgctttctcc 660
 ttgcgtggag cccaggaagc ctgcgcctcg ataggagccc gaatcgccac cccggagcag 720
 ctctatgctg cctacctcg cggtatgag cagtgtgatg caggctggct gtccgaccaa 780
 actgtgaggt accccatcca gaaccacga gaggcctgct ctggagacat ggatggctat 840
 cctggcgtgc ggaactacgg agtgggtgggt cctgatgatc tctatgatgt ctactgttat 900
 gccgaagacc taaatggaga actgttccta ggcgccccct ccagcaagct gacatgggag 960
 gaggctcggg actactgtct ggaacgtggt gcacagatcg ctacacaggg ccagctgtac 1020
 gcagcctgga atgggtggcct ggacagatgt agcctgggt ggctggctga tggcagcgtg 1080
 cgctatccca tcatcacacc cagccaacgc tgtggggggcg gcctgccagg agtcaagacc 1140
 ctcttctctt tcccaacca gactggcttc cccagcaagc agaaccgctt caatgtctac 1200
 tgcttccgag actctgccc tccctctgct tcctctgagg cctctagccc agcctcagat 1260
 ggacttgagg ccattgtcac agtgacagaa aagctggagg aactgcagct gcctcaggaa 1320
 gcgatggaga gcgagtctcg tggggccatc tactccatcc ccatctcaga agatggggga 1380
 ggaggaagct ccacccaga agaccagca gaggcccca ggactccgct agaatcggaa 1440
 acccaatcca ttgcaccacc taccgagtcc tcagaagagg aaggcgtagc cctggaggaa 1500
 gaagaaagat tcaaagactt ggaggctctg gaggaagaga aggagcagga ggacctgtgg 1560
 gtgtggccca gagagctcag cagccctctc cctactggct cagaaacaga gcattcactc 1620
 tcccaggtgt ccccaccagc ccaggcagtt ctacagctgg atgcgtcacc ttctcctggg 1680
 cctccaaggt tccgtggacc gcctgcagag actttgctcc ccccgaggga gtggagcgcc 1740
 acatctactc ctggtggggc aagagaagta gggggggaaa ctgggagccc tgagctctct 1800
 ggggttcctc gagagagcga ggaggcaggg agctccagct tggaggatgg cccttcccta 1860
 ctccagcta catgggcccc tgtgggtccc agggagctgg agacccctc agaagagaag 1920
 tctggaagaa ctgtcctggc aggcacctca gtgcaggccc agccagtgtc gccaccgac 1980
 agtgccagcc acggtggagt ggctgtggct ccctcatcag gtgactgtat cccagcccc 2040
 tgccacaatg gtgggacatg cttggaggag aaggagggtt tccgctgcct atgtttgcca 2100
 ggctatgggg gggacctgtg cgatgttggc cttcatttct gcagccctgg ctgggaggcc 2160
 ttccagggag cctgctacaa gcacttttcc acacgaagga gttgggagga ggcagaaagt 2220
 cagtgcogag cgctaggtgc tcatctgacc agcatctgca cccctgagga gcaagacttt 2280
 gtcaatgatc gataccggga gtaccagtgg attgggtctc atgacaggac catcgagggt 2340
 gacttcttgt ggtcagatgg tgcccctctg ctctatgaaa actggaacct tgggcagcct 2400
 gacagctact tcctgtctgg ggagaactgt gtggtcatgg tgtggcatga ccagggacag 2460
 tggagtgatg tgccctgcaa ctaccatcta tcctacacct gcaagatggg gcttgtgtcc 2520
 tgtgggcctc caccacagct acccctggct caaatatttg gtgcacctcg gctgcgctac 2580
 gcggtggata ctgtgcttcg atatcgatgc cgagacgggc tggctcagcg caacctgccg 2640
 ttgatccgct gccaggagaa tgggcttttg gaggccctc agatttctct tgtaccccg 2700
 aggctggcc gtgctctgcg ctccatggac gcccagaag gaccacgggg acagctctcg 2760
 aggcacagga aggcaccgtt gacaccgcc tccagtctct agggagcctg gaagactgct 2820
 gccccagca ggacctctc acatcaactg ccagtgtct tccccatgat agggggtgac 2880
 gtgagagggg tgggactgaa attcagagga cagcgtcga aggggtttct gggaaacact 2940
 tgggtggctc cgcacctca cacaagggcc tcaggtttta cccgtaagt ccctaagtgc 3000
 ctcaactgcc ctctcatgtc agctgcctcc ttgtccctcg atntcgtnag gggacactgt 3060
 gctattcgat cttgattgtc gaagagtttt taggatggag taccagcaaa accaggtgga 3120
 aataaagttg totgaaccca aagaaaaaa aaa 3153

<210> 74
<400> 74
000

<210> 75
<400> 75
000

<210> 76
<400> 76
000

<210> 77
<400> 77
000

<210> 78
<400> 78
000

<210> 79
<400> 79
000

<210> 80
<400> 80
000

<210> 81
<211> 2002
<212> DNA
<213> Gerbil

<400> 81
gtcgacccac gcgctccgctg cgtttctcacc cctgggaccac cctggggagaa cagttgaccg 60
aagtttgttt ggcagttgct gctggactat gtttctgctt ctggtggtac tcagccagct 120
gccagactt accctcgcgg ttcttcatac aagaagccta aagaattctg aacatgcccc 180
agaaggagtc tttgcatcaa aaaaagcagc aagcatcttt atgcaccgtc gcctcctata 240
caatagattt gatttagaac tcttcaactcc cgggaaacctg gagagagagt gctatgagga 300
gttctgtagt tatgaagaag ccagagagat cctcggggac aacgaagaaa tgatcacatt 360

```

ctggcgggaa tattcagtca aaggaccaac cacaagatca gatgtcaaca aagagaaaat 420
tgatgttatg ggccttctga ctggcttaat tgcggttgga gtattcttgg ttgtttttgg 480
cttacttggg tactatctgt gtatcaccaa gtgtaatagg cagccatata aaggttcttc 540
agctgtctac acaagaagga ccaggcacac accgtccatc attttcagaa cccatgagga 600
agctgtcttg tctccatcgt catcctcaga ggacgcggga ctaccttctt atgaacaggc 660
agtagctctg accagaaaac acagtgtctc accaccacct ccatatctct ggccagcaaa 720
aggatttagg gtatttaaaa agtcaatgtc actcccatct cactaagccc accttgccgc 780
cttgctgtgg tctgaataat atgttcttcc tgaaacaaca acaacaaaaa aatttgccctg 840
ttcagctttt tatgacaaag cacaaggaat aaaggaacac tatatacaga acagaattca 900
ccacagcccc gctttcagct ctgcccccaa ctggattgct gtcttggtta gagacttcta 960
ccgtgcttcc tcgaagttaa gaagaaagtg cctttttgca atgtaaactg tactggttca 1020
aacattcttg ctacagctag gtacctataa tccccacctt caggagactt aggcgggagg 1080
gatgagagtt caaggccagc ctggggcctg tcaggacgct gtctcaaaac aaagtttgtt 1140
atcaatagaa taattagaat taacaaacta ggattttcag tcttaagtca tgatattgga 1200
tcttctcttc agtaaggttt ctttttggct agaaatactt catagaattt gacatttttg 1260
tatacatctg tggccttgat acaatgactt gattttctgt ttttaattag gcagaggatt 1320
cagcaaatth gcaggtcttc attttgttcc ctgcctatcc atcgatcatg tttcagtgt 1380
ttaagaggag tcagccaggc gtggtggccc acacctgtga tcccagcact taggggggca 1440
taggcaggca gatctctgtg agctgaagga cagcctggcc tacaaagtcc aggacaaccg 1500
agaccacaca gagaaacctt gtcttgaaaa acaaaacaaa aacaagagag agagagagag 1560
agagagaaaa gagatgtcaa gaggtttttg tttttttttt tttaaattac tatttatggg 1620
cctcacttgg aaaagtgtt gccatgcaaa tagaaggaca ggagttcaat cctcattacc 1680
cacatttgaa acaataaaca agaaaaacaa accaaaaaac caaaacaaac aaaatcttga 1740
gaacttgagt gaataccggt aacctcaggg ctaggcactg taactgaatc aggagcctcc 1800
agatccaggg aaacgtgtc tcaacaaata aataaataag taagtcagtg aggtggtctt 1860
taaaccagc acttgagagc caaaggcagg cagagctcag tgagttggag accagcctgg 1920
tctacaaagc aagttctaag ggagccaggg cacagagaaa ccctgtctga aggaaaaaaa 1980
aaaaaaaaa aaggcgggcc gc
2002

```

<210> 82
<211> 675
<212> DNA
<213> Gerbil

```

<400> 82
atgtttctgc ttctggtggt actcagccag ctgccagac ttaccctcgc ggttcctcat 60
acaagaagcc taaagaattc tgaacatgcc ccagaaggag tctttgcatc aaaaaaagca 120
gcaagcatct ttatgcaccg tcgcctccta tacaatagat ttgatttaga actcttcact 180
cccggaacc tggagagaga gtgctatgag gagttctgta gttatgaaga agccagagag 240
atcctcgggg acaacgaaga aatgatcaca ttctggcggg aatattcagt caaaggacca 300
accacaagat cagatgtcaa caaagagaaa attgatgtta tgggccttct gactggctta 360
attgcggctg gagtattctt gggtgttttt ggcttacttg gttactatct gtgtatcacc 420
aagtgttaata ggcagccata tcaaggttct tcagctgtct acacaagaag gaccaggcac 480
acaccgtcca tcattttcag aacctatgag gaagctgtct tgtctccatc gtcactctca 540
gaggacgcgg gactaccttc ctatgaacag gcagtagctc tgaccagaaa acacagtgtc 600
tcaccaccac ctccatatoc tgggcccagca aaaggattta gggattttta aaagtcaatg 660
tcactcccat ctcac
675

```

<210> 83
<211> 225
<212> PRT
<213> Gerbil

<400> 83

Met Phe Leu Leu Leu Val Val Leu Ser Gln Leu Pro Arg Leu Thr Leu
1 5 10 15

Ala Val Pro His Thr Arg Ser Leu Lys Asn Ser Glu His Ala Pro Glu
20 25 30

Gly Val Phe Ala Ser Lys Lys Ala Ala Ser Ile Phe Met His Arg Arg
35 40 45

Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu
50 55 60

Glu Arg Glu Cys Tyr Glu Glu Phe Cys Ser Tyr Glu Glu Ala Arg Glu
65 70 75 80

Ile Leu Gly Asp Asn Glu Glu Met Ile Thr Phe Trp Arg Glu Tyr Ser
85 90 95

Val Lys Gly Pro Thr Thr Arg Ser Asp Val Asn Lys Glu Lys Ile Asp
100 105 110

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val
115 120 125

Val Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn Arg
130 135 140

Gln Pro Tyr Gln Gly Ser Ser Ala Val Tyr Thr Arg Arg Thr Arg His
145 150 155 160

Thr Pro Ser Ile Ile Phe Arg Thr His Glu Glu Ala Val Leu Ser Pro
165 170 175

Ser Ser Ser Ser Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala Val
180 185 190

Ala Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Pro Tyr Pro Gly
195 200 205

Pro Ala Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro Ser

210

215

220

His

225

<210> 84

<211> 17

<212> PRT

<213> Gerbil

<400> 84

Met Phe Leu Leu Leu Val Val Leu Ser Gln Leu Pro Arg Leu Thr Leu

1

5

10

15

Ala

<210> 85

<211> 208

<212> PRT

<213> Gerbil

<400> 85

Val Pro His Thr Arg Ser Leu Lys Asn Ser Glu His Ala Pro Glu Gly

1

5

10

15

Val Phe Ala Ser Lys Lys Ala Ala Ser Ile Phe Met His Arg Arg Leu

20

25

30

Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu Glu

35

40

45

Arg Glu Cys Tyr Glu Glu Phe Cys Ser Tyr Glu Glu Ala Arg Glu Ile

50

55

60

Leu Gly Asp Asn Glu Glu Met Ile Thr Phe Trp Arg Glu Tyr Ser Val

65

70

75

80

Lys Gly Pro Thr Thr Arg Ser Asp Val Asn Lys Glu Lys Ile Asp Val

85

90

95

Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val Val

100

105

110

Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn Arg Gln

115

120

125

Pro Tyr Gln Gly Ser Ser Ala Val Tyr Thr Arg Arg Thr Arg His Thr
 130 135 140

Pro Ser Ile Ile Phe Arg Thr His Glu Glu Ala Val Leu Ser Pro Ser
 145 150 155 160

Ser Ser Ser Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala Val Ala
 165 170 175

Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Pro Tyr Pro Gly Pro
 180 185 190

Ala Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro Ser His
 195 200 205

<210> 86

<211> 95

<212> PRT

<213> Gerbil

<400> 86

Val Pro His Thr Arg Ser Leu Lys Asn Ser Glu His Ala Pro Glu Gly
 1 5 10 15

Val Phe Ala Ser Lys Lys Ala Ala Ser Ile Phe Met His Arg Arg Leu
 20 25 30

Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu Glu
 35 40 45

Arg Glu Cys Tyr Glu Glu Phe Cys Ser Tyr Glu Glu Ala Arg Glu Ile
 50 55 60

Leu Gly Asp Asn Glu Glu Met Ile Thr Phe Trp Arg Glu Tyr Ser Val
 65 70 75 80

Lys Gly Pro Thr Thr Arg Ser Asp Val Asn Lys Glu Lys Ile Asp
 85 90 95

<210> 87

<211> 25

<212> PRT

<213> Gerbil

<400> 87

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val
1 5 10 15

Val Phe Gly Leu Leu Gly Tyr Tyr Leu
20 25

<210> 88

<211> 88

<212> PRT

<213> Gerbil

<400> 88

Cys Ile Thr Lys Cys Asn Arg Gln Pro Tyr Gln Gly Ser Ser Ala Val
1 5 10 15

Tyr Thr Arg Arg Thr Arg His Thr Pro Ser Ile Ile Phe Arg Thr His
20 25 30

Glu Glu Ala Val Leu Ser Pro Ser Ser Ser Glu Asp Ala Gly Leu
35 40 45

Pro Ser Tyr Glu Gln Ala Val Ala Leu Thr Arg Lys His Ser Val Ser
50 55 60

Pro Pro Pro Pro Tyr Pro Gly Pro Ala Lys Gly Phe Arg Val Phe Lys
65 70 75 80

Lys Ser Met Ser Leu Pro Ser His
85

<210> 89

<400> 89

000

<210> 90

<400> 90

000

<210> 91

<400> 91

000

<210> 92
 <211> 962
 <212> DNA
 <213> Mus sp.

<400> 92
 ccgtttctct ttaaccactt gcacggtctg gggttaaccc gcctgcggac tctggacctc 60
 tcctccaact ggctgaaaca tatctccatc cctgagttgg ctgcactgcc aacttatctc 120
 aagaacaggc tctacctgca caacaacccg ctgccctgtg actgcagcct ctaccacctg 180
 ctccggcgct ggcaccagcg gggcctgagt gccctgcatg attttgaacg cgagtacaca 240
 tgcttggtct ttaaggtgtc agagtcccga gtgcgctttt ttgagcacag ccgggtcttc 300
 aagaactgct ctgtggctgc agctccaggc ttagagctgc ctgaagagca gctgcacgcy 360
 cagggtgggc agtccttgag gctcttctgc aacaccagtg tgccctgccac tcgggtggcc 420
 tgggtctccc cgaagaatga gctgcttggt gcgccagcct ctcaggatgg tagcatcgct 480
 gtgttggtct atggcagctt agccataggc aggggtgcaag agcagcacgc aggcgtcttt 540
 gtgtgcctgg ccagtgggccc ccgcctgcac cacaaccaga cacttgagta caatgtgagt 600
 gtgcaaaagg ctgcgcccgga gccagagact ttcaacacag gctttaccac cctgctgggc 660
 tgtattgtgg gcctggtgct ggtgttgctc tacttgtttg caccaccctg tcgtggctgc 720
 tgtcactgct gtcagcgggc ctgccgcaac cgttgcctggc cccgggcac cagtccactc 780
 caggagctga gcgcacagtc ctccatgctt agcactacgc caccagatgc acccagccgc 840
 aaggccagtg tccacaagca tgttgtcttc ctggagccgg gcaagaaggc cctcaatggc 900
 cgtgtgcagc tcgcagtacc tccagactcc gatctgtgca accccatggg cttgcaactc 960
 aa 962

<210> 93
 <211> 320
 <212> PRT
 <213> Mus sp.

<400> 93
 Pro Phe Leu Phe Asn His Leu His Gly Leu Gly Leu Thr Arg Leu Arg
 1 5 10 15
 Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu
 20 25 30
 Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn
 35 40 45
 Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp
 50 55 60
 His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr
 65 70 75 80

Cys	Leu	Val	Phe	Lys	Val	Ser	Glu	Ser	Arg	Val	Arg	Phe	Phe	Glu	His	85	90	95	
Ser	Arg	Val	Phe	Lys	Asn	Cys	Ser	Val	Ala	Ala	Ala	Pro	Gly	Leu	Glu	100	105	110	
Leu	Pro	Glu	Glu	Gln	Leu	His	Ala	Gln	Val	Gly	Gln	Ser	Leu	Arg	Leu	115	120	125	
Phe	Cys	Asn	Thr	Ser	Val	Pro	Ala	Thr	Arg	Val	Ala	Trp	Val	Ser	Pro	130	135	140	
Lys	Asn	Glu	Leu	Leu	Val	Ala	Pro	Ala	Ser	Gln	Asp	Gly	Ser	Ile	Ala	145	150	155	160
Val	Leu	Ala	Asp	Gly	Ser	Leu	Ala	Ile	Gly	Arg	Val	Gln	Glu	Gln	His	165	170	175	
Ala	Gly	Val	Phe	Val	Cys	Leu	Ala	Ser	Gly	Pro	Arg	Leu	His	His	Asn	180	185	190	
Gln	Thr	Leu	Glu	Tyr	Asn	Val	Ser	Val	Gln	Lys	Ala	Arg	Pro	Glu	Pro	195	200	205	
Glu	Thr	Phe	Asn	Thr	Gly	Phe	Thr	Thr	Leu	Leu	Gly	Cys	Ile	Val	Gly	210	215	220	
Leu	Val	Leu	Val	Leu	Leu	Tyr	Leu	Phe	Ala	Pro	Pro	Cys	Arg	Gly	Cys	225	230	235	240
Cys	His	Cys	Cys	Gln	Arg	Ala	Cys	Arg	Asn	Arg	Cys	Trp	Pro	Arg	Ala	245	250	255	
Ser	Ser	Pro	Leu	Gln	Glu	Leu	Ser	Ala	Gln	Ser	Ser	Met	Leu	Ser	Thr	260	265	270	
Thr	Pro	Pro	Asp	Ala	Pro	Ser	Arg	Lys	Ala	Ser	Val	His	Lys	His	Val	275	280	285	
Val	Phe	Leu	Glu	Pro	Gly	Lys	Lys	Gly	Leu	Asn	Gly	Arg	Val	Gln	Leu	290	295	300	
Ala	Val	Pro	Pro	Asp	Ser	Asp	Leu	Cys	Asn	Pro	Met	Gly	Leu	Gln	Leu	305	310	315	320

<210> 94
 <211> 16
 <212> PRT
 <213> Mus sp.

<400> 94
 Pro Phe Leu Phe Asn His Leu His Gly Leu Gly Leu Thr Arg Leu Arg
 1 5 10 15

<210> 95
 <211> 304
 <212> PRT
 <213> Mus sp.

<400> 95
 Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu
 1 5 10 15

Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn
 20 25 30

Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp
 35 40 45

His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr
 50 55 60

Cys Leu Val Phe Lys Val Ser Glu Ser Arg Val Arg Phe Phe Glu His
 65 70 75 80

Ser Arg Val Phe Lys Asn Cys Ser Val Ala Ala Ala Pro Gly Leu Glu
 85 90 95

Leu Pro Glu Glu Gln Leu His Ala Gln Val Gly Gln Ser Leu Arg Leu
 100 105 110

Phe Cys Asn Thr Ser Val Pro Ala Thr Arg Val Ala Trp Val Ser Pro
 115 120 125

Lys Asn Glu Leu Leu Val Ala Pro Ala Ser Gln Asp Gly Ser Ile Ala
 130 135 140

Val Leu Ala Asp Gly Ser Leu Ala Ile Gly Arg Val Gln Glu Gln His
 145 150 155 160

Ala Gly Val Phe Val Cys Leu Ala Ser Gly Pro Arg Leu His His Asn

	165		170		175
Gln Thr Leu Glu Tyr Asn Val Ser Val Gln Lys Ala Arg Pro Glu Pro					
	180		185		190
Glu Thr Phe Asn Thr Gly Phe Thr Thr Leu Leu Gly Cys Ile Val Gly					
	195		200		205
Leu Val Leu Val Leu Leu Tyr Leu Phe Ala Pro Pro Cys Arg Gly Cys					
	210		215		220
Cys His Cys Cys Gln Arg Ala Cys Arg Asn Arg Cys Trp Pro Arg Ala					
225		230		235	240
Ser Ser Pro Leu Gln Glu Leu Ser Ala Gln Ser Ser Met Leu Ser Thr					
	245		250		255
Thr Pro Pro Asp Ala Pro Ser Arg Lys Ala Ser Val His Lys His Val					
	260		265		270
Val Phe Leu Glu Pro Gly Lys Lys Gly Leu Asn Gly Arg Val Gln Leu					
	275		280		285
Ala Val Pro Pro Asp Ser Asp Leu Cys Asn Pro Met Gly Leu Gln Leu					
	290		295		300

<210> 96
 <211> 197
 <212> PRT
 <213> Mus sp.

<400> 96
 Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu
 1 5 10 15
 Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn
 20 25 30
 Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp
 35 40 45
 His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr
 50 55 60

Cys Leu Val Phe Lys Val Ser Glu Ser Arg Val Arg Phe Phe Glu His
65 70 75 80

Ser Arg Val Phe Lys Asn Cys Ser Val Ala Ala Ala Pro Gly Leu Glu
85 90 95

Leu Pro Glu Glu Gln Leu His Ala Gln Val Gly Gln Ser Leu Arg Leu
100 105 110

Phe Cys Asn Thr Ser Val Pro Ala Thr Arg Val Ala Trp Val Ser Pro
115 120 125

Lys Asn Glu Leu Leu Val Ala Pro Ala Ser Gln Asp Gly Ser Ile Ala
130 135 140

Val Leu Ala Asp Gly Ser Leu Ala Ile Gly Arg Val Gln Glu Gln His
145 150 155 160

Ala Gly Val Phe Val Cys Leu Ala Ser Gly Pro Arg Leu His His Asn
165 170 175

Gln Thr Leu Glu Tyr Asn Val Ser Val Gln Lys Ala Arg Pro Glu Pro
180 185 190

Glu Thr Phe Asn Thr
195

<210> 97

<211> 20

<212> PRT

<213> Mus sp.

<400> 97

Gly Phe Thr Thr Leu Leu Gly Cys Ile Val Gly Leu Val Leu Val Leu
1 5 10 15

Leu Tyr Leu Phe
20

<210> 98

<211> 87

<212> PRT

<213> Mus sp.

<400> 98

Ala Pro Pro Cys Arg Gly Cys Cys His Cys Cys Gln Arg Ala Cys Arg

1	5	10	15
Asn Arg Cys Trp Pro Arg Ala Ser Ser Pro Leu Gln Glu Leu Ser Ala			
20	25	30	
Gln Ser Ser Met Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Arg Lys			
35	40	45	
Ala Ser Val His Lys His Val Val Phe Leu Glu Pro Gly Lys Lys Gly			
50	55	60	
Leu Asn Gly Arg Val Gln Leu Ala Val Pro Pro Asp Ser Asp Leu Cys			
65	70	75	80
Asn Pro Met Gly Leu Gln Leu			
85			

<210> 99
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: TANGO 331
 human radiation panel forward primer

<400> 99
 attattcaga aggatgtccc gtgg

24

<210> 100
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: TANGO 331
 human radiation panel reverse primer

<400> 100
 cctcctgatt acotacaatg gtc

23